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Recent years have seen an expansion beyond the more druggable biological targets into novel areas of 
biological space. However, drug discovery campaigns against these challenging targets have been 
afflicted with low hit rates during screening campaigns and high levels of candidate attrition during 
clinical trials. Subsequent studies have looked to explore the underlying factors to these challenges and 
have identified the lack of scaffold diversity and poor physicochemical properties in screening libraries 
as the leading causes. 
In an attempt to address this issue drug discovery strategies such as fragment-based drug discovery and 
lead-oriented synthesis have been developed which control and direct the compound properties within 
screening libraries towards relevant areas of chemical space. In addition, strategies such as diversity-
oriented synthesis aim to synthesise structurally complex and diverse compounds, expanding screening 
collections into previously under-explored areas of chemical space. 
This thesis reports the development of a step-efficient, modular and highly adaptable synthetic route for 
the synthesis of partially saturated bicyclic heteroaromatic scffolds (Figure i). The designed route takes 
advantage of the large chiral pool provided by amino acids, with each scaffold synthesised in just 4-6 
steps from these readily available enantiopure starting materials. The mild conditions allow for excellent 
functional group tolerance, thus enabling the incorporation of growth vectors for chemical elaboration 
from the outset, a strong advantage in the drug discovery process. 
Overall, 29 partially saturated bicyclic heteroaromatic compounds were synthesised based around 7 
different scaffolds. These demonstrated a number of possible areas for diversifation both on and around 
the scaffold, including variation of functional groups (Figure i, red), double (cis-diastereoisomers) and 
single (R2- and R3-positions) substitution patterns, variation of the 5-membered heterocycle (Figure i, 
green) and increased size of the saturated ring (Figure i, blue). Furthermore, careful selection of the 
substituents, heterocycle and size of the saturated ring would enable the synthesis of screening libraries 
within the constrainsts of fragment-like, lead-like or drug-like structures. 
The final library has been incorporated into the Diamond XChem high-throughput crystallography 
program and initial screening has identified a weakly binding hit for Activin A. 
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oC - degrees Celcius 
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ADMET - adsorption, distribution, metabolism, excretion, toxicity 
aq - aqueous 
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ARE - antioxidant response element  
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cat. - catalytic/catalyst 
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cm-1 - wavenumbers 
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d - doublet 
CH2Cl2 - dichloromethane 
DIPEA - N,N-diisopropylethylamine 




DME - dimethoxyethane 
DMF - N,N-dimethylformamide 
DMP - Dess-Martin periodinane 
DMSO - dimethylsulfoxide 
DOS - diversity oriented synthesis 
EDC - 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide 
eq. - equivalents 
Et - ethyl 
FBDD - fragment-based drug discovery 
FDA - US Food and Drug Administration 
FT - fourier transform 
g - gram(S) 
GSK - GlaxoSmithKline 
h - hour(S) 
H-bond - hydrogen bond 
HAC - heavy atom count 
HATU - N-[(dimethylamino)-1H-1,2,3-triazolo-[4,5-b]pyridin-1-ylmethylene]-N-
methylmethanaminium hexafluorophosphate N-oxide 
HBA - hydrogen bond donor 
HBD - hydrogen bond donor 
HBTU - O-(benzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium hexafluorophosphate 
HMBC - heteronuclear multiple bond connectivity 
HMQC - heteronuclear multiple quantum coherence 
HOAt - 1-hydroxy-7-azabenzotriazole 
HOBt - hydroxybenzotriazole 




HRMS - high resolution mass spectrometry 
HTS - high throughput screening 
Hz - hertz 
IBX - 2-iodoxybenzoic acid 
IC50 - half maximal inhibitory concentration 
ID - identification 
IR - infrared 
J - coupling constant 
KHMDS - potassium bis(trimethylsilyl)amide 
L - litre(S) 
LCMS - liquid chromatography-mass spectrometry 
LDA - lithium diisopropylamide 
L.E. - ligand efficiency 
Lit. - literature 
m.p. - melting point 
m - multiplet 
m - meta 
M - molar 
mCPBA - meta-chloroperoxybenzoic acid 
Me - methyl 
min - minute(S) 
mg - milligram(S) 
mL - millilitre(S) 
mmol - millimole(S) 
MOE - Molecular Operating Environment 




MW - molecular weight 
NBS - N-bromosuccinimide 
NCE - new chemical entity 
NME - new molecular entity 
NMM - N-methylmorpholine 
NMR - nuclear magnetic resonance 
NOESY - nuclear overhauser spectroscopy 
p - para 
PCA - principle component analysis 
PG - protecting group 
Ph - Phenyl 
PLS-DA - partial least squares discriminant analysis 
PMB - para-methoxybenzyl 
PMI - principle moments of inertia 
PPI - protein-protein interaction 
ppm - parts per million 
pTSA - topological polar surface area 
q - quartet 
R & D - Research and Development 
RBC - rotatable bond count 
Rf - retention factor 
rt - room temperature 
SAR - structure-activity relationship 
TEA - triethylamine 
Tf - triflic 




THF - tetrahydrofuran 
TLC - thin layer chromatography 
TMS - trimethylsilyl 
VEHICLe - virtual exploratory heterocyclic library 
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1.1. Drug Discovery Process and Challenges in the Pharmaceutical 
Industry 
 
Over the last 20 years, the pharmaceutical industry has seen a reduction in revenue, the approval of ever 
fewer new chemical entities (NCE’s) each year and a decrease in the quality of research and 
development (R & D) pipelines.1–3 In fact, clinical candidates are more likely to fail now than in the 
1970s with only 1 in 10 eventually marketed.4,5 These symptoms highlight the significant decline within 
the industry, the causes of which are widely considered to be complex and intertwined.1–3 Despite this, 
some changes within the industry have coincided with the decline and are therefore considered 
contributing factors: (i) a strong aversion to risk, (ii) addressing more challenging targets, (iii) 
increasing R & D costs, (iv) escalating clinical trial costs, (v) high levels of attrition during late-stage 
clinical trials, (vi) changes in the regulatory landscape and (vii) increased entry of generic drugs into 
the pharmaceutical market.6,7 
The process of drug discovery is lengthy and expensive with multiple stages, typically spanning 12-15 
years and costing over $2.6 billion.5,8 Target identification and validation begins the process: for a 
particular disease state, a biological target must be identified and the link between target modulation 
and clinical outcome demonstrated. This usually involves the use of so-called chemical probes or tool 
compounds to inhibit the target and study the outcome, thus delivering an understanding of the 
biological pathways and target(s) associated with the studied disease state. A lack of a thorough 
understanding of the pathways studied can result in target modulation failing to have the desired clinical 
outcome when tested during clinical trials (Figure 1.1).6  
Once a target has been validated, compound screening is used to identify molecules with the desired 
activity (‘hits’). Once a series of hits is identified they are refined into ‘leads’: potent and selective 
compounds with adequate pharmacokinetic properties for in vivo testing.5 These leads are then further 
optimised to improve potency and drug-like properties such that potent and selective preclinical 
candidates with good pharmacokinetic and pharmacodynamic properties can be identified. 
The preclinical candidate will then be subjected to safety and efficacy testing using both computer 
modelling and in vivo animal testing prior to entering human clinical trials. Phase I clinical trials are 
usually carried out on healthy volunteers, with the primary aim of assessing the safety and side effects 
of the drugs to thus determine an optimal dose. If a candidate is successful through phase I, phase II 




of concept’ studies are carried out. This is the most common point of failure in the drug discovery 
process. The final stage of clinical trials, phase III aims to ensure that the candidate is effective and safe 
for long term use.  
Upon successful completion of phase III clinical trials, the clinical candidate can then be registered and 
marketed. 
 





1.2. Screening Strategies, the Nature of Screening Libraries and 
Downstream Effects 
 
Drug discovery projects can and do fail at every stage of the long and arduous process outlined in Figure 
1.1. However, the nature of the library used for the initial screening is widely considered to be of central 
importance in this regard, since the outcome of this stage impacts upon all downstream phases.1–3,6,10,11 
The hit rate provided by a library is clearly significant, however, the quality of these hits is also a crucial 
consideration. High quality hits are generally considered to be those that can be efficiently optimised to 
generate lead compounds with improved efficacy and safety. 
Traditionally natural products have been a major source of new drugs; they are highly diverse with 
specific biological activity, proposed to be a result of their inherent receptor binding capacity. However, 
natural products are often difficult to source and challenging to identify, purify and chemically modify 
and this limits their use in screening libraries. Chemical synthesis has therefore dominated the 
generation of small molecule screening libraries, with the composition of the screening library 
dependent upon the screening strategy employed.5 
 
1.2.1. High Throughput Screening (HTS) of Combinatorial Libraries of drug-like 
small molecules 
High throughput screening techniques involve the rapid automated screening of thousands to millions 
of compounds to identify those with some degree of affinity for the target, and as such is currently the 
most widely used technology for identifying hits for drug discovery.12 It first came to prominence in 
the late 1980s, as a result of the development of combinatorial chemistry methods which enabled 
chemists to produce very large numbers of compounds in an efficient manner though the systematic 
and covalent linkage of various building blocks.13 The prevailing belief of the pharmaceutical industry 
at the time was that drug discovery was just a ‘numbers game’4,14 and, as such, it was assumed a plethora 
of new drug leads would be generated as a consequence of the sheer numbers of molecules being 
screened.15 Disappointingly, this hypothesis did not prove to be successful and the low hit rates, 
alongside the high levels of failure during phase I of clinical trials, led to the development of a number 
of guidelines to improve the molecular properties of screening compounds. The first of these, which is 
still widely used today, is Lipinski’s ‘rule of five’.16 It was developed in the early 1990’s to overcome 
the poor physicochemical properties which were believed to contribute to approximately 40% of 




Lipinski et al. used experimental and computational approaches to study the effect of physicochemcial 
properties on solubility and permeability in a drug discovery setting,16 resulting in four guidelines for 
oral bioavailability: 5 H-bond donors or fewer, 10 H-bond acceptors or fewer, molecular weight (MW) 
below 500 and calculated log P (Clog P) of 5 or less. It was suggested that violation of more than one 
of these guidelines would result in compounds with poor oral absorption and therefore poor 
pharmacokinetic and oral bioavailability properties causing likely attrition in phase I of clinical trials.16 
Lipinski’s ‘rule of 5’ guidelines were quickly and widely implemented in HTS libraries; and 
fortuitously, this reduced the attrition rate due to poor ADMET (adsorption, distribution, metabolism, 
excretion, toxicity) characteristics to just 10%.3,10  
Unfortunately, despite Lipinski’s efforts, HTS is still afflicted with issues as demonstrated by the low 
hit rates seen in the hunt for novel antibacterial drugs. GlaxoSmithKline (GSK) evaluated over 300 
bacterial genes and identified 160 essential targets between 1995 and 2001. They ran a total of 70 
screening campaigns, including 67 HTS campaigns and 3 whole cell screens each with over half a 
million small molecules and a cost of $1 million. The initial results were disappointing with only 16 
hits of which only 5 were developed into lead compounds, with the remainder unable to meet the 
required criteria, even after chemical modification. None of the 5 leads were carried forward due to: (i) 
a lack of antibacterial activity despite target modulation; (ii) some non-specific toxicity as a result of 
indiscriminate cell-membrane disruptions; (iii) a lack of the broad spectrum activity desired; and, (iv) 
insufficient drug-like properties.17 Of the hundreds of antibacterial screening campaigns run worldwide, 
only 2 compounds were identified with sufficient potency, antibacterial activity and broad spectrum 
activity for a novel target. 
This low hit rate is unsustainable.18–20 Whilst it has primarily been attributed to insufficient or improper 
molecular diversity in the screening libraries, the poor developability and inappropriate chemical 
properties of hits and leads also highlights the need for new criteria for screening library 
compounds.4,12,17–22 
 
1.2.2. Compound Properties in Screening Libraries 
Despite the implementation of Lipinski’s ‘rule of 5’, attrition of compounds in clinical trials is as 
prevalent as ever. However, the most common point of failure has shifted from phase I to phase II, 
which now has only a 25% success rate (Figure 1.2).2 Whilst ascribing a single reason to compound 
failure could be considered an oversimplification, phase II clinical trials are the point at which ‘proof 
of concept’ studies are first carried out and as a result, failure can often be attributed to lack of efficacy 





Figure 1.2: Demonstration of the success rate of clinical candidates, using data from 14 large pharmaceutical companies 
between 2005 and 2009 (Abbott, AstraZeneca, Bayer, Bristol-Myers Squibb, Boehringer-Ingelheim, Eli Lilly, 
GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Schering-Plough). Data from the 
Pharmaceutical Benchmarking Forum (hhtp://kmrgroup.com/ForumsPharms.html). Approval data based on approval by a 
regulatory authority in a major market (EU, US or Japan). Figure adapted from reference.2 
Given that at each stage of drug discovery there is an associated increase in overall cost of development, 
this late-stage failure poses a significant problem, and it is crucial to develop paradigms and 
methodologies to identify risk pre-clinically, and therefore limit late-stage failures and the associated 
costs.3 To this end, a number of studies have been carried out exploring the causes behind both efficacy 
and safety failures; physicochemical properties are found to be significant in both.1,6,10,11,23 
Efficacy-related attrition is multi-faceted, with poor biological validation and poor compound properties 
both significant contributing factors. The safest and most potent drug will still fail if target modulation 
does not give the required outcome, however when considering screening libraries, it is the failures due 
to compound properties that are most important. AstraZeneca estimated that 29% of efficacy failures 
could be attributed to compound properties, such as pharmacokinetic properties, as the compounds 
exposure to the target tissue could not be established. 
Safety issues are associated with promiscuity (off target interactions) and mechanism-based toxicity 
(unforeseen adverse effects due to on-target interactions). Whilst toxicity due to either will result in 
project failure, a study by AstraZeneca looking at the fate of their drug pipeline suggested that 75% of 
safety failures were related to compound properties.6 This ties in with a number of studies suggesting a 
link between compound properties and toxicity due to promiscuity.6,10,11,24,25 Given the complexity of 
biological systems large data sets are required to establish any kind of meaningful correlation between 
compound properties and toxicological outcomes.10 However, in general, an increased probability of 
failure is linked to the increased promiscuity of highly lipophilic compounds.10 
In an attempt to quantify this, a study from Pfizer using animal toxicology data found that if compounds 
had clog P greater than 3 and topological polar surface area (tPSA) less than 75Å2 they would be 2.5 
times more likely to have off-target toxicity.25 In contrast, in animal studies AstraZeneca’s found no 
correlation between compound-related toxicological attrition and clog P and PSA within the ranges 
studied (clog P: 1-6 and pTSA 30-120Å2). However, partial least squares discriminant analysis (PLS-
DA) found that increased sp3 atom count in pre-clinical candidates diminished toxicity attrition.24 The 




highlight how subjective and context dependent these studies can be, especially when using averaged 
or categorised data which can exaggerate the strength of correlations.10 Thus whilst it is important to 
take heed of the studies, it could be suggested that applying specific guidelines too rigorously might be 
counterproductive. At the same time, whilst highly lipophilic and aromatic compounds are likely to give 
higher hit rates, they will also be more promiscuous and their prevalence in screening libraries should 
therefore be limited to reduce toxicity related attrition. 
 
1.2.3. Aims for the Future of Drug Discovery 
HTS campaigns that employ these traditional combinatorial libraries are typically found to be associated 
with low hit rates (percentage of screening library identified as active) and low hit quality (that is, the 
suitability of hits for continued optimisation) and therefore, those hits that are developed into clinical 
candidates often suffer high levels of attrition during the later stages of the drug discovery process.  
Furthermore, the ‘low-hanging fruit’ within drug discovery have already been well studied, and thus 
only the more challenging targets remain.2 Some of these have historically been deemed “undruggable”, 
such as protein-protein interactions (PPIs),15 whilst others are only just coming to light as a result of 
advances in molecular biology. One such family which has become an important target area within 
medicinal chemistry is that of epigenetics. The epigenome comprises over 230 enzymes and recognition 
proteins involved in epigenetic regulation of gene expression and therefore has significant clinical 
applications in the field of oncology amongst others.2,26–28 The human proteome is vast, and many of 
the biological targets within it have never been identified or studied, with all marketed drugs estimated 
to target fewer than 500 biomolecules.12 
To attempt to modulate these novel targets, a shift in the composition of screening libraries needs to 
take place, not only to increase the structural diversity within the libraries but also to improve their 
compound properties: lowering lipophilicity and aromaticity and increasing the saturation of 
compounds. In recent years, in an attempt to address these complex issues a number of screening 
paradigms and strategies for library synthesis have been developed. 
In the rest of this introduction, the importance of structural diversity within libraries and these 




1.3. Structural Diversity in Drug Discovery 
 
Chemical space is vast, with an estimated 1060 possible organic molecules with up to 30 carbon, 
nitrogen, oxygen or sulphur atoms29 and since it is impossible to sample all of it, the huge conundrum 
within drug discovery is which regions of chemical space to explore.30 One way to guide the exploration 
of chemical space is the principle of chemical diversity.31 
Chemical diversity is an intuitive concept that can be measured in a wide variety of ways using a number 
of different molecular properties.31,32 The chemical diversity of a library depends almost entirely on the 
descriptors, metrics and multivariate methods used to assess it.33 Physicochemical and topological 
descriptors are common properties used in chemical diversity studies, however,33 structural diversity is 
most common within the remit of medicinal chemistry. With respect to small molecules, structural 
diversity generally incorporates four principle components:34–36 
1) Appendage diversity (or building block diversity): variation in different structural moieties 
attached to a common molecular skeleton; 
2) Functional group diversity: variation in the functional groups present; 
3)  Stereochemical diversity: variation in the spatial orientation of potential macromolecule-
interacting elements; and 
4) Scaffold diversity: presence of multiple distinct molecular skeletons (scaffolds).  
The scaffold is considered to be the core molecular framework that provides the basic shape, rigidity or 
flexibility of the molecule and can be used therefore to represent a compound collection.37,38 It also 
defines the three-dimensional spatial arrangement of the various substituents on its periphery. As such, 
the scaffold controls the alignment of the functional groups, determining whether they are positioned 
in a way that enables molecular recognition and interaction with the biological target. Scaffold diversity 
is, therefore, generally regarded to play the most significant role in determining the overall structural 
diversity of a small molecule set and can be considered the most important feature of a screening library. 






1.3.1. Scaffold Diversity in Drug Discovery 
The term ‘scaffold’ is very subjective, and there exist multiple ways of defining it. In general they entail 
abstracting or decomposing the drug framework into simpler sub-structural elements (Table 1.1, Figure 
1.3). 
These varied approaches, whilst valid and widely used within studies, will give subtly different pictures 
of library diversity due to the use of different scaffold definitions or different data sets.  
 
 
Figure 1.3: Illustration of the different scaffold representations using the HSP90 inhibitor NVP-AUY922 as an example. 












For a group of molecules clustered according to their chemical 
fingerprint, atom-by-atom matching is used to identify the largest 
common substructure for the cluster. Hence this method is entirely 






The scaffold is considered to be the largest central cyclic system, with 
smaller ring substituents not considered.44,45 
 
Murcko’s Scaffold Scaffolds derived from molecules by removing side chains and 
preserving the atoms in the ring system or linking rings systems and the 
sp2 atoms directly bonded to these atoms. As outlined by Bermis and 
Murcko.42,46,47 
 
Graph Scaffold (Cyclic 
skeleton concept - 
CSK) 
Follows the same principles as Murcko’s scaffold, however, all 
appendages are removed and all non-carbon atoms are converted into sp3 
carbons, thus a range of equivalent scaffolds are represented which vary 
in only their heteroatom substituents. 48 
 
Markush Scaffold Generic structures generated by using R groups to denote the substitution 








Molecular frameworks described by fragmenting molecules around 
bonds which are formed by common chemical reactions.33,50 
 
Pharmacophore The medicinal chemistry definition of a scaffold, constituting the core 
scaffold that is responsible for the biological activity through interaction 






A number of studies have been carried out utilising these different definitions of a scaffold to analyse 
the diversity of existing drugs and compound librraies. A general trend appears in which most librraies 
have an over-representation of a small number of scaffolds, and that there is a distinct lack of scaffold 
diversity in the field of medicinal chemistry as a whole.31,33,39,40,42,46,47,50,51 
The comprehensive medicinal chemistry (CMC) database is a database of the structures and properties 
of known drugs; in 1996, Murcko and Bemis used this to analyse the scaffold diversity at the Murcko 
scaffold and graph scaffold levels. They found that when using a graph framework, the 5120 compounds 
were comprised of 1179 unique graph scaffolds, of which just 32 scaffolds accounted for 50% of the 
total compounds, whilst 783 (66%) of the frameworks were found in only a single drug molecule. Even 
when using the more complex Murcko scaffolds (considering the atom type, hybridisation and bond 
roder), only 41 frameworks accounted for 24% of the drug molecules.46 
Lipkus et al. took this analysis one step further by analysing a much larger dataset, and not restricting 
their analysis to drug molecules. They used a subset of almost 25 million compounds from the CAS 
registry, a database of approximately 33 million known chemical substances from the literature.52 As 
with the analysis by Bemis and Murcko, they looked at both the simple graph scaffolds and the Murcko 
scaffolds, and the lack of scaffold diversity became even more apparent with the larger dataset analysed. 
The dataset was idenitifed as representing 2.5 million Murcko scaffolds and 0.8 million graph scaffolds. 
Considering the more complex Murcko scaffold it was found that 5% of these scaffolds were found in 
75.5% of compounds, meaning approximately 1.3 million frameworks occur in a single compound. 
Unsurprisingly, this becomes even more drastic at the simpler graph scaffold level, with just 0.2% of 
frameworks occurring in 70% of compounds and 47% of graph scaffolds having a single exemplar 
compound (Figure 1.4).31  
This in-depth analysis highlights that within chemical space a small number of scaffolds are playing a 











Figure 1.4: Graphs illustrating the percentage of compounds containing a particular percentage of scaffolds: a. using the 
Murcko scaffold definition; b. using the graph scaffold definition. They both show a greatly expanded x-axis, since the vast 
majority of compounds are represented by very few scaffolds. Figure taken from reference.31 
 
1.3.2. Rings in Drug Discovery 
Ring systems play an essential role as drug scaffolds. They give the molecules their fundamental shape 
and affect their flexibility as a result of having fewer degrees of freedom than non-cyclic systems. 
Furthermore, they are important for the positioning of substituents in three-dimensional space.51,53 The 
composition of ring systems can also play an important role in the global characteristics of molecules 
due to their electronic properties and hydrophobicity, and it is these global characteristics which are 
important for the bioavailability, metabolic stability and toxicity of the molecule when in a drug 
discovery setting.51 This is highlighted by a number of studies exploring the prevalence of rings within 
the pharmaceutical industry: although the exact values vary depending on the subset of compounds 
analysed, it is found that between 95 and 97% of bioactive or drug molecules contain at least one ring 
system, with 95% containing 6 rings or fewer and only 5.9% containing a single ring.31,51,53,54 
However, as with scaffold diversity more generally, as discussed in the previous section, within the sub-
set of rings there is an over-representation of a small number of scaffolds, with 83% of the ring scaffolds 
found in natural products not represented among commercial molecules.55 Furthermore, compared to 
natural products, ring scaffolds within screening libraries have fewer fused, bridged or spiro-ring 




When looking more closely at the distribution of ring types an analysis by Ertl et al. found that 75.6% 
of the bioactive molecules studied contained at least one aromatic ring, whilst 65.2% contain at least 
one aliphatic ring.51 Analysis by Roughley et al. found an even more extreme 99% of the compounds 
analysed contained an aromatic ring.57 This varies substantially from the proportions found in natural 
products, for which only 37.9% contained an aromatic ring compared to 73.2% with an aliphatic ring.51 
Given the inherent biological activity in natural products, this disparity therefore supports the current 
trend for an increase in the fraction of sp3 atoms in ring systems in drug discovery,53,58–61 and this can 
only be assisted by a move away from library construction using traditional combinatorial chemistry 
methods, in which 80% of ring systems generated were found to be aromatic.62 
Indeed flat compounds dominate combinatorial libraries; 71% of library members will not have a single 
chiral centre. The bias towards aromatic rings seen within the current and historic drug market is 
generally considered to be as a result of their commercial availability and more robust chemistry 
compared to three-dimensional scaffolds. The development of metal-mediated cross-coupling reactions, 
such as Suzuki and Sonogashira, and Friedel Crafts acylation and alkylation makes synthesis and 
modulation of scaffolds around aromatic rings simple and efficient compared to saturated rings. For 
aliphatic rings there is the added complication of the need to control stereo- and regiochemistry when 
carrying out modifications, and as a result, carbon-carbon bond forming reactions are far less common, 
with an over-reliance on modification through the heteroatoms.53,57  
Many studies suggest more three-dimensionality in screening library compounds will improve both the 
diversity of the screening library and their ADMET properties: thus providing a better starting point for 
the drug discovery process.53,59 By saturating an aromatic scaffold, there is not only an increase in 
complexity as a result of the increased three-dimensionality, there is also the possibility of increased 
structural diversity since for a very small increase in molecular weight there is the potential for 
significantly more isomers, this can be seen when comparing dimethylpiperidine and dimethylpyridine 
(Figure 1.5).59 From the other end of the drug discovery process, an increase in three-dimensionality 
has been shown to improve both the solubility and developability of compounds for drug discovery.59,63–
67 It has been suggested that ideally, screening libraries should be diversified by inclusion of more 





Figure 1.5: Isomers of dimethyl pyridine and dimethylpiperidine. This illustrates that a slight increase in molecular weight 
can enable access to significantly more isomers and the compounds accessed have greater three-dimensionality than their 
pyridine counter-parts. Where Fsp3 is the fraction of total carbons which are sp3 hybridised. Figure modified from reference.59 
 
1.3.3. Heterocyclic Scaffolds 
The analysis carried out by Lipkus et al. (Section 1.3.1) also found that 98.6% of Murcko scaffolds 
within the CAS registry contained at least one heteroatom.31,54 When applying this to rings, it is found 
that heteroaromatics are a dominant class of rings within bioactive molecules, often directly involved 
in interactions with receptors either through heteroatoms via hydrogen bonds, or through hydrophobic 
interactions.51 Their lack of flexibility reduces the entropic penalty of binding and their hydrogen 
bonding abilities can offer high levels of target selectivity. Synthetically, aryl-aryl couplings and the 
aromatic nature of heteroaromatics can enable rapid exploration of substitution patterns.68 However, 
they are not without their disadvantages. Their lack of flexibility can be a double edged sword, 
advantageously reducing the entropy penalty whilst simultaneously restricting structure-activity 
relationship (SAR) studies to a single plane. In a similar manner, the hydrophobic nature and flat shape 
can also result in low aqueous solubility, and the synthetic tractability can result in rapid inflation of 
the molecular weight, which will prove counter-productive further down the line. 68 
Of particular importance within the class of heterocycles are nitrogen heterocycles. In an analysis of the 
pharmaceuticals available in 1994, 1086 unique small molecule drugs (84%) were found to contain at 




far surpass the 26% and 13% seen for sulphur and fluorine respectively.69 More recently, in 2013, 80% 
of the top twenty best-selling brand name drugs were identified as containing a nitrogen hetercycle.70 
As discussed, there has been an over-emphasis within combinatorial chemistry on aromatic rings, and 
this trend is maintained with nitrogen based heterocycles, particularly when considering 5-membered 
rings, of which 62% are aromatic. Whilst only 28% of 6-membered nitrogen heterocycles are aromatic, 
the remaining aliphatic systems predominantly consist of unsubstituted piperidine and piperazine rings, 
demonstrating little scaffold diversity. Also surprisingly, fused rings are seen in just 14% of drugs, 
despite their propensity in natural products. 69,70 
As illustrated, heterocyclic rings dominate within marketed drugs, particularly, nitrogen-based 
heterocycles. As a result, the most synthetically tractable ring systems already have a strong presence 
in marketed drugs, making novelty for patenting difficult. Thus, there is a need to explore novel 
heteroaromatic scaffolds. 
Of the possible 23,895 unique aromatic ring systems, as predicted by Pitt et al. using the virtual 
exploratory heterocyclic library (VEHICLe), only 1701 were found to have been synthesised and 
published in the literature, which comprises just 7%.68 Just 5-10 novel aromatic heterocyclic scaffolds 
are estimated to be synthesised and published each year, and these estimates are falling year on year.68 
This is, therefore, an important under-explored area especially given the importance of rings, and in 
particular heteroaromatic rings, within drug discovery. It is necessary to extend the horizon into novel 





Table 1.2: Table showing the top 12 most common nitrogen heterocycles and their frequency in 640 nitrogen heterocycle 









































1.4. Beyond ‘Traditional’ Combinatorial Libraries 
Chemical synthesis provides chemists with the tools needed for the synthesis of novel scaffolds with 
new properties, and thus it is necessary to develop a systematic approach to the application of these 
tools to library construction.39 When considering composition, a balance is required between scaffold 
diversity and representation.42 Dense coverage of a small number of scaffolds provides thorough 
coverage of pharmacophore space for a target, but will have limited scaffold diversity. Conversely, 
sparse representation of a large number of scaffolds can be advantageous for screening against novel 
targets; however once hits have been identified, hit confirmation and rapid generation of SAR can be 
challenging from a library of singular examples.42  
To this end, a variety of synthetic approaches have evolved to address the problems associated with the 
use of ‘traditional’ combinatorial-type libraries through the de-novo synthesis of small molecule 
collections.71 Most of these look to avoid the mass synthesis and screening dogma which underpinned 
early combinatorial chemistry,71 instead seeking to create maximally diverse and biologically relevant 
libraries.40 Two such approaches that have evolved are:71 
1) the identification and targeting of biologically relevant chemical space, since compounds within 
these regions will have an increased probability of containing bioactive compounds. Methods 
which fall within this remit include privileged structure synthesis72 and biology inspired 
synthesis (BIOS),73 both of which focus on the synthesis of libraries based around the core 
scaffolds of known biologically active molecules;14 
2) the interrogation of wide and novel regions of chemical space within a single library of small 
molecules. Examples of this non-biased synthetic approach to library synthesis come from 
diversity-oriented synthesis (DOS)74 and DNA-encoded library technology, which combines 
split-pool synthesis with DNA-encoding to rapidly generate diverse libraries of compounds, 
each of which is encoded by a DNA tag.75,76 
 
1.4.1. Targeting Biologically Active Chemical Space 
In 1988 Evans et al. noted that certain “privileged structures” were capable of providing useful ligands 
for multiple receptors.72 Evans predicted that careful modification of these privileged scaffolds could 
provide ligands for novel targets,72 since privileged structures tend to already have highly favourable 
characteristics, and thus would provide an attractive starting point for drug discovery.77 Although there 
are no hard and fast rules which define a structure as privileged, they were typically found to contain 
two or three ring systems connected by a single bond or fused together and are often inspired by, or 




the development of reactions of broad scope combined with intelligent library design such that the 
compounds generated incorporate appropriate drug-like properties.79 
 
Figure 1.6: Examples of privileged scaffolds elucidated from natural products and drugs as revealed by Welsch et al.79 
An example of the synthesis of a library based on a privileged scaffold comes from the Nicolaou group, 
based around the 2,2-dimethylbenzopyran scaffold 1 (Scheme 1.1).80 The Nicolaou group developed a 
novel strategy that enabled them to systematically modify the entire skeleton, such that the rigidity of 
the heterocyclic core was maintained, but an entirely diverse natural product-like library of 10,000 
members was generated. In addition they ensured that the library members maintained drug-like 
properties, with molecular weights between 200 and 600 and 3-6 heteroatoms per compound. 
Preliminary results from biological studies suggest that these library members are cell-permeable and 
capable of high-affinity interactions with biological targets. A number of hits have been identified, one 





Scheme 1.1: Strategy developed by NIcolaou’s Group for the development of a natural product-like library of 10,000 
compounds based on the privileged scaffold of 2,2-dimethylbenzopyran 1. Nine aldehyde containing compounds were 
immobilised on a phenyl selenium resin before diversity generating reactions, such as organometallic additions to generate 
alcohols, reductive aminations to provide amines and Knoevenagel condensations to afford α,β-unsaturated compounds, were 
carried out. Each of these could then be further diversified or cleaved from the resin using hydrogen peroxide via a cyclisation 
sequence which removed all traces of the selenium since it might otherwise affect biological studies. Figure adapted from 
reference.80 
In a similar vein, Waldmann et al. developed the concept of biology-oriented synthesis (BIOS) which 
also takes into consideration the conservation within proteins. Despite over 10390 unique amino acid 
combinations of 300 residues being possible,81 of the 104-105 proteins or fewer encoded for within an 
organism, there are often highly conserved subdomains, and so a limited number of possible small 
molecule binding sites. Hence, the underlying principles of BIOS are: i) natural products have an 
inherent ability to bind and modulate the activities of multiple protein targets, with many natural 
products sharing a common scaffold with the varied substitution patterns providing the specificity.80-82 




structures”;72 ii) the arrangement of the secondary structure of the amino acid sequence of a protein 
determines its three-dimensional structure. Sub-folds within these protein structures, in turn, determine 
the size and shape of their ligand-binding sites, with the chemical properties of the site determined by 
the amino acid residues exposed. It is this amino acid variation that provides specificity for the binding 
of ligands, and the shape of the sub-fold which selects the three-dimensional shape of the ligand 
required, as determined by its scaffold.73,85 
A recent example of the synthesis of a BIOS library is illustrated from Jia et al. which describes the 
enantioselective synthesis of a library of spirotropanyl oxindole scaffolds 2 through bimetallic relay 
catalysis (Scheme 1.2).86 Spirotropanyl oxindoles were chosen due to their common incorporation into 
alkaloid scaffolds which can exhibit potent vasorelaxant, antiplasmodial and ganglionic-transmission-
inhibiting activity. 
 
Scheme 1.2: Illustration of the spirotropanyl oxindole scaffold 2 within natural products and their enantioselective biology-
oriented synthesis. This employs first a rhodium catalysed intramolecular carbenoid transfer from the α-diazo ketone to the 
ozime in 3, followed by a 1,3-dipolar cycloaddition between the rhodium generated azomethine ylide and the 3-alkenyl 
oxindoles 4 in which the enantioselectivity is induced by the interaction between 4, NdIII and the chiral N,N’-dioxide ligand, 




As with all scaffolds, it seems highly probable that there are dozens of privileged scaffolds yet to be 
defined.79 
 
1.4.2. Targeting Broad and Novel Regions of Chemical Space 
In these approaches, the aim is to access a wider range of chemical space by virtue of increased library 
structural diversity. One such approach is that of diversity-oriented synthesis (DOS), first conceived 
and developed in 2000 by Stuart Schreiber, which was born out of a desire to address the lack of 
structural diversity in ‘traditional’ combinatorial-type screening libraries.87,88  
DOS libraries should thus efficiently interrogate large areas of chemical space, including known 
biologically relevant and under-explored regions of chemical space.89 The key advantages to this 
approach are (i) the conversion of simple starting materials into complex and diverse scaffolds,9 and (ii) 
its efficient and modular nature, whereby scaffolds are formed in typically no more than five synthetic 
steps.37 
Broadly speaking, there are two basic approaches for the generation of scaffold diversity that have been 
employed in DOS campaigns to date (Figure 1.7):  
1) Reagent-based approach in which divergent reactions are carried out on a pluripotent substrate 
to afford a number of different compounds with distinct molecular scaffolds; thus it is the choice 
of the reagents and co-substrates that dictate the stereochemical and skeletal diversity within 
the final scaffold.  
2) Substrate-based approach; functional groups in the substrate are reacted together (“paired”) so 
as to fold the substrate into a distinct molecular scaffold. In this approach, scaffold diversity 
can be achieved in one of two ways, either: i) different reaction conditions can be applied to a 
single densely-functionalised molecule such that multiple scaffolds are progressed from a 
single scaffold; or 2) a single set of reactions conditions can be used on different starting 
materials to furnish products based around multiple scaffolds. Irrespective of the synthetic 






Figure 1.7: DOS strategies for the synthesis of distinct molecular scaffolds: a. reagent-based; b. substrate-based approach 
These two approaches are not orthogonal and most modern DOS strategies incorporate aspects of 
both.71,90,91 Other features of diversity (appendage, functional group and stereochemical) can be 
introduced into the compound libraries through variation in the starting materials and/or reagents 
used.71,74 
A powerful synthetic algorithm that has found widespread application in DOS pathways is the three 
phase build/couple/pair (B/C/P) strategy (Figure 1.8).92,93 The build phase focuses on the synthesis of 
building blocks containing orthogonal, and ideally some chiral functionalities. These building blocks 
can then be linked together, or to other substrates, in the couple phase to produce complex and densely 
functionalised molecules; this phase provides the basis for the introduction of stereochemical diversity. 
Finally, the pair phase involves the intramolecular coupling of different moieties to afford rigid 





Figure 1.8: Application of DOS via Build-Couple-Pair 
There are a multitude of examples of DOS campaigns resulting in structurally diverse libraries, using 
some or all of these strategies. A reagent-based example from the Spring group synthesised a DOS 
library for the development of modulators of mitosis.94 Rhodium carbenoid chemistry was employed to 
produce pluripotent substrates from which a range of structurally diverse small molecules could be 
regio- and diastereo-selectively synthesised. Overall, a library of 35 compounds was synthesised, with 
10 distinct molecular scaffolds. Computational analysis was used to generate a principal moment of 
inertia (PMI) plot which illustrates the shape, and therefore scaffold, diversity produced in this work. 
A phenotypic screen highlighted the utility of this DOS library through the identification of two library 
members, 19 and 20, which caused mitotic arrest (Scheme 1.3, Figure 1.9).94 
 
Figure 1.9: Principal Moment of Inertia (PMI) plot illustrating the degree of molecular shape diversity in the generated library 
of thrity-five compounds (red) compared to the top forty top-selling brand-name drugs (purple) and sixty diverse natural 
products (light blue). PMI is used to assess the three-dimensional shape diversity of a compound library, the individual 







Scheme 1.3: Example of reagent-based DOS applied to the synthesis of chemical probes for the modulation of mitosis. 
Phenyldiazo ester compounds (6 and 7) were chosen as highly functionalised substrates: a. Rhodium-catalysed 
cyclopropanation of 6 gave unsaturated densely functionalised compounds (8, 9 and 10) which were further diversified using 
C-H activation reactions, lactonisations and iodolactonisations followed by radical deionisation; b. Tandem 
cyclopropanation-cope rearrangement of styryl diazoester derivative 7 gave highly functionalised bicycle [3.2.1]octadiene 
11. This provided ample opportunity for further diversification: including ring opening/cross metathesis 12, stereoselective 
epoxidation 13; regio- and stereo-selective dihydroxylation 14; dihydroxylation, oxidative cleavage and reductive amination 
15 (2° amines) and 16 (1° amines); dihydroxylation, oxidative cleavage, reduction and transesterification 17; Suzuki cross 
couplings 18; c. Library members which caused mitotic arrest: 19 and 20. 
Whilst traditionally DOS has aimed to generate complex scaffolds from simple starting materials, 
Hergenrother et al. posited that the divergent modification of natural products could be employed to 
generate markedly different core scaffolds with novel bioactivity. This was particularly appealing since 
it harnessed the inherent biological activity and pre-encoded complexity of natural products and enables 
the rapid synthesis of novel, highly complex molecules without the lengthy syntheses usually required 







An example comes from Paciaroni et al. who used a tryptoline ring distortion strategy to synthesise 70 
complex and diverse compounds from the complex natural product Yohimbine, an indole alkaloid 
(Scheme 1.4).99 Phenotypic screening and reporter gene assays idenitified compounds with 
antproliferation activities against cancer cells with functional hypoxia inducible factors, nitric oxide 
inhibition and inhibition and activation of the antioxidant response element (ARE). 
 
Scheme 1.4: Example of a complexity-to-diversity approach to the synthesis of a diverse library of 70 complex compounds 
synthesised through the ring distortion of the tryptoline scaffold in indole alkaloid Yohimbine. Ring cleavage could be used to 
open the central 6-membered ring at position A to generate an open ring system and at position B to form a 10-memebered 






1.5. Alternative Screening Paradigms 
 
1.5.1. Lead-oriented synthesis 
Traditionally, combinatorial chemistry combined with high-throughput screening aimed to identify hits 
from drug-like molecules. In addition to the issues associated with a lack of compound diversity 
discussed above, this approach tends to generate hits that have a similar molecular weight and 
lipophilicity as marketed drugs. Therefore physical property inflation during the optimisation process 
can result in the poor physical properties that result in the high rates of attrition seen.101 Lead-oriented 
synthesis was introduced to address this issue by specifically targeting the synthesis of libraries of 
molecules with lead-like molecular properties (Table 1.3).102 
There are a number of properties and features that should be taken into account when constructing a 
lead-like library to ensure maximum chance of successful drug development (Table 1.3), such as 
avoiding chemically reactive, electrophilic or redox active groups which are known to cause problems 
during drug discovery. Similarly, higher numbers of aromatic rings and lower numbers of sp3 carbons 
are affiliated with poorer solubility and other undesirable properties.  
Table 1.3: Table describing the molecular properties and features used to describe lead-like small molecule, 102 as compared 
to the drug-like small molecules.103 
Molecular Properties and 
Features 
Preferred Lead-like Values Preferred Drug-like Values 
Lipophilicity -1 < clog P < 3 -2 < clog P < 5 
Molecular size 14 < HAC < 26 
200 < MW < 350 
20 < HAC < 70 
200 < MW < 500 
Number of Aromatic Rings ≤ 3 - 
Complexity Favour higher Fsp3 Fsp3 = 0.47 
Substructures Avoid molecules containing 
chemically reactive, electrophilic 
or redox active groups. 
- 
 
By restricting the molecular weight to between 200 and 350, which is the approximate equivalent of 14 
to 26 heavy atoms, it becomes easier to sample broader areas of chemical space, since every additional 
heavy atom added to an organic molecule is estimated to increase the number of biologically relevant 




Most significant is the consideration given to lipophilicity. Lipophilicity essentially reflects the key 
event of molecular desolvation as a drug transfers from the aqueous phase to cell membranes and protein 
binding sites, which are usually hydrophobic in nature. High lipophilicity can therefore enable binding 
to multiple targets, leading to promiscuity and the associated toxicity, often resulting in attrition during 
clinical trials.105 In addition, poor solubility and metabolic clearance have a strong positive correlation 
with high lipophilicity, causing efficacy issues and therefore also contributing to the probability of 
attrition. Lead-like space is therefore defined by molecules with clog P values in the range -1 to 3, since 
this range is considered to give the best balance of properties for oral drugs.  
These guidelines are predominantly targeted at orally dosed drugs, so drugs dosed via alternative 
methods may be amenable to a wider range of physical properties. However it is proposed that lead-
like molecules still represent a good starting point for optimisation, with the potential to undergo 
property inflation without exceeding drug-like space (Figure 1.10).104 Unfortunately, only 2.6% of the 
4.9 million compounds from commercial vendors reside within this lead-like space, and therefore novel 
synthetic approaches need to be developed to target this under-represented area of chemical space, in 
particular in a way that enables variation of the molecular scaffold in preparation for SAR studies and 
lead optimisation upon identification of a hit.102 
 
Figure 1.10: The optimal drug-like (green) and lead-like (blue) regions of chemical space can be defined in terms of 
lipophilicity (cLog P) and molecular weight. In general optimisation progresses through an increase in complexity causing 
increased molecular weight and increased lipophilicity, so the starting point should ideally have the scope for inflation of 
these properties, unlike early combinatorial space (red). Figure adapted from reference.104 
In terms of practical library generation, lead-oriented synthesis aims to synthesise a diverse array of 




transformations, such that follow up chemistry can be carried out rapidly. Furthermore, the chemistry 
used should be tolerant to a wide range of the polar functional groups that are attractive in drug 
discovery, whilst avoiding those functionalities with reactive centres that might prove counter-
productive in lead optimisation. An example of this comes from Foley et al. in which four α-amino 
acid-derived building blocks were used with six reaction methodologies to generate a library of 22 lead-
like scaffolds in 49 synthetic operations (Scheme 1.5).106 
 
Scheme 1.5: Synthesis of a lead-like library of 22 compounds from 4 α,α-disubstituted amino acids 21-24 using 6 reaction 
methodologies. For each α,α-disubstituted amino acid 5 different N-substituted compounds (acyl ureas 25, allylamines 26, 
1,2-diamines 27, Boc protected amines 28, o-bromobenzylamines 29) were prepared ready for cyclisation. Pairwise coupling 
of the nucleophilic allyl group with the nucleophilic N-acyl substituents (Boc and urea) upon activation with iodine and 
subsequent treatment with sodium azide gave cyclic carbamates and ureas. Pairwise coupling of the electrophilic carboxylate 
ester with nitrogen centred nucleophiles gave hydantoins (from the acyl urea) and lactams (from the amine). The aryl bromine 
could be exploited for a Heck cyclisation with the allyl group to give azepanes and azocanes, and finally a ring closing 
metathesis between the two allylic groups would furnish indolizidine alkaloid-like tetrahydropyridines. Figure adapted from 
reference.106 
 
1.5.2. Fragment-based Drug Discovery 
A drug can be considered as a combination of multiple binding interactions which generate the required 
selectivity and potency. Fragment-based drug discovery (FBDD) is a technique that exploits this by 




starting point or starting points for drug discovery.107,108 There are two primary advantages to using 
FBDD over other drug discovery methods: 
1) As the size of molecules decrease, the number of possible molecules also decreases 
exponentially, and therefore, using libraries of smaller molecules enables more efficient 
sampling of chemical space.109  
2) Molecular complexity is an important concept in drug discovery; developed by Hann et al. it 
suggests that molecules with increased complexity have the potential to make more interactions 
with a protein target.110 However, a molecule with multiple binding interactions can be rendered 
impotent by a single unfavourable binding interaction proving unfavourable to the overall 
binding.111 Larger molecules have an increased risk of mismatch with the target protein site due 
to an unfavourable interaction,112 FBDD aims to overcome this risk through the use of low 
molecular weight fragments. As a result of their small size, these bindings will be weak, 
however, they can provide the building blocks for a more complex series through combining 
and/or optimising fragments.109 (Figure 1.11).  
 
Figure 1.11: HTS hits often bind through multiple suboptimal interactions, whereas fragment hits involve fewer interactions, 
however the interactions present are of higher quality. Figure adapted from reference.113 
A pharmacophore is defined as a single binding interaction between a ligand and a protein. Drugs 
generally consist of multiple connected pharmacophores and therefore the individual pharmacophores, 
as the simplest possible components of the drug, can be considered to represent its constituent 
fragments.114 Within each pharmacophore, it is usually the polar interactions which drive binding, and 
therefore, fragments typically bind to “hot-spots” through these polar interactions within the ligand-
binding site of the target.115 
Once fragment hits have been identified, they can be optimised by linking, merging and growing into a 
high quality drug-like compound (Figure 1.12). However, chemical elaboration to grow the fragment 
can often be easier than merging and linking strategies.107,109 It is this aspect with means that FBDD is 




and innovative pathways to evolve structurally simple starting materials into complex drug-like 
molecules, resulting in under-represented or completely novel scaffolds.116 
 
Figure 1.12: Three commonly used strategies for optimisation of fragment hits into lead like molecules. a. Linking aims to join 
two distinct fragment hits from adjacent pockets without disrupting their binding modes; b. merging aims to combine two 
distinct fragment hits found in overlapping binding sites; c. growing aims to chemically elaborate a single hit so as to pick up 
further ligand-protein interactions. These strategies are not orthogonal and can often be used in union for a FBDD program. 
This approach to drug discovery has rapidly found success since its inception117 as not only does it 
enable efficient sampling of chemical space and result in the evolution of novel scaffolds from simple 
starting points, but it also addresses some of the underlying problems that contribute to the high levels 
of attrition in drug discovery due to inflation of unfavourable compound properties.101  
FBDD identifies low molecular weight hits that, although weak in potency, form high quality 
interactions with excellent binding energy relative to their small size and have the ‘space’ for 
optimisation into drug-like space. Therefore, the ideal fragment will have a high proportion of atoms 
directly involved in the binding interaction.107,118 Ligand efficiency (LE) was therefore developed as a 
way comparing the binding efficiency of compounds of different sizes (Equation 1.1).119,120 
Equation 1.1: Equation used to calculate ligand efficiency 
𝐿𝑖𝑔𝑎𝑛𝑑 𝐸𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑐𝑦 (𝐿𝐸) =
 𝐹𝑟𝑒𝑒 𝐸𝑛𝑒𝑟𝑔𝑦 𝑜𝑓 𝐵𝑖𝑛𝑑𝑖𝑛𝑔 (1.4 · 𝑝𝐼𝐶50)
𝑁𝑢𝑚𝑏𝑒𝑟 𝑜𝑓 𝐻𝑒𝑎𝑣𝑦 𝐴𝑡𝑜𝑚𝑠 (𝐻𝐴𝐶)
 
A ligand efficiency of greater than 0.3 kcal per heavy atom implies that careful optimisation of the 
initial hit has the potential to yield a rule of 5 compliant 10 nM inhibitor.118 Therefore an important aim 




highly efficient drug-like molecules with desirable pharmacokinetic properties can be generated. In fact, 
where FBDD is concerned, this is often considered more important than potency alone.120 
However, despite offering high ligand efficiency, the low molecular weights of fragments means that 
their binding affinity with the protein target will still be very weak, typically in the mM to 30 μM 
range107 and as such, progress within FBDD has historically been limited by the sensitivity of available 
biophysical screening methods.109,114 The development of both new and pre-existing biophysical 
techniques, including NMR screening,109,121 mass spectrometry, surface plasma resonance (SPR) and 
X-ray crystallography,109,122–124 has enabled the high-throughput screening of these weakly binding 
molecules. 
Overall, FBDD is a highly intuitive drug discovery approach with the potential to generate highly potent 
and selective inhibitors, in particular for novel targets. FBDD is a relatively young drug discovery 
process, and as such due to the long approval process very few compounds thus far been marketed. 
However, there are over 30 FBDD-derived compounds in clinical development alongside two FDA 
approved drugs: Venclexta™ and Zelboraf® (Figure 1.13).125 
 
Figure 1.13: Two FDA approved drugs developed by the FBDD process, with the original fragment hits highlighted in pale 
blue. a. Venclexta™ was developed by Abbvie Inc. to treat chronic lymphocytic leukaemia (CLL) by blocking the anti-apoptotic 
B-cell lymphoma-2 (Bcl-2) protein, leading to programmed cell death of CLL cells. It was FDA approved in 2015; b. Zelboraf® 
was developed by Plexxikon and Genentech to treat late-stage melanoma via inhibition of the B-Raf kinase. It was FDA 
approved in 2011. 
The development of Zelboraf® clearly illustrates the FBDD process (Figure 1.14).126 Approximately 
20,000 fragments were screened resulting in the idenitification of 238 compounds which demonstrated 
kinase inhibition across the three kinases screened, Pim-1, p38, and CSK. Co-crystallographic analysis 
of these fragments generated over 100 structures showing bound compounds. Of these, 7-azaindole 
demonstrated different binding modes across the four protein monomers in the asymmetric unit of Pim-
1, suggesting a weak binding affinity. To improve the affinity, screening of a group of mono-substituted 
7-azaindoles was carried out, and this identified the 3-aminophenyl analogue and mono-substituted 
azaindole, both which had single binding modes across the monomers but poor selectivity over other 




PLX4720 and PLX4032, which both showed excellent selectivity and in-vitro inhibition of the mutant 
kinase, B-RafV600E. Pre-clinical trials demonstrated that PLX4032 potentially had better 
pharmacokinetic properties and this analogue was therefore promoted to clinical trials and eventually 
marketed as Zelboraf in 2011.127 
 
Figure 1.14: Development of Zelboraf® from an initial screening of approximately 20,000 compounds. 
As with all the drug discovery processes described herein, success is generally determined by the quality 
of the screening library, and FBDD is no different.128 As such a number of guidelines exist to aid the 



















Incorporation of functional groups for binding to the protein (these constitute the 
pharmacophore): these are usually polar groups.  
Synthetic 
vectors 
Incorporation of multiple synthetically accessible vectors for fragment growth in 
three-dimensions to access new binding interactions. 
Physiochemical  
properties 
Molecular size: 140 ≤ MW ≤ 230 g mol-1, 10 ≤ HAC ≤ 16 heavy atoms; 
Lipophilicity: 0 ≤ clog P ≤ 2 
Screening properties: ≥ 5mM solubility in 5% DMSO, > 24h stability in solution 
Avoidance of functional groups known for high reactivity, aggregation in solution 
or false positives. 
Synthetic 
tractability 
Typically require 50-100 mg for screening  
Ideally ≤ 4 steps from commercially available starting materials 
Shape Variety of three-dimensional shapes for each scaffold and pharmacophore 
0 ≤ Freely rotatable bonds ≤ 3 
0 ≤ Chiral centres ≤ 2 
 
 Given the importance of scaffold diversity and since polar groups usually form the 
pharmacophore (ligand-protein binding interaction) it is necessary to incorporate multiple 
scaffolds for each binding pharmacophore. Therefore, when designing the synthetic routes for 
a fragment library, the most efficient approach is to choose conditions for each step that can 
tolerate the polar functionalities needed. 
 Fragment elaboration aims to increase potency through the design and synthesis of compounds 
with the potential for new points of interaction, as identified from the x-ray crystal of the ligand-
protein complex. Screening fragments with built-in functional handles streamlines the 
elaboration process, since it avoids the need to synthesise multiple new scaffolds to incorporate 
these handles and avoids the risk of changing the binding mode when these functional groups 
are incorporated further down the line.129,130  
 Molecular complexity must be finely balanced within FBDD, as increased complexity can 
reduce the probability of achieving the optimal ligand-protein interactions, whereas decreased 
complexity risks missing interesting interactions and raising the levels of promiscuity.130 In 
terms of three-dimensionality the same balancing act applies, with higher levels of three-
dimensionality risking lower hit rates, but the more three-dimensional hits, although fewer in 
number, are generally found to have better ligand efficiency and synthetic tractability.61 At the 
same time, final drug-like compounds with high levels of three-dimensionality can still be 




FBDD projects are often inhibited by the lack of synthetic methodology available since the synthetic 
methodologies needed for fragment library synthesis need to be compatible with heteroatoms and polar 
groups, and generate structures with stereo- and regio-control.114 By considering and developing robust 
methodology for fragment synthesis and elaboration, including elaboration in all three-dimensions 
(Figure 1.15), delays are avoided during the FBDD project without overly increasing the complexity of 
the fragments.114  
 
Figure 1.15: An example of an ideal fragment, with molecular weight and lipophilicity consist with the ranges specified, a 
polar functionality for protein binding (blue circle) and potential synthetically pre-planned growth vectors for fragment 








2. Aims of the Project: Synthesis of Partially Saturated 
Heteroaromatic Scaffolds 
 
Various screening paradigms have been, and continue to be, used in drug discovery, including those 
discussed: HTS, lead-oriented synthesis and FBDD. Within all of these paradigms, the success of 
screening endeavours is inherently dependent on the composition of the screening library employed. 
Going forwards, regardless of the paradigm being used, there needs to be greater consideration of the 
quality and composition of compound libraries, in particular ensuring that the libraries consist of diverse 
and biologically relevant molecules with appropriate physicochemcial properties. In addition, there 
needs to be an emphasis on the diversification of the libraries through the inclusion of more 
representative exemplars of singleton scaffolds.42  
Overall, analysis of existing screening libraries, and even marketed drugs, has highlighted not only the 
lack of scaffold diversity but also the astoundingly small percentage of molecular scaffolds represented 
despite the vast size of chemical space. Hence there is a clear need for novel or atypical molecular 
scaffolds with increased levels of three dimensionality in small molecule screening libraries with the 
aim of accessing under-explored or novel biologically relevant chemical space and potentially yielding 
modulators of novel biological targets. In addition, the use of novel scaffolds is vitally important in the 
context of intellectual property considerations and patentability. 
Ring systems are prevalent throughout biologically active chemical space, and within this sub-class 
nitrogen-containing heterocyclic ring systems represent scaffolds of particular utility, incorporating all 
the advantages of a ring system with the potential binding ability of heteroatoms into a single scaffold. 
Despite this, there is relatively little diversity in the nature of such scaffolds, with a particular lack of 
saturated systems and so novel sp3-enriched nitrogen-containing heterocyclic ring systems represent 
targets of particular interest. 
As highlighted, structural diversity within the library is extremely important for the success of screening 
endeavours. In this regard, it is important that the synthetic routes used to generate screening compounds 
be carefully designed such that multiple examples of the same scaffold can be easily accessed in order 
to address the prevalence of singular examples of scaffolds within current libraries. 
Furthermore, the ease with which the screening compounds can be developed (in hit-to-lead and 
subsequent optimisation) is also a crucial consideration. Ideally, scaffold synthesis should be designed 
in such a way as to incorporate higher levels of three-dimensionality and polar functional groups in 
screening members from the outset, since these properties are considered highly attractive within drug 




throughout the structure should be considered in these initial designs, so as to avoid the need to develop 
new methodology or remake the scaffold via an alternative route. 
Based on these considerations, partially saturated heterocyclic scaffolds of the general form 30 were 
identified as being of potential value and broad utility within drug discovery (Figure 2.1). It was 
envisaged these scaffolds could be synthesised in such a way as to be applicable to fragment-like, lead-
like or drug-like space dependent upon the size and properties of the compounds generated. As such, 
the particular focus of this work is to demonstrate the possibility of developing highly modular and 
efficient routes towards these types of molecules, such that multiple related scaffolds can be generated. 
Specifically, the targets would feature a bicycle consisting of an aromatic heterocycle fused to a partially 
saturated heterocycle, with variation in both the aromatic heterocycle and the size of the partially 
saturated heterocycle. 
 
Figure 2.1: General structure of the desired partially-saturated heterocyclic scaffold 30 and examples of some potential targets 
31-34. 
These partially saturated heteroaromatic scaffolds were chosen for a number of reasons: 
1) It was expected that the core scaffold would incorporate the advantages of both aromatic and 
saturated heterocyclic scaffolds. The sp3-enriched ring would increase the three-dimensional 
character relative to the majority of compounds in existing libraries, and the consequent 
increase in complexity should improve the potential selectivity and potency without decreasing 
the potential hit rate; 
2) Compounds featuring these types of partially saturated heteroaromatic scaffolds have been 
identified as having biological activity against a range of targets (Figure 2.2), and so a series of 
related fragments should not only demonstrate novel biological activity if developed into a 
screening collection, but will also increase library diversity by reducing the number of singular 
exemplars of these scaffolds; 
3) These scaffolds can form the basis of a diverse collection of compounds, through variation in 
the identity of the heteroaromatic, the size of the partially saturated heterocycle and the regio- 





Figure 2.2: Two examples of bioactive compounds containing functionalised partially-saturated scaffolds (highlighted in pale 
blue): A. KAF156, a potent compound with activity against the Plasmodium falciparum and Plasmodium vivax forms of the 
malaria parasite. Developed by Novartis, it finished Phase II clinical trials in 2017.131,132 B. Januvia is a potent inhibitor of 
dipeptidyl peptidase IV which is implicated in the treatment of hyperglycaemia for patients with type II diabetes. Developed 
by Merck & co. it has been FDA approved since 2006.133–135 
Partially saturated heterocyclic scaffolds have previously been synthesised a number of ways, including 
selective hydrogenation of bicyclic heteroaromatics136,137 and via catalytic, asymmetric intramolecular 
aza-Friedel-Crafts reactions.138 In all these cases, there is limited regio- and stereo-control of the 
substitution pattern in the partially saturated ring, restricting their utility in library synthesis. Previous 
examples to access non-fused piperidine rings diastereoselectively used deprotection of the amine 
enabling generation of the imine 36 followed by reductive amination to amine 37 (Scheme 2.1).139–143 
 
Scheme 2.1: Common route towards accessing diastereoselective piperidine rings. PG = Protecting Group 
This work proposed to harness this diastereoselective approach to the formation of a cyclic secondary 
amine, but within fused bicyclic system 38. Towards this end, it was anticipated that the final reductive 
amination and deprotection could be carried out on ketone 39, which in turn could be formed by 
alkylation of the corresponding heterocycle 40 (Scheme 2.2). It was hoped that all the desired 
heterocycles could be generated in minimal numbers of steps from simple starting materials, thus 
incorporating the key principles of DOS. The diversity of the library could be generated through 
variation of the heteroaromatic, the size of the partially saturated heterocycle and the nature and spatial 
arrangement of the functional groups R1-3. Furthermore, depending upon the size and nature of the R 





Scheme 2.2: General Retrosynthetic analysis of the partially saturated heterocyclic scaffolds.PG = protecting group  
To this end, the triazole-based partially saturated heteroaromatic scaffold 41 was targeted first, to 
demonstrate the robustness of the methodology, before applying it to other novel scaffolds. It was 
envisaged that reductive amination and deprotection would yield the desired bicyclic scaffold 41 from 
ketone 42. This is turn could be formed by alkylation of the triazole ring 43. It was proposed that 
cyclisation of an imidate 44 and an amino hydrazide 45 would form the triazole itself, with the amino 
hydrazide 45 coming from the corresponding amino acid 46 and the imidate derived from the 
corresponding nitrile 47: both inexpensive, simple and commercially available materials. 
 
 
Scheme 2.3: Retrosynthetic analysis of the partially saturated heterocyclic scaffold based around triazole: a. One-pot 
deprotection and reductive amination; b. nitrogen alkylation; c. triazole cyclisation; d. conversion of acid to hydrazide via 
ester; e. formation of imidate. 






3. Results and Discussion 
 
3.1. Studies towards Achieving Diastereoselctive Scaffolds 
3.1.1. Initial Studies with the Triazole-Based Scaffold  
The partially saturated triazole-based scaffold 41 was selected as the first target scaffold, on which to 
test the proposed synthetic route. In line with the retrosynthetic analysis detailed in Scheme 2.1, the 
first challenge was the construction of 3,5-bisubstituted 1,2,4-triazole scaffold 48 (Figure 3.1). 
 
 
Figure 3.1: 3,5-bisubstituted 1,2,4-triazole scaffold 1, P = Protecting Group 
A literature search revealed significant precedent for the construction of this type of scaffold.144,145,154–
161,146–153 The most commonly reported synthetic route towards the synthesis of these substrates was the 
reaction between an amino hydrazide derivative of an amino acid and an imidate. This was particularly 
appealing since it took advantage of the large chiral pool provided by both natural and unnatural amino 
acids. When considering the protecting group, examples of both tert-butoxycarbonyl (Boc) and 
carboxybenzyl (Cbz) groups were reported. Given the intended route, it was essential to use a base-
stable functionality, as well as a functionality with a deprotection method which would be compatible 
with both imine formation and reduction. As such, the carboxybenzyl (Cbz) group was chosen due to 
its well-known stability and possible removal via a variety of suitable methods.162 
For the initial studies, Cbz-L-phenylalanine 49 and benzonitrile 50 were chosen as the initial starting 
materials, due to the lack of reactivity of the phenyl and benzyl groups corresponding to R1 and R2 
respectively. The amino hydrazide derivative of Cbz-L-phenylalanine was constructed in two steps from 
49. First successful conversion to the amino ester 51 was carried out in excellent yield using excess 
thionyl chloride in methanol,163 followed by nucleophilic substitution of the ester using excess 





Scheme 3.1: Synthesis of benzyl (S)-(1-hydrazinyl-1-oxo-3-phenylpropan-2-yl)carbamate, 52, from the corresponding Cbz-L-
phenylalanine amino acid: a. Cbz-L-phenylalanine 49 (1.0 eq.), SOCl2 (1.4 eq.), CH3OH, 3h, rt, 100% 51; b. 51 (1.0 eq.), 
NH2NH2∙H2O (5.0 eq.), CH3OH, 12h, rt, 100%, 52. 
Simultaneously, the efficient transformation of benzonitrile 50 into the corresponding imidate 53 was 
carried out quantitatively using acetyl chloride and ethanol (Scheme 3.2).165 
 
 
Scheme 3.2: Synthesis of ethylphenylcarbimidate, 53, from the corresponding benzonitrile: a. Benzonitrile 50 (1.0 eq.), AcCl 
(8.0 eq.), EtOH (12.0 eq.), 12h, 0 °C to rt, 100% 53. 
With these two components in hand, the literature procedure for the synthesis of the 3,5-disubstituted 
triazole scaffold 54 was carried out. This entailed refluxing the two components, first in ethanol, then 
acetic acid.148 Of particular note is that all of these preliminary reactions could be carried out with 
consistently high yields on multi-gram scales (Scheme 3.3). 
 
 
Scheme 3.3: Synthesis of benzyl (S)-(2-phenyl-1-(3-phenyl-1H-1,2,4-triazol-5-yl)ethyl)carbamate, 54, from the corresponding 
amino hydrazide and imidate: a. i. 52 (1.0 eq.), 53 (1.2 eq.), EtOH, 6h, reflux; ii. AcOH, 2h, reflux, 95% 54. 
For the alkylation of triazole 54 a nucleophilic substitution using an α-bromoketone was envisaged. 
Whilst there are relatively few examples of triazole alkylations using this particular type of electrophile, 
there is a reasonable amount of literature precedent for alkylation in general.166–171 Potassium carbonate 
was by far the most prevalent base used for this type of reaction,166,167,169–171 and therefore was chosen 
as the starting point. Dimethyl formamide (DMF)170,171 and acetone166,169 are both commonly used 




chosen initially, and combined with 2-bromoacetophenone 55 gave an 80% yield. Unfortunately, the 
DMF proved difficult to remove and therefore a switch to acetone was trialled. Pleasingly, this proved 
equally suitable and an 84% yield was achieved (Scheme 3.4). 
 
 
Scheme 3.4: Synthesis of benzyl ((1-(2-oxo-2-phenylethyl)-3-phenyl-1H-1,2,4-triazol-5-yl)methyl)carbamate, 55, from the 
corresponding triazole: a. 54 (1.0 eq.), 2-bromoacetophenone 55 (1.2 eq.) K2CO3 (1.0 eq.), acetone, 12h, rt, 84% 56. 
With gram-scale quantities of 56 in hand, a number of routes towards achieving the cyclised amine 
were explored. It was hoped that this could be achieved in a single pot, with deprotection of the 
carboxybenzyl group enabling spontaneous cyclisation of the primary amine with the ketone, to form 
imine 57. Addition of a reductant would then enable reduction of imine 57 to amine 58, with a syn-
relationship between the phenyl and benzyl groups, as a result of the reduction being driven by the steric 
bulk of the benzyl group alpha to the imine (Figure 3.2, Scheme 3.5). 
 
Figure 3.2: Figure illustrating the three-dimensional shape of the imine such that the steric bulk of the benzyl group will drive 
the syn-diastereoselectivity of the reduction. 
 
 
Scheme 3.5: Proposed route to piperazine ring formation 
Carboxybenzyl deprotection is most commonly carried out either by catalytic hydrogenation or with a 





Table 3.1: Testing acidic conditions for the deprotection and following reductive amination. 
 
Entry Conditions Yield 58 
(%) 
1 i. HBr (33 wt % in AcOH), 15 mins, rt 
ii. NaBH4, THF, 1h, rt 
41 
2 i. HBr (33 wt % in AcOH), 15 mins, rt 
ii. LiBH4, Et2O, 1h, rt 
69 
3 i. HBr (33 wt % in AcOH), 15 mins, rt 
ii. NaCNBH3, CH3OH, 1h, rt 
66 
4 i. HBr (33 wt % in AcOH), CH2Cl2, 30 mins, rt 
ii. NaCNBH3, CH3OH, AcOH, 1h, rt 
65 
5 i. TFA, CH2Cl2, 12h, rt 
ii. NaCNBH3, CH3OH, 1h, rt 
0 
6 i. BBr3, CH2Cl2, 15 mins, rt 
ii. NaCNBH3, CH3OH, AcOH, 1h, rt 
63 
7 i. BCl3, CH2Cl2, 30 mins, rt 
ii. NaCNBH3, CH3OH, 1h, rt 
87a 
8 BF3·OEt2, Ph3SiH, CH2Cl2, 30 mins, -78 °C then 2h, rt 0 
a. This yield was not reproducible due to aromatisation issues. 
The use of hydrogen bromide in acetic acid, to remove the carboxybenzyl protecting group, has good 
precedent in the literature, and it was hoped that, if needed, the acid would catalyse the imine 
formation.174–177 The reactions were followed via LCMS, and this demonstrated successful deprotection 
and cyclisation to the imine 57, however there was evidence of some aromatisation of the six-membered 
ring 59. Nevertheless, the reduction step was tested, using sodium borohydride178,179 (Table 3.1, Entry 
1), lithium borohydride180 (Table 3.1, Entry 2) and the milder sodium cyanoborohydride181,182 (Table 
3.1, Entry 3), with the hope that the latter, milder reagent would be sufficient, so that it could be used 
as the standard reducing agent in all subsequent reductions. It was pleasing to note that this was the 
case, these three reactions giving 41%, 69% and 66% of the desired scaffold 58 respectively. With this 




In the hope of minimising aromatisation, a single equivalent of hydrogen bromide in dichloromethane 
was used (Table 3.1, Entry 4), diluting the deprotection and cyclisation step,183,184 however a similar, 
yield of 65% was achieved, again as a result of the aromatisation. In order to circumvent this, other 
acids were tested for the deprotection: trifluoroacetic acid (TFA)185 (Table 3.1, Entry 5), boron 
tribromide186,187 (Table 3.1, Entry 6) and boron trichloride188,189 (Table 3.1, Entry 7). Of these, the 
trifluoroacetic acid, was not sufficient to remove the protecting group, and starting material 56 remained 
after 12 hours; boron tribromide encountered the same problems as the hydrogen bromide, resulting in 
a moderate 63% yield with the remaining material aromatised; the milder boron trichloride was more 
successful, achieving an excellent 87%, with a small amount of the aromatic product 59 observed. 
Despite this promising yield, upon repetition, this reaction gave quite variable yields as a result of the 
aromatisation. Finally, boron trifluoride combined with triphenylsilane was tested (Table 3.1, Entry 8), 
in which it was hoped that the deprotection and reduction would take place without the need to add the 
reductant in a second step, and as a result the imine would be reduced upon formation, minimising the 
probability of aromatisation; however after 12 hours, only starting material remained.  
A paper from Sultane et al. suggested that the use of trimethylsilyl trifluoromethane sulfonate should 
enable imine formation without the deprotection, the triethylsilane then reducing the generated N-acyl 
iminium ion intermediate in-situ (Scheme 3.6).190 Monitoring via LCMS instead demonstrated the 
deprotection and imine formation alongside a small amount of reduction of the ketone before imine 
formation could take place, thus generating alcohol 60. After 24 hours with no evidence of in situ imine 
reduction, sodium cyanoborohydride was added to generate 58 in a moderate yield, as a result of the 
earlier ketone reduction circumventing imine formation. 
 
 
Scheme 3.6: Synthesis of (6R,8S)-8-benzyl-2,6-diphenyl-5,6,7,8-tetrahydro-[1,2,4]triazolo[1,5-a]pyrazine 58: i. 56 (1.0 eq.), 
TMSOTf (1.2 eq.), Et3SiH (1.2 eq.), CH2Cl2, 12h, -78 °C; ii. NaCNBH3 (1.2 eq.), CH3OH, 3h, rt, 68% 58. 
With the problems encountered using acidic conditions for the deprotection, catalytic hydrogenation 
was tested, in the hope that under reductive conditions the oxidation of the piperazine ring would not 





Hydrogen and catalytic palladium on carbon are commonly used for the deprotection,191,192 however, 
for this substrate no evidence of desired scaffold 58 was found; instead, reduction of the ketone was 
observed, alongside carboxybenzyl reduction such that both diastereomers of compound 60 were 
generated (Table 3.2, Entry 1). This suggested that the ketone reduction was happening at a faster rate 
than imine formation once the primary amine had been unveiled. In addition, there was some evidence 
of reduction of the triazole ring to give 61. Exploring the literature conditions for this step suggested 
that a switch to ethyl acetate as the solvent would favour imine formation under reductive conditions,193 
however, no reaction was observed under these conditions (Table 3.2, Entry 2). 
Finally, palladium dihydroxide on carbon was tested due to its prevalent use for the removal of 
carboxybenzyl protecting groups.162,172,173 Under these conditions, no reduction of the triazole ring was 
observed, even after 24 hours, however, LCMS analysis of the crude reaction mixture revealed 
significant formation of diastereomers 60, as a result of the rapid ketone reduction as observed with 
palladium on carbon (Table 3.2, Entry 3). As a result, only a 41% yield of 58 was achieved. 
Table 3.2: Testing of catalytic hydrogenation for carboxybenzyl removal and reductive amination. 
 
 
Given that reduction of the triazole was not apparent under these conditions, it was hoped that 
optimisation could supress the undesired ketone reduction (Table 3.3). 
For practical reasons, this optimisation process was carried out using ammonium formate as the 
hydrogen source.162,172,194 In an attempt to promote imine formation at a faster rate than ketone reduction 
2 equivalents of triethylamine were added, and this saw some improvement (Table 3.3, Entry 1); an 
increase to 15 equivalents further improved the ratio of products, although not to synthetically useful 
levels (Table 3.3, Entry 2). Following this, a range of solvents and bases were tested. Disappointingly, 
these all either returned the original triazole 54, starting material 56 or gave a poor ratio of products 
Entry Conditions Yield 58 
(%) 
1 a. H2, Pd/C, CH3OH,12h, rt 0 
2 a. H2, Pd/C, EtOAc, 12h, rt 0 




(Table 3.3, Entries 3 - 12). There was some literature precedent for the addition of water,195 and, upon 
testing, this gave the best ratio (Table 3.3, Entry 14). 
Table 3.3: Optimisation of conditions for the reductive deprotection and amination.  
 
Entry x Solvent Additives (eq.) Ratio 58:60 Side Products 
1 5 iPrOH NEt3 (2) 1:0.94 n/a 
2 1 CH3OH NEt3 (15) 1:0.61 n/a 
3 5 CH3OH K2CO3 (15) n/a 54 
4 5 CH3OH Pyridine (15) n/a 56 
5 5 CH3OH NaOAc (15) n/a 54 
6 5 CH3OH Pyrrolidine (15) n/a 56 
7 5 EtOAc K2CO3 (15) n/a 56 
8 5 EtOAc Pyridine (15) n/a 56 
9 5 EtOAc NEt3 (15) n/a 56 
10 5 Toluene K2CO3 (15) 1:0.67 n/a 
11 5 Toluene Pyridine (15) 1:0.08 n/a 
12 5 Toluene NEt3 (15) 1:0.67 n/a 
13 5 CH3OH:H2O 
(1:1 v/v) 
None 1:0.07 n/a 
 
With the identification of water as the additive required to supress the undesired reduction of the ketone, 
it was then necessary to optimise the conditions further. This was done by finely tuning the other 
variables, such as the equivalents of catalyst used, the ratio of methanol and water and the hydrogen 
source used (Table 3.4). From this optimisation process it was found that below 3:1 CH3OH:H2O, the 
reaction was significantly slower, with entry 4 showing a mixture of starting material 56 and product 




Table 3.4: Further optimisation of conditions.  
 
Entry x CH3OH:H2O 
(v:v) 
Hydrogen Source Ratio 58:60 Side Products 
1 10 3:1 CO2H·NH4 1:0.07 n/a 
2 10 3:1 H2 1:0.49 n/a 
3 20 3:1 CO2H·NH4 1:0.06 n/a 
4 20 2:1 CO2H·NH4 n/a 56 
5 20 1:3 CO2H·NH4 n/a 56 
6 20 0:1 CO2H·NH4 n/a 56 
 
 
Scheme 3.7: Synthesis of (6R, 8S)-8-benzyl-2,6-diphenyl-5,6,7,8-tetrahydro-[1,2,4]triazolo[1,5-a]pyrazine, 58, using the 
optimised reductive deprotection and amination conditions: a. 56 (1.0 eq.), NH4·CO2H (30 eq.), Pd(OH2)/C (20 mol%), 
CH3OH:H2O (3:1 v/v), 12h, rt, 91%, >20:1 d.r. 58. 
 
Key NOE interactions were identified to support the relative stereochemistry in compound 58; in 
particular, correlation of protons 7 and 14 provided evidence of their cis-relationship (Figure 3.3).  
 





Following these results, it was established that the best route from 62 and 65 to 70 was via the following 
route (Scheme 3.8).  
 
Scheme 3.8: Summary of the planned route for the synthesis of triazole-based scaffolds: a. Cbz-L-amino acid 62 (1.0 eq.), 
SOCl2 (1.4 eq.), CH3OH, 3h, rt; b. 63 (1.0 eq.), NH2NH2·H2O (5 eq.), CH3OH, 12h, rt; c. nitrile 65 (1.0 eq.), AcCl (8.0 eq.), 
EtOH (12.0 eq.), 12h, 0 °C to rt; d. i. 64 (1.0 eq.), 66 (1.2 eq.), EtOH, 6h, reflux, ii. AcOH, 2h, reflux; e. 67 (1.0 eq.), α-
bromoketone 68 (1.2 eq.) K2CO3 (1.0 eq.), acetone, 12h, rt; f. 69 (1.0 eq.), NH4·CO2H (30 eq.), Pd(OH2)/C (20 mol%), 





3.1.2. Scope of the Route  
With this in hand, it was necessary to demonstrate the applicability of this route to a range of functional 
groups. Both alkyl groups, to increase the molecular complexity and three-dimensionality, and aryl 
groups, that might be able to form π-π interactions with protein targets, were introduced. Additionally, 
polar groups that might be able to form hydrogen-bonding interactions with protein targets and increase 
the aqueous solubility. 
To this end, the first step was the construction of the imidate and amino hydrazide building blocks. The 
imidates, imidates 77 to 82, were synthesised as previously from the corresponding nitriles, 71 to 76 
(Table 3.5) in excellent yields. When considering the groups included in the R1 position, 5-hexene was 
chosen to illustrate the accessibility of alkyl chains, which are often incorporated to fill hydrophobic 
pockets. Although it was anticipated that alkene and alkyne groups would be reduced in the reductive 
deprotection and amination196 (Table 3.5, Entry 1), this functionality had been included from the outset 
in the anticipation that the deprotection step could be done under acidic conditions such that these 
groups could be tolerated. Cyclopropyl was included for two reasons: firstly to illustrate the 
compatibility with alkyl rings, and secondly since the cyclopropyl group is frequently identified in 
successful drugs (Table 3.5, Entry 2).197 The following three imidates included bear para-substituted 
aryl groups: trifluoromethyl is a common moiety within drug discovery,198,199 and in addition functions 
as an electron withdrawing example; on the other end of the scale, methoxy would provide the electron 
donating example, and if the methyl group were removed would provide an additional exit vector for 
adaptation; bromine is incorporated as it provides an exit vector for late-stage functionalisation (Table 
3.5, Entries 3-5). The same justifications lay behind the choice of the 2-p-bromobenzyl group, however, 
the additional flexibility provided by this methylene linker would allow the substrate to assume more 
conformations, thus improving the probability of it being accommodated into the pockets of potential 
protein targets (Table 3.5, Entry 6). The bromine-containing substituents were expected to be 
problematic in the final reductive amination step, since the palladium dihydroxide conditions used are 
similarly used for dehalogenation (Table 3.5, Entries 4 & 6).200 It was hoped that the deprotection and 
subsequent reductive amination might proceed faster than the dehalogenation, such that careful 





Table 3.5: Synthesis of imidates 77 – 82 with of a range of functional groups in the R1 position: a. Nitriles 71 - 76 (1.0 eq.), 
AcCl (8.0 eq.), EtOH (12.0 eq.), 12h, 0 °C to rt. 
 
Entry Starting Material R1 Compound Yield X 
(%) 
1 71 (CH2)3CHCH2 77 100 
2 72 Cyclopropyl 78 69 
3 73 p-PhCF3 79 80 
4 74 p-PhBr 80 66 
5 75 p-PhOMe 81 89 
6 76 CH2-p-PhBr 82 92 
 
Concurrently, the amino hydrazide building blocks were constructed from the analogous carboxybenzyl 
protected amino acids 83 to 88. First, the amino esters 89 to 94 were synthesised, in excellent yields, 
and all on a gram-scale (Table 3.6). From these, excess hydrazine monohydrate in methanol generated 
the desired amino hydrazides 95 to 100 in excellent yields. To showcase the potential of this route to 
generate a vast array of substrates, incorporating a variety of functional groups, careful thought was 
given into the selection of substituents at the R2 position. Serine, with its primary alcohol, would provide 
an excellent handle for late-stage modifications, such as esterifications, substitutions and oxidations 
(Table 3.6, Entry 1). Valine would provide proof of concept of a branched alkyl group suitable for 
filling small hydrophobic pockets (Table 3.6, Entry 2), whilst tryptophan would illustrate the 
compatibility of the methodology with non-integral nitrogen-based heterocycles, whilst simultaneously 
providing a second handle for functionalisation (Table 3.6, Entry 3). Tyrosine would illustrate the 
applicability of aryl groups and, as with serine, provide another alcohol-based exit vector (Table 3.6, 
Entry 4). Proline provided a particularly interesting example, since the final scaffold generated would 
be 5,6,5-tricyclic scaffold, bearing two saturated rings (Table 3.6, Entry 5). Finally, methionine would 
exemplify the possibility of including sulphur-based functional groups (Table 3.6, Entry 6). Although 
sulphur is a known poison for palladium-based catalysts,201–203 it was hoped that the use of 





Table 3.6: Synthesis of amino hydrazides 95 - 100 with a range of functional groups in the R2 position: a. Cbz-L-Amino 








1 83 Serine CH2OH 89 100 95 86 
2 84 Valine CH(CH3)2 90 100 96 98 
3 85 Tryptophan CH2-3-Indole 91 98 97 82 
4 86 Tyrosine CH2-p-PhOH 92 100 98 85 
5 87 Proline CH2CH2CH2-
NCbz 
93 96 99 96 
6 88 Methionine CH2CH2SCH3 94 100 100 81 
 
With these in hand, it was the simple case of combining them to generate desired triazole scaffolds 101 
to 112 (Table 3.7). For ease of results’ analysis and to have a better understanding of each group’s 
contribution to the compound’s properties, it was decided to vary either R1 or R2, with the other being 





Table 3.7: Synthesis of triazoles 101 - 112 with a range of functional groups in the R1 and R2 positions: a. i. 52, 95 - 100 (1.0 
eq.), 53, 77 - 82 (1.2 eq.), EtOH, 6h, reflux; ii. AcOH, 2h, reflux. 
 
Entry Starting Materials R1 R2 Yield Triazole (%) 
1 77 52 (CH2)3CHCH2 Bn 101 86 
2 78 52 Cyclopropyl Bn 102 81 
3 79 52 p-PhCF3 Bn 103 85 
4 80 52 p-PhBr Bn 104 91 
5 81 52 p-PhOMe Bn 105 87 
6 82 52 CH2-p-PhBr Bn 106 52 
7 53 95 Ph CH2OH 107 66 
8 53 96 Ph CH(CH3)2 108 82 
9 53 97 Ph CH2-3-Indole 109 74 
10 53 98 Ph CH2-p-PhOH 110 83 
11 53 99 Ph CH2CH2CH2-
NCbz 
111 70 
12 53 100 Ph CH2CH2SCH3 112 98 
 
Following the previously identified conditions for the alkylation step, potassium carbonate was used as 
the base, and acetone or DMF as the solvent (Table 3.8). As discussed, for triazoles 101 to 112, 
alkylation was carried out with 2-bromoacetophenone, such that R3 would be a simple phenyl ring. In 
general, these all proceeded smoothly, with moderate to excellent yields. There were a few exceptions 
to this for the variations in the R1 substituent these included 120, for which R1 was a cyclopropyl group 
(Table 3.8, Entry 2), and 124, for which R1 was a p-bromobenzyl group (Table 3.8, Entry 6). In these 
cases, the lower yield can be attributed to returning two different alkylated products one of which gave 
material alkylated at the 2-position of the 1,2,4-triazole, and which therefore would not be able to 
cyclise. It was hypothesised that this was the case due to the alkyl substituents having smaller steric 
bulk and therefore substitution in the adjacent positions becoming more favourable. Additionally, the 
lack of a conjugating group in the R1-position had the potential to change the electronics of the ring 
such that alkylation in the adjacent position would be more favourable. For the R2 substituents, more 
moderate yields were recorded for 125, which was descended from serine (Table 3.8, Entry 7), and 128, 




preferentially on the triazole, some double alkylation also occurred on the free alcohol, however, it was 
hoped further optimisation of the conditions could limit this undesired reaction if needed on a larger 
scale. 
Beginning from the simple triazole 54 on which the initial optimisation was carried out, it was then 
necessary to explore the scope of the R3 position 131 to 136. The adamantyl was chosen since it 
represented both alkyl groups and a very bulky substituent, to ensure that sterics would not prohibit 
cyclisation (Table 3.8, Entry 13). As with the methionine and tryptophan substituents, the inclusion of 
the thiophene group represented the compatibility of both heterocycles and sulphur heteroatoms (Table 
3.8, Entry 14). Moving onto the aryl groups, alongside common biologically relevant functionalities, 
both an electron withdrawing substituent (para-trifluoromethylphenyl) and electron donating 
substituent (meta-methoxyphenyl) were included (Table 3.8, Entries 15 & 16). In the hope of 
incorporating a functional handle for cross-couplings off the R3 phenyl ring, para-bromophenyl was 
also included (Table 3.8, Entry 17). Finally, para-nitrophenyl was accessed (Table 3.8, Entry 18). The 
nitro-functionality is often present in a drug discovery context,204 and would therefore be useful when 
developing a hit using a SAR approach; in addition, it masked an amine functionality via reduction of 
the nitro.205 Amino groups are particularly valuable within drug discovery not only as a functional 
handle, in which they can be used for amide couplings, azide formation and therefore click chemistry 
and cross-couplings, but also for their hydrogen bond donor properties, which is an important attribute 
within drug-protein interactions.69 Therefore, if the conditions cannot be controlled so as to avoid its 
reduction, it still offers important scope for this work. Pleasingly, all the various alkylations proceeded 





Table 3.8: Alkylation of the triazole with a range of functional groups in positions R1, R2 and R3: a. 54, 101-112 (1.0 eq.), α-








Bn Ph 119 65 
2 102 Cyclopropyl Bn Ph 120 53 
3 103 p-PhCF3 Bn Ph 121 73 
4 104 p-PhBr Bn Ph 122 83 
5 105 p-PhOMe Bn Ph 123 77 
6 106 CH2-p-PhBr Bn Ph 124 52 
7 107 Ph CH2OH Ph 125 55 
8 108 Ph CH(CH3)2 Ph 126 79 
9 109 Ph CH2-3-Indole Ph 127 81 
10 110 Ph CH2-p-PhOH Ph 128 33 
11 111 Ph CH2CH2CH2-
NCbz 
Ph 129 80 
12 112 Ph CH2CH2SCH3 Ph 130 93 
13 54 Ph Bn Adamantyl 131 87 
14 54 Ph Bn Thiophene 132 61 
15 54 Ph Bn p-PhCF3 133 66 
16 54 Ph Bn m-PhOMe 134 50 
17 54 Ph Bn p-PhBr 135 82 
18 54 Ph Bn p-PhNO2 136 50 
 
With 18 alkylated triazoles in hand, all that remained was to carry out the deprotection and reductive 
amination (Table 3.9). As expected, the reductive deprotection and amination for those compounds with 
alkyl substituents in each of the three positions, cyclopropyl, iso-propyl, and adamantyl proceeded 
smoothly to give the desired bicyclic scaffolds 138, 144 and 149 in excellent yields (74, 84 and 91% 
respectively, Table 3.9, Entries 2, 8 & 13). Unsurprisingly, the presence of an alkene functionality 




conditions to yield 137 (Table 9, Entry 1); which could be incorporated directly through the use of 
hexanenitrile for the imidate formation. However, we propose that if required such a functionality could 
be built in at a later stage through dehydration by early incorporation of an alcohol. This is made 
possible by the stability of alcohols, both alkyl and aryl, under these conditions as demonstrated by 143 
and 146 with yields of 82 and 83% respectively (Table 3.9, Entries 7 and 10). 
Pleasingly, both electron withdrawing and electron donating groups in both the R1 and R3 positions 
were well tolerated (Table 3.9, Entries 3, 5, 15 & 16). For the para-trifluoromethyl phenyl substituents 
moderate 59% (R1, 139) and 71% (R3, 151) yields were achieved, for the para-methoxyphenyl (R1, 141) 
77% and for the meta-methoxy phenyl (R3, 152) 77% were attained, further illustrating the broad scope 
of this reaction. 
The para-nitro phenyl group was chosen in the expectation that the nitro would undergo reduction to 
the aromatic amine concomitantly to the deprotection-cyclisation event (Table 3.9, Entry 18).206 That 
allowed us to showcase the potential of this route to generate relevant amine handles from reaction 
stable, amine-masking functionalities. Pleasingly the reductive deprotection, amination step and nitro 
reduction proceeded smoothly to yield the amine-bearing scaffold 154 in 71% yield. 
Given the presence of the triazole ring within the basic scaffold itself, we did not foresee any problems 
with the indole group 145 and pyrrolidine-based R2-group 147, and indeed these proceeded smoothly 
with a 93% and 60% yield respectively (Table 3.9, Entries 9 & 11). Although no oxygen-based 
heterocycles were tested, it was hoped that the tolerance of alcohol groups and methoxy moieties 
demonstrated their suitability. When reacting sulphur-containing substrates 130 and 132, the standard 
conditions were unable to yield the desired cyclised products 148 and 150; however, as discussed 
previously, it was hoped that increasing catalyst loading might overcome this (Table 3.9, Entries 12 & 
14). Indeed, when increasing palladium-loading to an excess of 2 equivalence we were pleased to 
register fruitful transformation of 130 into 148. In the case of thiophene bearing 132, however, only 
starting material was recovered even with such an excess of palladium. 
Unfortunately, for bromine-bearing substituents, the dehalogenation step was far more rapid than the 
deprotection, amination sequence, even with lower catalyst loading or lower temperatures. For 122 and 
135, this simply returned the previously synthesised substrate 58, and therefore no yield was taken 
(Table 3.9, Entries 4 & 17). For 124, although dehalogenation was encountered, this returned a novel 
compound, with an additional methylene unit between the triazole and a phenyl in the R1 position and 




Table 3.9: Reductive deprotection and amination to give the desired bicyclic scaffold with a range of functional groups in 











R3 Compound Yield  
(%) 
d.r. 
1 119 (CH2)4CH3 Bn Ph 137 60a >20:1 
2 120 Cyclopropyl Bn Ph 138 74 >20:1 
3 121 p-PhCF3 Bn Ph 139 59 >20:1 
4 122 p-PhBr Bn Ph 140 n/ab >20:1 
5 123 p-PhOMe Bn Ph 141 77 >20:1 
6 124 Bn Bn Ph 142 38c >20:1 
7 125 Ph CH2OH Ph 143 82 >20:1 
8 126 Ph CH(CH3)2 Ph 144 84 >20:1 
9 127 Ph CH2-3-Indole Ph 145 93 >20:1 
10 128 Ph CH2-p-PhOH Ph 146 83 >20:1 
11 129 Ph (CH2)3-NH Ph 147 60 >20:1 
12 130 Ph (CH2)3SCH3 Ph 148 51d >20:1 
13 131 Ph Bn Adamantyl 149 91 >20:1 
14 132 Ph Bn Thiophene 150 0d,e n/a 
15 133 Ph Bn p-PhCF3 151 71 >20:1 
16 134 Ph Bn m-PhOMe 152 77 >20:1 
17 135 Ph Bn p-PhBr 153 n/ab >20:1 
18 136 Ph Bn p-PhNH2 154 71f >20:1 
a. Reduction of the double bond was observed in the product, yield refers to cyclised product bearing a n-pentyl chain as R1; 
b. Dehalogenation was observed, product not isolated; c. Dehalogenation was observed, yield refers to cyclised product 
bearing a benzyl group as R1; d. 2 eq. of Pd(OH)2; e. Material remained as starting material; f. Reduction of the nitro was 





3.1.3. Studies Towards the Trans-diastereomer 
In order to take advantage of the modular nature of the route designed, it was hoped that the trans-
diastereomer could be achieved from common intermediate 69 (Scheme 3.8). It was assumed that the 
cis-diastereomer was always formed preferentially as a result of the axial hydride attack into the most 
stable half-chair of the imine intermediate. Therefore, it was hoped that by performing the reduction in 
the presence of a bulky Lewis acid, the natural stereoselective preference could be overcome. In this 
case, coordination of the nitrogen to a Lewis acid, such as trimethylaluminium, would shift the 
equilibrium towards the less favoured half-chair conformation, in which the R group lies axial, as this 
would minimise the allylic repulsion between the R group and the Lewis acid. As a result, axial hydride 
attack would lead to the trans-product (Scheme 3.9). A search of the literature highlighted a number of 
examples in which 2,6-trans-disubstituted piperidines 157 were generated in this way.139–141,207–212 No 
examples were found for piperazine rings, however it was hoped that they might behave in a similar 
way. 
 
Scheme 3.9: Scheme to demonstrate the possible use of Lewis acids to access the trans-diastereomer. Figure adapted from 
reference.210 
In order to generate the imine, substrate 56 was stirred in hydrogen bromide, and to avoid aromatisation 
was quenched with diethyl ether as soon as the starting material had been consumed; as a result, imine 
57 was isolated in a 99% yield. The imine was reacted on crude, at -78 °C, by the addition of 
trimethylaluminium, followed by lithium aluminium hydride. The product was isolated in a good yield 
after stirring overnight; however, NMR analysis revealed that the cis-diastereomer 58 had been formed 
(Scheme 3.10). We hypothesised that, compared to the literature examples, in which the two 
substituents are either alkyl chains or simple methyl groups, the preference for the bulkier benzyl group 





Scheme 3.10: Attempted synthesis of the trans-diastereomer using a Lewis acid to change the natural selectivity: a. 56 (1.0 
eq.), HBr (33 wt% in AcOH, excess), 30 mins, rt, 99% 57; b. 57 (1.0 eq.), AlMe3 (2.0 eq.), LiAlH4 (1.0 eq.), THF, 12h, -78 °C 
to -20 °C, 85% 58. 
By this reasoning, replacing the benzyl group with a sterically less demanding group would provide 
access to the trans-diastereomer, however this would result in restricting the scope of this methodology. 
As a result, it was proposed that a route was needed which would harness the natural bias of the 
substrate. One such possibility would be to generate imine 160 from the corresponding aldehyde 161: 
as a result, axial attack of a nucleophile, such as a Grignard reagent, would give the desired trans-
diastereomer 162 (Scheme 3.11). 
 
Scheme 3.11: Proposed route to take advantage of the natural stereoselective bias of the substrate. 
To this end, it was anticipated that the desired aldehyde 161 could be generated by reduction of ester 
163, which in turn could be synthesised from the same triazole scaffold 67 used in the synthetic route 
towards the cis-diastereomer. (Scheme 3.12). 
 
 
Scheme 3.12: Proposed retrosynthetic route from the desired aldehyde to the triazole used in the cis-diastereomer synthesis 
Therefore, using the simplest substituents, in which R1 is a phenyl ring and R2 is a benzyl group, triazole 
54 was alkylated with ethyl 2-bromoacetate. This proceeded smoothly in excellent yield following the 
conditions used for the equivalent ketones in the synthesis of the cis-diastereomer. It was hoped that 




without over reduction to the alcohol, however, this generated a mixture of the ester 164, the aldehyde 
165, the alcohol 166 and the amide 167 formed as a result of the deprotection of the nitrogen (Scheme 
3.13).  
 
Scheme 3.13: Attempted synthesis of aldehyde 165 via the ester 164: a. 54 (1.0 eq.), ethyl-2-bromoacetate (1.2 eq.), K2CO3 
(1.0 eq.), acetone, 12h, rt, 99% 164; b. 164 (1.0 eq.), DIBAL (1.1 eq.), toluene, 3h, -78 °C.  
In an attempt to avoid the over-reduction of the ester, it was proposed to instead attempt to generate the 
aldehyde from the corresponding nitrile 168. First, alkylation of triazole 54 would need to be carried 
out, this time with bromoacetonitrile, which pleasingly proved to have broad applicability and provided 
scaffold 168 in 89% yield. Once again, the reduction was attempted using DIBAL, a methodology with 
excellent precedence.213 Unfortunately, for this scaffold it gave a complex mixture of products (Scheme 
3.14). 
 
Scheme 3.14: Attempted synthesis of aldehyde 165 via the nitrile 168: a. 54 (1.0 eq.), bromoacetonitrile (1.2 eq.), K2CO3 
(1.0 eq.), acetone, 12h, rt, 89% 168; b. 168 (1.0 eq.), DIBAL (1.2 eq.), Et2O, 1h, 0 °C. 
Given that the aldehyde appeared to be inaccessible via reduction, alternative routes were considered. 
A literature search demonstrated that it was possible to form an imine by the controlled reduction of an 
amide, particularly for cyclic systems.214–217 To this end, the lactam could be generated spontaneously 
from the previously synthesised ester 164 by deprotection of the primary amine. The deprotection was 
carried out using hydrogen and palladium on carbon, to yield lactam 167 in excellent yield. When 
considering the possible conditions for reduction of the resultant amide 167 to the corresponding imine 
169, the majority of methods required the amide to be tert-butyloxycarbonyl (Boc) protected,215–217 




was carried forward in a Boc protection, to form 170 in good yield, whilst the rest was retained as the 
unprotected lactam 167 (Scheme 3.15). 
 
 
Scheme 3.15: Synthesis of the Lactam 167 and Boc-protected Lactam 170 from the ester 164: a. 164 (1.0 eq.), H2, Pd/C (10 
mol %), CH3OH, 3h, rt, 82% 167; b. 167 (1.0 eq.), Boc2O (1.5 eq.), DMAP (0.5 eq.), AcCN, 12h, rt, 76% 170.  
With the amide 167 and Boc-protected amide 170 in hand, the partial reduction of the lactam to the 
imine was attempted (Table 3.10). There was considerable precedent for this step using lithium 
triethylborohydride or “superhydride” as it is often referred to (Table 3.10, Entries 1 and 2). For the 
protected lactam 169, LCMS data suggested that whilst the imine had formed, it had reacted with itself. 
Meanwhile for the unprotected lactam 167, no reaction occurred, with the starting material recovered. 
Following on from this lack of success, a paper from Pelletier et al. was identified, in which they 
explored the controlled and chemoselective reduction of secondary amides.218 They proposed that the 
use of a less nucleophilic hydride source would prevent reduction all the way to the amine, enabling 
isolation of the reactive imine. The conditions they developed, also supported by other groups’ 
reports,219 used a one-pot secondary amide activation using triflic anhydride and 2-fluoropyridine and 
selective reduction with triethylsilane (Table 3.10, Entry 3 and 4). Unfortunately, for this system, whilst 
the triflation proceeded smoothly, the material was not reduced, leaving 171. In an attempt to drive the 
reduction, the procedure was repeated using the superhydride reductant; but this gave over-reduction to 
the undesired amine 172 (Table 3.10, Entry 4).  
Having exhausted the metal-free routes to accessing the imine 169, the use of metal reductants was 
explored. The use of catalytic iridium and diethylsilane for the reduction of secondary amides to imines 
had been reported by Cheng et al.,220 however a mixture of products was generated including, amine 
172 and the same dimer 173 seen for the Boc-protected reduction, along with a substantial amount of 
starting material, as identified by LCMS data (Table 3.10, Entry 5). Finally, a common literature 
procedure for this step involving the use of Schwarz reagent221,222 was tested, however, this failed to 




Table 3.10: Testing of conditions for the reduction of the lactam to a cyclic imine. 
 
Entry Starting Material Conditions Yield 
(%) 
Result 
1 170 LiEt3BH, THF, 12h, -25 °C to rt 0 173 
2 167 LiEt3BH, THF, 12h, -25 °C to rt 0 167 
3 167 2-fluoropyridine, Tf2O, Et3SiH, THF, 
12h, -78 °C to rt 
0 171 
4 167 2-fluoropyridine, Tf2O, LiEt3BH, 
THF, 12h, -78 °C to rt 
- 171 & 172 
5 167 [Ir(COE)2Cl]2, Et2SiH2, CH2Cl2, 12h, 
rt 
- 167, 169, 172, 173 
 
6 167 Cp2Zr(H)Cl, THF, 12h, -25 °C to rt 0 167 
 
With the over-reduction of the lactam to the amine proving to be a considerable problem, we returned 
to the synthesis of the aldehyde. Given that aldehyde 165 proved inaccessible under reductive 
conditions, it was proposed that it might instead be formed by oxidation from the corresponding primary 
alcohol. This in turn could be formed by reduction from ester 164, which was carried out successfully 
in an excellent 91% yield using lithium borohydride (Scheme 3.16). 
 
Scheme 3.16: Reduction of the ester 164 to the corresponding alcohol 174: a. 164 (1.0 eq.), LiBH4 (1.2 eq.), Et2O, 3h, 0 °C 
to rt, 91% 174.  
With the alcohol 174 in hand, oxidative conditions for the formation of the aldehyde 165 were explored 
(Table 3.11). The first conditions tested were the Swern conditions,223,224 since these offered no risk of 
over oxidation and were sufficiently mild as to be highly compatible with other functionalities, but this 




periodinane225,226 conditions similarly gave an inseparable mixture of products (Table 3.11, Entry 2). 
Graves et al. proposed using Oppenauer chemistry for the aluminium catalysed selective oxidation of 
alcohols, however this simply returned starting material (Table 3.11, Entry 3). Given the mildness of 
the conditions, we returned at this point to hypervalent iodide, in the hope that changing the reagent or 
solvents might enable isolation of the desired aldehyde. 2-Iodoxybenzoic acid (IBX) is a mild oxidising 
agent for alcohols, and following the procedure from Frigerio et al. this was trialled in DMSO,227 
yielding a complex mixture of products once again (Table 3.11, Entry 4). Finally, Bartlett and Beaudry 
used IBX in ethyl acetate to form β-diketones from β-hydroxyketones, and given the β-relationship 
between the hydroxyl and the triazole ring,228 we hoped these conditions might prove successful for our 
structure. This proved to be the case, although the aldehyde was not isolated, instead it was found that 
upon aldehyde formation, the Cbz-protected amine reacted with this highly reactive functional group, 
thus generating the hemi-aminal 175. It was hoped that this could be used in the same way as the 
aldehyde to generate the imine (Table 3.11, Entry 5). 
Table 3.11: Testing of conditions for the oxidation of the primary alcohol 174 to the corresponding aldehyde 165. 
 
Entry Conditions Yield X (%) Result 
1 COCl2, DMSO, DIPEA, 3h, -78 °C - rt 0 Complex Mixture 
2 DMP, CH2Cl2, 12h, rt 7 Complex Mixture 
3 AlMe3, 3-nitrotoluene, 12h, rt 0 174 
4 IBX, DMSO, 3h, rt 0 Complex Mixture 
5 IBX, EtOAc, 12h, reflux 99 175 
 
A literature search suggested the iminium salt could be formed, with the Cbz group still present, and it 
was hoped that this would be more stable than the free imine, removing the possibility of dimerization 
(Scheme 3.17). The addition of trifluoroacetic acid could be used to trigger the generation of the 
iminium triflate salt 176, which was generated in situ.229 Addition of allyl magnesium chloride,230 
unfortunately removed the Cbz-protecting group and therefore enabled dimerization of the highly 
reactive imines. In an attempt to avoid this, it was proposed to use a softer nucleophile that would not 
be sufficiently reactive as to remove the Cbz-protecting group. To this end, first the aminal 177 was 
generated from hemiaminal 175 using p-toluene sulfonic monohydrate in moderate yield.231,232 From 




iminium ion would immediately be quenched with the soft nucleophile.233,234 Unfortunately, this 
returned only starting material. 
 
Scheme 3.17: Attempts at generating the trans-diastereomer 178: a. 175 (1.0 eq.), TFA (excess), CH2Cl2, 12h, rt; b. allyl 
magnesium chloride (4.0 eq.), CH2Cl2, 12h, -78 °C to rt; c. 175 (1.0 eq.), p-toluene sulfonic acid monohydrate (0.1 eq.), 
CH3OH, 12h, rt, 65% 177; d. i. CuBr·Me2S (3.0 eq.), PhMgBr (3.0 eq.), Et2O, 1h, -40 °C, ii. BF3·OEt2 (3.0 eq.) 177 (1.0 eq.) 
12h, -78 °C to 0 °C. 
These rounds of optimisation showed that a delicate balance of reactivities would be needed to generate 
the trans-diastereomer from the iminium ion (e.g. a nucleophile finely tuned so as not to be too reactive 
and cleave the Cbz-group, but reactive enough so as to attack the iminium ion). We identified this as a 
major drawback in our quest for a general approach to synthesising a library of these molecules, 
therefore we sought an alternative route that could provide better scope, tolerance and selectivity. 
To this end, we considered whether the trans-diastereomer could be accessed from the cis-diastereomer 
in a controlled manner. It was proposed that if the nitrogen from the cis-diastereomer were to be 
protected with a bulky group, upon regeneration of the imine the bulky protecting group would lie on 
the opposite face to the pre-existing chiral centre (Figure 3.4). It was therefore hoped that reduction of 
this iminium ion would occur from the opposite face compared to the cis-formation as a result of the 
steric bulk of the protecting group, thus overcoming the natural bias of the substrate and generating the 
desired trans-diastereomer. 
 




Significant work has been carried out on the selective oxidation of tertiary amines to the corresponding 
iminium ions. This includes the use of ruthenium catalysts for the visible light photocatalytic oxidation 
of tertiary amines,235–239 oxidation to the N-oxide using meta-chloroperoxybenzoic acid (mCPBA) 
followed by treatment with trifilic anhydride,240,241 or oxidation with N-bromosuccinimide (NBS),242–244 
cerium ammonium nitrate (CAN)245 or tropylium bromide.246 
We proposed to utilise this work to generate the iminium ion, such that it could be reduced to give the 
desired trans-diastereomer. To this end, the secondary amine from cis-diastereomer 58 was protected 
with a benzyl group to generate the required tertiary centre (Scheme 3.18: a). As a result of the steric 
crowding around this position, this was low yielding, however this was not deemed to be a problem 
since the starting material was recovered. Work on the final three steps is ongoing. 
There are multiple positions in this molecule at which the proton could be lost/abstracted (Scheme 3.18: 
b), provided it occurs at either A or C, a desired trans-diastereomer would be generated. In order to 
definitively determine the stereochemistry x-ray crystallography and NOE studies will be required on 
the final scaffold.  
 
Scheme 3.18: A. Synthesis of the trans-diastereomer via stereocentre inversion: a. 58 (1.0 eq.), BnBr (3.0 eq.), K2CO3 (3.0 





3.1.4. Studies towards Other Heterocycles. 
Having established the accessibility of the cis-diastereomer for the triazole-based scaffold, it was hoped 
that the modular synthetic route could be applied more generally to a range of different heterocycles. 
Variations in the position of nitrogens and the nature of heterocycles is often a key step in hit to lead 
optimisation, and as such, ease of access is particularly important in demonstrating the utility of this 
route for drug discovery. 
The first step for all potential heterocycle-based scaffolds was the synthetic tractability of the 
heterocycle with the pendant carboxybenzyl-protected nitrogen 40, preferentially with a pre-formed 
chiral centre (Figure 3.5). Whilst ideally this pre-formed chiral centre would be incorporated from the 
chiral pool, a racemate of the cis-diastereomer would be obtained if that were not possible. This event 
would still lead to a relevant series of compounds for testing, which could be synthesised in their 
enantiomerically pure form at a later stage, if a hit were to be identified from screening. 
 
Figure 3.5: Proposed heterocyclic scaffolds required for the application of our newly designed modular route. 
Given the nature of the described pendant functional group, and the common approaches to heterocycle 
synthesis involving esters, ketones and amides, it was hoped that the synthesis of all heterocycles could 
revolve around amino acids (Scheme 3.19). The advantage of this would be two-fold: it would give 
access to a huge pool of potential functionalities in the R2 position, both natural and unnatural; and it 
would provide cheap and readily available enantiopure starting materials. 
 
 







The first heterocycle that was tackled was the imidazole-based scaffold. The first step was to identify 
the manner in which the initial heterocyclic-scaffold based on 40 could be accessed. After identifying 
suitable literature examples to generate similar scaffolds,247–251 we decided to concentrate on the most 
step efficient example, described by Breslin et al.248,249 in which an amide coupling between Cbz-L-
Alanine 183 and 2-aminoacetophenone hydrochloride 184, followed by heating in ammonium acetate 
of the amide coupled product 185, yielded the desired imidazole 186 in 79% over two steps (Scheme 
3.20).  
 
Scheme 3.20: Synthetic route carried out by Breslin et al. in the construction of imidazole scaffolds: a. Cbz-L-Alanine 183, 
2-aminoacetophenone hydrochloride 184, EDC, HOBt, NMM, CH2Cl2, 83% 185; b. 185, NH4OAc, AcOH, reflux, 95% 186.248 
This synthetic route was then applied to the synthesis of imidazole-based partially saturated 5,6 bicyclic 
scaffolds (Scheme 3.21). This was proposed to proceed first with an amide coupling between an α-
aminoketone hydrochloride salt 187 and a carboxybenzyl-protected amino acid 62. A cyclisation of the 
amide coupled product 188 would generate the required imidazole 189, from which an alkylation would 
introduce the third R group in preparation for the reductive deprotection and reductive amination of 190 
to form the imidazole-based bicyclic scaffold 191.  
 
 




To demonstrate the feasibility of this route to deliver the desired scaffold, the synthesis was applied to 
a simple scaffold in which R1 and R3 were unsubstituted phenyl rings and R2 a benzyl group (Scheme 
3.22). The amide coupling proceeded smoothly, using EDC, HOBt and NMM, to yield 192 in 
quantitative yield on a multi-gram scale. The cyclisation of amide 192 to the imidazole proved a little 
more challenging, the conditions used to generate imidazole 186 (Scheme 1.20) only provided a low 
36% yield of desired product 193. Further examination of the literature suggested that use of acetic acid 
as the solvent would be unnecessary, and the less reactive xylenes would be sufficient.250,251 
Gratifyingly, this proved to be the case, and the imidazole 193 was generated in an excellent 81% yield 
on gram scale by refluxing with ammonium acetate in xylenes. From 193, alkylation of the nitrogen 
using potassium carbonate in acetone, gave an excellent yield of 194, in preparation for the final 
diastereoselective step. Palladium dihydroxide and ammonium formate yielded the desired 5,6-bicyclic 




Scheme 3.22: Synthesis of an example of an imidazole-based scaffold, with R1 = Ph, R2 = Bn, R3 = Ph, 195: a. 49 (1.0 eq.), 
184 (1.0 eq.), EDC (1.05 eq.), HOBt (1.05 eq.), NMM (1.05 eq.), CH2Cl2, 3h, 0 °C to rt, 100% 192; b. 192 (1.0 eq.) NH4OAc 
(10.0 eq.), xylene, 8h, reflux, 81% 193; c. 193 (1.0 eq.), 2-bromoacetophenone 55 (1.2 eq.), K2CO3 (1.0 eq.), 12h, rt, 78% 194; 







Following the illustration of the applicability of the designed route to the imidazole-based scaffold, it 
was hoped that similar success could be found for the pyrazole-based scaffold. There are a number of 
approaches to the construction of pyrazole-based scaffolds 196 (Scheme 3.23), of which the two most 
common generate the pyrazole through addition of hydrazine into (i) a 1,3-dicarbonyl 197 (Scheme 
3.23, Route A)146,154,252 and (ii) an α,β-unsaturated ketone 198 (Scheme 3.23, Route B).253,254 The 1,3-
dicarbonyl 197 could be synthesised from the amino ester 51 in a single step, the α,β-unsaturated ketone 
198 in three steps from the amino acid 49. 
 
Scheme 3.23: Retrosynthetic analysis of the required pyrazole scaffold for the pyrazole-based 5,6-bicyclic scaffold. 
Given that route A would be more step efficient, this was first explored (Scheme 3.24). Overall, the 
proposed route began with the addition of the enol of a ketone 199 into the relevant Cbz-L-amino ester 
63, to form the 1,3-dicarbonyl 197 necessary for pyrazole synthesis. Addition of hydrazine across the 
1,3-dicarbonyl 197 would thus generate 196, for which alkylation followed by reductive deprotection 
and amination would give the desired scaffold. 
 




To illustrate the tractability of this proposed route, the synthesis was applied to a simple scaffold in 
which R1 and R3 were unsubstituted phenyl rings and R2 a benzyl group. Initially it was necessary to 
identify conditions for the single addition of the enolate of acetophenone into the amino ester of Cbz-
L-phenylalanine 51, synthesised previously for the construction of the triazole-based scaffolds (Table 
3.12). Potassium bis(trimethylsilyl)amide255 (Table 3.12, Entry 1) and the much more basic lithium 
diisopropylamide256 (Table 3.12, Entry 2) were tested with 51, however only starting material was 
recovered. More commonly for these additions, Weinreb amides are used to remove the risk of double 
addition,257,258 so the Weinreb amide 202 was also tested, with the much milder potassium tert-
butoxide259 (Table 3.12, Entry 3) and the strongly basic butyl lithium260 (Table 3.12, Entry 4). 
Disappointingly, only unreacted starting material was detected after 24 hours, and therefore the stepwise 
approach was attempted instead (scheme 1.23, Route B). 
Table 3.12: Exploration of conditions for the single addition of the enolate of acetophenone into the amino ester of Cbz-L-
phenylalanine: 51 or 202 (1.0 eq.), Acetophenone 203 (1.5 eq.), see table for conditions. 
 
Entry X Conditions Yield Outcome 
1 OMe KHMDS (1.6 eq.), THF, 0 °C to rt 0 Starting Material 
2 OMe LDA (1.6 eq.), THF, -20 °C to rt 0 Starting Material 
3 N(OMe)Me KOtBu (1.6 eq.), THF, 0 °C to rt 0 Starting Material 
4 N(OMe)Me nBuLi (3.5 eq.), THF, 0 °C to rt 0 Starting Material 
 
When considering the synthesis of pyrazole 196 through addition of hydrazide into an α,β-unsaturated 
ketone 198, first synthesis of 198 needed to be explored. From the literature, came the proposed route 
from the amino acid starting material 62 (Scheme 3.25).253,254 Conversion to the Weinreb amide 205 
would enable a single nucleophilic addition to generate the α,β-unsaturated ketone 206; a Michael 
addition into the alkyne with diethylamine would give 198, such that pyrazole 196 could be formed by 
addition of hydrazine. The final two steps would follow the previously described alkylation, reductive 






Scheme 3.25: Proposed synthetic route to pyrazole-based Scaffolds. 
Following the literature precedent, an example was synthesised in which the pyrazole ring was 
unsubstituted, whilst R2 and R3 remained the simple benzyl and phenyl groups respectively, with the 
assumption that they could be substituted for other groups, as illustrated for the triazole scaffold. 
Formation of the Weinreb amide 202 from Cbz-L-phenylalanine 49 proceeded quantitatively on multi-
gram scale. Addition into amide 202 with ethynyl magnesium bromide gave a good yield at 73%, and 
this was followed by the high yielding Michael addition with diethylamine. Pyrazole formation by 
refluxing the α,β-unsaturated ketone 210 with hydrazine and acid gave an excellent 89% yield. The 
alkylation proved more problematic, with the material remaining as starting material, however, it was 
found that changing the base from potassium carbonate to N,N-diisopropylethylamine and the solvent 
to tetrahydrofuran from acetone enabled a 59% yield to be achieved.261 The final step proceeded 





Scheme 3.26: Synthesis of an example of a pyrazole-based scaffold with R1 = H, R2 = Bn, R3 = Ph, 213: a. 49 (1.0 eq.), 
HNMeOMe.HCl (1.5 eq.), HOBt (1.1 eq.), HBTU (1.1 eq.) DIPEA (2.6 eq.), CH2Cl2, 12h, rt, 100% 202; b. 202 (1.0 eq.), 
ethynyl magnesium bromide (4.5 eq.), THF, 12h, -78 °C to rt, 73% 209; c. 209 (1.0 eq.), HNEt2 (1.1 eq.), CH2Cl2, 12h, rt, 95% 
210; d. 210 (1.0 eq.), N2HN2H·H2O (1.1 eq.), HCl (aq) (1.1 eq.), 3h, reflux, 89% 211; e.211 (1.0 eq.), 2-bromoacetophenone 
55 (1.2 eq.), DIPEA (1.0 eq.), THF, 12h, rt, 59% 212; f. 212 (1.0 eq.), NH4·CO2H (30 eq.), Pd(OH2)/C (20 mol%), CH3OH:H2O 
(3:1 v/v), 12h, rt, 82%, >20:1 d.r. 213. 
The successful synthesis for the unsubstituted pyrazole scaffold was encouraging; however, in order to 
maximise the potential vectors incorporated into the scaffold, it was important to ensure that pyrazole 
substitution wouldn’t affect the designed route. This was particularly important for the pyrazole, since 
alkylation could take place on either of the two nitrogen atoms, but only alkylation on one would enable 
formation of the final scaffold. As such, it was decided to synthesis an example for which R1 and R3 
would consist of simple phenyls, whilst R2 remained a benzyl group. 
After synthesis of the Weinreb amide 202, this required addition with phenylethylene magnesium 
bromide. Unfortunately, this was significantly slower, giving a 33% yield with the rest of the material 
remaining as starting material. Pleasingly, the Michael addition with diethylamine and following 
pyrazole formation remained high yielding at 100% and 83% respectively. The alkylation again proved 
slow, with poor conversion giving rise to only a 27% yield. For this scaffold, the final step also gave a 






Scheme 3.27: Synthesis of an example of an pyrazole-based scaffold, with R1 = Ph, R2 = Bn, R3 = Ph, 218: a. 49 (1.0 eq.), 
HNMeOMe.HCl (1.5 eq.), HOBt (1.1 eq.), HBTU (1.1 eq.) DIPEA (2.6 eq.), CH2Cl2, 12h, rt, 100% 202; b. 202 (1.0 eq.), 
phenylethylene magnesium bromide (4.5 eq.), THF, 12h, -78 °C to rt, 33% 214; c. 214 (1.0 eq.), HNEt2 (1.1 eq.), CH2Cl2, 12h, 
rt, 100% 215; d. 215 (1.0 eq.), N2HN2H·H2O (1.1 eq.), HCl (aq) (1.1 eq.), 3h, reflux, 83% 216; e. 216 (1.0 eq.), 2-
bromoacetophenone 55 (1.2 eq.), DIPEA (1.0 eq.), THF, 12h, rt, 51% 217; f. 217 (1.0 eq.), NH4·CO2H (30 eq.), Pd(OH2)/C 







With the successful application of the designed route to three different heterocycles, such that the effect 
of the position and number of nitrogens in the 5-membered heterocycle could be explored, it was hoped 
that it would be simple to grow the 5-membered heterocycle into a bicycle, enabling the potential for 
further π-π interactions to be exploited.  
The synthesis of scaffold 219 has excellent precedent in the literature,262–267 and, furthermore, multiple 
examples were found with a range of substituents on the phenyl ring of the benzimidazole. Whilst the 
example described herein utilises the basic scaffold, we hoped that the functional groups explored in 
section 3.1.2 would, by analogy, be stable on this ring. The route identified first entailed an amide 
coupling between a phenyldiamine 220 and the carboxybenzyl-protected amino acid 62. Heating in acid 
would thus present the required heterocycle 219 in preparation for the alkylation and subsequent 
reductive deprotection and amination (Scheme 3.28). 
 
 
Scheme 3.28: Proposed synthetic route towards benzimidazole-based scaffolds. 
The amide coupling proceeded smoothly using HATU to yield amide 225 in an excellent 91% yield. 
Following this, heating in acetic acid for two hours garnered the required benzimidazole scaffold 226 
in a moderate 56% yield, ready for the alkylation. This step proved more difficult, with the reaction 
failing to go to completion, and therefore presenting only a 50% yield; however, this was a pleasing 
83% based on recovered starting material. The final reductive deprotection and amination continued to 






Scheme 3.29: Synthesis of an example of an benzimidazole-based scaffold, with R2 = Bn, R3 = Ph, 228: a. Cbz-L-phenylalanine 
49 (1.0 eq.), o-phenylenediamine 224 (1.5 eq.), HATU (1.1 eq.), DIPEA (1.1 eq.), CH2Cl2, 12h, rt, 91% 225; b. 225 (1.0 eq.), 
AcOH (0.6 M), 2h, 40 °C, 56% 226; c. 226 (1.0 eq.), 2-bromoacetophenone 55 (1.2 eq.), K2CO3 (1.0 eq.), 12h, rt, 50% 227; 







A strategy within structure-activity relationship (SAR) explorations is to carry out a heteroatom or 
functional group “walk”.268 To anticipate this, it was hoped that the inclusion of an imidazo[4,5-
c]pyridine-based scaffold into the library would illustrate the efficient manner in which such walks 
could be carried out through this synthetic route. It was hoped that the replacement of the phenyl ring 
in benzimidazole with a pyridyl ring would not prohibit the same amide coupling and acid catalysed 
route used for the construction of the benzimidazole scaffold, and satisfyingly, a literature example was 
found in which this chemistry was applied to the construction of an imidazo[4,5-c]pyridine.269  
As such, the route proposed for the benzimidazole scaffold was applied to the imidazopyridine scaffold 
(Scheme 3.30). Starting with the amide coupling, this time between the carboxybenzyl-protected amino 
acids 62 and the relevant diaminopyridine 229, the acid-catalysed cyclisation then bore the 
imidazopyridine scaffold 231 in preparation for alkylation. It was considered highly probable that, 
under the basic conditions required for alkylation, there would be tautomerisation between the two 
imidazo-nitrogen atoms. Whilst this was without doubt also occurring during the synthesis of the 
benzimidazole scaffold, the symmetry of the compound made it irrelevant. This would not be the case 
for the imidazopyridine scaffold; however, under a SAR-exploration point of view, this could be turned 
to our advantage, since two different nitrogen positions could be explored as the product of a single 
reaction, and all four positions through only two reactions. Thus, the final step could be carried out 
either on a mixture of the isomers, or on the individual isomers if they were found to be separable.  
 
 
Scheme 3.30: Proposed synthetic route towards imidazopyridine-based scaffolds. 
As with benzimidazole, although a variety of substituents would be compatible with the reaction 
conditions, the simplest example was synthesised (Scheme 3.31). Beginning with the amide coupling 




acid-catalysed cyclisation proceeded quantitatively to produce 236 in preparation for the alkylation. As 
previously discussed, this yielded both possible alkylation products 237 & 238, in a 1:1 ratio, which 
proved to be inseparable by column chromatography, to give a combined yield of 30%. Whilst a more 
sensitive purification technique such as high pressure liquid chromatography (HPLC) could be used to 
separate them, the screening techniques proposed for this library would remain compatible with a 
mixture of known isomers, which could be separated at a later stage, in the case of the mixture proving 
to deliver a hit. Therefore, the mixture was carried forward to the final reductive deprotection and 
amination, delivering cyclised isomers 239 & 240 in an excellent 90% yield. 
 
Scheme 3.31: Synthesis of an example of an imidazopyridine-based scaffold, with R2 = Bn, R3 = Ph, 240: a. Cbz-L-
phenylalanine 49 (1.0 eq.), 3,4-diaminopyridine 234 (1.5 eq.), HATU (1.1 eq.), DIPEA (1.1 eq.), CH2Cl2, 12h, rt, 71% 235; b. 
235 (1.0 eq.), AcOH (0.6 M), 2h, 40 °C, 82% 236; c. 236 (1.0 eq.), 2-bromoacetophenone 55 (1.2 eq.), K2CO3 (1.0 eq.), 12h, 
rt 30%, 237 & 238; d. 237 & 238 (1.0 eq.), NH4·CO2H (30 eq.), Pd(OH2)/C (20 mol%), CH3OH:H2O (3:1 v/v), 12h, rt, 90%, 






3.1.5. Studies towards Larger Saturated Rings. 
Thus far, it has been demonstrated that the modular route designed for rapid library synthesis or SAR 
upon hit identification can be applied for significant variations in the size and nature of the 5-membered 
heterocyclic part of the scaffold, as well as the nature of the substituents in all three positions. 
When considering the modulation of more challenging drug targets, such as PPIs, it has been found that 
larger, more flexible rings are advantageous, since in these cases shallower pockets, with fewer and 
more spatially separated hotspots for interactions, are being targeted. Thus it was hoped that another 
aspect of the scaffold which could be harnessed for diversification was the 6-membered partially 
saturated ring. The logical approach to tackling this challenge was to consider alkylating the heterocycle 
40 with longer alkyl chains, such as a β-haloketone (yielding a 7-membered ring), or a γ-haloketone 
(yielding an 8-membered ring), with the final conditions unchanged (Scheme 3.32). 
 
Scheme 3.32: Proposed Route to larger saturated rings. 
The advantage of this approach would be its modular nature, in which the size of the saturated rings 
could be varied in two steps from the common intermediate 40, enabling rapid SAR. However, when 
considering the alkylation of 40, longer chains would be less reactive to SN2, without the carbonyl in a 
position to lower the energy of the lowest unoccupied molecular orbital and thus the transition state. In 
the event that the alkylation could be carried out successfully, the cyclisation would be significantly 
less favourable than for the 6-membered ring due to larger rings being less thermodynamically stable,270 
and with the increased flexibility of the rings, there was some concern that the diastereoselectivity 
would be reduced. 
With these concerns in mind, the synthesis of an example of both the 7- and 8-membered scaffolds was 
attempted, with the triazole ring, and the previously used phenyl and benzyl substituents. Pleasingly, 
the 7-membered ring proved to be extremely successful (Scheme 3.33). Alkylation was carried out 
smoothly using 3-chloropropiophenone 244, and 245 was isolated in 93% yield. The additional concern 
for the alkylation using β-bromoketones had been the risk of simply eliminating the chlorine under basic 
conditions, and therefore seeing no evidence of alkylation if subsequent conjugate addition did not take 
place. Pleasingly, no indication of this was observed The final reductive deprotection and amination 




diastereoselectivity, demonstrating the strong natural bias of these scaffolds for the cis-diastereomeric 
product. Although this was low yielding, with the remaining material found to be side product from the 
reduction of the ketone, we were pleased to achieve sufficient material for testing. 
 
 
Scheme 3.33: Synthesis of an example of an triazole-based scaffold with a7-membered saturated ring, with R1 = Ph, R2 = Bn, 
R3 = Ph, 246: a. 54 (1.0 eq.), 3-chloropropiophenone 244 (1.2 eq.), K2CO3 (1.0 eq.), 12h, rt, 93% 245; b. 245 (1.0 eq.), 
NH4·CO2H (30 eq.), Pd(OH2)/C (20 mol%), CH3OH:H2O (3:1 v/v), 12h, rt, 86%, >20:1 d.r. 246. 
 
Following on from this success, it was hoped that it could be replicated for the 8-membered ring. 
Unfortunately, the alkylation conditions used throughout this project for the alkylation step, were 
insufficient for an alkylation with 4-chlorobutyrophenone 247 (Table 3.13, Entry 1). A literature search 
suggested the addition of catalytic sodium iodide might improve the reactivity, with the iodide first 
displacing the chloride, before the desired SN2 reaction can take place (Table 3.13, Entry 2). With the 
iodide much easier to displace with its lower charge density making it significantly more stable in 
organic solvents. Despite stirring overnight, this remained as starting material 54. In the hope of driving 
the reaction forward, it was subjected to microwave heating at 120 °C, using the same conditions but 
with the solvent switched from acetone to the less volatile dimethoxyethane (Table 3.13, Entry 3). Once 
again, only starting material remained. Finally, the 4-iodobutyrophenone was used, but unfortunately 





Table 3.13: Optimisation of conditions for alkylation with γ-haloketones: 54 (1.0 eq.), 4-halobutyrophenone 248 (1.0 eq.), 
conditions in table. 
 
Entry Halo Conditions Yield 
(%) 
Outcome 
1 Cl K2CO3 (1.2 eq.), Acetone, 12h, rt 0 Starting 
Material, 54 
2 Cl K2CO3 (1.2 eq.), NaI (0.1 eq.), Acetone, 12h, rt 0 Starting 
Material, 54 




4 I K2CO3 (1.2 eq.), acetone, 12h, reflux 0 Starting 
Material, 54 
 
A paper from Karachev and Popkov suggested that two problems contribute to this lack of reactivity:271 
(i) the expected inactivity of the chlorine at the γ-position relative to the carbonyl; (ii) the formation of 
the stable intermediate phenyltetrahydrofuran carbocation 250, as first suggested in 1956 (Scheme 
3.34).271,272 
 
Scheme 3.34: Proposed route for the formation of the intermediate stable phenyltetrahydrofuran carbocation 250 
prohibiting the alkylation reaction.271 
The solution to this, proposed by the author of the aforementioned study, was to protect the ketone, 
prior to the alkylation step, such that formation of 250 would be prohibited,271 leaving the poorly 
reactive γ-chlorine as the only challenge. The advantage of this route is that the carbonyl can be unveiled 
simply through an acidic work-up, without the need for a separate deprotection step. To this end, 2-(3-
chloropropyl)-2-phenyl-1,3-dioxolane 251 was prepared, in which the carbonyl group was protected as 




with trifluorosulphonic acid as a catalyst and triethylorthoformate, in a moderate yield, providing 
sufficient material for exploring the alkylation conditions further. 
 
 
Scheme 3.35: Synthesis of 2-(3-chloropropyl)-2-phenyl-1,3-dioxolane, 251: a. 4-chlorobutyrophenone 247 (1.0 eq.), 
trifluoromethane sulfonic acid (0.01 eq.), triethylorthoformate (1.5 eq.), ethylene glycol (1.5 eq.), 12h, reflux, 67% 251. 
Pleasingly, alkylation proceeded smoothly once the ketone had been protected, with deprotection 
occurring during the work-up, such that the alkylated triazole was achieved in a moderate 56%. 
 
 
Scheme 3.36: Alkylation of triazole 54 with 2-(3-chloropropyl)-2-phenyl-1,3-dioxolane, 251: a. 54 (1.0 eq.), 2-(3-
chloropropyl)-2-phenyl-1,3-dioxolane 251 (1.2 eq.), K2CO3 (1.0 eq.) AcCN (0.2 M), 12h, reflux, 56% 249. 
With the successfully alkylated triazole 249 in hand, all that remained was to test whether the saturated 
8-membered ring 252 could be achieved using the palladium dihydroxide catalysed reductive 
deprotection and amination. Regrettably, the desired cyclised scaffold was not achieved, and instead 
the alcohol 253 was isolated in a 44% yield.  
 
 
Scheme 3.37: Attempted formation of the 5,8-triazole-based scaffold: a. 247 (1.0 eq.), NH4·CO2H (30 eq.), Pd(OH2)/C (20 




3.2. Studies towards Achieving Single Chiral Centres 
The ease with which these scaffolds can be achieved offers excellent opportunities for rapid SAR in 
terms of both the stereochemistry and functionalities at this position. However, within drug discovery, 
small pockets are often targeted, for which the compounds thus far synthesised have the potential to be 
too large. One way of circumventing this issue, beyond choosing smaller functional groups, would be 
to limit the saturated ring to a single chiral centre. It was hoped that the synthetic route proposed could 
be simply adapted to allow for the synthesis of scaffolds with a single substituent in both of the positions 
accessed. 
3.2.1. Single Substitution in the R2-Position 
For the R2 position, when exploring methods for reducing the hemiaminal 175 to the imine 169 (Section 
3.1.3), it was serendipitously identified that the palladium dihydroxide conditions used for the reductive 
deprotection and amination sequence could be used on this scaffold to carry out concomitant 
deprotection and hemiaminal reduction to generate amine 172.  
To this end, it was proposed that single enantiomers with a chiral centre in the R2 position of the 
scaffolds could be generated via hemiaminal 254 from the heterocyclic scaffolds 40 (Scheme 3.38). 
 
 
Scheme 3.38: General route to access enantiomerically pure heterocyclic scaffolds with a single substituent in the saturated 
ring in the R2 position: a. 40 (1.0 eq.), ethyl-2-bromoacetate (1.2 eq.), K2CO3 (1.0 eq.), 12h, rt, 255; b. 255(1.0 eq.), LiBH4 
(1.2 eq.), Et2O, 3h, 0 °C to rt, 256; c. 256 (1.0 eq.), IBX (3.0 eq.), EtOAc (0.1 M), 12h, reflux, 254; d. 254 (1.0 eq.), NH4·CO2H 
(30 eq.), Pd(OH2)/C (20 mol%), CH3OH:H2O (3:1 v/v), 12h, rt, 257. 
Amine 172 was synthesised from hemiaminal 175 in an excellent 78% yield (Scheme 3.39). One key 
feature of our methodology is the mildness of the conditions employed throughout the synthetic 
sequence, which would avoid epimerisation of the sensitive stereogenic centre. Enantiospecificty of the 





Scheme 3.39: Formation of a scaffold with a single chiral centre in the R2 position: a. 175 (1.0 eq.), NH4·CO2H (30 eq.), 
Pd(OH2)/C (20 mol%), CH3OH:H2O (3:1 v/v), 12h, rt, 78% 172. 
Thus for the purposes of SAR, a full library of compounds could be formed, with the availability of 
enantiopure amino acids being the only restriction onto the functionalities accessible in the R2 position 
via the following developed route. 
 
3.2.2. In the R3-position 
It was hoped that by repeating the synthesis of the desired scaffold with glycine, such that the R2 position 
would be unsubstituted, would enable a single chiral centre to be generated in the R3 position of the 
saturated ring. To this end, the initial synthesis was repeated with glycine 258 (Scheme 3.40). Its 
conversion to the corresponding amino hydrazide via the ester proceeded smoothly, with a yield of 94% 
over the two steps on a multi-gram scale. The cyclisation gave triazole 261 in a moderate 63%, followed 
by alkylation in a good 72% yield. The final reductive deprotection and amination progressed with an 
excellent 82% yield to give the racemic scaffold. 
 
Scheme 3.40: Synthesis of a scaffold with a single chiral centre at the R3 position: a. Cbz-L-phenylalanine 258 (1.0 eq.), SOCl2 
(1.4 eq.), CH3OH, 3h, rt, 96% 259; b. 259 (1.0 eq.), NH2NH2·H2O (5 eq.), CH3OH, 12h, rt, 98% 260; c. 260 (1.0 eq.), 53 (1.2 
eq.), EtOH, 6h, reflux, ii. AcOH, 2h, reflux, 63% 261; d. 261 (1.0 eq.), 2-bromoacetophenone 55 (1.2 eq.) K2CO3 (1.0 eq.), 
acetone, 12h, rt, 72% 262; e. 262 (1.0 eq.), NH4·CO2H (10 eq.), Pd(OH2)/C (20 mol%), CH3OH:H2O (3:1 v/v), 82% 263. 
For the purposes of initial screening it is unimportant that a racemic compound has been generated, 




enantiomer prior to further optimisation. To that end, although we have yet to follow through on this 
chemistry, there is significant literature precedent for the enantioselective reductive amination step, 





3.3. Computational Analysis 
 
As previously discussed, assessing the chemical diversity of a compound library is important for 
determining the potential for its success in drug discovery.277 Two common approaches are used to 
display the degree of diversity exhibited by compound libraries: “principle moments of inertia” analysis 
(PMI) and “principal component analysis” (PCA). 
To assess the three-dimensional shape diversity of a compound library, the individual constituents’ 
moments of inertia along three mutually orthogonal principle axes are calculated and plotted as 
normalised PMI ratios on the triangular PMI plot. This plot therefore provides a visual demonstration 
of how one-, two- and three-dimensional the molecular scaffolds are, which corresponds to how rod-
like, disk-like or sphere-like they are.277 
Multiple chemical “descriptors” can be used to describe compounds and, combined, these can be used 
to visualise each compound in a library as a single point in chemical space. PCA reduces these multi-
dimensional descriptors into two-dimensional vectors that can be plotted on a scatter plot. Whilst this 
is advantageous as it combines information from multiple descriptors, these are chosen by the operator 
and therefore are subject to human bias; also important to note is that any changes to the descriptors 
could drastically change the form of the scatter plot.62  
Computational analysis of the compounds synthesised in this thesis was performed using Molecular 
Operating Environment (MOE) software package version 2012.10 from the Chemical Computing 
Group. A detailed procedure of the PMI analysis and PCA is given in Section 7.1.  
 
3.3.1. Principal Moments of Inertia (PMI) Analysis 
An initial conformational search and energy minimisation on the library of compounds synthesised in 
this thesis was carried out, and the lowest energy conformation for each compound selected (see 
appendix 7.1.2) Principal moments of inertia were calculated for these lowest energy conformations, as 
well as for 40 top-selling drugs and 1,000 Maybridge fragment library members, so that we could 
compare the shape diversity between these collections and our library (full details of the PMI analysis 
can be found appendices 7.1.1. and 7.1.2.). The PMI plot produced is shown below (Figure 3.6). 
The aim of this project was to develop a synthetic route towards libraries of compounds with increased 
complexity when compared to two-dimensional molecules, but not to extend too far into three-
dimensional space where the increased complexity has the potential to drastically decrease the hit rate. 
The line parallel to the axis between rod-like and disk-like represents the edge of what can be considered 




without clustering together. Hence they demonstrate good diversity on the cusp of three-dimensionality. 
Compared to the Maybridge fragment library, for which a large proportion of the compounds lie flush 
with the two-dimensional axis, this demonstrates the improved molecular complexity achieved in this 
work. Whilst this work in general demonstrates less three-dimensionality than the known drugs plotted, 




Figure 3.6: Principle moments of inertia plot illustrating the shape diversity of our compound library and the 2 reference 





3.3.2. Principal Component Analysis (PCA) 
PCA was carried out using 17 molecular descriptors which covered a broad range of 17 physicochemical 
and structural properties, such as molecule flexibility (KierFlex), partition coefficient between octanol 
and water (Slog P), topological polar surface area (TPSA) and number of hydrogen bond donors (a_don) 
(For full list see appendix 7.1.3, Table 7.2). These 17 descriptors were then combined to construct 17 
new unit-less axes called “principal components”, each of which has contributions from each of the 
original descriptors. These 17-dimensional vectors were linearly transformed into two-dimensional 
vectors, calculated so as to represent as much of the variance in the database as possible and sorted by 
their contribution to the variance. The first six principle components were found to be responsible for 
over 95% of the variance exhibited by the library, with the first three principle components representing 
over 85% of the total variance (Table 3.14). As such, the first three components were deemed sufficient 
to construct the PCA plots (Figure 3.7). 
Table 3.14: Contribution of each principal component to the total library variance. 
PC Number Deviation Condition % Variance 
1 3.245 1.000 61.929 
2 1.624 3.994 77.436 
3 1.308 6.158 87.493 
4 0.943 11.831 92.727 
5 0.590 30.263 94.774 
6 0.494 43.108 96.210 
 
These PCA plots illustrate that the chemical space spanned by this work overlaps to some extent with 
that of synthetic drugs, but considerably less so with that of natural products. Furthermore, our library 
occupies some regions of the graph barely populated by the two reference sets, highlighting the potential 





Figure 3.7: PCA plots of this work and 2 reference libraries: a. PC1 versus PC2; b. PC1 versus PC3; c. PC2 versus PC3. 
This work (red dots), 40 synthetic drugs (blue triangles) 60 natural products (green rhombus). See appendix 7.1.1 for the three 
libraries. 
When considering the contributions of the 17 descriptors (Table 3.15) we can see those properties which 
gave the most significant contributions towards the variance in each principle component. When 
considering PC1, there are 11 descriptors with significant contributions, suggesting that the library 





Table 3.15: Component loadings of the 17 descriptors to the first six principal components, with the top contributing 
parameters to each principal component highlighted in blue, with darker blue indicating a greater contribution. The values 
were normalised automatically by the MOE software. For definitions of descriptors see appendix 7.1.3. 
 PCA 1 PCA 2 PCA 3 PCA 4 PCA 5 PCA 6 
a_acc 0.0182 0.0126 0.0197 0.0508 -0.0688 0.1204 
a_aro -0.0001 -0.0296 -0.0373 0.0164 -0.0054 0.0924 
a_don 0.0224 0.0271 -0.0424 0.0270 -0.1334 0.2482 
a_nN 0.0169 -0.0172 -0.1056 -0.0541 -0.2050 -0.1804 
a_nO 0.0150 0.0166 0.0214 0.0306 0.0653 -0.0151 
ASA_H 0.0003 -0.0009 0.0009 -0.0009 -0.0019 0.0002 
ASA_P 0.0006 0.0010 -0.0008 0.0016 0.0047 -0.0026 
b_rotN 0.0102 0.0036 -0.0141 -0.0623 0.1198 0.1262 
chiral 0.0127 0.0136 0.0482 0.0550 -0.0670 0.0629 
KierFlex 0.0130 0.0050 0.0155 -0.0386 -0.0111 -0.0083 
logS -0.0221 0.0872 -0.0157 0.0699 -0.1448 0.1092 
mr 0.0113 -0.0106 0.0036 -0.0095 -0.0074 -0.0391 
rings 0.0153 -0.1268 -0.0266 0.3202 0.1988 -0.1211 
SlogP -0.0103 -0.0668 0.0841 -0.0276 -0.0218 0.1199 
TPSA 0.0007 0.0007 -0.0009 0.0005 -0.0001 -0.0004 
Weight 0.0003 -0.0002 0.0001 -0.0001 0.0001 -0.0010 









3.4.1. High-Throughput X-ray Crystallography Screening 
The Diamond light source (DLS) synchrotron in Oxfordshire (UK) has developed the XChem screening 
facility at the beamline 104-1 for the high throughput X-ray crystallographic screening of fragment 
libraries. They use the ECHO acoustic liquid handler to soak target crystals with solutions of the 
fragments in singleton format, allowing 1,000 individual soaks to be carried out efficiently and 
accurately in less than 10 minutes.278 Crystal harvesting is semi-automated through the use of a 
microscope and x-y stage shifter such that approximately 100 crystals per hour can be harvested. The 
X-ray diffraction data collection is fully automated, enabling the screening of almost 700 crystals within 
24 hours, and PanDDA software enables efficient processing of multiple data sets for the detection and 
modelling of bound fragments.279 
The facility has established collaborations within both academia and industry all over the world: more 
recently, this has extended to the Spring group. The principle aim behind this collaboration was to 
enable the routine screening of the multiple DOS libraries developed within the group against novel 
biological targets provided by both internal and external users of the facility. From one such screening 
campaign conducted in 2017, one of the library members was identified by Joe McLoughlin from the 
Hyvönen Group, Cambridge as a weak binder of the protein Activin A (Figure 3.8). 
 
Figure 3.8: Compound 143 was identified as a weak binder for Activin A.  
The initial screening was carried out using 4% PEG300 within the soaking solution (Figure 3.9). When 
the compound was soaked under different conditions, without the PEG, no binding was seen, suggesting 
compound 143 was an extremely weak binder. PEG is often used in soaking solutions since it can act 
as a solubilising agent for poorly soluble compounds.280 Therefore, this result might also be attributable 
to the low solubility of compound 143 in the PEG-free conditions used. Given that another compound 
in a different DOS library from the Spring group was found to be a stronger binder, no follow up work 
was carried out on this initial hit. However, we hope future hits against novel biological targets might 











4. Conclusions and Future Work 
4.1. Conclusions 
This work aims to improve aspects of the current significant decline in the pharmaceutical industry, 
which is seen in the decreased number of approvals of NCEs, the lower quality of R&D pipelines and 
the reduction of revenue generated. We believe this can be attributed to the lack of diversity and poor 
quality of existing screening libraries. Library compounds should be diverse but also synthetically 
tractable and incorporate synthetic handles for growth such that chemical optimisation via SAR studies 
can be carried out effectively and efficiently. The synthesis of screening libraries through robust and 
tolerant synthetic strategies should aim to generate diverse libraries targeting novel scaffolds which 
incorporate the desired polar functional groups and synthetic handles in a step-efficient manner. In 
particular, there is a significant need for novel bicyclic heteroaromatic scaffolds within libraries, since 
these are not only under-represented in existing libraries, but are extremely useful in drug discovery 
due to their limited flexibility and ability to form important binding interactions. 
The development of a modular, divergent and step-efficient diastereoselective synthetic route for the 
synthesis of partially saturated bicyclic heteroaromatic scaffolds has been carried out in order to address 
this (Scheme 4.1). A particular focus of this was the incorporation of functional handles that could 
provide growth vectors for fragment or lead elaboration, and as such, the conditions developed are 
tolerant to a wide range of functional groups, such as alcohol, trifluoromethyl and amino functionalities. 
In addition, to enable rapid hit validation and optimisation, synthesis requires just 4-6 steps from 
commercially available starting materials. The use of amino acids is a key aspect of this work as they 
provide a large pool of inexpensive and commercially available starting materials, but significantly the 
chiral centre was essential for generating the diastereoselectivity during the reductive deprotection and 
amination step. 
 
Scheme 4.1: Final synthetic route developed. 
The initial work was carried out on a triazole-based scaffold for a 5,6-bicyclic system; however, this 




has 7 different scaffolds and 24 members. Furthermore, adaptations allow access to structures with a 
single chiral centre in either the R2- or R3-position, in which, the stereochemistry in the R2-position is 
predetermined by that of the starting amino acid, whilst currently in the R3-position synthesis is carried 
out racemically (Figure 4.1). 
 
Figure 4.1: Illustration of the scope for the synthesis of diverse scaffolds. 
Computational analysis determined that the library demonstrated enhanced sp3 character (Figure 3.6) 
and increased chirality compared to typical fragment libraries (Table 4.1). Since this work foccussed 
on developing a robust methodology for the synthesis of these scaffolds, phenyl rings were used as 
unreactive “place-holders” during the exploration of the scope of the synthetic strategy. As a result, 
when considering the physicochemical properties of the library generated (Table 4.1), the SlogP, 
molecular weight and number of aromatic rings lie well outside of the desirable range for fragment-
based drug discovery and lead-oriented synthesis. Pleasingly, the polar surface area and numbers of 
hydrogen bond donors, hydrogen bond acceptors rotatable bonds and chiral centres lie-close to, if not 
within these guidelines. Therefore, although the library itself does not comply to the drug discovery 
physicochemical property guidelines, the synthetic route designed has the potential to be applied to the 
construction of fragment-like, lead-like or drug-like compound libraries through careful selection of the 
substituents, heterocycle and the size of the saturated ring. Furthermore, whilst the library of compounds 
generated do not comply to the constraints of fragment-based drug discovery, some of the library 
members have been incorporated into Diamond’s XChem crystallography screening, and from this a 





Table 4.1: Comparison of some of the physicochemical properties of the compound library generated by this work, with the 
typical ranges with fragment-like,107 lead-like281 and drug-like103 compound libraries. 






SlogP -5.26 0 - 2 -1 - 3 ≤ 5 
Molecular Weight 359 140 - 230 200 - 350 ≤ 500 
Polar Surface Area (PSA) 45.2 ≤ 60 - ≤ 75 
Hydrogen Bond Acceptors (HBA) 3.00 ≤ 3 ≤ 9 ≤ 10 
Hydrogen Bond Donors (HBD) 1.08 ≤ 3 ≤ 5 ≤ 5 
Rotatable Bond Count (RBC) 3.92 ≤ 3 ≤ 10 ≤ 10 
Chiral centres 1.90 0 - 2 1-2 - 
Aromatic rings 3.68 - ≤ 3 - 
 
Given the necessity of developing new approaches for the step-efficient synthesis of diverse screening 
libraries, this work offers a highly efficient and adaptable route to highly sought after partially saturated 





4.2. Future Work 
This work has focussed on testing the tolerance of this route to different functionalities, and the ways 
in which it can be adapted for the synthesis of diverse scaffolds. However it has the potential to generate 
a library of millions of compounds based around multiple scaffolds. 
 
4.2.1. Expansion of the Chemistry 
To date, this work has extended the proposed synthetic route to the synthesis of 7 different heterocycle-
based scaffolds and 2 different saturated ring sizes. Furthermore, it has accessed a single enantiomer at 
the R2-position and a single chiral centre racemically in the R3-position. 
Future synthetic work on this project would focus on expanding the heterocycles that could be accessed. 
In addition, potentially even larger saturated heterocycles could be targeted, or different heteroatom-




Figure 4.2: Examples of other potential scaffolds a. heterocyclic-based scaffolds which could be targeted; b. potential 
heteroatom variation within the saturated ring. 
An important area which requires further investigation is that of accessing single enantiomers for a 
single chiral centre at the R3-position.  
 
4.2.2. Illustrating the Biological Relevance 
The biological relevance of these semi-saturated bicyclic heteroaromatic scaffolds was illustrated by 
their presence in phase II clinical trial candidate, KAF 156 and an FDA approved drug, Januvia©, with 
KAF 156 containing an imidazole-based scaffold and Januvia© (Sitagliptin) a triazole-based scaffold. 
Despite the presence of these semi-saturated bicyclic heteroaromatic scaffolds in approved drugs and 




and investigation of certain substitution patterns and stereoselectivities; however, by utilising this new 
methodology we hope that further biological applications can easily and efficiently be identified.  
 
4.2.2.1. KAF 156 
KAF 156 is awaiting the start of phase III clinical trials for treatment against the Plasmodium falciparum 
and Plasmodium vivax 
identified through a screening campaign on a library of approximately 2 million compounds using a 
cell-based proliferation assay of Plasmodium falciparum.282 From these initial five-thousand hits and 
after multiple rounds of SAR during the lead optimisation process the final clinical candidate KAF156 
was identified (Figure 4.3).131,132  
 
Figure 4.3: KAF156 developed by Novartis: a, b and c illustrate the positions at which substitution patterns were explored 
for SAR studies. 
We believe this lead optimisation process could have been streamlined through the use of a more 
modular synthetic route to the imidazolopiperazine scaffolds which formed the main pharmacophore. 
In particular, when considering the chemistry carried out (Scheme 4.2), a separate route was required 
in order to explore substitution in the three available positions of the piperazine ring (Figure 4.3, 
positions a, b and c). At positions b and c, only double substitutions were possible, and at no point were 
multiple positions in the ring substituted simultaneously. Furthermore, it was only possible to 






Scheme 4.2: The synthetic route used for the SAR studies carried out in the lead optimisation of second-generation antimalarial 
agents:132 a. K2CO3, DMF, rt, 84% 270; b. NH4OAC, toluene, reflux, 88% 271; c. ethyl 2-bromoacetate, Cs2CO3, DMF, rt, 
83% 272; d. Pd/C, H2 (1 atm), CH3OH, rt, 91%, 273; e. BH3·THF, THF, reflux, 95%, 274; f. N-Boc-glycine, HATU, DIPEA, 
CH2Cl2, rt, 70%, 275; g. Br2, AcOH, CH2Cl2, rt, 100% 276, 55% (281), 80% (284); h. ArNH2, Pd2(dba)3, xantphos, Cs2CO3, 
dioxane, 150 °C, 89% 277; i. TFA, CH2Cl2, rt, 52% 278, 55% (2 steps) 281, 46% (2 steps) 284; j. methallyl chloride, K2CO3, 
KI, DMF, rt, 55%; k. AcOH/MsOH (6:1), 210 °C, 39%; l. N-Boc-glycine, HATU, DIPEA, DMF, rt, 57% 280; m. TFA, 70 °C, 
quantitative; n. N-Boc-glycine, HATU, TEA, DMF, rt, 49% (281); o. PMBCl, KOH, DMF, 0 °C to rt, 63%; p. MeI, NaH, DMF, 
rt, 86%; q. BH3·THF, THF, reflux, 100% 283. 
When considering the application of the modular route described within this thesis (Scheme 4.3), whilst 
the stereo-control at position a is also achieved through the chiral amino acid starting materials, it offers 
the possibility of introducing substitution at positions a and b simultaneously and diastereoselectively. 




This route could therefore be used to access previously unexplored substitution patterns, as well as 
improving the efficiency of the synthesis of the compounds used for the SAR studies during the 
development of KAF 156 
 
Scheme 4.3: Scheme illustrating how the modular synthetic route for the synthesis of partially saturated bicyclic 
heteroaromatics could be applied to the rapid and step-efficient synthesis of analogues of KAF 156: a. 268, 269, K2CO3, DMF, 
rt; b. 270, NH4OAC, toluene, reflux; c. 271, α-bromoketone, K2CO3, acetone, rt. 
 
4.2.2.2. Januvia© 
Januvia© was FDA approved in 2006 for the treatment of type II diabetes through the inhibition of 
DPP-IV. It was developed from a β-amino acid-based structure which had high DPP-IV inhibitory 
potency but poor pharmacokinetic properties due to the metabolism of the heterocycle moiety (Scheme 
4.4).135 As a result, a study was carried out to replace the problematic piperazine ring with a more robust 
heterocycle, such as a fused heterocyclic system.  
 
Scheme 4.4: Optimisation of novel β-amino acid based potent inhibitors 286 and 287 of DPP-IV to improve the 
pharmacokinetic properties and metabolic stability lead to the development of Januvia.© Figure adapted from reference.135 
The initial SAR studies carried out revolved only around the substituent on the triazole ring and the 
substituents around the left hand phenyl ring (both highlighted blue, Scheme 4.4), possibly due to the 
synthetic challenges involved with regio- and stereo-selectively substituting the piperazine ring. The 




Selective reduction of the 6-membered ring then gave the partially saturated scaffold. Hence, any 
substituents incorporated at the pyrazine stage would give a racemic mixture upon reduction, and late-
stage substitution would be challenging to control. 
 
Scheme 4.5: Initial synthetic route used to synthesize analogues for the SAR studies which resulted in the identification of 
Januvia© as a clinical candidate for the treatment of type II diabetes:135 a. NH2NH2∙H2O, EtOH, reflux; b. NH2NH2∙H2O, 120 
°C, 45 mins; c. CH(OCH3)3 or C2H5C(OC2H5)3, reflux; d. (CF3CO)2O, 0 °C to rt; e. PPA, 140 °C, 18 h; f. CF3CF2CO2H or 
CF3CH2CO2H; g. PtO2, CH3OH, H2; h. H2, 10% Pd/C, EtOH; i. β-amino acid, HOBT, EDC, DIPEA, DMF, rt, 18 h; j. 
Saturated HCl, CH3OH; k. i. 1N, NaOH, EtOAc, ii. Fumaric acid, EtOH, rt 
Whilst Januvia© proved to be sufficiently potent without substituting the piperazine ring, a number of 
SAR studies have since been carried out focussing on different regions of the compounds. In particular, 
a study was carried out exploring the alkyl substitution around the triazolopiperazine moiety (Table 
4.2). The key challenge here was that multiple routes were required in order to access the various 
substitution positions, and furthermore almost all compound were synthesised racemically and the 
resultant diastereomers separated upon coupling to the enantiopure β-amino acid moiety, resulting in 





Table 4.2: The various Januvia© analogues synthesised through the SAR studies.134 
 
 R1 R2 R3 DPP-4 IC50 (nM) 
291 Meb  H H (S)-23; (R)-14 
292 H Mea,b H (S)-91; (R)-42 
293 H H Mea,b (S)-88; (R)-4.3 
294 Me, Me H H 92 
295 H H Me, Me 175 
296 Me H Me 100, 209, 12, 11 
297 H H Eta,b 113, 5.0 
298 H H CH2CF3a,b 123, 5.7 
299 H H CH2CHCH2a,b 1.5, 32 
300 H H CH2CON(CH3)2a,b 377, 2.8 
301 H H CH2Pha,b 140, 0.66 
302 H H CH2(4-methoxyphenyl)a,b 320, 0.43 
303 H H CH2(2-trifluoromethylphenyl)a,b 438, 0.31 
304 H H CH2(2-fluorophenyl)a,b 131, 0.46 
305 H H CH2(4-fluorophenyl)a,b 116, 0.18 
306 H H CH(OH)(4-fluorophenyl)a,b 430, 0.32, 90, 0.50 
307 H H CH2(3,5-bis-
trifluoromethylphenyl)a,b 
587, 6.3 
308 H H CH2(2-pyridyl)a,b 132, 0.40 
a. R1 and R3 S/R isomers synthesised in a single reaction and separated by flash column chromatography. bStereochemistry of 
the diasterioisomers unknown; order of the IC50 values corresponds with the elution order. Based on X-ray structure 
determination of the analogue with R1 = R2 = H, R3 = CH2(4-fluorophenyl), slower eluting isomers were tentatively assigned 
as (R)-isomers 
Application of the work described within this thesis to the synthesis of various Januvia© analogues 
would have significantly improved the stereoselectivity, efficiency and yields. In particular, substitution 
at the R3 position with (R)-stereochemistry was found to be of critical importance for superior potency, 
leading to the identification of compound (R)-293 which was found to have a 4-fold increase in DPP-




synthesised via this route (Scheme 4.6). Unfortunately, the compound was found to have intolerable 
side-effects in in vivo studies and was therefore taken no further. 
 
Scheme 4.6: Proposed step-efficient and stereo-selective synthesis of an improved DPP-IV inhibitor with high selectivity, a 
good pharmacokinetic profile and in vivo efficacy: a. i. EtOH, reflux, 3h, ii. AcOH, reflux, 2h; b. Ethyl bromoacetate, K2CO3, 
acetone, rt, 12h; c. LiBH4, CH2Cl2, -78 °C to rt, 12h; d. IBX, EtOAc, reflux, 12h; e. NH4·CO2H (30 eq.), Pd(OH2)/C (20 mol%), 
CH3OH:H2O (3:1 v/v), 12h, rt; f. β-amino acid, HOAT, HATU, DIPEA, DMF, rt, 18 g. satd. HCL/CH3OH. 
Work to synthesise analogues via the synthetic route described within this thesis is currently being 
carried out. 
 
4.2.3. Biological screening 
 
4.2.3.1. High-throughput X-ray Crystallography Screening 
Thus far, a proportion of the library synthesised in this work has been incorporated in the Diamond 
XChem crystallography screening library, and we hope this will continue to generate hits against novel 
targets. From these hits, synthesis of closely related analogues will be required for hit validation and 
optimisation, and this will be a simple and efficient process as a result of the forethought given in the 
design of the synthetic route to the scaffolds. 
 
4.2.3.2. In Silico Screening 
In silico screening is a well-established computational technique for the prediction of biological targets 
of compounds on the basis of chemical structure by using information from known bioactivity 
information.283 These predictions can then be validated experimentally afterwards. There are two 
commonly used approaches:284 
1) Structure-based methods exploit the available structural information on the protein and scoring 




2) Ligand-based methods use similarity searching on known ligand-target pairs available from 
chemogenomic databases, relying on the theory that the similar features between compounds 
are responsible for the target binding. 
Traditionally, these techniques have been used to identify the mode of action of molecules identified as 
biologically active through phenotypic screening. However, similarity matches from in silico screening 
can also be used to direct biological screening towards particular, more likely target classes. The Bender 
group have developed a target prediction protocol called PIDGIN which makes use of, not only known 
activity data, but also inactivity data, to give a more well-rounded analysis of the probability of 
activity.284 Our collaboration with the Bender group presents the possibility of analysing this work with 
PIDGIN, and using the resulting data to explore future phenotypic or target-based screening campaigns. 
 
4.2.3.3. Other Screening Aims 
In addition, given the opportunity, we would like to be able to include our library in the phenotypic or 
target-based screening campaigns. This would not only further validate the choice of scaffold as 
biologically relevant, but could potentially identify novel and synthetically tractable hits for challenging 
new targets. 
 
4.2.4. The Virtual Library and its Potential 
 
The work here has attempted to efficiently illustrate the broad applicability of the synthetic route 
designed. However, it has the potential, even within the constraints of those scaffolds already explored 
of generating almost 2 million different compounds (Table 4.3). Without a doubt, synthesising all 
possible combinations is an impossible task; however, with the ever increasing development and 
success of in-silico screening, we propose that the virtual library this generates based on commercially 
available starting materials could be screened in-silico, and only those compounds which demonstrate 
good potential for biological activity could be later synthesised and screened. Furthermore, it would be 
possible to synthesise the 1,454 fragments possible, a significantly more achievable goal, highlighting 





Table 4.3: Table demonstrating the number of different commercially available starting materials for each of the scaffolds 
explored in this work from Sigma Aldrich. The total possible scaffolds for each heterocycle therefore incorporates cis- and 
trans-diastereomers, as well as single substitutions on the piperazine ring in the R2 and R3 positions. a. Includes both 















Triazole 31 78 74 7 430,683 484 
Imidazole 10 78 74 7 138,930 397 
Pyrazole 36 78 74 7 500,140 502 
Benzimidazole 48 78 74 7 666,864 46 
Imidazopyridine 9 78 74 7 125,037 25 






5. Experimental Details 
 
5.1. General experimental details 
All non-aqueous reactions were performed in dry glassware under a stream of nitrogen using anhydrous 
solvents. Tetrahydrofuran was dried over sodium wire and distilled from a mixture of lithium 
aluminium hydride and calcium hydride with triphenylmethane as the indicator. Dichloromethane, 
toluene and methanol were all distilled from calcium hydride. Petroleum ether was distilled before use 
and refers to the fraction between 40-60 oC. 
Chemicals were purchased from Sigma Aldrich and used as received unless otherwise stated. 
Reactions were carried out at ambient temperature unless otherwise stated. All temperatures below 0 
oC were achieved with an external bath: those of 0 oC were maintained using an ice/water bath, those 
of lower temperatures using a dry ice/ acetone bath. Yields refer to chromatographically and 
spectroscopically pure compounds unless otherwise stated. 
Where possible, reactions were monitored using TLC or liquid chromatography-mass spectrometry 
(LCMS). Analytical thin layer chromatography (TLC) was performed on commercially available glass 
pre-coated Merck Kiesel gel 60 F254 plates. Visualisation was achieved by quenching of UV 
fluorescence (λmax = 254 nm) or by staining with potassium permanganate. Rf values are quoted to the 
nearest 0.01. LCMS was performed using a Waters ACQUITY H-Class UPLC with an ESCi Multi-
Mode Ionisation Waters SQ Detector 2 Spectrometer using MassLynz 4.1 software. 
Flash column chromatography was performed using slurry-packed SiO2 (Merck Grade 9385, 230-400 
mesh) under a positive pressure of N2. Celite refers to AW Standard Cuper-Cel NF. 
Optical rotations were recorded on an Anton Parr MCD 100 Polarimeter. [α]D
20 values are reported in 
10-1 deg cm2 g-1 at 589 nm, concentration (c) is given in g dL-1. 
Infrared spectra were recorded neat (unless otherwise stated) on a Perkin Elmer Spectrum One FT-IR 
spectrometer with internal referencing. Selected absorption maxima (νmax) are quoted in wavenumbers 
(cm-1) and are assigned as: weak (w), medium (m), strong (S) or broad (br). 
Proton nuclear magnetic resonance spectra (1H NMR) were recorded using an internal deuterium lock 
at ambient probe temperatures (unless otherwise stated) on the following instruments: Bruker DPX-400 
(400 MHz), Bruker Avance 400 QNP (400 MHz), Bruker BB 500 (500 MHz) and Bruker Avance 500 
Cryo Ultrashield (500 MHz). Chemical shifts (δH) are referenced to the residual non-deuterated solvent 
peak and quoted in parts per million (ppm) to the nearest 0.01 ppm. Coupling constants are quoted in 




[app = apparent; br = broad; s =s singlet; d = doublet; t = triplet; q = quartet; quin = quintet; m = 
multiplet; or as a combination of these, e.g. dd], coupling constant(S), assignment. Proton assignments 
were determined either on the basis of unambiguous chemical shift, coupling patterns, by patterns 
observed in the two-dimensional experiments (1H-1H COSY, HMBC and HMQC) or by analogy to fully 
interpreted spectra for related compounds. 
Carbon nuclear magnetic resonance spectra (13C NMR) were recorded by broadband proton spin 
decoupling at ambient probe temperatures (unless otherwise stated) using an internal deuterium lock on 
the following instruments: Bruker DPX-400 (100 MHz), Bruker Avance 400 QNP (100 MHz), Bruker 
BB 500 (125 MHz) and Bruker Avance 500 Cryo Ultrashield (125 MHz). Chemical shifts (δC) are 
referenced to the residual non-deuterated solvent peak and quoted in parts per million (ppm) to the 
nearest 0.1 ppm. Assignments are supported by either chemical shift, APT/DEPT, two dimensional 
experiments (HMBC and HMQC) or by analogy to fully interpreted spectra for related compounds. 
The numbering of molecules for the assignment of 13C and 1H spectra does not follow the IUPAC 
naming system. 
High resolution mass spectrometry (HRMS) measurements were carried out on a Micromass LCT 
Premier spectrometer using electron spray ionisation (ESI) techniques. Masses are quoted within the 





5.2. Efficient Synthesis of 1,2,4-Triazole heterocycles: cis-diastereomer 
 




General Procedure 1: Acetyl chloride (8 eq.) was added dropwise over 15 minutes to a stirred solution 
of the required nitrile in ethanol (12 eq.). The mixture was stirred at room temperature overnight. The 
solution was cooled to 0 oC before the addition of saturated aqueous sodium hydrogen carbonate until 
the evolution of gas ceased. The solution was then warmed to room temperature and extracted with 
diethyl ether (3 x 150 mL). The combined organic fractions were washed with brine (50 mL) and dried 
(MgSO4) before the solvent was removed under reduced pressure to yield the crude compound. The 
title compound was reacted on without further purification. 
 




Following General Procedure 1: benzonitrile 50 (5.00 mL, 48.5 mmol), acetyl chloride (27.6 mL, 388 
mmol) and ethanol (34 mL, 582 mmol) were used to yield the title compound 53 as a yellow liquid 
(7.11 g, 47.7 mmol, 98%). 
Rf = 0.66 (EtOAc) 
IR νmax = 3301 (w, N-H), 2980 (w, C-H), 1631 (s, C=N), 1578 (m, C=C) 
1H NMR (500 MHz, CDCl3): δH = 7.74 (2H, d, J = 5.5 Hz, H3), 7.46-7.38 (3H, m, H1 & 2), 4.33 (2H, 




13C NMR (126 MHz, CDCl3): δC = 167.9 (C5), 132.9 (C4), 130.7 (C1), 128.5 (C2), 126.6 (C3), 61.8 
(C7), 14.2 (C8) 
HRMS (ESI+): found [M + H]+ 150.0915, C9H12NO+ required 150.0919  
This data is in accordance with that previously reported.285 
 




Following General Procedure 1: 5-hexenenitrile 72 (0.910 mL, 8.00 mmol), acetyl chloride (4.55 mL, 
64.0 mmol) and ethanol (5.60 mL, 96.0 mmol) were used the yield the title compound 77 as an orange 
liquid (1.13 g, 8.00 mmol, 100%). 
Rf = 0.21 (20% EtOAc in hexane) 
IR νmax = 2936 (m, C-H), 1642 (s, C=N), 1537 (s, C=C) 
1H NMR (400 MHz, CDCl3): δH = 11.45 (1H, s, H7), 5.75 (1H, ddt, J = 17.1, 10.3, 7.1 Hz, H2), 4.98 - 
5.09 (2H, m, H1), 4.62 (2H, q, J = 6.9 Hz, H8), 2.73 (2H, t, J = 7.1 Hz, H5), 2.13 (2H, q, J = 7.1 Hz, 
H3), 1.83 (2H, quin, J = 7.1 Hz, H4), 1.47 (3H, t, J = 6.9 Hz, H9) 
13C NMR (101 MHz, CDCl3): δC = 179.1 (C6), 136.3 (C2), 116.3 (C1), 70.6 (C8), 32.6 (C3), 32.4 (C5), 
24.8 (C4), 13.5 (C9) 









Following General Procedure 1: cyclopropanebenzonitrile 72 (2.80 mL, 38.1 mmol), acetyl chloride 
(12.2 mL, 171 mmol) and ethanol (27 mL) was used the yield the title compound as a white solid 78 
(2.97 g, 26.2 mmol, 69%). 
Rf = 0.14 (20 %EtOAc in hexane) 
IR: νmax = 2924 (m, C-H), 1636 (s, C=N), 
1H NMR (400 MHz, d6DMSO): δH = 4.38 (2H, q, J = 7.0 Hz, H5), 2.19 (1H, tt, J = 7.8, 4.6 Hz, H2), 
1.29 (3H, q, J = 7.1 Hz, 6), 1.10 - 1.23 (4H, m, H1) 
13C NMR (101 MHz, CDCl3): δC = 178.9 (C3), 68.6 (C5), 13.2 (C6), 12.3 (C2), 10.0 (C1) 
This data is in accordance with that previously reported.287 
 




Following General Procedure 1: 4-(triflluoromethyl)benzonitrile 73 (123 mg, 0.73 mmol), acetyl 
chloride (0.40 mL, 5.70 mmol) and ethanol (0.5 mL) were used the yield the title compound 79 as a 
yellow liquid (127 mg, 0.58 mmol, 80%). 
Rf = 0.27 (20% EtOAc in hexane) 




1H NMR (400 MHz, d6-DMSO): δH = 8.31 (2H, d, J = 8.2 Hz, H3), 8.02 (2H, d, J = 8.2 Hz, H4), 4.65 
(2H, q, J = 7.0 Hz, H8), 1.49 (3H, t, J = 7.0 Hz, H9) 
13C NMR (101 MHz, CDCl3): δC = 169.8 (C6), 131.3 (C2), 130.4 (C5), 128.8 (C4), 126.4 (C3), 115.6 
(C1), 69.9 (C8), 13.9 (C9) 
HRMS (ESI+): found [M + H]+218.0798, C10H11F3NO+ required 218.0793 
This data is in accordance with that previously reported.288 
 




Following General Procedure 1: 4-bromobenzonitrile 74 (130 mg, 0.73 mmol), acetyl chloride (0.40 
mL, 5.70 mmol) and ethanol (0.5 mL) were used the yield the title compound 80 as a yellow liquid (110 
mg, 0.48 mmol, 66%) Yield calculated from NMR 
Rf = 0.27 (20 %EtOAc in hexane) 
IR νmax = 3403 (s, N-H), 3199 (m, C-H), 1656 (s, C=N), 1621 (s, C=C), 1589 (m, C=C) 
1H NMR (400 MHz, CDCl3): δH = 8.22 (2H, d, J = 8.4 Hz, H2), 7.65 (2H, d, J = 8.4 Hz, H3), 4.89 (2H, 
q, J = 6.4 Hz, H7), 1.57 (1H, t, J = 6.4 Hz, H8) 
13C NMR (101 MHz, CDCl3): δC = 170.2 (C5), 132.6 (C2), 131.3 (C4), 131.0 (C3), 124.1 (C1), 71.6 
(C7), 13.8 (C8) 
HRMS (ESI+): found [M + H]+ 228.0027, C9H11BrNO+ required 228.0024 









Following General Procedure 1: 4-methoxybenzonitrile 75 (1.06 g, 8.00 mmol), acetyl chloride (4.55 
mL, 64.0 mmol) and ethanol (5.6 mL, 96.0 mmol) were used the yield the title compound 81 as an 
orange liquid (1.28 g, 7.14 mmol, 89%). 
Rf = 0.84 (EtOAc) 
IR νmax = 2980 (m, C-H), 1630 (s, C=N), 1607 (s, C=C), 1512 (m, C=C)  
1H NMR (500 MHz, CDCl3): δH = 8.39 - 8.81 (1H, br s, H7), 7.80 (2H, d, J = 9.0 Hz, H4), 6.97 (2H, 
d, J = 9.0 Hz, H3), 4.20 (2H, q, J = 6.8 Hz, H8), 3.79 (3H, s, H1), 1.31 (2H, t, J = 6.8 Hz, H9) 
13C NMR (126 MHz, CDCl3): δC = 161.2 (C6), 131.3 (C2), 128.6 (C4), 114.1 (C5), 113.7 (C3), 60.6 
(C8), 55.4 (C1), 14.3 (C9) 
HRMS (ESI+): found [M + H]+180.1020, C10H14NO2+ required 180.1025 
This data is in accordance with that previously reported.290 
 




Following General Procedure 1: 4-bromophenylacetonitrile 75 (1.70 g, 8.67 mmol), acetyl chloride 
(4.55 mL, 64.0 mmol) and ethanol (5.6 mL, 96.0 mmol) were used the yield the title compound 82 as a 




Rf = 0.77 (EtOAc) 
IR νmax = 3413 (s, N-H), 3109 (m, C-H), 1626 (s, C=N), 1626 (s, C=C), 1523 (m, C=C) 
1H NMR (500 MHz, CDCl3): δH = 7.50 (2H, d, J = 8.5 Hz, H2), 7.23 (2H, d, J=8.5 Hz, H3), 4.07 (2H, 
q, J = 7.2 Hz, H8), 3.66 (2H, s, H5), 1.17 (3H, t, J = 7.2 Hz, H9) 
13C NMR (126 MHz, CDCl3): δC = 170.8 (C6), 134.0 (C4), 131.4 (C2), 131.2 (C3), 120.1 (C1), 60.4 
(C8), 39.0 (C5), 14.1 (C9) 
HRMS (ESI+): found [M + H]+ 242.0185, C10H13BrNO+ required 242.0180 











General Procedure 2: Thionyl chloride (1.4 eq.) was added dropwise over 10 minutes to a stirred 
solution of the N-(benzyloxycarbonyl)amino acid in methanol (0.2 M) at 0 oC. The mixture was stirred 
for 2 hours until the acid had been consumed. The methanol was removed under reduced pressure. The 
crude compound was purified by flash column chromatography on silica to yield the title compound. 
 




Following General Procedure 2: (benzyloxycarbonyl)-L-phenylalanine 49 (12.0 g, 40.1 mmol), thionyl 
chloride (4.09 mL, 56.1 mmol) and methanol (200 mL) were used. The crude product was purified by 
flash column chromatography eluting with ethyl acetate (100%) to yield the title compound 51 as a 
cloudy oil (12.53 g, 39.9 mmol, 99%). 
Rf = 0.70 (EtOAc) 
[𝛂]𝐃
𝟐𝟎 = -13.2 (c = 1.0 in CH3OH) - [Literature Value = -14.4 (c = 1.3 in CH3OH)]292 
IR νmax = 3344 (w, N-H), 2988 (s, C-H), 2901 (s, C-H), 1704 (s, br, C=O), 1497 (m, C=C), 1454 (m, 
C=C), 1406 (m, C=C) 
1H NMR (500 MHz, CDCl3): δH = 7.38-7.31 (5H, m, H1, 2 & 3), 7.30-7.23 (3H, m, H12 & 13), 7.12 




d, J = 12.2 Hz, H5b), 4.68 (1H, dt, J = 6.1, 5.8 Hz, H8), 3.74 (3H, s, H15), 3. 16 (1H, dd, J = 13.7, 5.8 
Hz, H9a), 3.11 (1H, dd, J = 13.8, 6.1 Hz, H9b) 
13C NMR (126 MHz, CDCl3): δC = 171.9 (C14), 155.6 (C6), 136.2 (C4), 135.6 (C10), 129.2 (C11), 
128.6 (C1), 128.5 (C2), 128.2 (C12), 128.1 (C3), 127.1 (C13), 67.0 (C5), 54.8 (C8), 52.3 (C15), 38.2 
(C9) 
HRMS (ESI+): found [M + H]+ 314.1382, C18H20NO4+ required 314.1392 
This data is in accordance with that previously reported.292 
 




Following General Procedure 2: methyl-(benzyloxycarbonyl)-L-serine 83 (9.9 g, 41.4 mmol), thionyl 
chloride (4.23 mL, 57.9 mmol) and methanol (165 mL) were used. The crude product was purified by 
flash column chromatography eluting with 40% ethyl acetate in 40-60 petroleum ether to yield the title 
compound 89 as a pale-yellow oil (10.5 g, 41.3 mmol, 100%). 
Rf = 0.29 (40% EtOAc in 40-60 petroleum ether) 
[𝛂]𝐃
𝟐𝟎 = -12.6 (c = 1.2 in CH3OH) - [Literature Value = -13.2 (c = 10.0 in CH3OH)]293 
IR νmax = 3359 (w, N-H), 3250 (w, br, O-H), 2987 (s, C-H), 2901 (s, C-H), 1695 (s, br, C=O), 1515 (m, 
C=C), 1453 (m, C=C), 1438 (m, C=C), 1406 (m, C=C) 
1H NMR (400 MHz, d6-DMSO): δH = 7.54 (1H, d, J = 8.2 Hz, H7), 7.35 - 7.40 (4H, m, H2 & 3), 7.29 
- 7.34 (1 H, m, H1) 5.04 (2H, s, H5), 4.97 (1 H, t, J = 6.0 Hz, H10) 4.15 (1H, dt, J = 8.2, 5.2 Hz, H8), 
3.66 (2H, t, J=5.2 Hz, H9), 3.63 (3H, s, H12),  
13C NMR (101 MHz, CDCl3): δC = 171.4 (C11), 156.1 (C6), 137.0 (C4), 128.5 (C2), 128.0 (C1), 127.9 
(C3), 65.7 (C5), 61.3 (C9), 56.8 (C8), 52.0 (C12) 
HRMS (ESI+): found [M + H]+ 254.1032, C12H16NO5+ required 254.1028  








Following General Procedure 2: methyl-(benzyloxycarbonyl)-L-valine 84 (9.90 g, 39.4 mmol), thionyl 
chloride (4.03 mL, 55.2 mmol) and methanol (165 mL) were used. The crude product was purified by 
flash column chromatography eluting with ethyl acetate (100%) to yield the title compound 90 as a 
cloudy oil (10.5 g, 39.4 mmol, 100%). 
Rf = 0.68 (EtOAc) 
[𝛂]𝐃
𝟐𝟎 = -19.7 (c = 1.0 in CH3OH) - [Literature Value = -19.4 (c = 1.0 in CH3OH)]294 
IR νmax = 3364 (w, N-H), 2972 (s, C-H), 2901 (s, C-H), 1705 (s, br, C=O), 1512 (m, C=C), 1454 (m, 
C=C), 1436 (m, C=C), 1406 (m, C=C) 
1H NMR (500 MHz, d6-DMSO): δH = 7.63 - 7.74 (1H, d, J = 8.1 Hz, H7), 7.33 - 7.40 (4H, m, H2 & 
H3), 7.29 - 7.33 (1H, m, H1), 5.03 (2H, s, H5), 3.92 (1H, dd, J = 8.1, 6.5 Hz, H8), 3.63 (3H, s, H13), 
2.02 (1H, qd, J = 6.8, 6.5 Hz, H9), 0.87 (3H, d, J = 6.8 Hz, H10/11), 0.86 (3H, d, J = 6.8 Hz, H10/11) 
13C NMR (126 MHz, d6-DMSO): δC = 127.8 (C12), 156.8 (C6), 137.4 (C4), 128.8 (C2), 128.3 (C1), 
128.2 (C3), 66.0 (C5), 60.2 (C8), 52.1 (C13), 30.1 (C9), 19.4, 18.7 (C10 & 11) 
HRMS (ESI+): found [M + Na]+ 266.1386, C14H20NO4+ required 266.1387 









Following General Procedure 2: methyl-(benzyloxycarbonyl)-L-tryptophan 85 (2.00 g, 5.91 mmol), 
thionyl chloride (0.60 mL, 8.27 mmol) and methanol (30 mL) were used. The crude product was 
purified by flash column chromatography eluting with 40% ethyl acetate in 40-60 petroleum ether to 
yield the title compound 91 as a brown oil (2.05 g, 5.82 mmol, 98%). 
Rf = 0.63 (40% EtOAc in 40-60 petroleum ether) 
[𝛂]𝐃
𝟐𝟎 = -10.1 (c = 0.7 in CH3OH) - [Literature Value = -11.0 (c = 0.4 in CH3OH)]295 
IR νmax = 3407 (w, br, N-H), 2988 (s, C-H), 2901 (s, C-H), 1697 (s, br, C=O), 1507 (m, C=C), 1455 (m, 
C=C), 1435 (m, C=C), 1407 (m, C=C) 
1H NMR (400 MHz, d6-DMSO): δH = ppm 10.88 (1H, br s, H17), 7.79 (1H, d, J = 7.8 Hz, H7), 7.51 
(1H, d, J = 7.5 Hz, H12), 7.25 - 7.38 (4H, m, H1, 2, 3 & 15), 7.17 (1H, d, J = 1.4 Hz, H18), 7.07 (1H, 
t, J = 7.2 Hz, H14), 6.95 - 7.02 (1H, m, H13), 4.92 - 5.06 (2H, m, H5), 4.21 - 4.41 (1H, m, H8), 3.61 
(3H, s, H20), 3.19 (1H, dd, J = 14.8, 5.2 Hz, H9a), 3.03 (1H, dd, J = 14.8, 9.2 Hz, H9b) 
13C NMR (101 MHz, d6-DMSO): δC = 172.8 (C19), 156.1 (C6), 136.9 (C4), 136.2 (C16), 128.4 (C2), 
127.9 (C1), 127.7 (C3), 127.1 (C11) 123.9 (C18), 121.1 (C14), 118.5 (C13), 118.1 (C12), 111.6 (C15), 
109.7 (C10), 65.2 (C5), 55.1 (C8), 52.0 (C20), 27.0 (C9) 
HRMS (ESI+): found [M + H]+ 353.1500, C20H21N2O4+ required 353.1501  











Following General Procedure 2: methyl-(benzyloxycarbonyl)-L-tyrosine 86 (2.00 g, 6.34 mmol), 
thionyl chloride (0.65 mL, 8.88 mmol) and methanol (35 mL) were used. The crude product was 
purified by flash column chromatography eluting with 40% ethyl acetate in 40-60 petroleum ether to 
yield the title compound 92 as a yellow-orange oil (2.09 g, 6.34 mmol, 100%). 
Rf = 0.54 (40% EtOAc in 40-60 petroleum ether) 
[𝛂]𝐃
𝟐𝟎 = -7.2 (c = 0.9 in CH3OH) - [Literature Value = -7.9 (c = 0.5 in CH3OH)]296 
IR νmax = 3362 (w, br, O-H), 3360 (w, N-H), 2988 (s, C-H), 2901 (s, C-H), 1694 (s, br, C=O), 1513 (s, 
C=C), 1437 (s, C=C), 1407 (s, C=C) 
1H NMR (400 MHz, d6-DMSO): δH = 9.27 (1H, s, H14), 7.77 (1H, d, J = 8.2 Hz, H7), 7.19 - 7.49 (5H, 
m, H1, 2 & 3), 7.02 (2H, d, J = 7.5 Hz, H11), 6.68 (2H, d, J = 7.5 Hz, H12), 4.98 (2H, s, H5), 4.04 - 
4.31 (1H, m, H8), 3.61 (3H, s, H16), 2.91 (1H, dd, J = 13.6, 4.4 Hz, H9a), 2.67 - 2.81 (1H, m, H9b) 
13C NMR (101 MHz, d6-DMSO): δC = 172.6 (C15), 156.1 (C13), 137.0 (C6), 130.1 (C11), 128.4 (C2), 
127.8 (C1), 127.6 (C3), 127.4 (C10), 115.1 (C12), 65.4 (C5), 56.0 (C8), 52.0 (C16), 35.9 (C9) 
HRMS (ESI+): found [M + H]+ 352.1152, C18H19NO5S+ required 352.1155 









Following General Procedure 2: methyl-(benzyloxycarbonyl)-L-proline 87 (2.00 g, 8.02 mmol), thionyl 
chloride (0.82 mL, 11.2 mmol) and methanol (40 mL) were used. The crude product was purified by 
flash column chromatography eluting with 40% ethyl acetate in 40-60 petroleum ether to yield the title 
compound 93 as a yellow oil (2.02 g, 7.67 mmol, 96%). 
Rf = 0.45 (40%EtOAc in 40-60 petroleum ether) 
[𝛂]𝐃
𝟐𝟎 = -52.8 (c = 1.0 in CH3OH) - [Literature Value = -57.0 (c = 1.0 in CH3OH)]297 
IR νmax = 2988 (s, C-H), 2901 (s, C-H), 1744 (s, C=O), 1699 (s, C=O), 1409 (s, C=C) 
1H NMR (400 MHz, d6-DMSO): δH = 7.22 - 7.42 (5H, m, H1, 2 & 3), 4.92 - 5.14 (2H, m, H5), 4.22 - 
4.36 (1H, m, H10), 3.52 - 3.68 (3H, m, H12), 3.30 - 3.50 (2H, m, H7), 2.12 - 2.33 (1H, m, H9a), 1.74 - 
1.96 (3H, m, H8 & 9b) – Mixture of rotamers 
13C NMR (101 MHz, d6-DMSO): δC = 173.1, 172.8 (C11), 154.1, 153.5 (C6), 137.0, 136.9 (C4), 128.5, 
128.4 (C2), 127.9, 127.8 (C1), 127.6, 127.3 (C3), 66.1, 66.1 (C5), 58.9, 58.4 (C10), 52.0 (C12), 46.9, 
46.3 (C7), 30.5, 29.5 (C9), 24.1, 23.2 (C8) 
HRMS (ESI+): found [M + Na]+ 286.1046, C14H17NO4Na+ required 286.1055 










Following General Procedure 2: methyl-(benzyloxycarbonyl)-L-methionine 88 (2.00 g, 7.06 mmol), 
thionyl chloride (0.72 mL, 9.88 mmol) and methanol (35 mL) were used. The crude product was 
purified by flash column chromatography eluting with 40% ethyl acetate in 40-60 petroleum ether to 
yield the title compound 94 as a yellow oil (2.10 g, 7.06 mmol, 100%). 
Rf = 0.88 (40% EtOAc in 40-60 petroleum ether) 
[𝛂]𝐃
𝟐𝟎 = -32.5 (c = 1.1 in CH3OH) - [Literature Value = -34.1 (c = 1.1 in CH3OH)]298 
IR νmax = 3339 (m, N-H), 2988 (s, C-H), 2901 (s, C-H), 1746 (s, C=O), 1685 (s, C=O), 1526 (s, C=C), 
1443 (m, C=C), 1406 (m, C=C) 
1H NMR (400 MHz, d6-DMSO): δH = 7.79 (1H, d, J = 7.8 Hz, H7), 7.24 - 7.44 (5H, m, H1, 2 & 3), 
5.04 (2H, s, H5), 4.15 - 4.27 (1H, m, H8), 3.64 (3H, s, H13), 2.52 - 2.48 (2H, m, H10), 2.02 (3H, s, 
H11), 1.80 - 1.98 (2H, m, H9) 
13C NMR (101 MHz, d6-DMSO): δC = 172.7 (C12), 156.2 (C6), 137.0 (C4), 128.5 (C2), 128.0 (C1), 
127.8 (C3), 65.6 (C5), 52.8 (C8), 52.1 (C13), 30.3 (C9), 29.6 (C10), 14.6 (C11) 
HRMS (ESI+): found [M + Na]+ 320.0920, C14H19NO4SNa+ required 320.0927 










General Procedure 3: A solution of the methyl ((benzyloxy)carbonyl) amino ester and hydrazine 
monohydrate (5 eq.) in methanol (0.5 M) was stirred overnight at room temperature. Water (0.25 M) 
was added and the product collected by vacuum filtration. The title compound was carried forward 
without further purification. 
 




Following General Procedure 3: methyl ((benzyloxy)carbonyl)-L-phenylalaninate 51 (12.92 g, 41.2 
mmol) and hydrazine monohydrate (10 mL, 206 mmol) in methanol (85 mL) were used to yield the title 
compound 52 as a white solid (12.24 g, 39.1 mmol, 95%). 
Rf = 0.23 (EtOAc) 
[𝛂]𝐃
𝟐𝟎 = -4.2 (c = 1.1 in CH3OH) - [Literature Value = +10.3 (c = 1.0 in CH3OH)]299 
IR νmax = 3298 (m, N-H), 2988 (s, C-H), 2901 (s, C-H), 1688 (m, C=O), 1651 (m, C=O), 1626 (m, 
C=C), 1606 (m, C=C), 1535 (s, C=C), 1493 (w, C=C), 1454 (w, C=C) 
1H NMR (500 MHz, d6-DMSO): δH = 9.22 (1H, br s, H15), 7.52 (1H, d, J = 8.5 Hz, H7), 7.03 - 7.41 
(10H, m, H1, 2, 3, 11, 12 & 13), 4.91 (2H, s, H5), 4.23 - 4.40 (2H, br, H16), 4.18 (1H, ddd, J = 10.2, 




13C NMR (126 MHz, CDCl3): δC = 170.8 (C14), 155.8 (C6), 138.2 (C10), 137.1 (C4), 129.3 (C12), 
128.4, 128.1 (C2 & 11), 127.8 (C1), 127.6 (C3), 126.3 (C13), 65.2 (C5), 55.0 (C8), 37.8 (C9) 
HRMS (ESI+): found [M + H]+ 314.1505, C17H20N3O3+ required 314.1505 
This data is in accordance with that previously reported.299 
 




Following General Procedure 3: methyl ((benzyloxy)carbonyl)-L-serinate 89 (9.00 g, 35.5 mmol) and 
hydrazine monohydrate (8.62 mL, 178 mmol) in methanol (65 mL) were used to yield the title 
compound 95 as a white solid (7.74 g, 30.5 mmol, 86%). 
Rf = 0.48 (EtOAc) 
[𝛂]𝐃
𝟐𝟎 = -18.0 (c = 1.0 in CH3OH)  
IR νmax = 3282 (s, br, O-H, N-H), 2988 (s, C-H), 2901 (s, C-H), 1690 (s, C=O), 1651 (s, C=O), 1615 
(m, C=C), 1536 (s, C=C), 1463 (m, C=C), 1451 (m, C=C) 
1H NMR (500 MHz, d6-DMSO): δH = 9.10 (1H, br s, H12), 7.35 - 7.40 (4H, m, H2 & 3), 7.27 - 7.34 
(1H, m, H1) 7.15 (1H, d, J = 8.5 Hz, H7), 5.02 (2H, s, H5), 4.84 (1H, t, J = 5.8 Hz, H10), 4.21 (2H, br 
s, H13), 4.02 (1H, dt, J = 8.5, 6.0 Hz, H8), 3.47 - 3.58 (2H, m, H9) 
13C NMR (126 MHz, d6-DMSO): δC = 169.8 (C11), 156.2 (C6), 137.5 (C4), 128.8 (C2), 128.2 (C1), 
128.2 (C3), 65.9 (C5), 62.2 (C9), 56.5 (C8) 
HRMS (ESI+): found [M + H]+ 254.1135, C11H16N3O4+ required 254.1141  










Following General Procedure 3: methyl ((benzyloxy)carbonyl)-L-valinate 90 (9.00 g, 33.92 mmol) and 
hydrazine monohydrate (8.23 mL, 169 mmol) in methanol (65 mL) were used to yield the title 
compound 96 as a white solid (8.85 g, 33.4 mmol, 98%). 
Rf = 0.78 (EtOAc) 
[𝛂]𝐃
𝟐𝟎 = +6.6 (c = 1.0 in DMF) - [Literature Value = -12.6 (c = 1.0 in CH3OH)]299 
 
IR νmax = 3313 (m, N-H), 3246 (m, N-H), 2971 (s, C-H), 2901 (s, C-H), 1683 (m, C=O), 1656 (s, C=O), 
1527 (s, C=C), 1469 (m, C=C), 1454 (m, C=C) 
1H NMR (500 MHz, CDCl3): δH = 9.09 (1H, br s, H13), 7.28 - 7.37 (5H, m, H1, 2 & 3), 7.25 (1H, d, J 
= 8.4 Hz, H7), 4.98 (2H, s, H5), 4.21 (2H, d, J = 4.0 Hz, H14), 3.73 (1H, t, J = 8.4 Hz, H8), 1.88 (1H, 
dq, J = 8.4, 6.7 Hz, H9), 0.83 (3H, d, J = 6.7 Hz, H10/11), 0.81 (3H, d, J = 6.7 Hz, H10/11) 
13C NMR (126 MHz, CDCl3): δC = 170.9 (C12), 156.4 (C6), 137.6 (C4), 128.8 (C2), 128.2 (C1), 128.1 
(C3), 65.8 (C5), 59.5 (C8), 30.7 (C9), 19.6, 19.0 (C10 & 11)  
HRMS (ESI+): found [M + H]+ 266.1494, C13H20N3O3+ required 266.1505 











Following General Procedure 3: methyl ((benzyloxy)carbonyl)-L-tryptophanate 91 (2.00 g, 4.26 mmol) 
and hydrazine monohydrate (1.38 mL, 28.4 mmol) in methanol (10 mL) were used to yield the title 
compound 97 as a beige solid (1.24 g, 3.51 mmol, 82%). 
Rf = 0.80 (EtOAc) 
[𝛂]𝐃
𝟐𝟎 = -20.6 (c = 1.0 in DMF)  
IR νmax = 3431 (w, N-H), 3296 (m, N-H), 3248 (w, N-H), 2988 (s, C-H), 2901 (s, C-H), 1682 (s, C=O), 
1648 (s, C=O). 1619 (m, C=C), 1538 (m, C=C), 1461 (m, C=C), 1490 (m, C=C) 
1H NMR (500 MHz, d6-DMSO): δH = 10.79 (1H, br s, H17), 9.24 (1H, s, H20), 7.61 (1H, d, J = 7.5 Hz, 
H12), 7.40 (1H, d, J = 8.2 Hz, H7), 7.20 - 7.35 (6H, m, H1, 2, 3 & 15), 7.13 (1H, s, H18), 7.05 (1H, t, 
J = 7.5 Hz, H14), 6.96 (1H, t, J = 7.5 Hz, H13), 4.94 (1H, d, J = 12.5 Hz, H5a), 4.90 (1H, d, J = 12.5 
Hz, H5b), 4.11 - 4.39 (2H, m, H8), 3.03 (1H, dd, J = 14.5, 5.0 Hz, H9a), 2.90 (1H, dd, J = 14.5, 9.6 Hz, 
H9b) 
13C NMR (126 MHz, d6-DMSO): δC = 171.2 (C19), 155.8 (C6), 137.1 (C4), 136.1 (C16), 128.4 (C2), 
127.8 (C1), 127.6 (C3), 127.3 (C11), 123.9 (C18), 120.9 (C14), 118.6, 118.3 (C12 & 13), 111.4 (C15), 
110.2 (C10), 65.3 (C5), 54.2 (C8), 28.1 (C9) 
HRMS (ESI+): found [M + H]+ 353.1622, C19H21N4O3+ required 353.1614  











Following General Procedure 3: methyl ((benzyloxy)carbonyl)-L-tyrosinate 92 (1.50 g, 4.55 mmol) and 
hydrazine monohydrate (1.10 mL, 22.8 mmol) in methanol (10 mL) were used to yield the title 
compound 98 as a white solid (1.27 g, 3.86 mmol, 85%). 
Rf = 0.78 (EtOAc) 
[𝛂]𝐃
𝟐𝟎 = -11.9 (c = 0.6 in DMF) - [Literature Value = -11.2 (c = 1.0 in DMF)]302 
IR νmax = 3295 (m, N-H), 3267 (m, O-H), 2988 (s, C-H), 2901 (s, C-H), 1689 (s, C=O), 1665 (s, C=O), 
1625 (m, C=C), 1532 (m, C=C), 1513 (m, C=C0, 1453 (m, C=C) 
1H NMR (400 MHz, d6-DMSO): δH = 9.17 (1H, s, H16/17), 9.16 (1H, s, H16/17), 7.44 (1H, d, J = 8.9 
Hz, H7), 7.20 - 7.36 (5H, m, H1, 2 & 3), 7.03 (2H, d, J = 8.7 Hz, H11), 6.63 (1H, d, J = 8.7 Hz, H12), 
4.92 (2H, s, H5), 4.21 (2H, br S, H17), 4.09 (1H, ddd, J = 10.2, 8.9, 4.8 Hz, H8), 2.77 (1H, dd, J = 13.6, 
4.8 Hz, H9a), 2.62 (1H, dd, J = 13.6, 10.2 Hz, H9b) 
13C NMR (101 MHz, d6-DMSO): δC = 171.0 (C15), 155.8, 155.7 (C6 & 13) 137.2 (C4), 130.2 (C11), 
128.4 (C2), 128.2 (C10), 127.7 (C1), 127.5 (C3), 114.9 (C12), 65.2 (C5), 55.4 (C8), 37.1 (C9) 
HRMS (ESI+): found [M + H]+ 330.1467, C17H20N3O4+ required 330.1454  












Following General Procedure 3: methyl ((benzyloxy)carbonyl)-L-pyrrolinate 93 (1.50 g, 5.70 mmol) 
and hydrazine monohydrate (1.38 mL, 28.5 mmol) in methanol (12 mL) were used to yield the title 
compound 99 as a brown solid (1.44 g, 5.47 mmol, 96%). 
Rf = 0.68 (EtOAc) 
[𝛂]𝐃
𝟐𝟎 = -48.5 (c = 1.0 in CH3OH) 
IR νmax = 3315 (w, br, N-H), 3248 (w, br, N-H), 2987 (s, C-H), 2901 (s, C-H), 1659 (s, br, C=O), 1520 
(m, C=C), 1411 (s, C=C) 
1H NMR (500 MHz, d6-DMSO): δH = 9.15 (2H, d, J = 11.9 Hz, H12), 7.25 - 7.44 (10H, m, H1, 2 & 3), 
5.00 - 5.10 (4H, m, H5), 4.21 (2H, br s, H13), 4.16 (1H, dd, J = 8.2, 3.4 Hz, H10), 4.12 (1H, dd, J = 
8.4, 3.2 Hz, H10), 3.37 - 3.52 (4H, m, H7), 2.01 - 2.17 (2H, m, H9a), 1.73 - 1.91 (6H, m, H8 & 9b) – 
mixture of rotamers 
13C NMR (126 MHz, d6-DMSO): δC = 171.9, 171.6 (C11), 154.4, 154.2 (C6), 137.5 (C4), 128.8, 128.8 
(C2), 128.2, 128.0 (C1), 127.9, 127.5 (C3), 66.3, 66.2 (C5), 59.3, 58.7 (C10), 47.5, 46.9 (C7), 31.6, 
30.5 (C9), 24.4, 23.5 (C8) 
HRMS (ESI+): found [M + H]+ 264.1336, C13H18N3O3+ required 264.1348  












Following General Procedure 3: methyl ((benzyloxy)carbonyl)-L-methionate 88 (1.05 g, 3.53 mmol) 
and hydrazine monohydrate (0.86 mL, 17.6 mmol) in methanol (10 mL) were used to yield the title 
compound 100 as a grey solid (849 mg, 2.86 mmol, 81%). 
Rf = 0.80 (EtOAc) 
[𝛂]𝐃
𝟐𝟎 = -17.9 (c = 1.0 in CH3OH) - [Literature Value = -14.1 (c = 1.0 in CH3OH)]304 
IR νmax = 3289 (s, N-H), 2988 (s, C-H), 2901 (s, C-H), 1691 (s, C=O), 1649 (s, C=O), 1534 (s, C=C), 
1443 (m, C=C) 
1H NMR (500 MHz, d6-DMSO): δH = 9.11 (1H, br s, H13), 7.44 (1H, d, J = 8.2 Hz, H7), 7.32 - 7.38 
(3H, m, H1 & 3), 7.26 - 7.32 (2H, m, H2), 4.99 (2H, s, H5), 4.20 (2H, br s, H14), 4.02 (1H, td, J = 8.2, 
5.8 Hz, H8), 2.35 - 2.48 (2H, m, H10), 2.01 (3H, s, H11), 1.73 - 1.88 (2H, m, H9) 
13C NMR (126 MHz, d6-DMSO): δC = 170.8 (C13), 155.9 (C6), 137.1 (C4), 128.4 (C2), 127.9 (C1), 
127.8 (C3), 65.5 (C5), 52.6 (C8), 31.8 (C9), 29.7 (C10), 14.6 (C11) 
HRMS (ESI+): found [M + H]+ 298.1219, C17H20N3O3S+ required 298.1225 











General Procedure 4: A stirred solution of the required imidate (1.2 eq.) and methyl 
((benzyloxy)carbonyl) amino hydrazide (1.0 eq.) in ethanol (0.5 M) was heated at reflux for 2 hours. 
Acetic acid (1 M) was added and the solution was refluxed for 2 hours. The solvent was removed under 
reduced pressure. The resultant crude product was purified by flash column chromatography to yield 
the title compound  
 




Following General Procedure 4: ethyl benzimidate 53 (4.00 g, 12.8 mmol) and benzyl (S)-(1-
hydrazinyl-1-oxo-3-phenylpropan-2-yl)carbamate 52 (2.28 g, 15.3 mmol) in ethanol (25 mL), followed 
by acetic acid (13 mL) were used. The crude product was purified by flash column chromatography 
eluting with 50% ethyl acetate in hexane to yield the title compound 54 as a white solid (4.35 g, 10.9 
mmol, 85%). 
Rf = 0.56 (50% EtOAc in hexane) 
[𝛂]𝐃




IR νmax = 3250 (w, br, N-H), 2988 (s, C-H), 2901 (s, C-H), 1691 (s, C=O), 1495 (m, C=C), 1454 (m, 
C=C) 
1H NMR (500 MHz, d6-DMSO): δH = 8.01 (2H, d, J = 7.0 Hz, H3), 7.50 (3H, br s, H 1 & 2), 7.33 (2H, 
d, J = 7.3 Hz, H18/19), 7.30 (1H, d, J = 7.3 Hz, H20), 7.25 - 7.29 (6H, m, H11, 12 & 18/19), 7.22 (1H, 
dt, J = 8.2, 4.1 Hz, H13), 5.00 (1H, d, J = 12.8 Hz, H16a), 4.96 (2H, d, J = 12.8 Hz, H8 & 16b), 3.29 
(1H, dd, J = 13.6, 4.4 Hz, H9a), 3.10 (1H, t, J = 13.6 Hz, H9b) 
13C NMR (126 MHz, d6-DMSO): δC = 161.0 (C7), 158.1 (C5), 155.8 (C15), 138.0 (C17), 137.2 (C10), 
131.5 (C4), 129.3 (C12), 128.9 (C1), 128.3 (C2), 128.2, 128.1 (C11 & 19) 127.7 (C20), 127.5 (C18), 
126.4 (C13), 125.9 (C3), 65.3 (C16), 49.8 (C8), 39.5 (C9) 
HRMS (ESI+): found [M + H]+ 399.1814, C24H23N4O2+ required 399.1816. 
 




Following General Procedure 4: ethyl hex-5-enimidate 77 (0.65 g, 4.62 mmol) and benzyl (S)-(1-
hydrazinyl-1-oxo-3-phenylpropan-2-yl)carbamate 52 (1.21 g, 3.85 mmol) in ethanol (8 mL), followed 
by acetic acid (4 mL) were used. The crude product was purified by flash column chromatography 
eluting with 40% ethyl acetate in 40-60 petroleum ether to yield the title compound 101 as a yellow 
liquid (1.29 g, 3.30 mmol, 86%). 
Rf = 0.32 (40% EtOAc in 40-60 petroleum ether) 
[𝛂]𝐃
𝟐𝟎 = -15.9 (c = 0.4 in CH3OH) 
IR νmax = 3237 (w, N-H), 2988 (s, C-H), 2902 (s, C-H), 1694 (s, C=O), 1522 (m, C=C), 1495 (m, C=C), 




1H NMR (500 MHz, d6-DMSO): δH = 13.34 - 13.43 (1H, m, H7), 7.68 (1H, d, J = 9.2 Hz, H15), 7.27 - 
7.36 (3H, m, H12/19 & 21), 7.15 - 7.26 (7H, m, H12/19, 13, 14 & 20), 5.83 (1H, ddd, J = 17.1, 10.4, 
7.5 Hz, H2), 4.91 - 5.08 (4H, m, H1 & 17), 4.83 (1H, td, J = 9.6, 5.5 Hz, H9), 3.15 (1H, dd, J = 13.7, 
5.5 Hz, H10a), 2.98 (1H, dd, J = 13.7, 9.6 Hz, H10b), 2.68 (2H, t, J = 7.5 Hz, H5), 2.06 (2H, q, J = 7.5 
Hz, H3), 1.75 (2H, quin, J = 7.5 Hz, H4) 
13C NMR (126 MHz, d6-DMSO): δC = 164.0 (C8), 157.0 (C6), 156.1 (C16), 139.0 (C11), 138.4 (C2), 
137.7 (C18), 129.7 (C13), 128.7, 128.4 (C12 & 19), 128.0 (C21), 127.8 (C19), 126.5 (C14), 115.8 (C1), 
65.4 (C17), 51.5 (C9), 39.5 (C10), 33.0 (C3), 27.0 (C4), 25.6 (C5) 
HRMS (ESI+): found [M + H]+ 391.2122, C23H26N4O2+ required 391.2134. 
 




Following General Procedure 4: ethyl cyclopropanecarbimidate 78 (0.95 g, 8.42 mmol) and benzyl (S)-
(1-hydrazinyl-1-oxo-3-phenylpropan-2-yl)carbamate 52 (2.10 g, 7.02 mmol) in ethanol (14 mL), 
followed by acetic acid (7 mL) were used. The crude product was purified by flash column 
chromatography eluting with 50% ethyl acetate in 40-60 petroleum ether to yield the title compound 
102 as a white solid (2.07 g, 5.71 mmol, 81%). 
Rf = 0.30 (50% EtOAc in 40-60 petroleum ether) 
[𝛂]𝐃
𝟐𝟎 = -16.0 (c = 0.2 in CH3Cl) 
IR νmax = 3315 (m, N-H), 2988 (s, C-H), 2901 (s, C-H), 1682 (s, C=O), 1511 (m, C=C), 1452 (w, C=C), 
1393 (m, C=C) 
1H NMR (500 MHz, d6-DMSO): δH = 17.87 (1H, d, J = 7.9 Hz, H4), 7.64 (1H, d, J = 8.9 Hz, H12), 




(1H, dd, J = 10.4, 5.8 Hz, H6), 3.11 (1H, dd, J = 13.5, 5.8 Hz, H7a), 2.95 (1H, dd, J = 13.5, 10.4 Hz, 
H7b), 1.88 - 2.02 (1H, m, H2), 0.99 (2H, d, J = 6.1 Hz, H1a), 0.86 (2H, br s, H1b) 
13C NMR (126 MHz, d6-DMSO): δC = 163.4 (C5), 158.6 (C3), 155.6 (C13), 138.5 (C8), 137.3 (C15), 
129.2 (C10), 128.2, 128.0 (C9 & 17), 127.6 (C18), 127.3 (C16), 126.1 (C11), 64.9 (C14), 51.0 (C6), 
8.0 (C1), 7.0 (C2) – Peak 7 obscured by DMSO peak 







Following General Procedure 4: ethyl 4-(trifluoromethyl)benzimidate 79 (0.84 g, 3.86 mmol) and 
benzyl (S)-(1-hydrazinyl-1-oxo-3-phenylpropan-2-yl)carbamate 52 (1.01 g, 3.22 mmol) in ethanol (7 
mL), followed by acetic acid (3.5 mL) were used. The crude product was purified by flash column 
chromatography eluting with 40% ethyl acetate in 40-60 petroleum ether to yield the title compound 
103 as a white solid (1.27 g, 2.73 mmol, 85%). 
Rf = 0.70 (40% EtOAc in 40-60 petroleum ether) 
[𝛂]𝐃
𝟐𝟎 = -2.3 (c = 0.4 in CH3OH) 
IR νmax = 3250 (w, N-H), 2988 (s, C-H), 2901 (s, C-H), 1698 (s, C=O), 1529 (m, C=C), 1439 (m, C=C) 
1H NMR (500 MHz, d6-DMSO): δH = 14.03 - 14.43 (1H, m, H7), 8.21 (2H, d, J = 8.0 Hz, H4), 8.03 
(1H, br s, H15), 7.86 (2H, d, J = 8.0 Hz, H3), 7.23 - 7.36 (9H, m, H12, 13, 19, 20 & 21), 7.18 - 7.23 
(1H, m, H14), 5.02 (1H, m, H9), 5.02 (1H, d, J = 16.0 Hz, H17a), 4.95 (1H, d, J = 16.0 Hz, H17b), 3.30 




13C NMR (126 MHz, d6-DMSO): δC = 159.7 (C6), 158.6 (C8), 155.8 (C16), 137.1 (C11), 136.1 (C18), 
135.3 (C5), 129.3 (C13), 128.4, 128.3, 127.8 (C12, 19, 21), 127.5 (C20), 126.8 (C2), 126.5 (C4), 125.9 
(C3), 125.4 (C14), 123.2 (C1), 65.4 (C17), 49.7 (C9), 38.9 (C10) 
HRMS (ESI+): found [M + H]+ 467.1690, C25H22F3N4O2+ required 467.1695. 
 




Following General Procedure 4: ethyl 4-bromobenzimidate 80 (0.86 g, 3.77 mmol) and benzyl (S)-(1-
hydrazinyl-1-oxo-3-phenylpropan-2-yl)carbamate 52 (0.99 g, 3.14 mmol) in ethanol (7 mL), followed 
by acetic acid (3.5 mL) were used. The crude product was purified by flash column chromatography 
eluting with 40% ethyl acetate in 40-60 petroleum ether to yield the title compound 104 as a white solid 
(1.36 g, 2.86 mmol, 91%). 
Rf = 0.66 (40% EtOAc in 40-60 petroleum ether) 
[𝛂]𝐃
𝟐𝟎 = +1.7 (c = 0.5 in CH3OH)  
IR νmax = 3250 (w, N-H), 2988 (s, C-H), 2901 (s, C-H), 1699 (m, C=O), 1533 (m, C=C), 1406 (m, C=C) 
1H NMR (500 MHz, d6-DMSO): δH = 14.02 (1H, br s, H6), 8.03 (1H, d, J = 6.7 Hz, H14), 7.96 - 7.92 
(2H, m, H3), 7.63 - 7.79 (2H, m, H2), 7.17 - 7.37 (10H, m, H11, 12, 13, 18, 19 & 20), 4.87 - 5.07 (3H, 
m, H8 & 16), 3.28 (1H, m, J = 18.3 Hz, H9a), 3.11 (1H, m, J = 18.3 Hz, H9b) 
13C NMR (126 MHz, d6-DMSO): δC = 160.5 (C5), 158.7 (C7), 156.2 (C15), 138.0 (C10), 137.4 (C17), 
132.2 (C2), 131.1 (C4), 129.7 (C12), 128.7 (C19), 128.6 (C11), 128.2 (C20), 128.1 (C3), 127.9 (C18), 
126.9 (C13), 122.6 (C1), 65.4 (C16), 49.6 (C8), 38.9 (C9) 








Following General Procedure 4: ethyl 4-methoxybenzimidate 81 (0.75 g, 4.20 mmol) and benzyl (S)-
(1-hydrazinyl-1-oxo-3-phenylpropan-2-yl)carbamate 52 (1.10 g, 3.50 mmol) in ethanol (9 mL), 
followed by acetic acid (4.5 mL) were used. The crude product was purified by flash column 
chromatography eluting with 50% ethyl acetate in 40-60 petroleum ether to yield the title compound 
105 as a white solid (1.31 g, 3.05 mmol, 87%). 
Rf = 0.52 (50% EtOAc in 40-60 petroleum ether) 
[𝛂]𝐃
𝟐𝟎 = +4.7 (c = 0.5 in CH3OH)  
IR νmax = 3220 (w, br, N-H), 2988 (s, C-H), 2901 (s, C-H), 1692 (s, C=O), 1614 (m, C=C), 1583 (w, 
C=C), 1496 (m, C=C) 
1H NMR (400 MHz, d6-DMSO): δH = 7.89 (2H, d, J = 8.5 Hz, H4), 7.29 (3H, dd, J = 5.2, 1.8 Hz, H20 
& 21), 7.20 - 7.25 (2H, m, H12), 7.15 - 7.19 (3H, m, H13 & 14), 7.09 (2H, d, J = 5.2 Hz, H19), 6.90 
(2H, d, J = 8.5 Hz, H3), 6.31 (1H, d, J = 7.4 Hz, H15), 5.29 (1H, q, J = 7.4 Hz, H9), 5.09 (1H, d, J = 
12.5 Hz, H17a), 4.96 (1H, d, J = 12.2 Hz, H17b), 3.83 (3H, s, H1), 3.30 (1H, dd, J = 13.7, 6.7 Hz, 
H10a), 3.24 (1H, dd, J = 13.7, 7.9 Hz, H10b) 
13C NMR (126 MHz, CDCl3): δC = 160.9, 158.9 (C2 & 6), 156.3 (C8), 136.5 (C11), 136.1 (C18), 129.3 
(C13), 128.4, 128.4 (C12 & 20), 128.0 (C19), 127.8 (C3), 126.7 (C14), 121.4 (C5), 114.2 (C4), 66.9 
(C17) 55.3 (C1), 50.2 (C9), 40.5 (C10) 









Following General Procedure 4: ethyl 2-(4-bromophenyl)acetimidate 82 (0.89 g, 3.67 mmol) and benzyl 
(S)-(1-hydrazinyl-1-oxo-3-phenylpropan-2-yl)carbamate 52 (0.96 g, 3.06 mmol) in ethanol (7 mL), 
followed by acetic acid (3.5 mL) were used. The crude product was purified by flash column 
chromatography eluting with 40% ethyl acetate in 40-60 petroleum ether to yield the title compound 
106 as a white solid (0.78 g, 1.58 mmol, 52%). 
Rf = 0.32 (40% EtOAc in 40-60 petroleum ether) 
[𝛂]𝐃
𝟐𝟎 = -4.7 (c = 0.4 in CH3OH) 
IR: νmax = 3337 (w, N-H), 2988 (s, C-H), 2901 (s, C-H), 1682 (m, C=O), 1522 (m, C=C), 1488 (m, 
C=C), 1446 (m, C=C) 
1H NMR (500 MHz, d6-DMSO): δH = 13.57 (1H, br s, H7), 7.65 - 7.96 (1H, m, H15), 7.44 - 7.57 (2H, 
m, H2), 7.31 (2H, m, H19/20), 7.15 - 7.26 (10H, m, H3, H12, 13, 14, 19/20 & 21), 4.88 - 5.04 (2H, m, 
H17), 4.85 (1H, m, J = 7.3 Hz, H9), 3.85 - 4.14 (2H, m, H5), 3.15 (1H, d, J = 12.5 Hz, H10a), 2.99 (1H, 
d, J = 12.5 Hz, H10b) 
13C NMR (126 MHz, d6-DMSO): δC = 163.9, (C8), 161.6 (C6), 155.6 (C15), 138.4 (C11), 137.2 (C18), 
136.4 (C4), 131.4 (C2), 131.1 (C3), 130.9 (C13), 129.2, 128.3, 128.0 (C12, 20 & 21), 127.6 (C19), 
126.1 (C14), 119.8 (C1), 119.3 (C1), 65.3 (C17), 50.9 (C9), 33.4 (C10), 31.3 (C5) 










Following General Procedure 4: ethyl benzimidate 53 (1.62 g, 10.9 mmol) and benzyl (S)-(1-
hydrazinyl-3-methyl-1-oxobutan-2-yl)carbamate 95 (2.30 g, 9.08 mmol) in ethanol (7 mL), followed 
by acetic acid (3.5 mL) were used. The crude product was purified by flash column chromatography 
eluting with 50% ethyl acetate in heptane to yield the title compound 107 as a white solid (2.03 g, 6.00 
mmol, 66%). 
Rf = 0.57 (50% EtOAc in heptane) 
[𝛂]𝐃
𝟐𝟎 = -44.8 (c = 0.2 in CH3OH)  
IR νmax = 3397 (w, O-H), 3254 (w, N-H), 2988 (s, C-H), 2901 (s, C-H), 1678 (s, C=O), 1519 (s, C=C), 
1470 (m, C=C), 1444 (m, C=C) 
1H NMR (500 MHz, CDCl3): δH = 14.00 (1H, br s, H6), 7.96 (2H, d, J=7.0 Hz, H3), 7.63 (1H, br s, 
H11), 7.44 - 7.51 (2H, m, H2), 7.42 (1H, d, J = 7.0 Hz, H1), 7.32 - 7.39 (4H, m, H15 & 16), 7.27 - 7.32 
(1H, m, H17), 5.06 (1H, d, J = 12.3 Hz, H13a), 5.02 (1H, d, J = 12.3 Hz, H13b), 4.79 (1H, q, J = 6.7 
Hz, H8), 3.80 (1H, dd, J = 10.5, 5.6 Hz, H9a), 3.69 (1H, dd, J = 10.5, 7.2 Hz, H9b) 
13C NMR (126 MHz, CDCl3): δC = 164.2, 164.1 (C5 & 6), 156.4 (C12), 137.5, 137.5 (C4 & 14), 129.3, 
129.2 (C1 & 2), 128.8, 128.3, 128.2 (C15, 16 & 17), 126.3 (C3), 66.0 (C13), 63.0 (C9), 53.1 (C8) 










Following General Procedure 4: ethyl benzimidate 53 (1.55 g, 10.4 mmol) and benzyl (S)-(1-
hydrazinyl-3-methyl-1-oxobutan-2-yl)carbamate 96 (2.30 g, 8.67 mmol) in ethanol (7 mL), followed 
by acetic acid (3.5 mL) were used. The crude product was purified by flash column chromatography 
eluting with 40% ethyl acetate in 40-60 petroleum ether to yield the title compound 108 as a white solid 
(2.48 g, 7.08 mmol, 82%). 
Rf = 0.52 (40% EtOAc in 40-60 petroleum ether) 
[𝛂]𝐃
𝟐𝟎 = -62.2 (c = 0.4 in CH3OH)  
IR νmax = 3250 (w, N-H), 2988 (s, C-H), 2901 (s, C-H), 1679 (s, C=O), 1552 (m, C=C), 1496 (m, C=C), 
1452 (m, C=C) 
1H NMR (500 MHz, CDCl3): δH = 7.99 (2H, br s, H3), 7.38 - 7.48 (3H, m, H1 & 2), 7.27 - 7.35 (5H, 
m, H16, 17 & 18), 6.13 (1H, d, J = 8.2 Hz, H12), 5.16 (1H, d, J = 12.5 Hz, H14a), 5.07 (1H, d, J = 12.5 
Hz, H14b), 4.81 (1H, t, J = 8.2 Hz, H8), 2.34 (1H, dd, J = 8.2, 6.7 Hz, H9), 0.99 (3H, d, J = 6.7 Hz, 
H10/11), 0.91 (3H, d, J = 6.7 Hz, H10/11) 
13C NMR (126 MHz, CDCl3): δC = 160.1 (C7), 159.8 (C5), 156.7 (C13), 136.1 (C15), 129.8 (C1), 129.4 
(C4), 128.8 (C2), 128.5 (C18), 128.2 (C16), 128.0 (C17), 126.5 (C3), 67.2 (C14), 54.5 (C8), 32.3 (C9), 
19.2, 18.4 (C10 & 11) 











Following General Procedure 4: ethyl benzimidate 53 (0.51 g, 3.41 mmol) and benzyl (S)-(1-
hydrazinyl-3-(1H-indol-3-yl)-1-oxopropan-2-yl)carbamate 97 (1.00 g, 2.84 mmol) in ethanol (5 mL), 
followed by acetic acid (3 mL) were used. The crude product was purified by flash column 
chromatography eluting with 50% ethyl acetatein heptane to yield the title compound 109 as a yellow 
solid (0.91 g, 2.09 mmol, 74%). 
Rf = 0.48 (50% EtOAc in heptane) 
[𝛂]𝐃
𝟐𝟎 = +9.4 (c = 0.4 in CH3OH) 
IR νmax = 3258 (w, N-H), 2988 (s, C-H), 2901 (s, C-H), 1669 (s, C=O), 1614 (m, C=C), 1515 (s, C=C), 
1475 (m, C=C), 1444 (m, C=C) 
1H NMR (500 MHz, d6-DMSO): δH = 13.90 (1H, br s, H6), 10.79 (1H, br s, H17), 8.00 (2H, d, J = 7.3 
Hz, H3), 7.58 (1H, d, J = 7.5 Hz, H12), 7.40 - 7.53 (3H, m, H1 & 2), 7.30 - 7.34 (3H, m, H15 & 23/24), 
7.25 - 7.29 (3H, m, H23/24 & 25), 7.08 (1H, d, J = 1.8 Hz, H18), 7.05 (1H, t, J = 7.5 Hz, H14), 6.96 
(1H, t, J = 7.5 Hz, H13), 5.03 (1H, d, J = 6.4 Hz, H8), 4.93 (2H, s, H22), 3.35 - 3.45 (1H, m, H9a), 3.18 
- 3.28 (1H, m, H9b) 
13C NMR (126 MHz, d6-DMSO): δC = 161.8 (C5), 161.3 (C7), 156.2 (C20), 137.5 (C22), 136.5 (C16), 
132.0 (C4), 129.2, 128.8 (C1 & 2), 128.1, 127.9, 127.7 (C23, 24 & 25), 127.2 (C11), 126.3 (C3), 124.2 
(C18), 121.3 (C14), 118.8, 118.7 (C12 & 13), 111.8 (C15), 110.3 (C10) 79.4 (C21), 65.7 (C8), peak for 
C9 obscured by DMSO peak. 









Following General Procedure 4: ethyl benzimidate 53 (0.65 g, 4.34 mmol) and benzyl (S)-(1-
hydrazinyl-3-(4-hydroxyphenyl)-1-oxopropan-2-yl)carbamate 98 (1.19 g, 3.62 mmol) in ethanol (8 
mL), followed by acetic acid (3.6 mL) were used. The crude product was purified by flash column 
chromatography eluting with 50% ethyl acetate in 40-60 petroleum ether to yield the title compound 
110 as a yellow solid (1.25 g, 3.01 mmol, 83%). 
Rf = 0.73 (50% EtOAc in 40-60 petroleum ether) 
[𝛂]𝐃
𝟐𝟎 = +9.5 (c = 0.4 in CH3OH) 
IRνmax = 3411 (m, O-H), 3322 (w, N-H), 3254 (m, N-H), 2971 (s, C-H), 2901 (s, C-H), 1699 (s, C=O), 
1615 (w, C=C), 1533 (s, C=C), 1469 (m, C=C), 1454 (m, C=C), 1443 (m, C=C) 
1H NMR (500 MHz, d6-DMSO): δH = 9.30 (1H, br s, H14), 7.96 (2H, d, J = 7.5, H3), 7.82 (1H, br s, 
H15), 7.42 - 7.47 (3H, m, H1 & 2), 7.25 - 7.32 (3H, m, H20 & 21), 7.22 (1H, d, J = 7.0 Hz, H19), 7.01 
(1H, d, J = 8.5 Hz, H11), 6.62 (1H, d, J = 8.5 Hz, H12), 4.98 (1H, d, J = 13.0 Hz, H17a), 4.92 (1H, d, 
J = 13.0 Hz, H17b), 4.86 (1H, dd, J = 9.9, 6.0 Hz, H8), 3.12 (1H, dd, J = 13.6, 6.0 Hz, H9a), 2.93 (1H, 
dd, J = 13.6, 9.9 Hz, H9b) 
13C NMR (126 MHz, d6-DMSO): δC = 172.5 (C7), 170.8 (C5), 156.3, 156.2 (C13 & 16), 137.6 (C18), 
130.6 (C11), 129.3 (C1), 129.8 (C2), 128.7 (C20), 128.1 (C21), 127.8 (C19), 127.0 (C4), 126.3 (C3), 
115.4 (C12), 65.6 (C17), 60.2 (C8), C9 hidden by DMSO peak. 









Following General Procedure 4: ethyl benzimidate 53 (0.61 g, 4.10 mmol) and benzyl (S)-2-
(hydrazinecarbonyl)pyrrolidine-1-carboxylate 99 (0.90 g, 3.42 mmol) in ethanol (8 mL), followed by 
acetic acid (4 mL) were used. The crude product was purified by flash column chromatography eluting 
with 50% ethyl acetate in 40-60 petroleum ether to yield the title compound 111 as a white solid (0.83 
g, 2.39 mmol, 70%). 
Rf = 0.36 (50% EtOAc in 40-60 petroleum ether) 
[𝛂]𝐃
𝟐𝟎 = -73.5 (c = 0.4 in CH3OH) 
IR νmax = 3062 (m, C-H), 1670 (s, br, C=O), 1555 (w, C=C) 
1H NMR (500 MHz, d6-DMSO): δH = 13.75 - 14.32 (1H, m, H6), 7.99 (2H, br s, H3), 7.28 - 7.59 (5H, 
m, H1, 2, 15/16 &17), 6.99 - 7.19 (2H, m, H15/16), 4.85 - 5.15 (3H, m, H8 & 13), 3.55 - 3.70 (1H, m, 
H11a), 3.48 (1H, t, J = 7.9 Hz, H11b), 2.19 - 2.40 (1H, m, H9a), 1.83 - 2.11 (3H, m, H9b & 10) 
13C NMR (126 MHz, CDCl3): δC = 161.4 (C7), 159.6, 159.3 (C5), 154.6, 154.2 (C12), 137.6, 137.3 
(C14), 132.0, 131.7 (C4), 130.5 (C1), 129.5 129.3, 129.1, 128.8, 128.7, 128.5, 127.9, 127.1 (C2, 15, 16 
& 17), 126.4, 126.2 (C3), 66.5, 66.2 (C13), 54.5,54.1 (C8), 47.4, 46.8 (C11), 33.3, 32.3 (C9), 24.2, 23.4 
(C10) - mixture of rotamers. 










Following General Procedure 4: ethyl benzimidate 53 (181 mg, 1.21 mmol) and benzyl (S)-(1-
hydrazinyl-4-(methylthio)-1-oxobutan-2-yl)carbamate 100 (300 mg, 1.01 mmol) in ethanol (2 mL), 
followed by acetic acid (1 mL) were used. The crude product was purified by flash column 
chromatography eluting with 50% ethyl acetate in 40-60 petroleum ether to yield the title compound 
112 as a white solid (370 mg, 0.97 mmol, 98%). 
Rf = 0.71 (50% EtOAc in 40-60 petroleum ether) 
[𝛂]𝐃
𝟐𝟎 = -40.2 (c = 0.6 in CH3OH) 
IR νmax = 3269 (w, N-H), 2988 (s, C-H), 2901 (s, C-H), 1691 (m, C=O), 1532 (m, C=C)  
1H NMR (500 MHz, CDCl3): δH = 8.00 (1H, d, J = 7.0 Hz, H3), 7.39 - 7.48 (3H, m, H 1 & 2), 7.28 - 
7.38 (5H, m, H 16, 17 & 18), 5.08 - 5.17 (3H, m, H8 & 14), 2.51 - 2.64 (2H, m, H10), 2.33 (1H, dt, J = 
14.3 6.4 Hz, H9a), 2.24 (1H, dt, J = 14.3, 7.5 Hz, H9b), 2.10 (3H, s, H11) 
13C NMR (126 MHz, CDCl3): δC = 160.6 (C7), 160.0 (C5), 156.2 (C13), 136.2 (C18), 129.8 (C1), 128.7 
(C4), 128.6 (C2), 128.8, 128.2, 128.2 (C16, 17 & 18), 126.4 (C3), 67.1 (C14), 48.2 (C8), 33.8 (C9), 
30.1 (C10), 15.4 (C11) 












General Procedure 5: A solution of the required triazole carbamate (1.0 eq.), the required α-
bromoketone (1.2 eq.) and potassium carbonate (1.0 eq.) in DMF or acetone (0.2 M) was stirred at room 
temperature until complete. The reaction was quenched with water and extracted with ethyl acetate (3 
x 20 mL). The combined organic fractions were washed brine (10 mL) and dried (MgSO4). The solvent 
was removed under reduced pressure. The resultant crude compound was purified by flash column 
chromatography on silica to yield the title compound. 
 
5.2.5.1. Benzyl ((1-(2-oxo-2-phenylethyl)-3-phenyl-1H-1,2,4-triazol-5-yl)methyl)carbamate (56) 
 
 
Following General Procedure 5: benzyl ((3-phenyl-1H-1,2,4-triazol-5-yl)methyl)carbamate 54 (500 
mg, 1.26 mmol), 2-bromoacetophenone 55 (300 mg, 1.51 mmol) and potassium carbonate (174 mg, 
1.26 mmol) in DMF (3 mL) were used. The crude product was purified by flash column chromatography 
eluting with 50% ethyl acetate in heptane to yield the title compound 56 as a yellow white solid (521 
mg, 1.01 mmol, 80%). 
Rf = 0.65 (50% EtOAc in heptane) 
[𝛂]𝐃




IR νmax = 3209 (w, N-H), 2936 (w, C-H), 1771 (w, C=O), 1711 (s, C=O), 1539 (m, C=N) 
1H NMR (500 MHz, CDCl3): δH = 8.10 (2H, dd, J = 8.1, 1.4 Hz, H3), 7.92 (2H, d, J = 7.5 Hz, H23), 
7.65 (1H, tt, J = 7.5, 1.2 Hz, H25), 7.52 (2H, t, J = 7.5 Hz, H24), 7.38 - 7.47 (3H, m, H1 & 2), 7.25 - 
7.34 (6H, m, H10, 12, 17 & 19), 7.18 - 7.24 (4H, m, H11 & 18), 5.73 (1H, d, J = 8.2 Hz, H13), 5.66 
(1H, d, J = 18.0 Hz, H20a), 5.37 (1H, d, J = 18.0 Hz, H20b), 5.01 (1H, d, J = 12.5 Hz, H15a), 4.96 (1H, 
d, J = 8.2 Hz, H7), 4.92 (1H, d, J = 12.5 Hz, H15b), 3.41 (2H, d, J = 7.3 Hz, H8) 
13C NMR (126 MHz, CDCl3): δC = 191.1 (C21), 161.4 (C5), 157.3 (C6), 156.0 (C14), 136.7 (C9), 136.0 
(C16), 134.3 (C25), 134.1 (C22), 130.8 (C4) 129.4 (C1), 129.3 (C11), 129.0 (C24), 128.7 (C12), 128.6 
(C17), 128.5 (C19), 128.3 (C2), 128.2 (C23) 127.8 (C18), 127.0 (C10), 126.5 (C3), 67.0 (C15), 54.5 
(C20), 48.7 (C7), 40.5 (C8) 







Following General Procedure 5: benzyl (S)-(1-(3-(pent-4-en-1-yl)-1H-1,2,4-triazol-5-yl)-2-
phenylethyl)carbamate 101 (146 mg, 0.370 mmol), 2-bromoacetophenone 55 (92.0 mg, 0.460 mmol) 
and potassium carbonate (52.0 mg, 0.370 mmol) in DMF (1 mL) were used. The crude product was 
purified by flash column chromatography eluting with 0-60% ethyl acetate in 40-60 petroleum ether to 
yield the title compound 119 as a yellow liquid (123 mg, 0.240 mmol, 65%). 
Rf = 0.42 (40% EtOAc in 40-60 petroleum ether) 
[𝛂]𝐃




IR: νmax = 3367 (w, N-H), 2988 (s, C-H), 2901 (s, C-H), 1699 (s, C=O), 1597 (w, C=C), 1496 (m, C=C), 
1450 (m, C=C) 
1H NMR (500 MHz, CDCl3): δH = 7.97 (2H, d, J = 7.9 Hz, H24), 7.63 - 7.72 (1H, m, H26), 7.49 - 7.58 
(2H, m, H25), 7.28 - 7.40 (5H, m, H18, 19 & 20), 7.14 - 7.23 (3H, m, H11 & 13), 6.98 - 7.08 (2H, m, 
H12), 5.71 - 5.84 (1H, m, H2), 5.51 (1H, d, J = 7.9 Hz, H16a), 5.46 (2H, s, H21), 5.17 - 5.26 (1H, m, 
H16b), 4.92 - 5.15 (3H, m, H1 & 8), 3.25 - 3.32 (1H, m, H9a), 3.17 - 3.24 (1H, m, H9b), 2.60 (2H, t, J 
= 7.4 Hz, H5), 2.12 (2H, q, J = 7.4 Hz, H3), 1.87 (2H, quin, J=7.4 Hz, H4) 
13C NMR (126 MHz, CDCl3): δC = 190.5 (C22), 162.3 (C7), 157.9 (C6), 155.6 (C15), 137.6 (C2), 136.6 
(C10), 136.6 (C17), 134.4 (C26), 134.1 (C23), 129.7 (C12), 129.1 (C25), 128.5, 128.4, 128.4 (C18, 19 
& 20), 128.1 (C24), 128.0 (C11), 126.5 (C13), 115.6 (C1), 66.6 (C16), 54.1 (C21), 50.8 (C8), 41.0 (C9), 
33.0 (C3), 26.5 (C4), 25.1 (C5) 






Following General Procedure 5: benzyl (S)-(1-(3-cyclopropyl-1H-1,2,4-triazol-5-yl)-2-
phenylethyl)carbamate 102 (763 mg, 2.11 mmol), 2-bromoacetophenone 55 (503 mg, 2.53 mmol) and 
potassium carbonate (291 mg, 2.11 mmol) in acetone (2 mL) were used. The crude product was purified 
by flash column chromatography eluting with 30% ethyl acetate in 40-60 petroleum ether to yield the 
title compound 120 as a yellow-white solid (540 mg, 1.12 mmol, 53%). 
Rf = 0.26 (30% EtOAc in 40-60 petroleum ether) 
[𝛂]𝐃




IR νmax = 2902 (s, C-H), 2851 (m, C-H), 1711 (s, C=O), 1604 (w, C=C), 1496 (m, C=C), 1453 (m, 
C=C) 
1H NMR (400 MHz, CDCl3): δH = 7.91 (2H, d, J = 7.6 Hz, H21), 7.66 (1H, t, J = 7.6 Hz, H23), 7.52 
(2H, t, J = 7.6 Hz, H22), 7.30 - 7.37 (4H, m, H15 & 16), 7.21 - 7.28 (4H, m, H9, 10 & 17), 7.15 (2H, d, 
J = 5.6 Hz, H8), 5.46 - 5.58 (2H, m, H11 & 18a), 5.25 (1H, d, J = 17.9 Hz, H18b), 5.00 (1H, d, J = 12.2 
Hz H13a), 4.93 (1H, d, J = 12.2 Hz, H13b), 4.86 (1H, q, J = 7.6 Hz, H5), 3.29 (2H, d, J = 7.6 Hz, H6), 
1.99 - 2.08 (1H, m, H2), 0.95 - 1.01 (4H, m, H1) 
13C NMR (126 MHz, CDCl3): δC = 191.2 (C19), 165.2 (C4), 156.4 (C12), 155.8 (C3), 136.6 (C7), 136.0 
(C14), 134.2, 134.1 (C20 & 23), 129.3 (C22), 128.9 (C9), 128.7 (C21), 128.6 (C16), 128.4 (C8), 128.1 
(C17), 127.7 (C15), 126.9 (C10), 66.9 (C13), 54.0 (C18), 48.4 (C5), 40.4 (C6), 8.9 (C2), 7.8 (C1) 







Following General Procedure 5: benzyl (S)-(2-phenyl-1-(3-(4-(trifluoromethyl)phenyl)-1H-1,2,4-
triazol-5-yl)ethyl)carbamate 103 (185 mg, 0.400 mmol), 2-bromoacetophenone 55 (95.0 mg, 0.480 
mmol) and potassium carbonate (55.0 mg, 0.400 mmol) in acetone (4 mL) were used. The crude product 
was purified by flash column chromatography eluting with 0-40% ethyl acetate in 40-60 petroleum 
ether to yield the title compound 121 as a white solid (169 mg, 0.290 mmol, 73%). 
Rf = 0.45 (20% EtOAc in 40-60 petroleum ether) 
[𝛂]𝐃




IR: νmax = 3314 (w, N-H), 2988 (s, C-H), 2901 (s, C-H), 1697 (s, C=O), 1614 (w, C=C), 1533 (m, C=C), 
1478 (m, C=C), 1435 (m, C=C), 1406 (m, C=C) 
1H NMR (500 MHz, d6-DMSO): δH = 8.21 (2H, d, J = 8.0 Hz, H4), 8.11 (1H, d, J = 8.9 Hz, H14), 8.01 
- 8.06 (2H, m, H24), 7.85 (2H, d, J = 8.0 Hz, H3), 7.69 - 7.75 (1H, m, H26), 7.55 - 7.62 (2H, m, H25), 
7.16 - 7.32 (8H, m, H11, 12, 13, 19 & 20), 7.07 (2H, dd, J = 7.3, 2.1 Hz, H18), 6.20 (1H, d, J = 18.3 
Hz, H21a), 6.03 (1H, d, J = 18.3 Hz, H21b), 5.05 (1H, ddd, J = 10.1, 8.9, 4.9 Hz, H8), 4.77 (1H, d, J = 
12.8 Hz, H16a), 4.67 (1H, d, J = 12.8 Hz, H16b), 3.28 (1H, dd, J = 14.0, 10.1 Hz, H9a), 3.24 (1H, dd, 
J = 14.0, 4.9 Hz, H9b) 
13C NMR (126 MHz, d6-DMSO): δC = 192.7 (C22), 159.2 (C7), 159.0 (C6), 156.3 (C15), 138.0 (C10), 
137.2 (C17), 135.1 (C5), 134.7, 134.6 (C23 & 26), 129.8 (C25), 129.5 (C12), 128.7 (C24), 128.5, 128.1 
(C19 & 20), 127.8 (C13), 126.9 (C18), 126.8 (C4), 126.4 (C11), 126.3 (C3), 123.6 (C2), 121.4 (C1), 
65.8 (C16), 55.7 (C21), 48.1 (C8), 38.5 (C9) 







Following General Procedure 5: benzyl (S)-(1-(3-(4-bromophenyl)-1H-1,2,4-triazol-5-yl)-2-
phenylethyl)carbamate 104 (216 mg, 0.260 mmol), 2-bromoacetophenone 55 (63.0 mg, 0.320 mmol) 
and potassium carbonate (36.0 mg, 0.260 mmol) in acetone (2.6 mL) were used. The crude product was 
purified by flash column chromatography eluting with 0-40% ethyl acetate in 40-60 petroleum ether to 
yield the title compound 122 as a white solid (128 mg, 0.210 mmol, 83%). 





𝟐𝟎 = +2.7 (c = 0.4 in CHCl3) 
IR: νmax = 3249 (w, N-H), 2988 (s, C-H), 2902 (s, C-H), 1697 (s, C=O), 1528 (m, C=C), 1406 (m, C=C) 
1H NMR (500 MHz, d6-DMSO): δH = 8.11 (1H, d, J = 9.0 Hz, H13), 8.05 (2H, d, J = 7.6 Hz, H23), 
7.96 (2H, d, J = 8.5 Hz, H3), 7.72 - 7.76 (1H, m, H25), 7.70 (2H, d, J = 8.5 Hz, H2), 7.58 - 7.63 (2H, 
m, H24), 7.18 - 7.34 (8H, m, H10, 11, 12, 18 & 19), 7.07 - 7.13 (2H, m, H17), 6.18 (1H, d, J = 18.6 Hz, 
H20a), 6.01 (1H, d, J = 18.6 Hz, H20b), 5.04 (1H, td, J = 9.0, 5.2 Hz, H7), 4.78 (1H, d, J = 12.5 Hz, 
H15a), 4.69 (1H, d, J = 12.5 Hz, H15b), 3.29 (1H, dd, J = 14.0, 9.0 Hz, H8a), 3.24 (1H, dd, J = 14.0, 
5.2 Hz, H8b) 
13C NMR (126 MHz, d6-DMSO): δC = 192.7 (C21), 159.3 (C5), 158.9 (C7), 156.3 (C14), 138.1 (C9), 
137.2 (C16), 134.6 (C25), 134.6 (C22), 132.3 (C2), 130.5 (C4), 129.8 (C11), 129.4 (C24), 128.7, 128.7 
(C10 & 19), 128.6 (C23), 128.2 (C3), 128.1 (C19) 127.8(C17), 126.9 (C12), 122.9 (C1), 65.8 (C15), 
55.6 (C20), 48.1 (C7), 38.5 (C8) 











Following General Procedure 5: benzyl (S)-(1-(3-(4-methoxyphenyl)-1H-1,2,4-triazol-5-yl)-2-
phenylethyl)carbamate 105 (500 mg, 1.17 mmol), 2-bromoacetophenone 55 (279 mg, 1.40 mmol) and 
potassium carbonate (162 mg, 1.17 mmol) in DMF (7 mL) were used. The crude product was purified 
by flash column chromatography eluting with 0-40% ethyl acetate in 40-60 petroleum ether to yield the 
title compound 123 as a pale yellow solid (494 mg, 0.900 mmol, 77%). 
Rf = 0.68 (40% EtOAc in 40-60 petroleum ether) 
[𝛂]𝐃
𝟐𝟎 = +2.5 (c = 0.4 in CHCl3) 
IR: νmax = 3321 (w, N-H), 2988 (s, C-H), 2901 (s, C-H), 1697 (s, C=O), 1613 (w, C=C), 1534 (m, C=C), 
1477 (m, C=C), 1451 (m, C=C), 1434 (m, C=C), 1421 (m, C=C) 
1H NMR (500 MHz, d6-DMSO): δH = 8.08 (1H, d, J = 8.5 Hz, H14), 8.04 (2H, dd, J = 7.8, 1.2 Hz, 
H24), 7.90 - 7.95 (2H, m, H4), 7.71 (1H, t, J = 7.8 Hz, H26), 7.58 (2H, t, J = 7.8 Hz, H25), 7.16 - 7.32 
(8H, m, H11 , 12, 13, 19 & 20), 7.08 (2H, dd, J = 7.5, 2.0 Hz, H18), 7.02 (2H, dd, J = 8.5, 2.0Hz, H3), 
6.13 (1H, d, J = 18.3 Hz, H21a), 5.95 (1H, d, J = 18.3 Hz, H21b), 4.98 (1H, ddd, J = 10.1, 8.5, 4.9 Hz, 
H8), 4.77 (1H, d, J = 12.5 Hz, H16a), 4.68 (1H, d, J = 12.5 Hz, H16b), 3.80 (1H, s, H1), 3.27 (1H, dd, 
J = 14.0, 10.1 Hz, H9a), 3.22 (1H, dd, J = 14.0, 4.9 Hz, H9b) 
13C NMR (126 MHz, d6-DMSO): δC = 192.9 (C22), 160.4, 160.1 (C2 & 6), 158.4 (C7), 156.3 (C15), 
138.2 (C10), 137.2 (C17), 134.6, 134.5 (C23 & 26), 129.8 (C12), 129.4 (C25), 128.7 (C11), 128.7 
(C19), 128.5 (C24), 128.1 (C20), 127.7 (C18), 127.6 (C3), 126.8 (C13), 124.0 (C5), 114.6 (C4), 65.7 
(C16), 55.7 (C1), 55.4 (C21), 48.2 (C8), 38.6 (C9) 









Following General Procedure 5: benzyl (S)-(1-(3-(4-bromobenzyl)-1H-1,2,4-triazol-5-yl)-2-
phenylethyl)carbamate 106 (300 mg, 0.610 mmol), 2-bromoacetophenone 55 (128 mg, 0.640 mmol) 
and potassium carbonate (85.0 mg, 0.610 mmol) in DMF (2.5 mL) were used. The crude product was 
purified by flash column chromatography eluting with 0-40% ethyl acetate in 40-60 petroleum ether to 
yield the title compound 124 as a yellow solid (193 mg, 0.320 mmol, 52%). 
Rf = 0.43 (30% EtOAc in 40-60 petroleum ether) 
[𝛂]𝐃
𝟐𝟎 = +25.0 (c = 0.2 in CHCl3) 
IR: νmax = 3321 (w, N-H), 2988 (s, C-H), 2901 (s, C-H), 1696 (s, C=O), 1534 (m, C=C), 1479 (m, C=C), 
1406 (m, C=C) 
1H NMR (500 MHz, d6-DMSO): δH = 8.01 (2H, d, J = 7.5 Hz, H24), 7.71 (1H, t, J = 7.5 Hz, H26), 7.57 
(2H, t, J = 7.5 Hz, H25), 7.49 (2H, d, J = 8.2 Hz, H2), 7.14 - 7.31 (11H, m, H3, 11, 13, 14, 18, 19 & 
20), 7.05 - 7.11 (2H, m, H12), 6.03 (1H, d, J = 18.3 Hz, H21a), 5.84 (1H, d, J = 18.3 Hz, H21b), 4.93 
(1H, td, J = 9.2, 5.6 Hz, H8), 4.77 (1H, d, J = 13.0 Hz, H16a), 4.68 (1H, d, J = 13.0 Hz, H16b), 3.97 
(2H, s, H5), 3.18 (1H, dd, J = 14.5, 9.2 Hz, H9a), 3.13 (1H, dd, J = 14.5, 5.6 Hz, H9b) 
13C NMR (126 MHz, d6-DMSO): δC = 192.9 (C22), 161.1 (C6), 158.0 (C7), 156.2 (C15), 138.2 (C1), 
138.1 (C10), 137.2 (C17), 134.6, 134.5 (C23 & 26), 131.6, 131.5 (C2 & 3), 129.8 (C12), 129.3 (C25), 
128.7, 128.6, 128.5 (C11, 19 & 24), 128.1 (C20), 127.7 (C18), 126.8 (C13), 119.9 (C4), 65.7 (C16), 
55.1 (C21), 48.1 (C8), 38.6 (C9), 33.8 (C5) 









Following General Procedure 5: benzyl (S)-(2-hydroxy-1-(3-phenyl-1H-1,2,4-triazol-5-
yl)ethyl)carbamate 107 (300 mg, 0.890 mmol), 2-bromoacetophenone 55 (212 mg, 1.07 mmol) and 
potassium carbonate (123 mg, 0.890 mmol) in acetone (4 mL) were used. The crude product was 
purified by flash column chromatography eluting with ethyl acetate (0-40%) in 40-60 petroleum ether 
to yield the title compound 125 as a white solid (220 mg, 0.480 mmol, 55%). 
Rf = 0.58 (50% EtOAc in 40-60 petroleum ether) 
[𝛂]𝐃
𝟐𝟎 = -23.8 (c = 0.4 in CHCl3) 
IR: νmax = 3297 (w, br, O-H), 3254 (w, N-H), 2987 (s, C-H), 2901 (s, C-H), 1690 (s, C=O), 1532 (m, 
C=C), 1446 (m, C=C), 1407 (m, C=C) 
1H NMR (500 MHz, CDCl3): δH = 8.06 (2H, dd, J = 8.1, 1.7 Hz, H3), 8.01 (2H, d, J = 7.8 Hz, H20), 
7.67 (1H, t, J = 7.8 Hz, H22), 7.55 (2H, t, J = 7.8 Hz, H21), 7.38 - 7.45 (3H, m, H1 & 2), 7.30 - 7.36 
(3H, m, H15 & 16), 7.27 (2H, dd, J = 8.0, 1.8 Hz, H14), 6.07 (1H, d, J = 8.0 Hz, H10), 6.07 (1H, d, J = 
8.9 Hz, H17a), 5.94 (1H, d, J = 8.9 Hz, H17b), 5.04 (1H, d, J = 12.2 Hz, H12a), 4.91 (1H, d, J = 12.2 
Hz, H12b), 4.80 (1H, ddd, J = 8.0, 3.7, 2.1 Hz,H7), 4.31 (1H, dd, J = 11.4, 2.1 Hz, H8a), 3.94 (1H, dd, 
J = 11.4, 3.7 Hz, H8b) 
13C NMR (126 MHz, CDCl3): δC = 191.6 (C18), 161.0 (C5), 156.9 (C6), 156.3 (C11), 135.8 (C13), 
134.4 (C22), 134.1 (C19), 130.2 (C4), 129.5, 129.4 (C1 & 16), 129.1 (C21), 128.6, 128.5 (C2 & 15), 
128.2 (C20) 127.9 (C14), 126.4 (C3) , 67.2 (C12), 64.0 (C8), 55.1 (C17), 46.6 (C7) 








Following General Procedure 5: benzyl (S)-(2-methyl-1-(3-phenyl-1H-1,2,4-triazol-5-
yl)propyl)carbamate 108 (509 mg, 1.45 mmol), 2-bromoacetophenone 55 (347 mg, 1.74 mmol) and 
potassium carbonate (201 mg, 1.45 mmol) in DMF (3 mL) were used. The crude product was purified 
by flash column chromatography eluting with 0-40% ethyl acetate in 40-60 petroleum ether to yield the 
title compound 126 as a white solid (520 mg, 1.14 mmol, 79%). 
Rf = 0.50 (30% EtOAc in 40-60 petroleum ether) 
[𝛂]𝐃
𝟐𝟎= -62.1 (c = 0.5 in CHCl3) 
IR: νmax = 3291 (w, N-H), 2988 (s, C-H), 2901 (s, C-H), 1694 (s, C=O), 1597 (w, C=C), 1540 (m, C=C), 
1503 (m, C=C), 1470 (m, C=C), 1445 (m, C=C), 1406 (m, C=C) 
1H NMR (500 MHz, d6-DMSO): δH = 8.06 (2H, dd, J = 7.5, 1.5 Hz, H21), 7.99 (3H, dt, J = 8.2, 1.2 Hz, 
H3 & 11), 7.74 (1H, tt, J = 7.5, 1.2 Hz, H23), 7.61 (2H, t, J = 7.5 Hz, H22), 7.45 - 7.50 (2H, m, H2), 
7.42 (1H, t, J=7.0 Hz, H1), 7.27 - 7.36 (5H, m, H15, 16 & 17), 6.17 (1H, d, J = 18.5 Hz, H18a), 6.08 
(1H, d, J = 18.5 Hz, H18b), 4.95 (1H, d, J = 12.5 Hz, H13a), 4.89 (1H, d, J = 12.5 Hz, H13b), 4.53 (1H, 
t, J = 9.2 Hz, H7), 2.33 (1H, dt, J = 9.2, 6.7 Hz, H8), 1.00 (3H, d, J = 6.7 Hz, H9/10), 0.84 (3H, d, J = 
6.7 Hz, H9/10) 
13C NMR (126 MHz, d6-DMSO): δC = 192.7 (C19), 160.2 (C5), 158.5 (C6), 156.6 (C12), 137.3 (C16), 
134.7, 134.5 (C20 & 23), 131.4 (C4), 129.6 (C1), 129.4, 129.2 (C2 & 22), 128.8, 128.7 (C16 & 21), 
128.3 (C17), 128.1 (C15), 126.1 (C3), 66.0 (C13), 55.4 (C18), 52.8 (C7), 31.3 (C8), 20.0, 19.4 (C9 & 
10) 









Following General Procedure 5: benzyl (S)-(2-(1H-indol-3-yl)-1-(3-phenyl-1H-1,2,4-triazol-5-
yl)ethyl)carbamate 109 (100 mg, 0.230 mmol), 2-bromoacetophenone 55 (55.0 mg, 0.270 mmol) and 
potassium carbonate (32.0 mg, 0.230 mmol) in DMF (1 mL) were used. The crude product was purified 
by flash column chromatography eluting with 0-70% ethyl acetate in 40-60 petroleum ether to yield the 
title compound 127 as a white solid (103 mg, 0.190 mmol, 81%). 
Rf = 0.56 (50% EtOAc in 40-60 petroleum ether) 
[𝛂]𝐃
𝟐𝟎 = +39.3 (c = 0.4 in CHCl3) 
IR: νmax = 3316 (w, N-H), 2988 (s, C-H), 2901 (s, C-H), 1698 (s, C=O), 1533 (m, C=C), 1445 (m, C=C), 
1408 (m, C=C) 
1H NMR (500 MHz, d6-DMSO): δH = 10.84 (1H, d, J = 2.1 Hz, H16), 8.16 (1H, d, J = 8.2 Hz, H18), 
8.07 (2H, d, J = 7.3 Hz, H28), 8.04 (2H, dt, J = 7.3, 1.5 Hz, H3), 7.74 (1H, tt, J = 7.3, 1.3 Hz, H30), 
7.62 (2H, t, J = 7.3 Hz, H29), 7.48 - 7.53 (3H, m, H2 & 11), 7.45 (1H, tt, J = 7.3, 1.8 Hz, H1), 7.33 (1H, 
d, J = 7.0 Hz, H14), 7.24 - 7.31 (3H, m, H23 & 24), 7.22 (1H, d, J = 2.1 Hz, H17), 7.15 (2H, dd, J = 
7.6, 1.8 Hz, H22), 7.04 (1H, t, J = 7.0 Hz, H13), 6.88 (1H, t, J = 7.0 Hz, H12), 6.16 (1H, d, J = 18.3 Hz, 
H25a), 6.00 (1H, d, J = 18.3 Hz, H25b), 4.91 (1H, ddd, J = 10.1, 8.2, 5.0 Hz, H7), 4.83 (1H, d, J = 12.5 
Hz, H20a), 4.78 (1H, d, J = 12.5 Hz, H20b), 3.43 (1H, dd, J = 14.9, 10.1 Hz, H8a), 3.34 (1H, dd, J = 
14.9, 5.0 Hz, H8b) 
13C NMR (126 MHz, d6-DMSO): δC =193.0 (C26), 160.2 (C5), 159.0 (C6), 156.4 (C19), 137.1 (C21), 




(C23 & 28), 128.2 (C24), 127.9 (C22), 127.5 (C10), 126.2 (C3), 124.7 (C17), 121.3 (C13), 118.8 (C12), 
118.5 (C11), 111.9 (C14), 110.3 (C9), 65.9 (C20), 55.6 (C25), 47.7 (C7), 28.9 (C8) 







Following General Procedure 5: benzyl (S)-(2-(4-hydroxyphenyl)-1-(3-phenyl-1H-1,2,4-triazol-5-
yl)ethyl)carbamate 110 (131 mg, 0.320 mmol), 2-bromoacetophenone 55 (75.0 mg, 0.380 mmol) and 
potassium carbonate (47.0 mg, 0.320 mmol) in acetone (1 mL) were used. The crude product was 
purified by flash column chromatography eluting with 0-60% ethyl acetate in 40-60 petroleum ether to 
yield the title compound 128 as a white solid (57.0 mg, 0.110 mmol, 33%). 
Rf = 0.47 (40% EtOAc in 40-60 petroleum ether) 
[𝛂]𝐃
𝟐𝟎 = +43.5 (c = 0.2 in CH3OH) 
IR: νmax = 3318 (w, N-H), 3290 (w, br, O-H), 2988 (s, C-H), 2901 (s, C-H), 1689 (s, C=O), 1598 (w, 
C=C), 1515 (m, C=C), 1474 (m, C=C), 1448 (m, C=C) 
1H NMR (500 MHz, d6-DMSO): δH = 9.18 (1H, s, H13), 8.04 (2H, d, J = 7.8 Hz, H24), 7.95 - 8.05 
(3H,m , H3 & 14), 7.72 (1H, t, J = 7.8 Hz, H26), 7.59 (2H, t, J = 7.8 Hz, H25), 7.47 (2H, t, J = 7.6 Hz, 
H2), 7.39 - 7.44 (1H, m, H1), 7.23 - 7.28 (3H, m, H19 & 20), 7.08 (3H, t, J = 8.5 Hz, H10 & 18), 6.62 




td, J = 10.0, 5.3 Hz, H7), 4.79 (1H, d, J = 13.0 Hz, H16a), 4.69 (1H, d, J = 13.0 Hz, H16b), 3.15 (1H, 
dd, J = 14.0, 10.0 Hz, H8a), 3.09 (1H, dd, J = 14.0, 5.3 Hz, H8b) 
13C NMR (126 MHz, d6-DMSO): δC = 192.8 (C22), 160.2 (C5), 158.7 (C6), 156.3, 156.3 (C12 & 15), 
137.2 (C17), 124.8 (C23), 134.7 (C26), 134.5 (C4), 131.2 (C9), 130.7 (C10), 129.4 (C1), 129.3 (C25), 
128.7 (C2), 128.6 (C24), 128.2, 128.1 (C19 & 20), 127.6 (C18), 126.1 (C3), 115.4 (C11), 65.7 (C16), 
55.4 (C21), 48.5 (C7), 37.8 (C8) 







Following General Procedure 5: benzyl (S)-2-(3-phenyl-1H-1,2,4-triazol-5-yl)pyrrolidine-1-
carboxylate 111 (300 mg, 0.860 mmol), 2-bromoacetophenone 55 (180 mg, 0.900 mmol) and potassium 
carbonate (119 mg, 0.860 mmol) in DMF (2 mL) were used. The crude product was purified by flash 
column chromatography eluting with 0-50% ethyl acetate in 40-60 petroleum ether to yield the title 
compound 129 as a pale yellow solid (322 mg, 0.690 mmol, 80%). 
Rf = 0.41 (30% EtOAc in 40-60 petroleum ether) 
[𝛂]𝐃
𝟐𝟎 = +3.9 (c = 0.4 in CHCl3) 
IR: νmax = 2987 (s, C-H), 2901 (s, C-H), 1694 (s, C=O), 1597 (w, C=C), 1581 (w, C=C), 1479 (w, 




1H NMR (500 MHz, d6-DMSO): δH = 8.12 (2H, d, J = 7.3 Hz, H20), 7.94 - 8.01 (5H, m, H3 & 20), 
7.71 - 7.79 (2H, m, H22), 7.57 - 7.66 (4H, m, H21), 7.39 - 7.51 (6H, m, H1 & 2), 7.26 - 7.36 (5H, m, 
H15 & 16), 7.15 - 7.25 (2H, m, H14), 7.09 (2H, d, J = 7.3 Hz, H14), 6.24 (1H, d, J = 18.6 Hz, H17a), 
6.13 (1H, d, J = 18.6 Hz, H17b), 5.90 (1H, d, J = 18.6 Hz, H17a), 5.79 (1H, d, J = 18.6 Hz, H17b), 5.11 
(1H, dd, J = 7.2, 4.1 Hz, H7), 5.06 (1H, dd, J = 7.2, 4.1 Hz, H7), 5.00 - 5.05 (2H, m, H12), 4.93 - 5.00 
(2H, m, H12), 3.56 - 3.65 (2H, m, H10a), 3.48 - 3.55 (2H, m, H10b), 2.28 - 2.42 (2H, m, H9a), 2.16 - 
2.28 (2H, m, H8a), 2.08 - 2.01 (2H, m, H8b), 1.85 - 2.00 (2H, m, H9b) – mixture of rotamers. 
13C NMR (126 MHz, d6-DMSO): δC = 193.1, 192.8 (C18), 160.4, 160.2 (C5), 159.6, 159.1 (C6), 154.6, 
153.8 (C11), 137.3, 137.2 (C13), 134.7, 134.6, 134.5 (C19 & 22), 131.3 (C4), 129.6 (C1), 129.4, 129.4 
(C21), 129.2 (C2), 128.8, 128.7 (C20), 128.6 (C15), 128.2, 128.1 (C16), 127.8, 127.8 (C14), 126.2, 
126.1 (C3), 66.5 (C12), 55.4, 55.0 (C17), 52.3, 51.7 (C7), 47.4, 46.8 (C10), 33.0, 31.8 (C8), 24.6, 23.6 
(C9) 







Following General Procedure 5: benzyl (S)-(3-(methylthio)-1-(3-phenyl-1H-1,2,4-triazol-5-
yl)propyl)carbamate 112 (500 mg, 1.00 mmol), 2-bromoacetophenone 55 (239 mg, 1.20 mmol) and 
potassium carbonate (138 mg, 1.00 mmol) in DMF (2 mL)were used. The crude product was purified 
by flash column chromatography eluting with -60% ethyl acetate in 40-60 petroleum ether to yield the 




Rf = 0.90 (50% EtOAc in 40-60 petroleum ether) 
[𝛂]𝐃
𝟐𝟎 = -23.1 (c = 0.2 in CHCl3) 
IR: νmax = 3280 (w, N-H), 2987 (s, C-H), 2901 (s, C-H), 1691 (s, C=O), 1596 (w, C=C), 1526 (m, C=C), 
1512 (m, C=C), 1475 (m, C=C), 1445 (m, C=C) 
1H NMR (500 MHz, d6-DMSO): δH = 8.08 (1H, d, J = 8.2 Hz, H11), 8.05 (2H, d, J = 7.8 Hz, H21), 
7.97 (2H, dd, J = 8.4, 1.4 Hz, H3), 7.69 - 7.78 (1H, m, H23), 7.60 (2H, t, J = 7.8 Hz, H22), 7.44 - 7.48 
(2H, m, H2), 7.41 (1H, m, J = 1.4 Hz, H1), 7.29 - 7.32 (5H, m, H15, 16 & 17), 6.17 (1H, d, J = 18.5 
Hz, H18a), 6.04 (1H, d, J = 18.5 Hz, H18b), 4.92 (1H, d, J = 12.5 Hz, H13a), 4.85 - 4.90 (1H, m, H7), 
4.83 (1H, d, J = 12.5 Hz, H13b), 2.42 - 2.52 (1H, m, H9a), 2.41 - 2.47 (1H, m, H9b), 2.17 (2H, m, H8), 
1.99 (3H, s, H10) 
13C NMR (126 MHz, d6-DMSO): δC = 192.9 (C19), 160.3 (C5), 158.6 (C6), 156.5 (C12), 137.1 (C14), 
134.7, 134.6 (C20 & 23), 131.3 (C4), 129.6 (C1), 129.4, 129.2 (C2 & 22), 128.8, 128.7 (C16 & 21), 
128.3 (C17), 128.1 (C15), 126.1 (C3), 66.1 (C13), 55.5 (C18), 45.7 (C7), 32.5 (C8), 30.0 (C9), 14.9 
(C10) 







Following General Procedure 5: benzyl (S)-(2-phenyl-1-(3-phenyl-1H-1,2,4-triazol-5-
yl)ethyl)carbamate 54 (300 mg, 0.750 mmol), 1-((3R, 5R, 7R)-adamantam-1-yl)-2-bromo-ethan-1-one 




The crude product was purified by flash column chromatography eluting with 0-40% ethyl acetate in 
40-60 petroleum ether to yield the title compound 131 as a white solid (374 mg, 0.650 mmol, 87%). 
Rf = 0.67 (30% EtOAc in 40-60 petroleum ether) 
[𝛂]𝐃
𝟐𝟎 = -20.7 (c = 0.4 in CHCl3) 
IR: νmax = 3313 (w, N-H), 2971 (s, C-H), 2902 (w, C-H), 1698 (s, C=O), 1536 (m, C=C), 1475 (m, 
C=C), 1445 (m, C=C), 1404 (m, C=C) 
1H NMR (500 MHz, d6-DMSO): δH = 8.12 (1H, d, J = 8.9 Hz, H13), 7.97 (2H, dt, J = 7.4, 1.4 Hz, H3), 
7.46 (2H, t, J = 7.4 Hz, H2), 7.41 (1H, tt, J = 7.4, 1.4 Hz, H1), 7.24 - 7.31 (7H, m, H10, 11, 18 & 19), 
7.21 (1H, tt, J = 6.6, 2.5 Hz, H12), 7.16 (2H, d, J = 6.1 Hz, H17), 5.53 (1H, d, J = 18.5 Hz, H20a), 5.46 
(1H, d, J = 18.5 Hz, H20b), 4.93 (1H, d, J = 12.5 Hz, H15a), 4.87 (1H, d, J = 12.5 Hz, H15b), 4.78 (1H, 
ddd, J = 10.1, 8.9, 4.6 Hz, H7), 3.26 (1H, dd, J = 13.7, 10.1 Hz, H8a), 3.15 (1H, dd, J = 13.7, 4.6 Hz, 
H8b), 2.01 (3H, br s, H24), 1.87 (6H, q, J = 12.2 Hz, H23), 1.69 (6H, br s, H25) 
13C NMR (126 MHz, d6-DMSO): δC = 207.7 (C21), 160.1 (C5), 158.4 (C6), 156.4 (C14), 138.2 (C9), 
137.2 (C16), 131.3 (C4), 129.8 (C11), 129.6 (C1), 129.2 (C2), 128.7, 128.6, 128.2 (C10, 18 & 19), 
127.8 (C17), 126.9 (C12), 126.1 (C3), 65.9 (C15), 53.9 (C20), 48.2 (C7), 45.4 (C22), 38.6 (C8), 37.6 
(C23), 36.3 (C25), 27.7 (C24) 







Following General Procedure 5: benzyl (S)-(2-phenyl-1-(3-phenyl-1H-1,2,4-triazol-5-




mmol) and potassium carbonate (138 mg, 1.00 mmol) in DMF (4 mL) were used. The crude product 
was purified by flash column chromatography eluting with 0-60% ethyl acetate in 40-60 petroleum 
ether to yield the title compound 132 as a white solid (321 mg, 0.610 mmol, 61%). 
Rf = 0.52 (50% EtOAc in heptane) 
[𝛂]𝐃
𝟐𝟎 = +7.1 (c = 0.4 in CHCl3) 
IR: νmax = 3298 (w, N-H), 2988 (s, C-H), 2901 (s, C-H), 1693 (s, C=O), 1532 (m, C=C), 1475 (m, C=C), 
1445 (m, C=C), 1404 (m, C=C) 
1H NMR (500 MHz, d6-DMSO): δH = 8.70 (1H, dd, J = 2.7, 1.2 Hz, H25), 8.12 (1H, d, J = 8.5 Hz, 
H13), 7.95 - 8.03 (2H, m, H3), 7.72 (1H, dd, J = 5.2, 2.7 Hz, H24), 7.57 (1H, dd, J = 5.2, 1.2 Hz, H23), 
7.47 (2H, t, J = 7.2 Hz, H2), 7.42 (1H, t, J = 7.2 Hz, H1), 7.29 7.32 (2H, m, H11), 7.22 - 7.29 (5H, m, 
H10, 18 & 19), 7.19 (1H, t, J = 7.3 Hz, H12), 7.12 (2H, dd, J = 7.5, 1.7 Hz, H17), 6.03 (1H, d, J = 18.3 
Hz, H20a), 5.87 (1H, d, J = 18.3 Hz, H20b), 4.98 (1H, ddd, J = 10.1, 8.5, 4.9 Hz, H7), 4.83 (1H, d, J = 
12.5 Hz, H15a), 4.74 (1H, d, J = 12.5 Hz, H15b), 3.27 (1H, dd, J = 14.5, 10.1 Hz, H8a), 3.21 (1H, dd, 
J = 14.5, 4.9 Hz, H8b) 
13C NMR (126 MHz, d6-DMSO): δC = 187.2 (C21), 160.2 (C5), 158.7 (C6), 156.3 (C14), 139.2 (C22), 
138.2 (C9), 137.2 (C16), 135.4 (C25), 131.3 (C4), 129.8 (C11), 129.6 (C1), 129.2 (C2), 128.7, 128.6 
(C10 & 18), 128.5 (C19), 128.1 (C24), 127.8 (C17), 126.9, 126.9 (C12 & 23), 126.1 (C3), 65.8 (C15), 
55.7 (C20), 48.3 (C7), 38.6 (C8) 











Following General Procedure 5: benzyl (S)-(2-phenyl-1-(3-phenyl-1H-1,2,4-triazol-5-
yl)ethyl)carbamate 54 (300 mg, 0.750 mmol), 2-bromo-1-(4-(trifluoromethyl)phenyl)ethan-1-one 115 
(240 mg, 0.900 mmol) and potassium carbonate (104 mg, 0.750 mmol) in acetone (1.5 mL) were used. 
The crude product was purified by flash column chromatography eluting with 0-40% ethyl acetate in 
40-60 petroleum ether to yield the title compound 133 as a white solid (290 mg, 0.500 mmol, 66%). 
Rf = 0.67 (50% EtOAc in heptane) 
[𝛂]𝐃
𝟐𝟎 = +3.8 (c = 0.4 in CHCl3) 
IR: νmax = 3310 (w, N-H), 2974 (s, C-H), 2901 (s, C-H), 1698 (s, C=O), 1535 (m, C=C), 1475 (m, C=C), 
1445 (m, C=C), 1408 (m, C=C) 
1H NMR (500 MHz, d6-DMSO): δH = 8.21 (2H, d, J = 8.2 Hz, H23), 8.09 (1H, d, J = 9.4 Hz, H13), 
7.99 - 8.03 (2H, m, H3), 7.96 (2H, d, J = 8.2 Hz, H24), 7.45 - 7.51 (2H, m, H2), 7.42 (1H, tt, J = 7.3, 
1.8 Hz, H1), 7.31 (2H, d, J = 7.0 Hz, H11), 7.16 - 7.28 (6H, m, H10, 12, 18 & 19), 7.06 (2H, dd, J = 
7.2, 2.3 Hz, H17), 6.23 (1H, d, J = 18.6 Hz, H20a), 6.06 (1H, d, J = 18.6 Hz, H20b), 5.06 (1H, td, J = 
9.4, 5.0 Hz, H7), 4.76 (1H, d, J = 12.5 Hz, H15a), 4.67 (1H, d, J = 12.5 Hz, H15b), 3.26 - 3.30 (1H, m, 
H8a), 3.22 (1H, dd, J = 14.0, 5.0 Hz, H8b)  
13C NMR (126 MHz, d6-DMSO): δC = 192.5 (C21), 160.3 (C5), 158.6 (C6), 156.2 (C14), 138.1, 137.8 
(C9 & 22), 137.2 (C16), 133.7 (C25), 131.3 (C4), 129.9 (C11), 129.6 (C1), 129.3 (C23), 129.1 (C10), 
128.7, 128.5 (C2 & 18), 128.1 (C19), 127.7 (C17), 126.9 (C12), 126.3, 126.2 (C3 & 24), 123.1 (C26), 
65.7 (C15), 55.8 (C20), 48.0 (C7), 38.5 (C8) 









Following General Procedure 5: benzyl (S)-(2-phenyl-1-(3-phenyl-1H-1,2,4-triazol-5-
yl)ethyl)carbamate 54 (200 mg, 0.500 mmol), 2-bromo-3’-methoxyacetophenone 116 (137 mg, 0.600 
mmol) and potassium carbonate (69.0 mg, 0.500 mmol) in acetone (1 mL). The crude product was 
purified by flash column chromatography eluting with 0-60% ethyl acetate in 40-60 petroleum ether to 
yield the title compound 134 as a white solid (137 mg, 0.250 mmol, 50%). 
Rf = 0.74 (50% EtOAc in 40-60 petroleum ether) 
[𝛂]𝐃
𝟐𝟎 = +10.0 (c = 0.3 in CHCl3) 
IR: νmax = 3300 (w, N-H), 2972 (s, C-H), 2901 (s, C-H), 1698 (s, C=O), 1536 (m, C=C), 1475 (m, C=C), 
1445 (m, C=C), 1408 (m, C=C) 
1H NMR (500 MHz, CDCl3): δH = 8.11 (2H, d, J = 7.0 Hz, H3), 7.40 - 7.52 (7H, m, H1, 2, 18, 24 & 
25), 7.29 - 7.36 (5H, m, H10, 12, 19 & 27), 7.23 - 7.27 (2H, m, H17), 7.22 (1H, dd, J = 2.6, 1.1 Hz, 
H23), 7.21 (2H, dt, J = 4.0, 1.5 Hz, H11), 5.58 - 5.70 (2H, m, H13 & 20a), 5.32 (1H, d, J = 18.0 Hz, 
H20b), 5.03 (1H, d, J = 12.2 Hz, H15a), 4.92 - 4.99 (2H, m, H7 & 15b), 3.88 (3H, s, H28), 3.43 (1H, 
dd, J=14.0, 7.9 Hz, H8a), 3.39 (1H, dd, J = 14.0, 6.4 Hz, H8b) 
13C NMR (126 MHz, CDCl3): δC = 191.0 (C21), 161.4 (C5), 160.0 (C26), 157.3 (C6), 155.9 (C14), 
136.6 (C22), 136.0 (C9), 135.4 (C16), 130.8 (C4), 130.0 (C18), 129.4 (C11), 129.2 (C1), 128.7 (C10), 
128.5, 128.5 (C2 & 27), 128.1 (C19), 127.8 (C17), 127.0 (C12), 126.4 (C3), 120.9, 120.6 (C23 & 24), 
112.3 (C25), 67.0 (C15), 55.5 (C28), 54.5 (C20), 48.7 (C7), 40.6 (C8) 









Following General Procedure 5: benzyl (S)-(2-phenyl-1-(3-phenyl-1H-1,2,4-triazol-5-
yl)ethyl)carbamate 54 (400 mg, 1.00 mmol), 2,4’-dibromoacetophenone 117 (335 mg, 1.21 mmol) and 
potassium carbonate (139 mg, 1.00 mmol) in DMF (5 mL) were used. The crude product was purified 
by flash column chromatography eluting with 0-40% ethyl acetate in 40-60 petroleum ether to yield the 
title compound 135 as a white solid (486 mg, 0.820 mmol, 82%). 
Rf = 0.62 (30% EtOAc in 40-60 petroleum ether) 
[𝛂]𝐃
𝟐𝟎 = +17.1 (c = 0.4 in CHCl3) 
IR: νmax = 3307 (w, N-H), 2973 (s, C-H), 2901 (s, C-H), 1698 (s, C=O), 1536 (m, C=C), 1475 (w, C=C), 
1445 (m, C=C), 1407 (m, C=C) 
1H NMR (500 MHz, d6-DMSO): δH = 8.10 (1H, d, J = 9.4 Hz, H13), 8.01 (2H, dd, J = 7.6, 1.2 Hz, H3), 
7.97 (2H, d, J = 8.5 Hz, H23), 7.81 (2H, d, J = 8.5 Hz, H24), 7.48 (2H, t, J = 7.6 Hz, H2), 7.43 (1H, tt, 
J = 7.6, 1.2 Hz, H1), 7.28 - 7.33 (2H, m, H11), 7.30 – 7.22 (5H, m, H10, 18 & 19), 7.20 (1H, t, J = 7.0 
Hz, H12), 7.09 (2H, dd, J = 7.2, 2.0 Hz, H17), 6.16 (1H, d, J = 18.6 Hz, H20a), 5.98 (1H, d, J = 18.6 
Hz, H20b), 5.04 (1H, td, J = 9.4, 5.0 Hz, H7), 4.79 (1H, d, J = 12.5 Hz, H15a), 4.69 (1H, d, J = 12.5 
Hz, H15b), 3.29 (1H, dd, J = 14.0, 9.4 Hz, H8a), 3.23 (1H, dd, J = 14.0, 5.0 Hz, H8b) 
13C NMR (126 MHz, d6-DMSO): δc = 192.2 (C21), 160.2 (C5), 158.6 (C6), 156.3 (C14), 138.1 (C9), 
137.2 (C16), 133.6 (C22), 132.5 (C24), 131.3 (C4), 130.6 (C23), 129.8 (C11), 129.6 (C1), 129.2 (C2), 
128.8, 128.7, 128.5 (C10, 18 & 25), 128.1 (C19), 127.7 (C17), 126.9 (C12), 126.1 (C3), 65.7 (C15), 
55.5 (C20), 48.1 (C7), 38.6 (C8) 










Following General Procedure 5: benzyl (S)-(2-phenyl-1-(3-phenyl-1H-1,2,4-triazol-5-
yl)ethyl)carbamate 54 (185 mg, 0.460 mmol), 2-bromo-4’-nitroacetophenone 118 (136 mg, 0.560 
mmol) and potassium carbonate (64.0 mg, 0.460 mmol) in DMF (5 mL) were used. The crude product 
was purified by flash column chromatography eluting with 0-40% ethyl acetate in 40-60 petroleum 
ether to yield the title compound 136 as a yellow solid (131 mg, 0.230 mmol, 50%). 
Rf = 0.24 (30% EtOAc in 40-60 petroleum ether) 
[𝛂]𝐃
𝟐𝟎 = +18.3 (c = 0.1 in CHCl3) 
IR: νmax = 3299 (w, N-H), 2971 (s, C-H), 2901 (s, C-H), 1698 (s, C=O), 1536 (s, N-O), 1475 (m, C=C), 
1445 (m, C=C), 1407 (m, C=C), 1324 (m, N-O) 
1H NMR (500 MHz, d6-DMSO): δH = 8.38 (2H, d, J = 8.9 Hz, H24), 8.24 (2H, d, J = 8.9 Hz, H23), 
8.10 (1H, d, J = 9.4 Hz, H13), 8.00 (2H, d, J = 7.3 Hz, H3), 7.48 (2H, t, J = 7.3 Hz, H2), 7.43 (1H, t, J 
= 7.3 Hz, H1), 7.31 (2H, d, J = 7.3 Hz, H11), 7.15 - 7.26 (6H, m, H10, 12, 18 & 19), 7.04 - 7.10 (2H, 
m, H17), 6.26 (1H, d, J = 18.6 Hz, H20a), 6.07 (1H, d, J = 18.6 Hz, H20b), 5.08 (1H, td, J = 9.4, 5.0 
Hz, H7), 4.77 (1H, d, J = 12.5 Hz, H15a), 4.68 (1H, d, J = 12.5 Hz, H15b), 3.26 - 3.30 (1H, m, H8a), 
3.23 (1H, dd, J = 14.0, 5.0 Hz, H8b) 
13C NMR (126 MHz, d6-DMSO): δC = 192.3 (C21), 160.3 (C5), 158.7 (C6), 156.3 (C14), 150.8 (C25), 
139.3 (C22), 138.0 (C9), 137.2 (C16), 131.3 (C4), 130.1 (C23), 129.9 (C11), 129.7 (C1), 129.3 (C2), 
128.7, 128.5 (C10 & 18), 128.1 (C19), 127.7 (C17), 126.9 (C12), 126.2 (C3), 124.4 (C24), 65.7 (C15), 









5.2.6. General procedure for Cyclisation to the Amine 
 
 
General Procedure 6: To a stirred solution of benzyl –(S)-(2-R2-((3-R1-1H-1,2,4-triazol-5-
yl)methyl)carbamate (1.0 eq.) in minimal ethyl acetate, methanol and water (v/v, 3:1), was added 
ammonium formate (30 eq.) and palladium dihydroxide (20 mol %). The mixture was stirred overnight 
until complete conversion to the amine was observed. The catalyst was removed by filtration through 
celite and the filter pad washed with methanol (3 x 30 mL). The solvent was removed under reduced 
pressure. The crude compound was purified by flash column chromatography on silica to yield the title 
compound. 
For the purpose of stability, to a stirred solution of the title compound in minimal dichloromethane was 
added hydrochloride solution (10 eq., 2M in diethyl ether), and the desired salt collected by filtration. 
 




Following General Procedure 6: benzyl (S)-(1-(1-(2-oxo-2-phenylethyl)-3-phenyl-1H-1,2,4-triazol-5-
yl)-2-phenylethyl)carbamate 56 (188 mg, 364 μmol), ammonium formate (688 mg, 10.9 mmol) and 
palladium dihydroxide (51.0 mg, 72.8 μmol) in ethyl acetate (1 mL), methanol and water (2 mL, 3:1 
v:v,) were. The crude product was purified by flash column chromatography eluting with 0-40% ethyl 
acetate in 40-60 petroleum ether to yield the title compound 58 as a yellow solid (121 mg, 330 μmol, 
91%). 
Rf = 0.53 (30% EtOAc in 40-60 petroleum ether) 
[𝛂]𝐃




IR νmax = 3028 (m, C-H), 1697 (m, C=N), 1602 (m, C=C) 
1H NMR (500 MHz, CD3OD): δH = 8.07 - 8.14 (2H, m, H3), 7.65 - 7.70 (2H, m, H17), 7.55 - 7.60 (3H, 
m, H18 & 19), 7.54 (2H, d, J = 7.3 Hz, H10), 7.49 (3H, d, J = 6.4 Hz, H1 & 2), 7.42 (2H, t, J = 7.3 Hz, 
H11), 7.36 (1H, t, J = 7.3 Hz, H12), 5.31 (1H, dd, J = 8.9, 5.2 Hz, H7), 5.18 (1H, dd, J = 11.0, 5.8 Hz, 
H14), 4.84 (1H, dd, J = 14.0, 5.8 Hz, H15a), 4.81 (1H, dd, J = 14.0, 11.0 Hz, H15b), 3.96 (1H, dd, J = 
14.8, 5.2 Hz, H8a), 3.42 (1H, dd, J = 14.8, 8.9 Hz, H8b) 
13C NMR (126 MHz, CD3OD): δC = 164.0 (C5), 151.2 (C6), 135.9 (C9), 133.4 (C16), 131.9 (C19), 
131.7 (C4), 131.1 (C1), 131.0 (C10), 130.9 (C18), 130.3 (C11), 129.9 (C2), 129.4 (C17), 129.1 (C12), 
127.6 (C3), 59.8 (C14), 58.2 (C7), 50.6 (C15), 38.1 (C8) 
HRMS (ESI+): found [M + H]+ 367.1931, C24H23N4+ required 367.1923. 
 




Following General Procedure 6: benzyl (S)-(1-(1-(2-oxo-2-phenylethyl)-3-(pent-4-en-1-yl)-1H-1,2,4-
triazol-5-yl)-2-phenylethyl)carbamate 119 (102 mg, 201 μmol), ammonium formate (379 mg, 6.02 
mmol) and palladium dihydroxide (28.0 mg, 40.1 μmol) in ethyl acetate (1 mL), methanol and water (1 
mL, 3:1 v:v,) were used. The crude product was purified by flash column chromatography eluting with 
30% ethyl acetate in hexane to yield the title compound 137 as a white solid (44.0 mg, 125 μmol, 60%). 
Rf = 0.14 (20% EtOAc in hexane) 
[𝛂]𝐃
𝟐𝟎 = -16.4 (c = 0.1 in CH3OH) 
IR νmax = 2929 (m, C-H), 1508 (m, C=C) 
1H NMR (500 MHz, CD3OD): δH = 7.64 (2H, dd, J = 7.6, 4.0 Hz, H17), 7.51 - 7.55 (3H, m, H18 & 
19), 7.47 (2H, d, J = 7.3 Hz, H11), 7.39 (2H, t, J = 7.3 Hz, H12), 7.32 (1H, t, J = 7.3 Hz, H13), 5.20 




dd, J = 14.8, 3.7 Hz, H9a), 3.37 (1H, dd, J = 14.8, 8.5 Hz, H9b), 2.78 (2H, t, J = 7.3 Hz, H5), 1.79 (2H, 
quin, J = 7.3 Hz, H4), 1.37 - 1.43 (4H, m, H2 & 3), 0.95 (3H, t, J = 6.7 Hz, H1) 
13C NMR (126 MHz, CD3OD): δC = 165.9 (C6), 150.7 (C7), 135.8 (C10), 133.9 (C16), 131.7 (C19), 
130.9 (C11), 130.7 (C18), 130.3 (C12), 129.3 (C17), 129.1 (C13), 59.6 (C16), 57.8 (C8), 50.7 (C15), 
38.0 (C9), 32.6 (C3), 29.0, 28.9 (C4 & 5), 23.6 (C2), 14.5 (C1) 







Following General Procedure 6: benzyl (S)-(1-(3-cyclopropyl-1-(2-oxo-2-phenylethyl)-1H-1,2,4-
triazol-5-yl)-2-phenylethyl)carbamate 120 (100 mg, 208 μmol), ammonium formate (394 mg, 6.24 
mmol) and palladium dihydroxide (29.0 mg, 41.6 μmol) in ethyl acetate (1 mL), methanol and water (1 
mL, 3:1 v:v,) were used. The crude product was purified by flash column chromatography eluting with 
30% ethyl acetate in hexane to yield the title compound 138 as a white solid (51.0 mg, 154 μmol, 74%). 
Rf = 0.32 (30% EtOAc in hexane) 
[𝛂]𝐃
𝟐𝟎 = -40.5 (c = 0.2 in CH3OH) 
IR: νmax = 2862 (m, C-H), 1575 (m,C=C) 
1H NMR (500 MHz, CD3OD): δH = 7.60 (2H, dd, J = 3.7, 2.1 Hz, H14), 7.51 - 7.56 (3H, m, H15 & 
16), 7.45 (2H, d, J = 7.0 Hz, H8), 7.39 (2H, ddt, J = 7.6, 7.0, 1.5 Hz, H9), 7.33 (1H, tt, J = 7.6, 1.5 Hz, 
H10), 5.17 (1H, dd, J = 8.9, 4.6 Hz, H5), 5.05 (1H, dd, J = 11.3, 5.2 Hz, H11), 4.64 - 4.70 (1H, m, 
H12a), 4.61 (1H, dd, J = 12.2, 5.2 Hz, H12b), 3.82 (1H, dd, J = 15.0, 4.6 Hz, H6a), 3.27 (1H, dd, J = 





13C NMR (126 MHz, CD3OD): δC = 159.6 (C3), 150.4 (C4), 135.8 (C7), 133.6 (C13), 131.8 (C16), 
130.9 (C8), 130.8 (C15), 130.3 (C9), 129.3 (C14), 129.1 (C10), 59.6 (C11), 57.9 (C5), 50.4 (C12), 38.1 
(C6), 9.6 (C2), 8.7 (C1) 






Following General Procedure 6: benzyl (S)-(1-(1-(2-oxo-2-phenylethyl)-3-(4-(trifluoromethyl)phenyl)-
1H-1,2,4-triazol-5-yl)-2-phenylethyl)carbamate 121 (100 mg, 171 μmol), ammonium formate (323 mg, 
5.13 mmol) and palladium dihydroxide (24.0 mg, 34.2 μmol) in ethyl acetate (1 mL), methanol and 
water (1 mL, 3:1 v:v,) were used. The crude product was purified by flash column chromatography 
eluting with 30% ethyl acetate in hexane to yield the title compound 139 as a white solid (44.0 mg, 101 
μmol, 59%). 
Rf = 0.82 (30% EtOAc in hexane) 
[𝛂]𝐃
𝟐𝟎 = -98.2 (c = 0.3 in CH3OH) 
IR νmax = 2972 (m, C-H), 1625 (m, C=N), 1529 (m, C=C) 
1H NMR (500 MHz, CD3OD): δH = 8.27 (2H, d, J = 8.1 Hz, H4), 7.78 (2H, d, J = 8.1 Hz, H3), 7.67 - 
7.71 (2H, m, H17), 7.50 - 7.57 (5H, m, H12, 18 & 19), 7.40 (2H, t, J = 7.3 Hz, H11), 7.33 (1H, tt, J = 
7.3, 1.2 Hz, H13), 5.30 (1H, dd, J = 8.7, 5.3 Hz, H8), 5.16 (1H, dd, J = 9.8, 6.7 Hz, H15a), 4.80 - 4.85 
(2H, m, H14 & 15b) 3.93 (1H, dd, J = 14.8, 5.33 Hz, H9a), 3.45 (1H, dd, J = 14.8, 8.7 Hz, H9b) 
13C NMR (126 MHz, CD3OD): δC = 162.7 (C6), 151.8 (C7), 136.0 (C10), 135.5 (C5), 133.5 (C16), 
132.7 (C2), 131.9 (C19), 131.0 (C12), 130.9 (C18), 130.3 (C11), 129.5 (C17), 129.0 (C13), 128.0 (C4), 
126.9 (C3), 124.6 (C1), 59.8 (C15), 58.1 (C8), 50.8 (C14), 38.0 (C9) 









Following General Procedure 6: benzyl (S)-(1-(3-(4-methoxyphenyl)-1-(2-oxo-2-phenylethyl)-1H-
1,2,4-triazol-5-yl)-2-phenylethyl)carbamate 123 (137 mg, 251 μmol), ammonium formate (474 mg, 
7.52 mmol) and palladium dihydroxide (35.0 mg, 50.1 μmol) in methanol and water (1 mL, 3:1 v:v,) 
were used. The crude product was purified by flash column chromatography eluting with 30% ethyl 
acetate in hexane to yield the title compound 141 as a white solid (78.1 mg, 197 μmol, 77%). 
Rf = 0.39 (30% EtOAc in hexane) 
[𝛂]𝐃
𝟐𝟎 = -48.6 (c = 0.3 in CH3OH) 
IR νmax = 2969 (m, C-H), 1611 (m, C=N), 1539 (m, C=C) 
1H NMR (500 MHz, CD3OD): δH =
 8.01 (2H, dt, J = 9.1, 2.1 Hz, H4), 7.65 - 7.69 (2H, m, H17), 7.51 - 
7.56 (4H, m, H10 & 18), 7.50 (1H, s, H19), 7.39 (2H, t, J = 7.5 Hz, H11), 7.32 (1H, t, J = 7.5 Hz, H12), 
7.01 (2H, dt, J = 9.1, 2.7 Hz, H3), 5.26 (1H, dd, J = 8.7, 4.7 Hz, H8), 5.14 (1H, dd, J = 10.1, 6.4 Hz, 
H15), 4.74 - 4.81 (2H, m, H14), 3.93 (1H, dd, J = 14.8, 4.7 Hz, H9a), 3.85 (3H, s, H1), 3.42 (1H, dd, J 
= 14.8, 8.7 Hz, H9b) 
13C NMR (126 MHz, CD3OD): δC = 163.9 (C6), 162.8 (C2), 151.0 (C7), 136.0 (C10), 133.4 (C16), 
131.9 (C18), 131.0 (C19), 130.8 (C12), 130.3 (C11), 129.5 (C17), 129.1, 129.1 (C4 & 13), 124.1 (C5), 
115.3 (C3), 59.3 (C15), 58.2 (C8), 56.0 (C1), 50.5 (C14), 38.0 (C9) 










Following General Procedure 6: benzyl (S)-(1-(3-(4-bromobenzyl)-1-(2-oxo-2-phenylethyl)-1H-1,2,4-
triazol-5-yl)-2-phenylethyl)carbamate 124 (19.9 mg, 32.7 μmol), ammonium formate (62.1 mg, 98.1 
μmol) and palladium dihydroxide (4.60 mg, 6.54 μmol) in ethyl acetate (1 mL), methanol and water (1 
mL, 3:1 v:v,) were used. The crude product was purified by flash column chromatography eluting with 
50% ethyl acetate in hexane to yield the title compound 142 as a white solid (4.70 mg, 12.4 μmol, 38%). 
Rf = 0.41 (60% EtOAc in hexane) 
[𝛂]𝐃
𝟐𝟎 = -38.3 (c = 0.1 in CH3OH) 
IR: νmax = 2927 (m, C-H), 1603 (w, C=C), 1495 (m, C=C) 
1H NMR (500 MHz, CD3OD): δH = 7.55 (2H, dd, J = 7.6, 1.5 Hz, H17), 7.45 – 7.49 (3H, m, H18 & 
19), 7.38 (2H, d, J = 7.0 Hz, H2), 7.28 - 7.35 (7H, m, H1, 3, 11 & 12), 7.22 - 7.26 (1H, m, H13), 4.71 - 
4.82 (1H, m, H14), 4.53 (1H, d, J = 11.3 Hz, H15a), 4.36 - 4.40 (1H, m H15b), 4.09 (2H, s, H5), 3.71 
(1H, dd, J = 14.5, 3.2 Hz, H9a), 3.21 (1H, dd, J = 14.5, 8.9 Hz, H9b) – H8 obscured by MeOD peak 
13C NMR (126 MHz, CD3OD): δC = 169.0 (C6), 167.8 (C7), 139.2 (C4), 135.4 (C9), 135.1 (C16), 130.9 
(C2), 130.9 (C18), 130.5 (C19), 130.0 (C1), 130.0 (C11), 129.7 (C3), 128.9 (C17), 128.6 (C13), 127.8 
(C12), 59.2 (C14), 59.1 (C8), 53.3 (C15), 37.0 (C9), 35.4 (C5) 






5.2.6.7.  ((6R,8R)-2,6-diphenyl-5,6,7,8-tetrahydro-[1,2,4]triazolo[1,5-a]pyrazin-8-yl)methanol (143) 
 
 
Following General Procedure 6: benzyl (S)-(2-hydroxy-1-(1-(2-oxo-2-phenylethyl)-3-phenyl-1H-
1,2,4-triazol-5-yl)ethyl)carbamate 143 (56.0 mg, 123 μmol), ammonium formate (232 mg, 3.68 mmol) 
and palladium dihydroxide (17.0 mg, 24.5 μmol) in ethyl acetate (1 mL), methanol and water (1 mL, 
3:1 v:v,) were used. The crude product was purified by flash column chromatography eluting with 80% 
ethyl acetate in hexane to yield the title compound 125 as a brown solid (31.0 mg, 101 μmol, 82%). 
Rf = 0.44 (80% EtOAc in hexane) 
[𝛂]𝐃
𝟐𝟎 = -108.6 (c = 0.3 in CH3OH) 
IR νmax = 2927 (m, C-H), 1686 (m, C=N), 1611 (m, C=C), 1556 (m, C=C) 
1H NMR (500 MHz, CD3OD): δH = 8.07 - 8.11 (2H, m, H3), 7.72 - 7.77 (2H, m, H13), 7.59 - 7.64 (3H, 
m, H14 & 15), 7.46 - 7.51 (3H, m, H1 & 2), 5.28 (1H, dd, J = 11.3, 4.9 Hz, H10), 5.14 (1H, dd, J = 7.3, 
3.7 Hz, H7), 4.85 (1H, ddd, J = 13.7, 4.9, 0.6 Hz, H11a), 4.79 (1H, ddd, J = 13.7, 11.3, 1.2 Hz, H11b), 
4.48 (1H, dd, J = 12.2, 3.7 Hz, H8a), 4.28 (1H, dd, J = 12.2, 7.3 Hz, H8b) 
13C NMR (126 MHz, CD3OD): δC = 164.1 (C5), 149.2 (C6), 133.3 (C4), 131.9 (C15), 131.6 (C12), 
131.1 (C1), 130.9 (C14), 129.9 (C2), 129.4 (C13), 127.6 (C3), 60.6 (C8), 59.1 (C10), 58.6 (C7), 50.5 
(C11) 











Following General Procedure 6: benzyl (S)-(2-methyl-1-(1-(2-oxo-2-phenylethyl)-3-phenyl-1H-1,2,4-
triazol-5-yl)propyl)carbamate 126 (173 mg, 369 μmol), ammonium formate (693 mg, 11.1 mmol) and 
palladium dihydroxide (52.0 mg, 73.8 μmol) in ethyl acetate (1 mL), methanol and water (3 mL, 3:1 
v:v,) were used. The crude product was purified by flash column chromatography eluting with 30% 
ethyl acetate in hexane to yield the title compound 144 as a white solid (99.0 mg, 311 μmol, 84%). 
Rf = 0.66 (30% EtOAc in hexane) 
[𝛂]𝐃
𝟐𝟎 = -64.8 (c = 0.2 in CH3OH) 
IR νmax = 2974 (m, C-H), 2905 (m, C-H), 1537 (m, C=N), 1520 (m, C=C0, 1488 (m, C=C) 
1H NMR (500 MHz, CD3OD): δH = 8.08 (2H, dd, J = 7.9, 1.8 Hz, H3), 7.74 - 7.79 (2H, m, H15), 7.56 
- 7.61 (3H, m, H16 & 17), 7.43 - 7.48 (3H, m, H1 & 2), 5.22 (1H, dd, J = 11.4, 5.2 Hz, H12), 4.92 (1H, 
d, J = 4.9 Hz, H7), 4.82 (1H, dd, J = 13.7, 11.4 Hz, H13a), 4.78 (1H, dd, J = 13.7, 5.2 Hz, H13b), 2.65 
(1H, dsep, J = 4.9, 7.0 Hz, H8), 1.38 (3H, d, J = 7.0 Hz, H9/10), 1.38 (3H, d, J = 7.0 Hz, H9/10) 
13C NMR (400 MHz, CD3OD): δC = 163.9 (C5), 150.7 (C6), 133.3 (C14), 132.0 (C17), 131.8 (C4), 
131.0 (C1), 130.9 (C16), 129.9 (C2), 129.7 (C15), 127.5 (C3), 62.5 (C7), 60.2 (C12), 50.4 (C13), 31.9 
(C8), 19.7 (C9/10), 18.9 (C9/10) 











Following General Procedure 6: benzyl (S)-(2-(1H-indol-3-yl)-1-(1-(2-oxo-2-phenylethyl)-3-phenyl-
1H-1,2,4-triazol-5-yl)ethyl)carbamate 125 (100 mg, 180 μmol), ammonium formate (340 mg, 5.40 
mmol) and palladium dihydroxide (25.0 mg, 36.0 μmol) in ethyl acetate (1 mL), methanol and water (1 
mL, 3:1 v:v) were used. The crude product was purified by flash column chromatography eluting with 
30% ethyl acetate in hexane to yield the title compound 145 as an orange solid (68.0 mg, 168 μmol, 
93%). 
Rf = 0.41 (30% EtOAc in hexane) 
[𝛂]𝐃
𝟐𝟎 = -57.9 (c = 0.2 in CH3OH) 
IR: νmax = 2969 (m, C-H), 2920 (m, C-H), 1697 (m, C=N), 1618 (m, C=C), 1521 (m, C=C) 
1H NMR (400 MHz, CD3OD): δH = 8.15 (2H, d, J = 7.8 Hz, H3), 7.80 (1H, d, J = 7.8 Hz, H11), 7.65 
(2H, d, J = 3.7 Hz, H21), 7.47 - 7.57 (6H, m, H1, 2, 22 & 23), 7.41 (1H, d, J = 8.2 Hz, H14), 7.39 (1H, 
s, H17), 7.14 - 7.20 (1H, m, H13), 7.08 - 7.14 (1H, m, H12), 5.32 (1H, dd, J = 8.9, 3.1 Hz, H7), 5.14 
(1H, dd, J = 9.4, 5.6 Hz, H18), 4.76 - 4.85 (2H, m, H19), 4.16 (1H, dd, J = 15.3, 3.1 Hz, H8a), 3.68 
(1H, dd, J = 15.3, 8.9 Hz, H8b) 
13C NMR (101 MHz, CD3OD): δH = 163.7 (C5), 151.3 (C6), 138.4 (C15), 133.3 (C20), 131.6 (C2), 
131.4 (C4), 131.1 (C1), 130.7 (C22), 129.9 (C23), 129.7 (C21), 128.6 (C10), 127.6 (C3), 126.5 (C17), 
123.0 (C13), 120.4 (C12), 119.3 (C11), 112.8 (C14), 107.9 (C9), 59.8 (C18), 57.6 (C7), 50.8 (C19), 
28.1 (C8) 









Following General Procedure 6: benzyl (S)-(1-(1-(2-(4-hydroxyphenyl)-2-oxoethyl)-3-phenyl-1H-
1,2,4-triazol-5-yl)-2-phenylethyl)carbamate 128 (54.0 mg, 101 μmol), ammonium formate (192 mg, 
3.04 mmol) and palladium dihydroxide (14.0 mg, 20.3 μmol) in ethyl acetate (1 mL), methanol and 
water (1 mL, 3:1 v:v) were used. The crude product was purified by flash column chromatography 
eluting with 50% ethyl acetate in hexane to yield the title compound 146 as a white solid (32.0 mg, 83.7 
μmol, 83%). 
Rf = 0.55 (55% EtOAc in hexane) 
[𝛂]𝐃
𝟐𝟎 = -87.6 (c = 0.2 in CH3OH) 
IR: νmax = 3209 (m, br, O-H), 2929 (m, C-H), 1701 (m, C=N), 1612 (m, C=C), 1514 (m, C=C) 
1H NMR (500 MHz, CD3OD): δH = 8.10 (2H, dd, J = 7.3, 1.5 Hz, H3), 7.68 (2H, d, J = 3.4 Hz, H17), 
7.55 (3H, d, J = 3.4 Hz, H18 & 19), 7.43 - 7.52 (3H, m, H1 & 2), 7.33 (2H, d, J = 8.2 Hz, H10), 6.82 
(2H, d, J = 8.2 Hz, H11), 5.09 - 5.25 (2H, m, H7 & 14), 4.80 (2H, d, J = 6.1 Hz, H15), 3.87 (1H, d, J = 
13.7 Hz, H8a), 3.36 (1H, dd, J = 13.7, 8.2 Hz, H8b) 
13C NMR (126 MHz, CD3OD): δC = 164.0 (C5), 158.5 (C12), 151.3 (C6), 133.4 (C16), 132.1 (C11), 
131.8 (C19), 131.7 (C18), 131.1 (C1), 130.8 (C4), 129.9 (C2), 129.5 (C17), 127.6 (C3), 126.2 (C9), 
117.0 (C10), 59.8 (C14), 58.5 (C7), 50.6 (C15), 37.3 (C8) 











Following General Procedure 6: benzyl (S)-2-(1-(2-oxo-2-phenylethyl)-3-phenyl-1H-1,2,4-triazol-5-
yl)pyrrolidine-1-carboxylate 129 (65.6 mg, 141 μmol), ammonium formate (267 mg, 4.24 mmol) and 
palladium dihydroxide (19.8 mg, 28.2 μmol) in ethyl acetate (1 mL), methanol and water (1 mL, 3:1 
v:v) were used. The crude product was purified by flash column chromatography eluting with 30% 
ethyl acetate in hexane to yield the title compound 147 as a yellow solid (26.8 mg, 84.7 μmol, 60%). 
Rf = 0.27 (30% EtOAc in 40-60 petroleum ether) 
[𝛂]𝐃
𝟐𝟎 = -29.3 (c = 0.1 in CH3OH) 
IR: νmax = 2918 (m, C-H), 1703 (m, C=N), 1675 (m, C=C) 
1H NMR (500 MHz, CD3OD): δH =
 8.01 - 8.10 (2H, m, H3), 7.75 (2H, dd, J = 3.4, 2.1 Hz, H14), 7.57 
- 7.63 (3H, m, H15 & 16), 7.43 - 7.50 (3H, m, H1 & 2), 5.57 (1H, dd, J = 11.7, 3.8 Hz, H11), 5.44 - 
5.46 (1H, m, H7), 5.18 (1H, dd, J = 13.1, 11.7 Hz, H12a), 3.56 - 3.67 (1H, m, H8a), 2.72 (2H, t, J = 6.7 
Hz, H10), 2.19 (1H, td, J = 14.3, 6.7 Hz, H9a), 2.10 (1H, td, J = 14.3, 6.7 Hz, H9b) – H8b & H12b 
obscured by solvent 
13C NMR (126 MHz, CD3OD): δC = 164.2 (C5), 150.1 (C6), 132.5 (C16), 131.6 (C13), 131.4 (C4), 
131.2 (C1), 131.1 (C15), 130.5 (C14), 130.0 (C2), 127.6 (C3), 62.9 (C7), 60.7 (C11), 52.5 (C8), 37.5 
(C10), 22.7 (C9) –C12 obscured by solvent 












Following General Procedure 6: benzyl (S)-(3-(methylthio)-1-(1-(2-oxo-2-phenylethyl)-3-phenyl-1H-
1,2,4-triazol-5-yl)propyl)carbamate 130 (123 mg, 245 μmol), ammonium formate (463 mg, 7.34mmol) 
and palladium dihydroxide (68.7 mg, 489 μmol) in ethyl acetate (1 mL), methanol and water (1 mL, 3:1 
v:v) were used. The crude product was purified by flash column chromatography eluting with 50% 
ethyl acetate in hexane to yield the title compound 148 as a white solid (43.7 mg, 125 μmol, 51%). 
Rf = 0.50 (30% EtOAc in hexane) 
[𝛂]𝐃
𝟐𝟎 = -31.0 (c = 0.2 in CH3OH) 
IR: νmax = 2916 (m, C-H), 1705 (m, C=N), 1687 (m, C=C) 
1H NMR (500 MHz, CD3OD): δH = 8.08 (2H, dd, J = 7.5, 2.1 Hz, H3), 7.66 - 7.71 (2H, m, H14), 7.57 
- 7.62 (3H, m, H15 & 16), 7.42 - 7.48 (3H, m, H1 & 2), 5.25 (1H, dd, J = 11.7, 4.9 Hz, H11), 5.20 (1H, 
t, J = 6.6 Hz, H7), 4.82 (1H, dd, J = 13.7, 4.9 Hz, H12a), 4.73 (1H, dd, J = 13.7, 11.7 Hz, H12b), 3.05 
- 3.17 (2H, m, H9), 2.70 (1H, td, J = 14.1, 7.4 Hz, H8a), 2.34 (1H, td, J = 14.1, 7.3 Hz, H8b), 2.21 (3H, 
s, H10) 
13C NMR (126 MHz, CD3OD): δC = 164.1 (C5), 151.4 (C6), 133.4 (C13), 132.1 (C16), 131.7 (C4), 
131.1, 131.0 (C1 & 15), 129.9 (C2), 129.3 (C14), 127.5 (C3), 59.5 (C11), 55.2 (C7), 50.5 (C12), 31.7 
(C8), 31.0 (C9), 15.2 (C10) 












Following General Procedure 6: benzyl ((1S)-1-(1-(2-((1S,3R)-adamantan-1-yl)-2-oxoethyl)-3-phenyl-
1H-1,2,4-triazol-5-yl)-2-phenylethyl)carbamate 131 (117 mg, 204 μmol), ammonium formate (385 mg, 
6.11 mmol) and palladium dihydroxide (29.0 mg, 40.7 μmol) in ethyl acetate (1 mL), methanol and 
water (1 mL, 3:1 v:v) were used. The crude product was purified by flash column chromatography 
eluting with 10% ethyl acetate in hexane to yield the title compound 149 as a white solid (79.0 mg, 186 
μmol, 91%). 
Rf = 0.16 (10% EtOAc in hexane) 
[𝛂]𝐃
𝟐𝟎 = -81.1 (c = 0.3 in CH3OH) 
IR: νmax = 2920 (m, C-H), 1703 (m, C=N), 1632 (m, C=C) 
1H NMR (400 MHz, d6-DMSO): δH = 8.01 (2H, m, J = 4.4 Hz, H3), 7.63 (2H, d, J = 7.2 Hz, H11), 7.41 
- 7.49 (5H, m, H1, 2 & 10), 7.35 (1H, t, J = 7.2 Hz, H12), 5.18 (1H, dd, J = 8.7, 3.6 Hz, H7), 4.67 (1H, 
dd, J = 13.6, 4.4Hz, H14a), 4.47 - 4.56 (1H, m, H14b), 3.81 (1H, dd, J = 12.1, 4.4 Hz, H13), 3.64 (1H, 
dd, J = 14.3, 3.6 Hz, H8a), 3.54 (1H, dd, J = 14.3, 8.7 Hz, H8b), 2.12 - 2.20 (3H, m, H17), 2.00 (3H, d, 
J = 11.9 Hz, H16a), 1.80 - 1.93 (6H, m, H18), 1.77 (3H, d, J = 11.9 Hz, H16b) 
13C NMR (101 MHz, d6-DMSO): δC = 163.6 (C5), 151.6 (C6), 137.1 (C9), 131.5 (C4), 131.0 (C11), 
130.9, (C1), 129.7 (C2), 129.6 (C10), 128.4 (C12), 127.3 (C3), 65.2 (C13), 58.0 (C7), 45.7 (C14), 38.7 
(C16), 37.6 (C8), 37.3 (C18), 35.9 (C15), 29.5 (C17) 











Following General Procedure 6: benzyl (S)-(1-(1-(2-oxo-2-(4-(trifluoromethyl)phenyl)ethyl)-3-phenyl-
1H-1,2,4-triazol-5-yl)-2-phenylethyl)carbamate 133 (66.3 mg, 113 μmol), ammonium formate (215 
mg, 3.40 mmol) and palladium dihydroxide (15.9 mg, 22.7 μmol) in ethyl acetate (1 mL), methanol and 
water (1 mL, 3:1 v:v) were used. The crude product was purified by flash column chromatography 
eluting with 50% ethyl acetate in hexane to yield the title compound 151 as a white solid (35.0 mg, 80.6 
μmol, 71%). 
Rf = 0.75 (30% EtOAc in 40-60 petroleum ether) 
[𝛂]𝐃
𝟐𝟎 = -45.7 (c = 0.4 in CH3OH) 
IR: νmax = 2919 (m, C-H), 1702 (m, C=N), 1595 (m, C=C)  
1H NMR (500 MHz, CD3OD): δH = 8.10 (2H, d, J = 7.9 Hz, H3), 7.89 (2H, d, J = 8.2 Hz, H17), 7.85 
(2H, d, J = 8.2 Hz, H16), 7.53 (2H, d, J = 7.3 Hz, H10), 7.48 (3H, dd, J = 7.9, 1.2 Hz, H1 & 2), 7.41 
(2H, t, J = 7.3 Hz, H11), 7.34 (1H, t, J = 7.3 Hz, H12), 5.25 (1H, dd, J = 8.9, 4.3 Hz, H7), 5.20 (1H, dd, 
J = 11.3, 4.3 Hz, H13), 4.81 (1H, dd, J = 13.4, 4.3 Hz, H14a), 4.76 (1H, d, J = 13.4, 11.3 Hz, H14b), 
3.96 (1H, dd, J = 14.8, 4.3 Hz, H8a), 3.44 (1H, dd, J = 14.8, 8.9 Hz, H8b) 
13C NMR (126 MHz, CD3OD): δC = 163.8 (C5), 151.7 (C6), 136.2 (C15), 133.5 (C9), 133.3 (C18), 
131.6 (C4), 131.1 (C1), 131.0 (C10), 130.3, 130.2 (C11 & 17), 129.9 (C2), 129.0 (C12), 127.6, 127.5 
(C3 & 16), 124.3 (C19), 59.0 (C13), 58.1 (C7), 50.9 (C14), 38.3 (C8) 










Following General Procedure 6: benzyl (S)-(1-(1-(2-(4-methoxyphenyl)-2-oxoethyl)-3-phenyl-1H-
1,2,4-triazol-5-yl)-2-phenylethyl)carbamate 134 (100 mg, 183 μmol), ammonium formate (346 mg, 
5.49 mmol) and palladium dihydroxide (26.0 mg, 36.9 μmol) in ethyl acetate (1 mL), methanol and 
water (1 mL, 3:1 v:v) were used. The crude product was purified by flash column chromatography 
eluting with 20% ethyl acetate in hexane to yield the title compound 152 as a white solid (56.0 mg, 141 
μmol, 77%). 
Rf = 0.32 (20% EtOAc in hexane) 
[𝛂]𝐃
𝟐𝟎 = -18.2 (c = 0.2 in CH3OH) 
IR: νmax = 2930 (m, C-H), 1678 (m, C=N), 1607 (m, C=C) 
1H NMR (400 MHz, CD3OD): δH = 8.03 - 8.14 (2H, m, H3), 7.55 (2H, d, J = 7.5 Hz, H10), 7.44 - 7.50 
(3H, m, H1 & 2), 7.37 - 7.43 (4H, m, H11, 17 & 20), 7.32 (1H, t, J = 7.2 Hz, H12), 7.28 (1H, d, J = 7.2 
Hz, H16), 7.06 (1H, d, J = 8.2 Hz, H18), 5.27 - 5.29 (1H, m, H7), 5.14 (1H, d, J = 8.2 Hz, H13), 4.76 
(1H, d, J = 13.6 Hz, H14b), 3.95 (1H, d, J = 14.6 Hz, H8a), 3.86 (3H, s, H21), 3.56 (1H, dd, J = 14.6, 
7.5 Hz, H8b) – H14a obscured by methanol peak 
13C NMR (101 MHz, CD3OD): δC = 163.9 (C5), 162.0 (C19), 151.2 (C6), 136.0 (C9), 134.7 (C15), 
131.9 (C4), 131.7 (C17), 131.1 (C10), 131.0 (C1), 130.2 (C11), 129.9 (C2), 129.0 (C12), 127.5 (C3), 
121.4 (C16), 117.3 (C18), 115.1 (C20), 59.8 (C14), 58.3 (C7), 56.3 (C21), 50.7 (C13), 37.9 (C8) 











Following General Procedure 6: benzyl (S)-(1-(1-(2-(4-nitrophenyl)-2-oxoethyl)-3-phenyl-1H-1,2,4-
triazol-5-yl)-2-phenylethyl)carbamate 136 (68.0 mg, 121 μmol), ammonium formate (229 mg, 3.63 
mmol) and palladium dihydroxide (17.0 mg, 24.2 μmol) in ethyl acetate (1 mL), methanol and water (1 
mL, 3:1 v:v) were used. The crude product was purified by flash column chromatography eluting with 
30% ethyl acetate in 40-60 petroleum ether to yield the title compound 154 as a white solid (32.6 mg, 
85.4 μmol, 71%). 
Rf = 0.25 (60% EtOAc in hexane) 
[𝛂]𝐃
𝟐𝟎 = -119.0 (c = 0.2 in CH3OH) 
IR: νmax = 3319 (w, N-H), 2729 (m, C-H), 1518 (C=N), 1491 (m, C=C)  
1H NMR (500 MHz, CD3OD): δH = 8.04 - 8.12 (2H, m, H3), 7.86 (2H, d, J = 8.5 Hz, H16), 7.53 (2H, 
d, J = 7.5 Hz, H10), 7.49 (2H, d, J = 8.5 Hz, H17), 7.43 - 7.48 (3H, m, H1 & 2), 7.39 (2H, t, J = 7.5 Hz, 
H11), 7.32 (1H, t, J = 7.5 Hz, H12), 5.23 (1H, dd, J = 9.2, 4.8 Hz, H7), 5.16 (1H, dd, J = 10.4, 6.0 Hz, 
H13), 4.73 - 4.83 (2H, m, H14), 3.94 (1H, dd, J = 14.7, 4.8 Hz. H8a), 3.48 (1H, dd, J = 14.7, 9.2 Hz, 
H8b) 
13C NMR (126 MHz, CD3OD): δC = 163.8 (C5), 151.5 (C6), 144.7 (C18), 136.2 (C9), 131.6 (C4), 131.6 
(C16), 131.1 (C1), 131.1 (C10), 130.3 (C11), 129.9 (C2), 129.4 (C15), 129.0 (C12), 127.6 (C3), 124.6 
(C17), 58.9 (C13), 58.1 (C7), 50.7 (C14), 38.2 (C8) 















Following General Procedure 5: benzyl ((3-phenyl-1H-1,2,4-triazol-5-yl)methyl)carbamate 54 (900 
mg, 2.26 mmol), ethyl 2-bromoacetate (300 μL, 2.71 mmol) and potassium carbonate (312 mg, 2.26 
mmol) in DMF (3 mL) were used. The crude product was purified by flash column chromatography 
eluting with 20% ethyl acetate in 40-60 petroleum ether to yield the title compound 164 as a white solid 
(1.08 g, 2.25 mmol, 99%). 
Rf = 0.42 (10% EtOAc in 40-60 petroleum ether) 
[𝛂]𝐃
𝟐𝟎 = -14.6 (c = 0.1 in CHCl3) 
IR: νmax = 3675 (m, N-H), 2988 (s, C-H), 2901 (s, C-H), 1743 (s, C=O), 1697 (s, C=O), 1406 (m, C=C), 
1394 (m, C=C), 1382 (m, C=C) 
1H NMR (400 MHz, CDCl3): δH = 8.08 (2H, dd, J = 8.0, 1.5 Hz, H3), 7.39 - 7.49 (4H, m, H1, 2 & 19), 
7.28 - 7.37 (7H, m, H11, 12, 17 & 18), 7.16 (2H, dd, J = 7.5, 1.4 Hz, H10), 5.59 (1H, d, J = 8.5 Hz, 
H13), 5.09 (1H, d, J = 12.3 Hz, H20a), 5.04 (1H, t, J = 7.5 Hz, H7), 5.03 (2H, d, J = 12.3 Hz, H20b), 
4.92 (1H, d, J = 17.7 Hz, H15a), 4.53 (1H, d, J = 17.7 Hz, H15b), 4.19 (2H, q, J = 7.0 Hz, H22), 3.37 
(1H, dd, J = 14.0, 7.5 Hz, H8a), 3.30 (1H, dd, J = 14.0, 7.5 Hz, H8b), 1.25 (3H, t, J = 7.0 Hz, H23) 
13C NMR (101 MHz, CDCl3): δC = 166.9 (C21), 166.8 (C5), 161.4 (C6), 156.8 (C14), 136.3 (C9), 136.0 




(C17), 127.1 (C12), 126.4 (C3), 67.1 (C7/20), 62.2 (C22), 49.5 (C7/20), 48.6 (C15), 40.8 (C8), 14.0 
(C23) 







Following General Procedure 5: benzyl ((3-phenyl-1H-1,2,4-triazol-5-yl)methyl)carbamate 54 (850 
mg, 2.13 mmol), bromoacetonitrile (180 μL, 2.56 mmol) and potassium carbonate (295 mg, 2.13 mmol) 
in DMF (3 mL) were used. The crude product was purified by flash column chromatography eluting 
with 30% ethyl acetate in 40-60 petroleum ether to yield the title compound 168 as a white solid (825 
mg, 1.89 mmol, 89%). 
Rf = 0.33 (30% EtOAc in 40-60 petroleum ether) 
[𝛂]𝐃
𝟐𝟎 = +10.9 (c = 0.1 in CHCl3) 
IR: νmax = 3320 (m, C-H), 2158 (m, C≡N), 1686 (s, C=O), 1531 (s, C=C) 
1H NMR (500 MHz, d6-DMSO): δH = 8.24 (1H, d, J = 7.9 Hz, H13), 8.01 (2H, d, J = 6.7 Hz, H3), 7.45 
- 7.53 (3H, m, H1 & 2), 7.24 - 7.35 (7H, m, H10, 11, 18 & 19), 7.22 (3H, d, J = 7.3 Hz, H12 & 17), 
5.60 (1H, d, J = 17.8 Hz, H20a), 5.55 (1H, d, J = 17.8 Hz, H20b), 5.22 (1H, dd, J = 9.2, 7.9 Hz, H7), 
4.99 (1H, d, J = 12.6 Hz, H15a), 4.93 (1H, d, J = 12.6 Hz, H15b), 3.26 (2H, d, J = 9.2 Hz, H8) 
13C NMR (126 MHz, d6-DMSO): δC = 160.7 (C5), 157.9 (C6), 156.1 (C14), 137.1 (C9), 136.7 (C16), 
130.1 (C4), 129.8 (C1), 129.4 (C11), 129.0 (C2), 128.4, 128.3 (C10 & 18), 127.9 (C19), 127.6 (C17), 




HRMS (ESI+): found [M + H]+ 438.1941, C26H24N5O2+ required 438.1930. 
 




To a stirred solution of ethyl (S)-2-(5-(1-(((benzyloxy)carbonyl)amino)-2-phenylethyl)-3-phenyl-1H-
1,2,4-triazol-1-yl)acetate 164 (318 mg, 0.661 mmol, 1.0 eq.) in methanol (7.0 mL, 0.1 M) was added 
the palladium on carbon catalyst (10%, 108 mg, 10% w/w, 10 mol%). The reaction was stirred under 
hydrogen atmosphere for 3 h. The catalyst was removed by filtration through Celite and washed with 
hot methanol (3 x 30 mL). The combined filtrates were concentrated under reduced pressure. The 
resultant crude compound was purified by flash column chromatography on silica eluting with 0-100% 
ethyl acetate in 40-60 petroleum ether to yield the title compound 167 as a white solid (165 mg, 0.954 
mmol, 82%). 
Rf = 0.46 (EtOAc) 
[𝛂]𝐃
𝟐𝟎 = -138.5 (c = 0.1 in CHCl3) 
IR: νmax = 2962 (m, C-H), 1673 (s, C=O), 1629 (s, C=O), 1439 (s, C=C) 
1H NMR (400 MHz, CDCl3): δH = 8.13 (2H, dd, J = 7.9, 1.5 Hz, H3), 7.44 - 7.54 (3H, m, H1 & 2), 7.27 
- 7.36 (3H, m, H11 & 12), 7.03 - 7.09 (2H, m, H10), 6.96 (1H, br s, H15), 5.16 - 5.19 (1H, m, H7), 4.67 
(1H, dd, J = 18.0, 1.5 Hz, H14a), 4.03 (1H, d, J = 18.0 Hz, H14b), 3.45 (1H, dd, J = 13.7, 3.8 Hz, H8a), 
3.26 (1H, dd, J = 13.7, 6.1 Hz, H8b) 
13C NMR (101 MHz, CDCl3): δC = 165.0 (C13), 163.3 (C6), 149.6 (C5), 133.9 (C9), 130.4 (C4), 
129.8 (C10), 129.7 (C1), 128.9 (C11), 128.7 (C2), 127.8 (C12), 126.4 (C3), 51.5 (C7), 48.9 (C14), 
42.4 (C8) 









To a stirred solution (S)-8-benzyl-2-phenyl-7,8-dihydro-[1,2,4]triazolo[1,5-a]pyrazin-6(5H)-one 167 
(18.0 mg, 0.060 mmol, 1.0 eq.) in acetonitrile (0.90 mL, 0.3 M) were successively added DMAP (4.00 
mg, 0.030 mmol, 0.5 eq.) and di-tert-butyl dicarbonate (19.0 mg, 0.090 mmol, 1.5 eq.) and the mixture 
was stirred at rt for 1 h. The solvent was removed under reduced pressure. The resultant crude compound 
was purified by flash column chromatography on silica eluting with 35% diethyl ether in 40-60 
petroleum ether to yield the title compound 170 as a white solid (21.0 mg, 0.050 mmol, 88%). 
Rf = 0.44 (30% EtOAc in 40-60 petroleum ether) 
[𝛂]𝐃
𝟐𝟎 = -56.0 (c = 0.1 in CH3OH) 
IR: νmax = 2962 (m, C-H), 1764 (s, C=O), 1694 (s, C=O), 1623 (m, C=C) 
1H NMR (500 MHz, CDCl3): δH 8.12 (2H, dd, J = 8.1, 1.4 Hz, H3), 7.44 - 7.53 (3H, m, H1 & 2), 7.32 
(1H, t, J = 7.3 Hz, H12), 7.23 (2H, t, J = 7.3 Hz, H11), 6.78 (2H, d, J = 7.3 Hz, H10), 5.94 (1H, t, J = 
3.7 Hz, H7), 4.52 (1H, d, J = 18.3 Hz, H14a), 3.54 (1H, dd, J = 14.0, 3.7 Hz, H8a), 3.37 (1H, dd, J = 
14.0, 3.7 Hz, H8b), 3.01 (1H, d, J = 18.3 Hz, H14b), 1.65 (9H, s, H18) 
13C NMR (126 MHz, CDCl3): δC = 163.3 (C13), 163.2 (C6), 150.7 (C5), 150.3 (C15), 133.5 (C9), 130.4 
(C4), 130.3 (C10), 129.7 (C1), 129.0 (C11), 128.7 (C2), 128.1 (C12), 126.4 (C3), 85.3 (C17), 54.8 (C7), 
49.9 (C14), 41.2 (C8), 28.0 (C18) 











To a stirred solution of ethyl (S)-2-(5-(1-(((benzyloxy)carbonyl)amino)-2-phenylethyl)-3-phenyl-1H-
1,2,4-triazol-1-yl)acetate 164 (700 mg, 1.44 mmol, 1.0 eq.) in ethanol (9.0 mL, 0.2 M) at 0 °C, was 
added lithium borohydride (2.63 mL, 2.63 mmol, 1.8 eq.). The reaction was stirred at room temperature 
for 18 h before it was quenched with a saturated aqueous solution of ammonium chloride (10 mL) and 
extracted with ethyl acetate (3 x 20 mL). The combined organic fractions were washed with brine (10 
mL) and dried (MgSO4). The solvent was removed under reduced pressure. The resultant crude 
compound was purified by flash column chromatography on silica eluting with 0-100% ethyl acetate in 
40-60 petroleum ether to yield the title compound 174 as a white solid (578 mg, 1.31 mmol, 91%). 
Rf = 0.57 (50% EtOAc in 40-60 petroleum ether) 
[𝛂]𝐃
𝟐𝟎 = +53.3 (c = 0.2 in CHCl3) 
IR: νmax = 3676 (m, O-H), 2988 (s, C-H), 2901 (s, C-H), 1697 (m, C=O), 1406 (m, C=C), 1394 (m, 
C=C), 1382 (m, C=C)  
1H NMR (500 MHz, d6-DMSO): δH = 8.16 (1H, d, J = 8.5 Hz, H13), 7.99 (2H, d, J = 7.0 Hz, H3), 7.46 
(2H, t, J = 7.0 Hz, H2), 7.40 (1H, t, J = 7.0 Hz, H1), 7.30 - 7.34 (2H, m, H11), 7.24 - 7.29 (5H, m, H10, 
18 & 19), 7.18 - 7.23 (3H, m, H12 & 17), 5.13 (1H, ddd, J = 9.8, 8.5, 5.2 Hz, H7), 5.10 (1H, t, J = 5.3 
Hz, H22), 4.95 (1H, d, J = 12.8 Hz, H15a), 4.90 (2H, d, J = 12.8 Hz, H15b), 4.42 (1H, ddd, J = 14.1, 
8.9, 5.0 Hz, H20a), 4.16 (1H, dt, J = 14.1, 4.1 Hz, H20b), 3.71 - 3.78 (1H, m, H21a), 3.61 - 3.65 (1H, 




13C NMR (126 MHz, d6-DMSO): δC = 159.7 (C5), 157.7 (C6), 155.9 (C14), 137.9 (C9), 136.9 (C16), 
131.1 (C4), 129.4 (C11), 129.0 (C1), 128.7 (C2), 128.3, 128.1 (C10 & 18), 127.7 (C19), 127.4 (C17), 
126.4 (C12), 125.6 (C3), 65.4 (C15), 59.7 (C21), 50.5 (C20), 48.0 (C7), 38.6 (C8) 






A stirred solution of ethyl (S)-2-(5-(1-(((benzyloxy)carbonyl)amino)-2-phenylethyl)-3-phenyl-1H-
1,2,4-triazol-1-yl)acetate 174 (300 mg, 0.681 mmol, 1.0 eq.) and 2-iodoxybenzoic acid (570 mg, 2.03 
mmol, 3.0 eq.) in ethyl acetate (7.0 mL, 0.1 M) was heated to reflux for 12 hours. The reaction mixture 
was quenched with water, filtered through Celite®, and then extracted with ethyl acetate (3 x 20 mL). 
The combined organic fractions were washed brine (10 mL) and dried (MgSO4). The solvent was 
removed under reduced pressure. The resultant crude compound was purified by flash column 
chromatography on silica eluting with 0-100% ethyl acetate in 40-60 petroleum ether to yield the title 
compound 175 as a white solid (298 mg, 0.681 mmol, 99%). 
Rf = 0.50 & 0.61 (50% EtOAc in 40-60 petroleum ether) 
[𝛂]𝐃
𝟐𝟎 = +4.0 (c = 0.1 in CHCl3) 
IR: νmax = 2962 (m, C-H), 1709 (s, C=O) 
1H NMR (500 MHz, CDCl3): δH = 8.07 - 8.17 (6H, m, H1a/b, 3a, 3b), 7.62 (1H, tt, J = 7.4 Hz, H1a/b), 
7.29 - 7.54 (13H, m, H2a, 2b, 17a, 17b, 18a, 18b, 19a & 19b), 7.19 - 7.27 (6H, m, H10a/b, 11a/b,12a & 
12b), 7.15 (2H, t, J=7.9 Hz, H11a/b), 6.64 (2H, d, J = 7.0 Hz, H10a/b), 6.37 - 6.39 (1H, m, H13a), 5.75 
(1 H, t, J = 0.9 Hz, H13b), 5.71 (1H, t, J = 3.1 Hz, H7a), 5.61 (1H, dd, J = 4.4, 2.7 Hz, H7b), 5.39 (2H, 
s, H15b), 5.04 (1H, d, J=11.7, H15aa), 4.51 (1H, d, J = 11.7, H15ab), 4.34 (2H, s, H20a), 4.01 (2H, d, 
J = 13.4 Hz, H8aa), 3.53 3.65 (1H, m, H8ba), 3.44 (2H, s, H20b), 3.19 (1H, dd, J=13.7, 2.7 Hz, H8bb), 




13C NMR (126 MHz, CDCl3): δC = 170.2, 170.2 (C5a & 5b), 162.2, 162.1 (C6a & 6b), 151.7, 151.7 
(C14a & 14b), 137.6, 137.0 (C9a & 9b), 135.4, 135.4 (C16a & 16b), 133.7 (C1a/b), 130.8, 130.7 (C4a 
& 4b), 130.2 (C1a/b), 130.1, 129.9 (C10a & 10b), 129.4, 129.4 (C2a & 2b), 129.3, 128.9, 128.8, 128.6, 
128.4, 128.3 (C17a, 17b, 18a, 18b, 19a & 19b), 128.5, 128.5 (C11a & 11b), 127.4, 127.4 (C12a & 12b), 
126.4, 126.4 (C3a & 3b), 74.9 (C13b), 73.7 (C13a), 68.6 (C15b), 68.3 (C15a), 53.4 (C7a), C53.4 (C7b), 
51.5 (C20a), 51.1 (C20b), 49.4 (C8a), 49.4 (C8b)– ratio of diastereomers 1:1 







A solution of benzyl 8-benzyl-6-hydroxy-2-phenyl-5,6-dihydro-[1,2,4]triazolo[1,5-a]pyrazine-7(8H)-
carboxylate 175 (100 mg, 0.231 mmol, 1.0 eq.) and p-toluene sulfonic monohydrate (6.00 mg, 230 
μmol, 0.1 eq.) in methanol (1.0 mL, 0.1 M) was stirred at room temperature for 18 hours. The reaction 
mixture was quenched by addition of a saturated aqueous solution of sodium hydrogen carbonate (5 
mL) and extracted with diethyl ether (3 x 5 mL). The solvent was removed under reduced pressure. The 
resultant crude compound was purified by flash column chromatography on silica eluting with 0-100% 
ethyl acetate in 40-60 petroleum ether to yield the title compound 177 as a white solid (68.0 mg, 0.151 
mmol, 65%). 
Rf = 0.36 & 0.45 (30% EtOAc in 40-60 petroleum ether) 
[𝛂]𝐃
𝟐𝟎 = -0.6 (c = 0.2 in CHCl3) 
IR: νmax = 2944 (m, C-H), 1703 (s, C=O) 
1H NMR (500 MHz, d6-DMSO): δH = 8.12 (2H, dd, J = 8.1, 1.4 Hz, H3), 8.02 (3H, d, J = 7.0 Hz, H3), 
7.28 - 7.52 (25H, m, H1 & 2, 10, 11, 12, 17, 18 & 19), 7.19 (1H, t, J = 7.0 Hz, H12), 7.10 (2H, t, J = 
7.0 Hz, H11), 6.53 (2H, d, J = 7.0 Hz, H10), 6.05 (1H, d, J = 3.1 Hz, H13), 5.65 (1H, t, J = 6.9 Hz, H7), 




4.55 - 4.64 (3H, m, H20), 4.30 (2H, dd, J = 13.0, 3.1 Hz, H20), 3.99 (3H, dd, J = 10.4, 1.5 Hz, H15b), 
3.56 (4.5H, s, H21), 3.45 (1H, dd, J = 13.7, 5.8 Hz, H8a), 3.33 (3H, br s, H21), 3.10 - 3.29 (4H, m, H8) 
– ratio of diastereomers 1:1.5 
13C NMR (126 MHz, d6-DMSO): δC = 162.0 (C5), 155.4 (C6), 151.4 (C14), 137.5 (C9), 135.7 (C4), 
135.2 (C16), 130.9 (C1), 129.9, 129.8 (C10), 128.7 (C19), 128.6 (C18), 128.5 (C2), 128.2(C11), 127.2 
(C12), 126.7 (C17), 126.3 (C3), 80.9 (C13), 68.2 (C15), 56.7 (C21), 53.6 (C7), 50.9 (C20), 42.6 (C8) 







A solution of (6R,8S)-8-benzyl-2,6-diphenyl-5,6,7,8-tetrahydro-[1,2,4]triazolo[1,5-a]pyrazine 58 (100 
mg, 0.270 mmol, 1.0 eq.), benzyl bromide (90.0 μL, 0.811 mmol, 3.0 eq.) and potassium carbonate (111 
mg, 0.811 mmol, 3.0 eq.) in DMF (1 mL, 0.2 M) was stirred at room temperature for 18 hours. The 
reaction was quenched with water and extracted with ethyl acetate (3 x 20 mL). The combined organic 
fractions were washed with brine (10 mL) and dried (MgSO4). The solvent was removed under reduced 
pressure. The resultant crude compound was purified by flash column chromatography on silica eluting 
with 0-100% ethyl acetate in 40-60 petroleum ether to yield the title compound 180 as a yellow solid 
(27.0 mg, 69.0 μmol, 25%, 95% BRSM). 
Rf = 0.40 (30% EtOAc in 40-60 petroleum ether) 
[𝛂]𝐃
𝟐𝟎 = -79.2 (c = 0.2 in CHCl3) 
IR: νmax = 2925 (m, C-H), 2854 (m, C-H), 1701 (m, C=C), 1493 (m, C=C) 
1H NMR (500 MHz, d6-DMSO): δH = 8.10 (2H, d, J = 7.0 Hz, H3), 7.27 - 7.47 (12H, m, H1, 2, 11, 16, 




Hz, H7), 4.09 (1H, t, J = 9.2 Hz, H13), 4.05 (1H, dd, J = 12.8, 9.2 Hz, H14a), 4.01 (1H, d, J = 14.3 Hz, 
H19a), 3.72 (1H, d, J = 14.3 Hz, H19b), 3.30 (1H, dd, J = 12.8, 9.2 Hz, H14b), 2.97 (2H, d, J = 4.6 Hz, 
H8) 
13C NMR (126 MHz, d6-DMSO): δC = 161.5 (C5), 154.2 (C6), 139.6 (C15), 137.1 (C9), 136.8 (C20), 
131.0 (C4), 130.2 (C10), 129.9 (C21), 129.2 (C1), 129.0 (C2), 128.5 (C17), 128.4 (C16), 128.2 (C18), 
127.8 (C22), 127.7 (C23), 127.0 (C12), 126.6 (C11), 126.3 (C3), 61.3 (C13), 57.7 (C7), 56.4 (C19), 
50.6 (C14), 40.4 (C8) 





5.4. Efficient Synthesis of 1,3-Imidazole Heterocycles 
 




To a stirred solution of 2-aminoacetophenone hydrochloride 184 (2.00 g, 11.7 mmol, 1.0 eq.) and Cbz-
L-phenylalanine 49 (3.49 g, 11.7 mmol, 1.0 eq.) in dichloromethane (100 mL, 0.1 M) was added 1-
ethyl-3-(3-dimethylaminopropyl) carbodiimide (2.35 g, 12.2 mmol, 1.05 eq.), N-methylmorpholine 
(1.35 mL, 12.2 mmol, 1.05 eq.) and 1-hydroxy-7-azabenzotriazole (1.66 g, 12.2 mmol, 1.05 eq.) at 0 
oC. The reaction mixture was then stirred at room temperature for 3 hours. Upon completion the reaction 
mixture was quenched with saturated aqueous sodium hydrogen carbonate solution and extracted with 
dichloromethane (3 x 150 mL). The combined organic fractions were washed with brine (50 mL) and 
dried (MgSO4) before the solvent was removed under reduced pressure to yield the crude compound. 
The resultant crude product was purified by flash column chromatography on silica eluting with 0-
100% ethyl acetate in 40-60 petroleum ether to yield the title compound 192 as a yellow solid (4.44 g, 
11.7 mmol, 100%). 
Rf = 0.20 (30% EtOAc in 40-60 petroleum ether) 
[𝛂]𝐃
𝟐𝟎 = -15.8 (c = 1.0 in CH3OH) 
IR: νmax = 3675 (m, N-H), 3298 (m, N-H), 2988 (s, C-H), 2901 (s, C-H), 1694 (s, C=O), 1644 (s, C=O), 
1597 (m, C=C), 1531 (m, C=C), 1494 (m, C=C), 1448 (m, C=C) 
1H NMR (400 MHz, d6-DMSO): δH = 8.43 (1H, t, J = 5.4 Hz, H7), 8.01 (1H, d, J = 7.4 Hz, H3), 7.68 
(1H, t, J = 7.4 Hz, H1), 7.57 (2H, q, J = 7.4 Hz, H2 & 15), 7.12 - 7.38 (10H, m, H12, 13, 14, 19, 20 & 
21), 4.94 (2H, s, H17), 4.71 (1H, dd, J = 18.5, 5.4 Hz, H6a), 4.71 (1H, dd, J = 18.5, 5.4 Hz, H6b), 4.37 





13C NMR (101 MHz, d6-DMSO): δC = 195.2 (C5), 172.2 (C8), 156.0 (C16), 138.4 (C11), 137.1 (C18), 
135.0 (C4), 133.7 (C1), 128.9 (C2), 129.3, 128.4, 128.2, 127.7 (C12, 13, 20 & 21), 127.9 (C3), 127.5 
(C19), 126.3 (C14), 65.3 (C17), 56.3 (C9), 46.1 (C6), 46.1 (C10) 
HRMS (ESI+): found [M + H]+ 417.1796, C25H25N2O4+ required 417.1814 
This data is in accordance with that previously reported.249 
 




A solution of benzyl (S)-(1-oxo-1-((2-oxo-2-phenylethyl)amino)-3-phenylpropan-2-yl)carbamate 192 
(1.00 g, 2.40 mmol, 1.0 eq.) and ammonium acetate (1.85 g, 24.0 mmol, 10.0 eq.) in xylene (8 mL, 0.3 
M) was refluxed using Dean-Stark apparatus. After complete consumption of the starting material, the 
reaction mixture was concentrated. The residue was re-dissolved in dichloromethane, washed with brine 
(10 mL) and dried (MgSO4). The solvent was removed under reduced pressure. The resultant crude 
compound was purified by flash column chromatography on silica eluting with 0-100% ethyl acetate in 
40-60 petroleum ether to yield the title compound 193 as an orange solid (768 mg, 1.93 mmol, 81%). 
Rf = 0.41 (40% EtOAc in 40-60 petroleum ether) 
[𝛂]𝐃
𝟐𝟎 = -0.1 (c = 0.7 in CH3OH) 
IR: νmax = 3675 (m, N-H), 2988 (s, C-H), 2901 (s, C-H), 1690 (m, br, C=O), 1494 (m, C=C), 1453 (m, 
C=C), 1406 (m, C=C) 
1H NMR (500 MHz, d6-DMSO): δH = 11.96 (1H, br s, H7), 7.81 (1H, d, J = 8.9 Hz, H15), 7.78 (2H, d, 
J = 7.3 Hz, H3), 7.63 (1H, d, J = 7.3 Hz, H21), 7.51 (1H, d, J = 1.5 Hz, H6), 7.39 (1H, t, J = 7.8 Hz, 
H14), 7.29 - 7.37 (4H, m, H2 & 20), 7.15 - 7.28 (7H, m, H1, 12, 13, 19), 5.02 (1H, d, J = 12.8 Hz, 
H17a), 4.96 (1H, d, J = 12.8 Hz, H17b), 4.93 (1H, ddd, J = 9.3, 8.9, 5.8 Hz, H9), 3.31 (1H, dd, J = 13.6, 




13C NMR (126 MHz, d6-DMSO): δC = 156.2 (C16), 149.0 (C8), 140.0 (C5), 138.8 (C11), 137.6 (C18), 
135.4 (C4), 129.7 (C13), 129.3 (C14), 128.8 (C2), 128.7, 128.5 (C12 & 19), 127.8 (C20), 126.7 (C21), 
126.3 (C1), 124.7 (C3), 113.0 (C6), 65.6 (C17), 51.5 (C9), 39.5 (C10) 
HRMS (ESI+): found [M + H]+ 398.1865, C25H24N3O2+ required 398.1869 







Following General Procedure 5: benzyl (S)-(2-phenyl-1-(5-phenyl-1H-imidazol-2-yl)ethyl)carbamate 
193 (200 mg, 0.501 mmol), 2-bromoacetophenone (105 mg, 0.531 mmol) and potassium carbonate 
(70.0 mg, 0.501 mmol) in DMF (2 mL) were used. The crude product was purified by flash column 
chromatography on silica eluting with 50% ethyl acetate in 40-60 petroleum ether to yield the title 
compound 194 as a pale yellow solid (202 mg, 0.391 mmol, 78%). 
Rf = 0.44 (30% EtOAc in 40-60 petroleum ether) 
[𝛂]𝐃
𝟐𝟎 = -18.8 (c = 0.4 in CH3OH) 
IR: νmax = 2927 (m, C-H), 1689 (S, C=O), 1684 (s, C=O), 1521 (m, C=C), 1496 (m, C=C) 
1H NMR (500 MHz, CDCl3): δH = 7.87 (2H, d, J = 7.3 Hz, H24), 7.79 (2H, dd, J = 8.2, 1.2 Hz, H3), 
7.65 (1H, tt, J = 7.3, 1.2 Hz, H26), 7.51 (2H, t, J = 7.3 Hz, H25), 7.37 - 7.41 (3H, m, H2 & 20), 7.28 - 
7.33 (3H, m, H1 & 18), 7.20 - 7.26 (H, m, H11, 13 & 19), 7.16 (2H, t, J = 5.8 Hz, H12), 7.05 (1H, s, 
H6), 5.84 (1H, d, J = 7.3 Hz, H14), 5.17 (1H, d, J = 18.3 Hz, H21a), 5.03 - 4.96 (2H, m, H16a & 




13C NMR (126 MHz, CDCl3): δC = 191.6 (C22), 155.8 (C15), 148.0 (C7), 140.7 (C5), 137.4 (C10), 
136.3 (C17), 134.2, 134.1, 134.0 (C4, 23 & 26), 129.6 (C12), 129.0 (C25), 128.5, 128.5, 128.5 (C2, 11 
& 19), 128.2, (C20), 128.0 (C24), 127.8 (C18), 126.8, 126.7 (C1 & 13), 125.0 (C3), 116.7 (C6), 66.7 
(C16), 51.4 (C21), 49.2 (C8), 41.3 (C9) 
HRMS (ESI+): found [M + H]+ 516.2271, C33H30N3O3+ required 516.2287. 
 




Following the General Procedure 6: benzyl (S)-(1-(1-(2-oxo-2-phenylethyl)-5-phenyl-1H-imidazol-2-
yl)-2-phenylethyl)carbamate 194 (93.0 mg, 0.181 mmol), ammonium formate (341 mg, 5.42 mmol) and 
palladium dihydroxide (25.0 mg, 36.0 μmol) in ethyl acetate (1 mL) and methanol and water (1 mL, 3:1 
v:v,) were used. The crude product was purified by flash column chromatography eluting with 30% 
ethyl acetate in 40-60 petroleum ether to yield the title compound 195 as a yellow solid (46.0 mg, 130 
μmol, 74%). 
Rf = 0.44 (50% EtOAc in 40-60 petroleum ether) 
[𝛂]𝐃
𝟐𝟎 = +82.9 (c = 0.1 in CH3OH) 
IR: νmax = 2974 (m, C-H), 1713 (s, C=N), 1521 (m, C=C), 1485 (m, C=C) 
1H NMR (500 MHz, CD3OD): δH = 7.98 (1H, s, H6), 7.83 (2H, d, J = 7.3 Hz, H3), 7.71 (2H, d, J = 6.4 
Hz, H16), 7.56 - 7.62 (2H, m, H2), 7.52 - 7.56 (3H, m, H1 & 11), 7.45 - 7.52 (3H, m, H17 & 18), 7.40 
(2H, t, J = 7.5 Hz, H12), 7.33 (1H, t, J = 7.6 Hz, H13), 5.33 (1H, d, J = 8.3 Hz, H8), 4.62 - 4.76 (2H, 




13C NMR (126 MHz, CD3OD): δC = 143.2 (C7), 136.5 (C5), 135.5 (C15), 135.4 (C10), 131.4 (C1), 
131.2 (C18), 131.1 (C11), 130.7 (C2), 130.5 (C17), 130.3 (C12), 129.3 (C16), 129.1 (C13), 127.9 (C4), 
127.4 (C3), 118.9 (C6), 58.7 (C14), 56.3 (C8), 50.8 (C13), 38.2 (C9) 






5.5. Efficient Synthesis of 1,2-Pyrazole Heterocycles 
 
5.5.1. Synthesis of the Unsubstituted Pyrazole Scaffold 
 
5.5.1.1. Benzyl (S)-(1-(methoxy(methyl)amino)-1-oxo-3-phenylpropan-2-yl)carbamate (202) 
 
 
To a stirred solution of Cbz-L-phenylalanine 49 (1.0 g, 3.34 mmol, 1.0 eq.) and N,O-
dimethylhydroxylamine hydrochloride (489 mg, 5.01 mmol, 1.5 eq.) in dichloromethane (15 mL, 0.2 
M) was added HOBt (496 mg, 3.67 mmol, 1.1 eq.), HBTU (1.39 g, 3.37 mmol, 1.1 eq.) and 
diisopropylethylamine (1.51 mL, 8.69 mmol, 2.6 eq.). The solution was stirred at room temperature 
until the starting material had been consumed. The reaction was quenched with saturated aqueous 
sodium hydrogen carbonate solution (15 mL) and extracted with dichloromethane (3 x 20 mL). The 
combined organic fractions were washed with brine (15 mL), dried (MgSO4) and concentrated under 
reduced pressure. The crude compound was purified by flash column chromatography on silica eluting 
with dichloromethane to yield the title compound 202 as a cloudy liquid (975 mg, 3.34 mmol, 100%).  
Rf = 0.53 (Dichloromethane) 
[𝛂]𝐃
𝟐𝟎 = +22.5 (c = 0.2 in CHCl3) - [Literature Value = +20.0 (c = 0.1 in CH2Cl2)]305 
IR: νmax = 3305 (m, N-H), 2943 (m, C-H), 1714 (s, C=O), 1650 (s, C=O), 1522 (m, C=C), 1496 (m, 
C=C) 
1H NMR (400 MHz, CDCl3): δH = 7.31 - 7.40 (5H, m, H1, 2 & 3), 7.21 - 7.30 (3H, m, H11 & 12), 7.17 
(2H, d, J = 6.7 Hz, H10), 5.44 (1H, d, J = 8.5 Hz, H16), 5.11 (1H, d, J = 12.2 Hz, H5a), 4.97 - 5.08 (2H, 
m, H5b & 7), 3.70 (3H, s, H14), 3.20 (3H, s, H15), 3.10 (1H, dd, J = 13.6, 6.0 Hz, H8a), 2.93 (1H, dd, 
J = 13.6, 7.3 Hz, H8b) 
13C NMR (101 MHz, d6-DMSO): δC = 171.9 (C13), 156.7 (C6), 155.8 (C9), 136.3 (C4), 129.4 (C11), 
128.5, 128.4 (C2 & 10), 128.1 (C1), 128.0 (C3), 126.9 (C12), 66.8 (C5), 61.5 (C7), 52.1 (C15), 38.7 




HRMS (ESI+): found [M + H]+ 343.1644, C19H22N2O4+ required 343.1658 
This data is in accordance with that previously recorded.305 
 





Ethynyl magnesium bromide (9.30 mL, 0.5 M solution in THF, 4.67 mmol, 4.5 eq.) was added dropwise 
to a stirred solution of benzyl (S)-(1-(methoxy(methyl)amino)-1-oxo-3-phenylpropan-2-yl)carbamate 
202 (350 mg, 1.02 mmol, 1.0 eq.) in THF (7.0 mL, 0.15M) at -78 °C. The resulting mixture was stirred 
at room temperature overnight. After cooling to 0 °C, the reaction was quenched with a saturated 
aqueous solution of ammonium chloride (10 mL). After stirring for 1 h at room temperature, the reaction 
was extracted with ethyl acetate (3 x 10 mL); the combined organic fractions were washed with brine 
(15 mL), dried (MgSO4) and concentrated under reduced pressure. The crude compound was purified 
by flash column chromatography on silica eluting with 30% ethyl acetate in 40-60 petroleum ether to 
yield the title compound 209 as a yellow solid (228 mg, 0.741 mmol, 73%). 
Rf = 0.58 (25% EtOAc in 40-60 petroleum ether) 
[𝛂]𝐃
𝟐𝟎 = +30.8 (c = 0.1 in CHCl3) - [Literature Value = +1.27 (c = 1.1 in CHCl3)]253  
IR: νmax = 3343 (s, N-H), 3032 (m, C≡C-H), 2095 (s, C≡C), 1683 (s, C=O), 1670 (s, C=O), 1531 (s, N-
H) 
1H NMR (400 MHz, CDCl3): δH = 7.28 - 7.22 (8H, m, H1, 2, 3, 10 & 12), 7.13 (2H, dd, J = 7.5, 1.7 
Hz, H11), 5.23 (1H, d, J = 7.5 Hz, H16), 5.11 (2H, s, H5), 4.74 - 4.84 (1H, m, H7), 3.41 (1H, s, H15), 
3.27 - 3.34 (1H, m, H8a), 3.20 - 3.27 (1H, m, H8b) 
13C NMR (101 MHz, CDCl3): δC = 184.9 (C13), 155.6 (C6), 136.1 (C4), 134.9 (C9), 129.4 (C11), 
128.7, 128.5, 128.3 (C1, 2 & 10), 128.1 (C3), 127.3 (C12), 82.6 (C15), 79.7 (C14), 67.1 (C5), 62.3 




HRMS (ESI+): found [M + H]+ 308.1298, C19H18NO3+ required 308.1287 
This data is in accordance with that previously recorded.253 
 
5.5.1.3. Benzyl (S)-(5-(diethylamino)-3-oxo-1-phenylpent-4-en-2-yl)carbamate (210) 
 
 
Diethylamine (0.07 mL, 0.70 mmol, 1.1 eq.) was added dropwise to a stirred solution of benzyl (S)-(3-
oxo-1-phenylpent-4-yn-2-yl)carbamate 209 (196 mg, 0.642 mmol, 1.0 eq.) in dichloromethane (5.0 mL, 
0.15 M) at 0 °C. The mixture was stirred at room temperature for 18 hours, before dilution with water 
(15 mL). The reaction was extracted with dichloromethane (3 x 20 mL) and the combined organic 
fractions were washed with brine (15 mL), dried (Mg SO4) and concentrated under reduced pressure. 
The crude compound was purified by flash column chromatography on silica eluting with 50% ethyl 
acetate in 40-60 petroleum ether to yield the title compound 210 as a yellow oil (232 mg, 0.611 mmol, 
95%). 
Rf = 0.40 (50% EtOAc in 40-60 petroleum ether) 
[𝛂]𝐃
𝟐𝟎 = +37.0 (c = 0.1 in CHCl3) - [Literature Value = +34.4 (c = 1.1 in CHCl3)]253 
IR: νmax = 2973 (m, C-H), 2934 (m, C-H), 1715 (s, C=O), 1647 (s, C=O), 1555 (s, N-H), 1495 (m, C=C) 
1H NMR (400 MHz, CDCl3): δH = 7.29 - 7.39 (6H, m, H1, 2, 3 & 15), 7.23 - 7.27 (2H, m, H11), 7.13 - 
7.23 (3H, m, H10 & 12), 5.84 (1H, d, J = 7.2 Hz, H20), 5.11 (2H, s, H5), 4.87 (1H, d, J = 12.6 Hz, 
H14), 4.58 (1H, m, H7), 3.25 (2H, br s, H16/18), 2.95 - 3.12 (4H, m, H8 & 16/18), 1.20 (2H, t, J = 6.5 
Hz, H17/19), 1.06 (2H, t, J = 6.6 Hz, H17/19) 
13C NMR (101 MHz, CDCl3): δC = 193.1 (C13), 155.7 (C6), 137.5, 136.8 (C4 & 9), 129.6 (C11), 128.4 
(C10), 128.2 (C15), 128.1 (C2), 128.0 (C1), 127.9 (C3), 126.4 (C12), 66.4 (C5), 50.5, 42.6 (C16 & 18), 




HRMS (ESI+): found [M + Na]+ 403.2014, C23H28N2O3Na+ required 403.1998 
This data is in accordance with that previously recorded.253 
 




A solution of benzyl (S)-(5-(diethylamino)-3-oxo-1-phenylpent-4-en-2-yl)carbamate 210 (200 mg, 
0.530 mmol, 1.0 eq.), hydrazine monohydrate (30.0 μL, 0.551 mmol, 1.1 eq.), and concentrated aqueous 
hydrochloric acid (37% w/w, 50.0 μL, 0.551 mmol, 1.1 eq.) in ethanol (3 mL, 0.16 M) was refluxed for 
3 h. The reaction was cooled to room temperature and the solvent removed under reduced pressure. The 
resulting residue was diluted with water (10 mL) and extracted with ethyl acetate (3 x 15 mL). The 
combined organic fractions were washed with saturated aqueous sodium hydrogen carbonate (10 mL), 
brine (10 mL), dried (MgSO4) and concentrated under reduced pressure. The crude compound was 
purified by flash column chromatography on silica eluting with 50% ethyl acetate in 40-60 petroleum 
ether to yield the title compound 211 as a white solid (151 mg, 0.470 mmol, 89%). 
Rf = 0.38 (50% EtOAc in 40-60 petroleum ether) 
[𝛂]𝐃
𝟐𝟎 = +37.0 (c = 0.1 in CHCl3) 
IR: νmax = 3351 (m, N-H), 2920 (m, C-H), 1689 (s, C=O), 1533 (s, N-H) 
1H NMR (400 MHz, CDCl3): δH = 7.44 (1H, s, H1), 7.27 - 7.38 (6H, m, H14, 15, 16 & 17), 7.14 - 
7.24 (3H, m, H8 & 9), 7.08 (2H, d, J = 6.6 Hz, H7), 6.06 (1H, s, H2), 5.48 (1H, br s, H10), 5.12 (1H, 
m, J = 6.8 Hz, H4), 5.08 (2H, s, H12), 3.18 (2H, d, J = 6.8 Hz, H5) 
13C NMR (101 MHz, CDCl3): δC = 155.9 (C11), 148.9 (C3), 137.1 (C6), 136.4 (C13), 129.5 (C1), 
128.5, 128.3 (C8 & 15), 128.1 (C7), 127.9 (C16), 126.6 (C14), 124.7 (C9), 103.4 (C2), 66.8 (C12), 50.3 
(C4), 41.4 (C5) 




This data is in accordance with that previously recorded.253 
 




Following General Procedure 5: benzyl (S)-(2-phenyl-1-(1H-pyrazol-5-yl)ethyl)carbamatete 211 (200 
mg, 0.620 mmol), 2-bromoacetophenone 55 (136 mg, 0.681 mmol) and potassium carbonate (86.0 mg, 
0.620 mmol) in acetone (2 mL) were used. The crude product was purified by flash column 
chromatography eluting with 30% ethyl acetate in 40-60 petroleum ether to yield the title compound 
212 as a white solid (174 mg, 0.390 mmol, 64%). 
Rf = 0.30 (30% EtOAc in 40-60 petroleum ether) 
[𝛂]𝐃
𝟐𝟎 = -13.3 (c = 0.1 in CH3OH) 
IR: νmax = 2928 (m, C-H), 1702 (s, C=O), 1496 (m, C=C) 
1H NMR (400 MHz, CDCl3): δH = 8.00 (2H, d, J = 7.5 Hz, H20), 7.66 (1H, t, J = 7.5 Hz, H21), 7.54 
(2H, d, J = 7.8 Hz), 7.40 (1H, d, J = 2.4 Hz, H1), 7.30 - 7.38 (5H, m, H14, 15 & 16), 7.18 - 7.27 (4H, 
m, H7, 9 & 10), 7.09 (2H, d, J = 6.8 Hz, H8), 6.06 (1H, d, J=2.4 Hz, H2), 5.44 (2H, d, J = 8.2 Hz, H17), 
5.04 - 5.19 (3H, m, H7 & 12), 3.13 - 3.28 (2H, m, H5)  
13C NMR (101MHz, CDCl3): δC = 191.9 (C18), 155.4 (C11), 152.3 (C3), 137.0 (C16), 136.3 (C13), 
134.2 (C19), 133.8 (C1), 131.3 (C20), 129.8 (22), 129.4 (C15), 129.2 (C8), 128.7 (C21), 128.1 (C7), 
127.8 (C14), 127.7 (C16), 126.0 (C9), 104.7 (C2), 66.3 (C12), 57.4 (C17), 50.8 (C4), 41.6 (C5) 






5.5.1.6. (4S,6R)-4-benzyl-6-phenyl-4,5,6,7-tetrahydropyrazolo[1,5-a]pyrazine (213) 
 
 
Following General Procedure 6: benzyl (S)-(1-(1-(2-oxo-2-phenylethyl)-1H-pyrazol-5-yl)-2-
phenylethyl)carbamate 212 (14.0 mg, 31.9 μmol), ammonium formate (8.60 mg, 1.37 mmol) and 
palladium dihydroxide (6.00 mg, 6.37 μmol) in ethyl acetate (1 mL) and methanol and water (1 mL, 3:1 
v:v,) was used. The crude product was purified by flash column chromatography eluting with 10% 
methanol in ethyl acetate to yield the title compound 213 as a white solid (7.00 mg, 26.3 μmol, 82%). 
Rf = 0.24 (30% CH3OH in EtOAc) 
[𝛂]𝐃
𝟐𝟎 = +53.9 (c = 0.2 in CH3OH) 
IR: νmax = 2921 (m, C-H), 1597 (m, N-H) 
1H NMR (500 MHz, CD3OD): δH = 7.39 - 7.43 (1H, m, H1), 7.21 - 7.35 (8H, m, H7, 9, 13, 14 & 15), 
7.17 (2H, d, J = 7.9 Hz, H8), 6.12 - 6.16 (1H, m, H2), 5.00 (1H, t, J = 5.8 Hz, H11), 4.54 (1H, td, J = 
7.5, 3.1 Hz, H4), 4.25 - 4.31 (2H, m, H16), 3.20 - 3.24 (2H, m, H5) 
13C NMR (126 MHz, CD3OD): δC = 150.4 (C3), 143.2 (C12), 137.5 (C6), 133.7 (C1), 130.7 (C8), 
129.9, 129.6 (C7 & 14), 129.1 (C15), 128.4 (C9), 127.3 (C13), 104.8(C2), 74.2 (C15), 60.3 (C16), 52.4 
(C4), 41.8 (C5) 






5.5.2. Synthesis of the Substituted Pyrazole Scaffold 
 




Phenylethylene magnesium bromide (8.80 mL, 1 M solution in THF, 8.76 mmol, 4.5 eq.) was added 
dropwise to a stirred solution of benzyl (S)-(1-(methoxy(methyl)amino)-1-oxo-3-phenylpropan-2-
yl)carbamate 202 (1.00 g, 2.92 mmol, 1.0 eq.) in THF (15 mL, 0.15M) at -78 °C. The resulting mixture 
was stirred at room temperature overnight. After cooling to 0 °C, the reaction was quenched with a 
saturated aqueous solution of ammonium chloride (10 mL). After stirring for 1 h at room temperature, 
the reaction mixture was extracted with ethyl acetate (3 x 10 mL); the combined organic fractions were 
washed with brine (15 mL), dried (MgSO4) and concentrated under reduced pressure. The crude 
compound was purified by flash column chromatography on silica eluting with 30% ethyl acetate in 40-
60 petroleum ether to yield the title compound 214 as a yellow solid (183 mg, 0.470 mmol, 33%). 
Rf = 0.25 (10% EtOAc in 40-60 Petroleum Ether) 
[𝛂]𝐃
𝟐𝟎 = -+1.8 (c = 0.1 in CHCl3) - [Literature Value = -26.6 (c = 1.3 in CHCl3)]306 
IR: νmax = 3343 (m, N-H), 2950 (m, C-H), 2206 (m, C≡C), 1702 (s, C=O), 1678 (S, C=O), 1526 (s, N-
H), 1494 (m, C=C) 
1H NMR (400 MHz, CDCl3): δH = 7.57 (2H, d, J = 6.8 Hz, H18), 7.52 (1H, tt, J = 7.8, 2.4 Hz, H20), 
7.42 (2H, t, J = 7.8 Hz, H19), 7.29 - 7.38 (5H, m, H1, 2 & 3), 7.23 - 7.29 (3H, m, H10 & 12), 7.20 (2H, 
dd, J = 8.2, 1.7 Hz, H11), 5.38 (1H, d, J = 7.8 Hz, H16), 5.14 (2H, s, H5), 4.90 (1H, dt, J = 7.8, 5.8 Hz, 




13C NMR (101 MHz, CDCl3): δC = 185.3 (C13), 155.6 (C6), 136.2 (C4), 135.3 (C9), 133.3 (C18), 131.3 
(C20), 129.5 (C11), 128.7 (C19), 128.6 (C3), 128.5 (C10), 128.2 (C1), 128.1 (C2), 127.2 (C12), 119.4 
(C17), 95.3 (C15), 86.2 (C14), 67.0 (C5), 62.3 (C7), 37.4 (C8) 
HRMS (ESI+): found [M + H]+ 384.1584, C25H22NO3+ required 384.1600 
This data is in accordance with that previously reported.306 
 




Diethylamine (40.0 μL, 0.433 mmol, 1.1 eq.) was added dropwise to a stirred solution of benzyl (S)-(3-
oxo-1,5-diphenylpent-4-yn-2-yl)carbamate 214 (150 mg, 0.391 mmol, 1.0 eq.) in dichloromethane (1.5 
mL, 0.15 M) at 0 °C. The mixture was stirred at room temperature for 18 hours, before dilution with 
water (15 mL). The reaction was extracted with dichloromethane (3 x 20 mL) and the combined organic 
fractions were washed with brine (15 mL), dried (Mg SO4) and concentrated under reduced pressure. 
The crude compound was purified by flash column chromatography on silica eluting with 50% ethyl 
acetate in 40-60 petroleum ether to yield the title compound 215 as a yellow oil (193 mg, 0.391 mmol, 
100%). 
Rf = 0.43 (40% EtOAc in 40-60 petroleum ether) 
[𝛂]𝐃
𝟐𝟎 = +0.8 (c = 0.5 in CHCl3) 
IR: νmax = 2933 (m, C-H), 1713 (s, C=O), 1641 (m, C=O), 1517 (s, C=C), 1493 (s, C=C)  
1H NMR (400 MHz, CDCl3): δH = 7.42 - 7.48 (mH, m, H22 & 23), 7.19 - 7.37 (9H, m, H2, 3, 10, 11 & 
24), 7.14 (1H, d, J = 4.1 Hz, H12), 7.08 (1H, d, J = 3.1 Hz, H1), 5.80 (1H, d, J = 7.5 Hz, H20), 5.08 




7.5, 5.4 Hz, H7), 3.21 - 2.91 (4H, m, H16 & 18) 3.08 (1H, dd, J = 13.5, 5.4 Hz, H8a), 2.93 (1H, dd, J = 
13.5, 8.2 Hz, H8b), 0.78 - 1.20 (6H, m, H17 & 19) 
13C NMR (101 MHz, CDCl3): δC = 190.7 (C13), 162.6 (C15), 155.6 (C6), 137.9 (C9), 136.9 (C4), 136.6 
(C21), 129.6 (C11), 128.4 (C22), 128.3 (C2), 128.1 (C23), 127.7 (C24), 127.6 (C10), 127.4 (C1), 127.1 
(C12), 126.3 (C3), 93.7 (C14), 66.1 (C5), 60.4 (C7), 44. 0 (C16 & 18), 40.5 (C8), 11.2 (C17 & 19)  
HRMS (ESI+): found [M + Na]+ 479.2291, C29H32N2O3Na+ required 479.2311. 
 




A solution of benzyl (S)-(5-(diethylamino)-3-oxo-1,5-diphenylpent-4-en-2-yl)carbamate 215 (150 mg, 
0.331 mmol, 1.0 eq.), hydrazine monohydrate (20.0 μL, 0.341 mmol, 1.1 eq.), and concentrated aqueous 
hydrochloric acid (37% w/w, 10.0 μL, 0.341 mmol, 1.1 eq.) in ethanol (1.5 mL, 0.16 M) was refluxed 
for 3 h. The reaction was cooled to room temperature and the solvent removed under reduced pressure. 
The resulting residue was diluted with water (10 mL) and extracted with ethyl acetate (3 x 15 mL). The 
combined organic fractions were washed with saturated aqueous sodium hydrogen carbonate (10 mL), 
brine (10 mL), dried (MgSO4) and concentrated under reduced pressure. The crude compound was 
purified by flash column chromatography on silica eluting with 50% ethyl acetate in 40-60 petroleum 
ether to yield the title compound 216 as a white solid (108 mg, 0.272 mmol, 83%). 
Rf = 0.27 (40% EtOAc in 40-60 petroleum ether) 
[𝛂]𝐃
𝟐𝟎 = -1.2 (c = 0.4 in CHCl3) 
IR: νmax = 3304 (m, N-H), 3294 (m, N-H), 3032 (m, C-H), 1698 (s, C=O), 1539 (s, C=O), 1494 (s, N-
H)  
1H NMR (500 MHz, CDCl3): δH = 7.62 (2H, d, J = 7.3 Hz, H3), 7.40 (2H, t, J = 7.3 Hz, H2), 7.27 - 




6.4 Hz, H11), 6.37 (1H, br s, H6), 5.53 - 5.65 (1H, br s, H14), 5.17 (1H, d, J = 6.7 Hz, H8), 5.11 (1H, 
d, J = 12.2 Hz, H16a), 5.05 (1H, d, J = 12.2 Hz, H16b), 3.23 (2H, s, H9) 
13C NMR (101 MHz, CDCl3): δC = 156.2 (C15), 150.3 (C7), 147.1 (C5), 136.9 (C10), 136.3 (C17), 
131.2 (C4), 129.4 (C11), 128.9 (C2), 128.5, 128.4 (C12 & 19), 128.2 (C1), 128.1 (C18), 128.0 (C20), 
126.8 (C13), 125.6 (C3), 100.8 (C6),. 66.9 (C16), 49.9 (C8), 43.1 (C9) 
HRMS (ESI+): found [M + H]+ 398.1877, C25H24N3O2+ required 398.1869 
This data is in accordance with that previously reported.146 
 





Following General Procedure 5: benzyl (S)-(2-phenyl-1-(3-phenyl-1H-pyrazol-5-yl)ethyl)carbamate 
216 (87.0 mg, 0.220 mmol), 2-bromoacetophenone (52.0 mg, 0.260 mmol) and diisopropylethylamine 
(0.04 mL, 0.220 mmol) in THF (1 mL) were used. The crude product was purified by flash column 
chromatography eluting with 0-50% ethyl acetate in 40-60 petroleum ether to yield the title compound 
217 as a dark yellow oil (31.0 mg, 0.060 mmol, 27%). 
Rf = 0.68 (30% EtOAc in hexane) 
[𝛂]𝐃
𝟐𝟎 = +3.8 (c = 0.1 in CH3OH) 
IR: νmax = 2917 (m, C-H), 1698 (s, C=O), 1597 (m, C=C) 
1H NMR (400 MHz, CDCl3): δH = 7.93 - 8.02 (2H, m, H3), 7.80 (2H, d, J = 7.2 Hz, H25), 7.64 (1H, t, 




12, 18, 19, 20 & 27), 7.12 - 7.15 (1H, m, H13), 6.63 (1H, s, H6), 5.75 (2H, m, H22), 4.97 - 5.06 (2H, 
m, H8 & 14), 4.86 (1H, d, J = 12.3 Hz, H16a), 4.70 (1H, d, J = 12.3 Hz, H16b), 3.41 (1H, dd, J = 12.3, 
4.4 Hz, H9a), 3.10 - 3.23 (1H, m, H9b) 
13C NMR (101 MHz, CDCl3): δC = 191.9 (C23), 155.8 (C15), 151.2 (C7), 145.5 (C5), 136.6 (C10), 
135.3 (C17), 134.5 (C24), 134.1 (C4), 134.0 (C1), 133.2 (C27), 129.3 (C12), 128.9 (C2), 128.7 (C19), 
128.6 (C11), 128.5 (C26), 128.4, (C3), 128.1 (C13), 127.8 (C18), 126.9 (C20), 125.8 (C25), 101.6 (C6), 
74.7 (C16), 57.7 (C22), 56.2 (C8), 41.0 (C9) 
HRMS (ESI+): found [M + H]+ 516.2267, C33H30N3O3+ required 516.2287. 
 




Following General Procedure 6: benzyl (S)-(1-(1-(2-oxo-2-phenylethyl)-1H-pyrazol-5-yl)-2-
phenylethyl)carbamate 217 (27.0 mg, 52.3 μmol), ammonium formate (99.0 mg, 1.57 mmol) and 
palladium dihydroxide (8.00 mg, 10.4 μmol) in ethyl acetate (1 mL) and methanol and water (1 mL, 3:1 
v:v,) was used. The crude product was purified by flash column chromatography eluting with 30% ethyl 
acetate in 40-60 petroleum ether to yield the title compound 218 as a pink solid (3.90 mg, 10.7 μmol, 
20%). 
Rf = 0.55 (30% EtOAc in hexane) 
[𝛂]𝐃
𝟐𝟎 = -20.9 (c = 0.1 in CH3OH) 
IR: νmax = 2911 (m, C-H), 1633 (m, C=N), 1606 (m, C=C), 1550 (w, C=C), 1496 (m, C=C) 
1H NMR (500 MHz, CD3OD): δH = 7.65 - 7.72 (4H, m, H3 & 17), 7.56 - 7.62 (3H, m, H1 & 2), 7.46 - 
7.53 (4H, m, H11 & 18), 7.37 - 7.44 (3H, m, H12 & 19), 7.34 (1H, t, J = 7.6 Hz, H13), 6.35 (1H, s, H6), 




H14a), 4.68 (1H, dd, J = 13.4, 11.9 Hz, H14b), 3.54 (1H, dd, J = 14.3, 8.2 Hz, H9a), 3.47 (1H, dd, J = 
14.3, 6.7 Hz, H9b) 
13C NMR (126 MHz, CD3OD): δC = 153.8 (C5), 138.1 (C7), 136.1 (C10), 133.9 (C4), 133.6 (C16), 
131.8 (C1), 130.9 (C2), 130.7 (C18), 130.5 (C11), 129.9 (C12), 129.6 (C13), 129.3 (C19), 129.2 (C17), 
126.7 (C3), 102.3 (C6), 59.8 (C15), 57.0 (C8), 51.2 (C14), 39.4 (C9) 







5.6. Efficient Synthesis of Benzimidazole Heterocycles 
 




A solution of Cbz-L-phenylalanine 49 (1.00 g, 3.34 mmol, 1.0 eq.), HATU (1.40 g, 3.67 mmol, 1.1 eq.) 
and diisopropylethylamine (3.00 mL, 16.7 mmol, 5.0 eq.) was stirred at room temperature for 5 minutes, 
before the addition of o-phenylenediamine 224 (542 mg, 5.01 mmol, 1.5 eq.). The reaction was then 
stirred at room temperature overnight. The reaction was diluted with water (20 mL) and extracted with 
ethyl acetate (3 x 20 mL). The combined organic fractions were washed with brine (15 mL), dried 
(MgSO4) and concentrated under reduced pressure. The crude compound was purified by flash column 
chromatography on silica eluting with 0-100% ethyl acetate in 40-60 petroleum ether to yield the title 
compound 225 as a yellow solid (1.19 g, 3.05 mmol, 91%). 
Rf = 0.58 (50% EtOAc in 40-60 petroleum ether) 
[𝛂]𝐃
𝟐𝟎 = +6.3 (c = 0.4 in CHCl3) 
IR: νmax = 3344 (m, N-H), 3304 (m, N-H), 1690 (s, C=O), 1648 (m, C=O), 1526 (s, N-H), 1453 (m, 
C=C) 
1H NMR (500 MHz, CDCl3): δH = 7.47 (2H, br s, H1), 7.32 - 7.40 (7H, m, H13, 20, 21 & 22), 7.23 - 
7.31 (3H, m, H14 & 15), 7.16 (1H, s, H8), 7.07 (1H, d, J = 7.6 Hz, H6), 7.03 (1H, td, J = 7.6, 1.1 Hz, 
H4), 6.75 (1H, td, J = 7.6, 1.1 Hz, H5), 6.72 (1H, dd, J = 7.6, 1.1 Hz, H3), 5.57 (1H, br s, H16), 5.11 
(2H, s, H18), 4.57 (1H, q, J = 7.4 Hz, H10), 3.20 (1H, dd, J = 13.7, 7.4 Hz, H11a), 3.16 (1H, dd, J = 
13.7, 7.4 Hz, H11b) 
13C NMR (126 MHz, CDCl3): δC =169.7 (C9), 156.2 (C17), 140.3 (C2), 136.3 (C12), 136.0 (C19), 
129.4 (C14), 129.0 (C13), 128.6 (C21), 128.3 (C22), 128.1 (C20), 127.4 (C4), 126.4 (C15), 125.5 (C6), 
123.1 (C7), 119.3 (C5), 117.5 (C3), 67.3 (C18), 57.1 (C10), 38.5 (C11) 








A solution of benzyl (1-((2-aminophenyl)amino)-1-oxo-3-phenylpropan-2-yl)carbamate 225 (652 mg, 
1.67 mmol, 1.0 eq.) was stirred in acetic acid (2 mL, 0.6 M) at 40 °C for 2 h. The reaction was neutralised 
with a saturated aqueous sodium carbonate solution and extracted with ethyl acetate (3 x 50 mL). The 
combined organic fractions were washed with brine (20 mL), dried (MgSO4) and concentrated under 
reduced pressure. The crude compound was purified by flash column chromatography on silica eluting 
with 0-30% ethyl acetate in 40-60 petroleum ether to yield the title compound 226 as an orange liquid 
(706 mg, 1.67 mmol, 100%). 
Rf = 0.87 (30% EtOAc in 40-60 petroleum ether) 
[𝛂]𝐃
𝟐𝟎 = -15.0 (c = 0.2 in CHCl3) 
IR: νmax = 3032 (m, N-H), 1694 (s, C=O), 1520 (s, N-H), 1496 (m, C=C), 1454 (m, C=C) 
1H NMR (500 MHz, CDCl3): δH = 7.43 (2H, dd, J = 5.3, 2.9 Hz, H2 & 5), 7.29 - 7.36 (4H, m, H15, 20 
& 21), 7.21 - 7.26 (4H, m, H3, 4 & 19), 7.15 - 7.20 (3H, m, H12 & 14), 7.07 - 7.13 (2H, m, H13), 5.30 
(1H, q, J = 7.6 Hz, H9), 5.03 (1H, d, J = 12.5 Hz, H17a), 4.96 (1H, d, J = 12.5 Hz, H17b), 3.38 (2H, d, 
J = 7.6 Hz, H10) 
13C NMR (126 MHz, CDCl3): δC = 157.1 (C16), 154.0 (C8), 136.6 (C11), 136.4 (C1), 136.3 (C6), 136.1 
(C18), 129.2 (C13), 128.6 (C12), 128.5 (C20), 128.1 (C21), 127.6 (C19), 126.9 (C14), 123.2, 123.3 (C3 
& 4), 114.9 (br, C2 & 5), 67.0 (C17), 51.6 (C9), 40.2 (C10) 











Following general procedure 5: benzyl (1-(1H-benzo[d]imidazol-2-yl)-2-phenylethyl)carbamate 226 
(400 mg, 1.07 mmol), 2-bromoacetophenone (257 mg, 1.29 mmol) and potassium carbonate (149 mg, 
1.07 mmol) in acetone (4 mL) were used. The crude product was purified by flash column 
chromatography eluting with 0-50% ethyl acetate in 40-60 petroleum ether to yield the title compound 
227 as a white solid (321 mg, 0.650 mmol, 61%). 
Rf = 0.34 (30% EtOAc in 40-60 petroleum ether) 
[𝛂]𝐃
𝟐𝟎 = +23.8 (c = 0.2 in CHCl3) 
IR: νmax = 3300 (m, N-H), 2928 (m, C-H), 1689 (s, C=O), 1523 (m, N-H), 1460 (m, C=C) 
1H NMR (500 MHz, CDCl3): δH = 7.99 (2H, d, J = 7.6 Hz, H24), 7.82 (1H, d, J = 7.9 Hz, H2), 7.70 
(1H, t, J = 7.6 Hz, H26), 7.56 (2H, t, J = 7.6 Hz, H25), 7.29 - 7.34 (4H, m, H3, 19 & 20), 7.27 (1H, d, 
J = 7.9 Hz, H4), 7.25 - 7.26 (1H, m, H13), 7.24 (2H, d, J = 2.4 Hz, H12), 7.18 (4H, d, J = 4.0 Hz, H11 
& 18), 7.14 (1H, d, J = 7.9 Hz, H5), 5.76 (1H, d, J = 7.0 Hz, H14), 5.59 (1H, d, J = 18.3 Hz, H21a), 
5.41 (1H, d, J = 18.3 Hz, H21b), 5.11 (1H, q, J = 7.0 Hz, H8), 4.95 (1H, d, J = 12.5 Hz, H16a), 4.81 
(1H, d, J = 12.5 Hz, H16b), 3.50 (1H, dd, J = 13.7, 7.0 Hz, H9a), 3.46 (1H, dd, J = 13.7, 7.0 Hz, H9b) 
13C NMR (126 MHz, CDCl3): δC = 191.5 (C22), 155.9 (C15), 154.4 (C7), 142.2 (C1), 136.9 (C10), 
136.1 (C23), 135.2 (C17), 134.3 (C26), 134.2 (C6), 129.4 (C11), 129.2 (C25), 129.0 (C12), 128.4 (C20), 
128.1 (C24), 128.0 (C19), 127.6 (C18), 126.8 (C13), 123.1 (C3), 122.5 (C4), 119.8 (C2), 109.3 (C5), 
66.8 (C16), 49.3, 49.2 (C8 & 21), 40.8 (C9) 









Following general procedure 6: benzyl (1-(1-(2-oxo-2-phenylethyl)-1H-benzo[d]imidazol-2-yl)-2-
phenylethyl)carbamate 227 (90.0 mg, 0.180 mmol), ammonium formate (348 mg, 5.51 mmol) and 
palladium dihydroxide (26.0 mg, 36.7 μmol) in methanol and water (1 mL, 3:1 v:v,) were used. The 
crude product was purified by flash column chromatography eluting with 0-40% ethyl acetate in 40-60 
petroleum ether to yield the title compound 228 as a yellow solid (55.0 mg, 0.160 mmol, 89%). 
Rf = 0.23 (20% EtOAc in 40-60 petroleum ether) 
[𝛂]𝐃
𝟐𝟎 = +3.0 (c = 0.1 in CH3OH) 
IR: νmax = 2905 (m, C-H), 1694 (m, C=C), 1617 (m, C=C), 1536 (m, C=C) 
1H NMR (500 MHz, CD3OD): δH = 7.83 - 7.90 (2H, m, H2 & 5), 7.63 - 7.71 (4H, m, H3, 4 & 10), 7.43 
- 7.51 (5H, m, H11, 12 & 17), 7.34 - 7.39 (2H, m, H18), 7.27 - 7.32 (1H, m, 19), 5.28 (1H, dd, J = 9.8, 
3.7 Hz, H14), 4.83 (1H, dd, J = 11.7, 4.1 Hz, H8), 4.75 (1H, dd, J = 11.7, 4.1 Hz, H7a), 4.48 (1H, t, J 
= 11.7 Hz, H7b), 3.83 (1H, dd, J = 14.3, 3.7 Hz, H15a), 3.50 (1H, dd, J = 14.3, 9.8 Hz, H15b) 
13C NMR (126 MHz, CD3OD): δC = 149.9 (C20), 137.3 (C9), 136.1 (C16), 133.3, 133.2 (C1 & 6), 
131.0 (C12), 130.7 (C17), 130.4 (C11), 130.2 (C19), 129.0 (C18), 128.9 (C10), 128.5, 127.6 (C3 & 4), 
115.8 (C2), 113.7 (C5), 58.1 (C8), 56.3 (C14), 49.8 (C7), 38.77 (C15) 





5.7. Efficient Synthesis of Imidazopyridine Heterocycles 
 





A solution of Cbz-L-phenylalanine 49 (1.00 g, 3.34 mmol, 1.0 eq.), HATU (1.40 g, 3.67 mmol, 1.1. eq.) 
and diisopropylethylamine (3 mL, 16.7 mmol, 5.0 eq.) was stirred at room temperature for 5 minutes, 
before the addition of 3,4-diaminopyridine 234 (550 mg, 5.01 mmol, 1.5 eq.). The reaction was then 
stirred at room temperature overnight. The reaction was diluted with water (20 mL) and extracted with 
ethyl acetate (3 x 20 mL). The combined organic fractions were washed with brine (15 mL), dried 
(MgSO4) and concentrated under reduced pressure. The crude compound was purified by flash column 
chromatography on silica eluting with 0-30% methanol in diethyl ether to yield the title compound 235 
as a yellow solid (931 mg, 2.39 mmol, 71%). 
Rf = 0.41 (EtOAc) 
[𝛂]𝐃
𝟐𝟎 = +128.0 (c = 0.1 in CHCl3) 
IR: νmax = 3348 (m, N-H), 3175 (m, N-H), 1676 (s, C=O), 1586 (m, C=C), 1510 (s, N-H) 
1H NMR (500 MHz, CDCl3): δH = 8.06 (1H, s, H5), 7.96 (1H, d, J = 5.2 Hz, H4), 7.55 - 7.57 (1H, m, 
H3), 7.29 - 7.40 (9H, m, H12, 14, 19, 20, 21), 7.25 (2H, d, J = 7.3 Hz, H13), 5.57 (1H, br s H15), 5.13 
(2H, s, H17), 4.58 (1H, dd, J = 7.2, 6.4 Hz, H9), 3.18 (2H, dd, J=7.2, 3.5 Hz, H10) 
13C NMR (126 MHz, CDCl3): δc =169.9 (C8), 156.8, 152.3 (C2 & 16), 140.3 (C4), 136.0 (C5), 135.8 
(C11), 129.3 (C13), 129.1, 128.8, 128.6 (C12, 20 & 21), 128.4 (C21), 128.0 (C19), 127.3 (C14), 116.6 
(C6), 109.9 (C3), 67.5 (C17), 51.7 (C9), 39.2 (C10) 









A solution of benzyl (1-((4-aminopyridin-3-yl)amino)-1-oxo-3-phenylpropan-2-yl)carbamate 235 (375 
mg, 0.960 mmol, 1.0 eq.) was stirred in acetic acid (4 mL, 0.6 M) at 40 °C for 2h. The reaction was 
neutralised with a saturated aqueous sodium carbonate solution and extracted with ethyl acetate (3 x 25 
mL). The combined organic fractions were washed with brine (10 mL), dried (MgSO4) and concentrated 
under reduced pressure. The crude compound was purified by flash column chromatography on silica 
eluting with 0-30% methanol in ethyl acetate to yield the title compound 236 as a clear liquid (292 mg, 
0.780 mmol, 82%). 
Rf = 0.64 (10% CH3OH in EtOAc) 
[𝛂]𝐃
𝟐𝟎 = -35.8 (c = 0.5 in CHCl3) 
IR: νmax = 3219 (m, N-H), 2882 (m, C-H), 1684 (s, C=O), 1621 (m, C=C), 1586 (m, C=C), 1560 (s, N-
H) 
1H NMR (500 MHz, CDCl3): δH = 8.91 (1H, s, H4), 8.31 (1H, d, J = 5.8 Hz, H3), 7.51 (1H, d, J = 5.8 
Hz, H2), 7.27 - 7.30 (3H, m, H18 & 20), 7.21 - 7.26 (5H, m, H11, 13 & 19), 7.16 (2H, dd, J = 6.6, 2.9 
Hz, H12), 6.05 (1H, d, J = 7.0 Hz, H14), 5.32 (1H, q, J = 7.0 Hz, H8), 5.06 (1H, d, J = 12.2 Hz, H16a), 
5.01 (1H, d, J = 12.2 Hz, H16b), 3.38 - 3.54 (2H, m, H9) 
13C NMR (126 MHz, CDCl3): δC = 159.0 (C7), 156.7 (C15), 143.6 (C1), 139.1 (C3), 137.1 (C5), 136.9 
(C4), 136.1 (C10), 135.8 (C17), 129.2 (C12), 128.8, 128.5 (C11 & 19), 128.3 (C20), 127.9 (C18), 127.2 
(C13), 110.2 (C2), 67.3 (C16), 51.9 (C8), 39.5 (C9) 











Following General Procedure 5: benzyl (1-(3H-imidazo[4,5-c]pyridin-2-yl)-2-phenylethyl)carbamate 
236 (200 mg, 0.53 mmol), 2-bromoacetophenone 55 (128 mg, 0.64 mmol) and potassium carbonate (74 
mg, 0.53 mmol) in acetone (2.5 mL) were used. The crude product was purified by flash column 
chromatography eluting with 0-30% methanol in ethyl acetate to yield the title compounds 237 & 238 
as a yellow solid (79.6 mg, 0.16 mmol, 30%).  
Rf = 0.61 & 0.68 (30% CH3OH in EtOAc) 
[𝛂]𝐃
𝟐𝟎 = +37.3 (c = 0.3 in CHCl3) 
IR: νmax = 3031 (m, N-H), 2928 (m, C-H), 1694 (s, C=O), 1610 (m, C=C), 1581 (m, C=C), 1527 (m, 
C=C), 1494 (m, C=C) 
1H NMR (500 MHz, CDCl3): δH = 9.14 (1H, s, H2a), 8.60 (1H, s, H4b), 8.50 (1H, d, J = 5.5 Hz, H2b), 
8.43 (1H, d, J = 5.5 Hz, H4a), 7.99 (4H, d, J = 7.3 Hz, H23a & 23b), 7.72 - 7.74 (2H, m H25a & 25b), 
7.71 (1H, dt, J = 2.7, 1.3 Hz, H3a), 7.58 (4H, td, J = 7.7, 3.5 Hz, H24a & 24b), 7.29 - 7.33 (6H, m, 
H17a, 17b 19a & 19b), 7.24 - 7.27 (6H, m, H12a, 12b, 18a & 18b), 7.14 - 7.21 (8H, m, H10a, 10b, 11a, 
11b), 7.10 (1H, d, J = 5.5 Hz, H3b), 5.71 (2H, t, J = 4.3 Hz, H13a & 13b), 5.59 - 5.68 (2H, m, H20b), 
5.48 (1H, d, J = 14.6 Hz, H20aa), 5.45 (1H, d, J = 15.0 Hz, H20ab), 5.11 (2H, dd, J = 18.0, 7.6 Hz, H7a 
& 7b), 4.91 - 4.99 (2H, m, H15b), 4.84 (1H, d, J = 12.5 Hz, H15aa), 4.79 (1H, d, J = 12.5 Hz, H15ab), 
3.51 (1H, dd, J = 14.0, 6.7 Hz, H8aa), 3.41 - 3.48 (3H, m, H8b & 8ab) 
13C NMR (126 MHz, CDCl3): δH = 190.9, 190.8 (C21a & 21b), 157.7 (C6b), 156.1 (C6a), 155.9, 155.9 
(C14a & 14b), 147.4 (C1b), 142.7 (C2a), 142.5 (C4a), 142.4 (C2b), 140.4, (C1a), 139.5 (C5a), 136.5, 




133.0 (C5b), 132.9 (C4b), 129.4, 129.3 (C10a & 10b), 129.2, 129.2 (C24a & 24b), 128.7, 128.7 (C18a 
& 18b), 128.5, 128.5 (C17a & 17b), 128.2, 128.2 (C19a & 19b), 128.1, 128.1 (C23a & 23b), 127.7, 
127.7 (C11a & 11b), 127.1, 127.0 (C12a & 12b), 114.5 (C3a), 105.0 (C3b), 67.0, 67.0 (C15a & 15b), 
49.5, 49.4, 49.2 (C7a, 7b, 20a & 20b), 40.7, 40.6 (C8a & 8b) 
HRMS (ESI+): found [M + H]+ 491.2103, C30H27N4O3+ required 491.2083. 
 
5.7.4. (7R,9S)-9-benzyl-7-phenyl-6,7,8,9-tetrahydropyrido[3',4':4,5]imidazo[1,2-





Following General Procedure 6: benzyl (1-(1-(2-oxo-2-phenylethyl)-1H-imidazo[4,5-c]pyridin-2-yl)-
2-phenylethyl)carbamate 237 and benzyl (1-(3-(2-oxo-2-phenylethyl)-3H-imidazo[4,5-c]pyridin-2-yl)-
2-phenylethyl)carbamate 238 (44.0 mg, 89.7 μmol), ammonium formate (170 mg, 2.69 mmol) and 
palladium dihydroxide (13.0 mg, 17.9 μmol) in methanol and water (1 mL, 3:1 v:v,) were used. The 
crude product was purified by flash column chromatography eluting with 0-40% ethyl acetate in 40-60 
petroleum ether to yield the title compounds 239 & 240 as a yellow solid (30.0 mg, 89.3 μmol, 90%). 
Rf = 0.22 & 0.28 (30% CH3OH in EtOAc) 
[𝛂]𝐃
𝟐𝟎 = 0.0 (c = 0.2 in CH3OH) 
IR: νmax = 2972 (m, C-H), 2900 (m, C-H), 1643 (m, C=N), 1615 (m, C=C), 1546 (m, C=C) 
1H NMR (500 MHz, CD3OD): δH = 9.44 (2H, s, H2b & H4a), 8.61 - 8.69 (2H, m, H3a & 3b), 8.24 - 
8.34 (2H, m, H2a & 4b), 7.83 (4H, dd, J = 7.5, 2.3 Hz, H9a & 9b), 7.51 - 7.61 (10H, m, H10a, 10b, 11a, 
11b, 16a & 16b), 7.36 - 7.43 (4H, m, H17a & 17b), 7.29 - 7.34 (2H, m, H18a & 18b), 5.55 (2H, ddd, J 
= 14.3, 8.9, 5.2 Hz, H13a & 13b), 5.18 - 5.27 (2H, m, H7a & 7b), 4.99 - 5.10 (4H, m, H6a & 6b), 4.00 




13C NMR (126 MHz, CD3OD): δC = 159.6, 156.4 (C19a & 19b), 154.3 (C1a), 145.9 (C1b), 141.4 (C5b), 
136.5 (C2b), 136.2, 136.1 (C15a & 15b), 135.4, 135.3 (C3a & 3b), 134.0, 133.7 (C8a & 8b), 131.8 
(C16a & 16b), 131.0, 130.8 (C10a, 10b, 11a &11b), 130.3, 130.2 (C17a & 17b), 129.9 (C9a & 9b), 
129.7, 129.7 (C16a & 16b), 129.6 (C4a), 129.0, 129.0 (C18a & 18b), 118.5 (C2a), 110.8 (C4b), 59.3, 
59.2 (C7a & 7b), 58.9, 58.8 (C13a & 13b), 48.0, 47.8 (C6a & 6b), 38.2, 38.1 (C14a & 14b) 






5.8. Efficient synthesis of 7- and 8-membered saturated rings. 
 







Following General Procedure 5: benzyl (1-(1H-indol-2-yl)-2-phenylethyl)carbamate 54 (100 mg, 0.25 
mmol), 3-chloropropiophenone (46 mg, 0.28 mmol) and potassium carbonate (35 mg, 0.25 mmol) in 
acetone (1 mL), were used. The crude product was purified by flash column chromatography eluting 
with 20% ethyl acetate in 40-60 petroleum ether to yield the title compound 245 as a white solid (124 
mg, 0.23 mmol, 93%). 
Rf = 0.25 (20% EtOAc in 40-60 petroleum ether) 
[𝛂]𝐃
𝟐𝟎 = +13.5 (c = 0.3 in CHCl3) 
IR: νmax = 3030 (m, C-H), 1697 (s, C=O), 1600 (m, C=C), 1524 (m, N-H) 
1H NMR (400 MHz, CDCl3): δH = 8.07 (2H, dd, J = 8.0, 1.5 Hz, H3), 7.87 (2H, d, J = 7.5 Hz, H24), 
7.59 (1H, tt, J = 7.2, 1.5 Hz, H1), 7.40 - 7.50 (5H, m, H2, 25 & 26), 7.30 - 7.39 (5H, m, H17, 18 & 19), 
7.23 (2H, t, J = 7.5 Hz, H11), 7.16 (3H, d, J = 7.5 Hz, H10 & 12), 5.81 (1H, d, J = 8.6 Hz, H13), 5.34 
(1H, td, J = 8.6, 6.3 Hz, H7), 5.16 (1H, d, J = 12.3 Hz, H15a), 5.10 (1H, d, J = 12.3 Hz, H15b), 4.23 
(2H, t, J = 6.8 Hz, H20), 3.36 - 3.51 (2H, m, H8a & H21a), 3.25 (1H, dd, J = 12.9, 8.6 Hz, H8b), 2.89 
(1H, dt, J = 18.1, 7.0 Hz, H21b) 
13C NMR (101 MHz, CDCl3): δC =196.7 (C22), 161.4 (C5), 155.8 (C6), 155.6 (C14), 136.4 (C9), 136.2 




128.5 (C2, 18 & 19), 128.2 (C1), 128.1, 128.0 (C17 & 24), 127.1 (C12), 126.3 (C3), 67.0 (C15), 48.8 
(C7), 43.0 (C20), 41.7 (C8), 37.9 (C21) 







Following the protocol for the ring closure, benzyl (S)-(1-(1-(2-oxo-2-phenylethyl)-5-phenyl-1H-
imidazol-2-yl)-2-phenylethyl)carbamate 245 (75.0 mg, 141 μmol), ammonium formate (267 mg, 4.24 
mmol) and palladium dihydroxide (19.8 mg, 28.3 μmol) in methanol and water (1 mL, 3:1 v:v,) were 
used. The crude product was purified by flash column chromatography eluting with 30% ethyl acetate 
in 40-60 petroleum ether to yield the title compound 246 as a white solid (10.6 mg, 27.9 μmol, 20%). 
Rf = 0.78 (30% EtOAc in hexane) 
[𝛂]𝐃
𝟐𝟎 = +103.1 (c = 0.1 in CH3OH) 
IR: νmax = 2925 (m, C-H), 1684 (m, C=N), 1604 (m, C=C), 1482 (m, C=C) 
1H NMR (400 MHz, CD3OD): δH = 8.08 (2H, dd, J = 7.9 H3), 7.65 (2H, d, J = 7.6 Hz, H16), 7.41 - 
7.58 (8H, m, H1, 2, 10, 17 & 18), 7.34 (2H, t, J = 7.3 Hz, H11), 7.25 (1H, d, J = 7.3 Hz, H12), 5.27 
(1H, dd, J = 10.5, 1.9 Hz, H7), 5.07 (1H, d, J = 11.4, 3.4 Hz, H14), 4.80 (1H, dd, J = 13.4, 3.4 Hz, 
H20a), 4.68 (1H, dd, J = 13.4, 11.4, H20b), 3.98 (1H, dd, J = 13.0, 10.5 Hz, H8a), 3.57 (1H, dd, J = 
13.0, 1.9 Hz, H8b), 2.33 - 2.50 (2H, m, H19) 
13C NMR (101 MHz, CD3OD): δC = 161.9 (C5), 152.6 (C6), 138.7 (C15), 137.1 (C9), 132.0 (C4), 131.3 
(C10), 131.2 (C1), 130.8 (C17), 130.7 (C2), 129.9 (C18), 129.6 (C11), 128.6 (C16), 128.4 (C12), 127.4 




HRMS (ESI+): found [M + H]+ 381.2079, C25H25N4+ required 381.2079. 
 







A stirred solution of 4-chlorobutyrophenone 247 (0.501 mL, 3.11 mmol, 1.0 eq.), triethyl orthoformate 
(0.780 mL, 4.67 mmol, 1.5 eq.), trifluoromethane sulfonic acid (0.030 mL, 0.31 mmol, 0.1 eq.) and 
ethylene glycol (0.260 mL, 4.67 mmol, 1.5 eq.) in toluene (2 mL) was heated to reflux for 12 hours. 
Upon complete consumption of starting material, as detected using TLC (10% ethyl acetate in 40-60 
petroleum ether) the reaction was quenched with water (20 mL) and extracted with dichloromethane (3 
x 20 mL). The combined organic fractions were washed with brine (15 mL), dried (MgSO4) and 
concentrated under reduced pressure. The crude compound was distilled under vacuum to yield 2-(3-
chloropropyl)-2-phenyl-1,3-dioxolane 251 (470 mg, 2.08 mmol, 67%). 
Following General Procedure 5: benzyl (1-(1H-indol-2-yl)-2-phenylethyl)carbamate 54 (100 mg, 0.251 
mmol), 2-(3-chloropropyl)-2-phenyl-1,3-dioxolane 251 (57.2 mg, 0.252 mmol) and triethylamine (38.5 
μL, 0.276 mmol) in acetonitrile (1 mL) were used. The crude product was purified by flash column 
chromatography eluting with 30% EtOAc in 40-60 petroleum ether. The protected ketone was dissolved 
in dichloromethane and washed with an aqueous solution of 1 M hydrochloric acid, dried (MgSO4) and 
concentrated under reduced pressure to yield the title compound 249 as a white solid (77.4 mg, 0.142 
mmol, 56%). 
Rf = 0.52 (30% EtOAc in 40-60 petroleum ether) 
[𝛂]𝐃




IR: νmax = 3271 (m, N-H), 2929 (m, N-H), 1674 (s, C=O), 1629 (s, C=O), 1520 (m, C=C), 1503 (m, 
C=C) 
1H NMR (500 MHz, CDCl3): δH = 8.05 (2H, dt, J = 6.7, 1.5 Hz, H3), 7.91 (2H, d, J = 7.6 Hz, H25), 
7.56 (1H, t, J = 7.3 Hz, H27), 7.39 - 7.48 (5H, m, H1, 2 & 26), 7.30 - 7.38 (5H, m, H17, 18 & 19), 7.20 
(2H, t, J = 7.3 Hz, H11), 7.15 (1H, t, J = 7.3 Hz, H12), 7.10 (2H, d, J = 7.3 Hz, H10), 5.76 (1H, d, J = 
8.5 Hz, H13), 5.18 (1H, ddd, J = 9.8, 8.5, 5.8 Hz, H7), 5.14 (1H, d, J = 12.5 Hz, H15a), 5.05 (1H, d, J 
= 12.5 Hz, H15b), 3.92 (1H, quin, J = 7.0 Hz, H20a), 3.85 (1H, quin, J = 7.0 Hz, H20b), 3.37 (1H, dd, 
J = 12.8, 5.8 Hz, H8a), 3.28 (1H, dd, J = 12.8, 9.8 Hz, H8b), 2.88 (1H, dt, J = 17.7, 7.0 Hz, H22a), 2.78 
(1H, dt, J = 17.7, 7.0 Hz, H22b), 1.92 - 2.04 (2H, m, H21) 
13C NMR (126 MHz, CDCl3): δC = 198.7 (C23), 161.1 (C5), 155.6 (C6), 155.5 (C14), 136.7 (C24), 
136.1 (C16), 133.0 (C27), 131.1 (C9), 131.0 (C4), 129.4 (C10), 129.1 (C1), 128.7 (C11), 128.6 (C17), 
128.5 (C26), 128.5 (C2), 128.5 (C18), 128.2 (C19), 128.0 (C25), 127.1 (C12), 126.3 (C3), 67.0 (C15), 
48.8 (C7), 47.0 (C20), 41.7 (C8), 34.8 (C22), 23.8 (C21)  







Following General Procedure 6: benzyl (S)-(1-(1-(2-oxo-2-phenylethyl)-5-phenyl-1H-imidazol-2-yl)-
2-phenylethyl)carbamate 249 (38.1 mg, 70.0 μmol), ammonium formate (132 mg, 2.09 mmol) and 
palladium dihydroxide (10.0 mg, 14.0 μmol) in methanol and water (1 mL, 3:1 v:v,) was used. The 
crude product was purified by flash column chromatography eluting with ethyl acetate to yield the title 




Rf = 0.13 (EtOAc) 
[𝛂]𝐃
𝟐𝟎 = +116.7 (c = 0.2 in CH3OH) 
IR: νmax = 2926 (m, C-H), 2878 (m, C-H), 1600 (m, C=C), 1485 (m, C=C) 
1H NMR (400 MHz, CD3OD): δH = 8.07 (2H, dd, J = 7.7, 1.7 Hz, H3), 7.39 - 7.49 (3H, m, H1 & 2), 
7.16 - 7.37 (8H, m, H11, 12, 19, 20 & 21), 7.02 - 7.10 (2H, m, H10), 4.91 (1H, dd, J = 10.2, 5.3 Hz, 
H7), 4.52 (1H, dd, J = 7.3, 5.4 Hz, H17), 3.64 - 3.74 (1H, m, H14a), 3.52 - 3.63 (1H, m, H14b), 3.40 
(1H, dd, J = 13.1, 5.3 Hz, H8a), 3.25 - 3.27 (1H, m, H8b), 1.37 - 1.61 (4H, m, H15 & 16) 
13C NMR (126 MHz, CD3OD): δC = 163.0 (C5), 153.3 (C6), 146.3 (C18), 135.6 (C9), 132.1 (C4), 
130.8 (C10), 130.8 (C1), 130.3 (C20), 129.8 (C2), 129.5 (C11), 129.3 (C12), 128.5 (C21), 127.4 (C3), 
127.1 (C19), 74.6 (C17), 41.0 (C8), 36.9 (C16), 27.2 (C15) – C7 and 14 obscured by solvent peak 





5.9. Efficient Synthesis of Scaffolds with a Single Chiral Centre 
 
5.9.1. Single Substiution in the R2 position 
 




Following General Procedure 6: benzyl 8-benzyl-6-hydroxy-2-phenyl-5,6-dihydro-[1,2,4]triazolo[1,5-
a]pyrazine-7(8H)-carboxylate 175 (38.0 mg mg, 86.3 μmol), ammonium formate (163 mg, 2.59 mmol) 
and palladium (12.1 mg, 17.3 μmol) in methanol and water (1 mL, 3:1 v:v) was used. The crude product 
was purified by flash column chromatography eluting with ethyl acetate to yield the title compound 172 
as a yellow solid (19.5 mg, 67.2 μmol, 78%). 
Rf = 0.31 (60% EtOAc in hexane) 
[𝛂]𝐃
𝟐𝟎 = -97.2 (c = 0.1 in CH3OH) 
IR: νmax = 2922 (m, C-H), 2850 (m, C-H), 1633 (w, C=C), 1491 (m, C=C) 
1H NMR (500 MHz, CD3OD): δH = 8.10 (2H, m, H3), 7.45 - 7.52 (7H, m, H1, 2, 10 & 11), 7.42 (1H, J 
= 3.5, 2.9 Hz, H12), 5.16 (1H, dd, J = 10.2, 4.3 Hz, H7), 4.62 (1H, ddd, J = 13.7, 5.1, 2.4 Hz, H13a), 
4.53 (1H, ddd, J = 13.7, 10.9, 5.2 Hz, H13b), 3.97 (1H, dd, J = 15.1, 4.3 Hz, H8a), 3.90 (1H, ddd, J = 
13.4, 5.2, 2.4 Hz, H14a), 3.76 (1H, ddd, J = 13.6, 10.9, 5.1 Hz, H14b), 3.25 (1 H, dd, J = 15.1, 10.2 Hz, 
H8b) 
13C NMR (126 MHz, CD3OD): δC = 164.0 (C6), 151.2 (C5), 135.5 (C9), 131.8 (C4), 131.3 (C1), 
131.0 (C2), 130.8 (C11), 130.1 (C10), 129.6 (C12), 127.7 (C3), 57.0 (C7), 44.9 (C13), 42.6 (C14), 
38.2 (C8) 





5.9.2. Single Substiution in the R3 position 
 




Following General Procedure 2: Cbz-L-glycine 258 (15.0 g, 71.7 mmol), thionyl chloride (7.30 mL, 
100 mmol) and methanol (350 mL) were used. The crude product was purified by flash column 
chromatography eluting with 50% ethyl acetate in 40-60 petroleum ether to yield the title compound 
259 as a cloudy white oil (15.4 g, 68.9 mmol, 96%).  
Rf = 0.17 (50% EtOAc in 40-60 petroleum ether) 
IR: νmax = 3351 (m, C-N), 2954 (m, C-H), 1704 (s, C=O), 1520 (s, N-H) 
1H NMR (400 MHz, CDCl3): δH = 7.28 - 7.40 (5H, m, H1, 2 & 3), 5.31 (1H, br s, H7.), 5.13 (2H, s, 
H5), 3.99 (2H, d, J = 5.5 Hz, H8), 3.75 (3H, s, H10) 
13C NMR (500 MHz, CDCl3): δc = 170.4 (C9), 156.2 (C6), 136.2 (C4), 128.5 (C2), 128.2 (C1), 128.1 
(C3), 67.1 (C5), 52.3 (C10), 42.6 (C8) 
HRMS (ESI+): found [M + Na]+ 246.0741, C11H13NO4Na+ required 246.0737 
This data is in accordance with that previsouly recorded.307 
 







Following General Procedure 3: methyl ((benzyloxy)carbonyl)glycinate 259 (15.0 g, 67.2 mmol) and 
hydrazine monohydrate (16.0 mL, 336 mmol) in methanol (130 mL) were used to yield the title 
compound 260 as a white solid (14.8 g, 66.3 mmol, 98%). 
Rf = 0.42 (EtOAc) 
IR: νmax = 3302 (s, N-H), 3034 (m, C-H), 1726 (s, C=O), 1651 (s, C=O), 1604 (m, C=C), 1528 (s, N-
H) 
1H NMR (500 MHz, CDCl3): δH = 7.29 - 7.43 (5H, m, H1, 2 & 3), 5.41 (1H, br s, H7), 5.14 (2H, s, H5), 
3.87 (3H, app. d, J = 6.1 Hz, H8 & 10), 1.63 (2H, br s, H11) 
13C NMR (126 MHz, CDCl3): δC = 169.7 (C9), 156.6 (C6), 135.9 (C4), 128.6 (C2), 128.4 (C1), 128.2 
(C3), 67.4 (C5), 43.4 (C8) 
HRMS (ESI+): found [M + H]+ 224.1030, C10H14N3O3+ required 224.1030. 
 




Following General Procedure 4: ethyl benzimidate 53 (4.01 g, 26.9 mmol) and benzyl (2-hydrazinyl-2-
oxoethyl)carbamate 260 (5.00 g, 22.4 mmol) in ethanol (45 mL), followed by acetic acid (22.5 mL) 
were used. The crude product was purified by flash column chromatography eluting with 0-100% ethyl 
acetate in 40-60 petroleum ether to yield the title compound 261 as a white solid (4.32 g, 14.0 mmol, 
63%). 
Rf = 0.33 (50% EtOAc in 40-60 petroleum ether) 
IR: νmax = 3318 (m, N-H), 3126 (m, N-H), 2917 (m, C-H), 1682 (s, C=O), 1537 (s, N-H) 
1H NMR (400 MHz, CDCl3): δH = 8.02 (2H, d, J = 7.2 Hz, H12), 7.45 - 7.58 (3H, m, H13 & 14), 7.30 
- 7.42 (5H, m, H1, 2 & 3), 5.81 (1H, br s, H7), 5.18 (2H, s, H5), 4.71 (2H, d, J = 5.8 Hz, H8) 
13C NMR (101 MHz, CDCl3): δC = 165.3 (C10), 163.5 (C9), 156.1 (C6), 135.9 (C4), 131.8 (C14), 129.0 
(C13), 128.5 (C2), 128.2 (C3), 128.1 (C1), 126.9 (C12), 123.4 (C11), 67.3 (C5), 36.2 (C8) 








Following General Procedure 5: benzyl ((3-phenyl-1H-1,2,4-triazol-5-yl)methyl)carbamate 261 (4.00 
mg, 13.0 mmol), 2-bromoacetophenone (3.10 mg, 15.6 mmol) and potassium carbonate (1.79 mg, 13.0 
mmol) in acetone (10 mL) were used. The crude product was purified by flash column chromatography 
eluting with 0-60% ethyl acetate in 40-60 petroleum ether to yield the title compound 262 as a pale 
yellow solid (3.99 mg, 9.33 mmol, 72%). 
Rf = 0.47 (40% EtOAc in 40-60 petroleum ether) 
IR: νmax = 3209 (m, N-H), 2936 (m, C-H), 1771 (m, C=O), 1711 (s, C=O), 1539 (m, N-H) 
1H NMR (500 MHz, CDCl3): δH = 8.08 (2H, dd, J = 8.1, 1.4 Hz, H12), 8.03 (2H, d, J = 7.6 Hz, H18), 
7.70 (1H, t, J = 7.6 Hz, H20), 7.57 (2H, t, J = 7.9 Hz, H19), 7.39 - 7.48 (3H, m, H13 & 14), 7.31 - 7.37 
(3H, m, H1 & 2), 7.30 (2H, m, H3), 5.92 (2H, s, H15), 5.71 (1H, br s, H7), 5.00 (2H, s, H5), 4.54 (2H, 
d, J = 6.1 Hz, H8) 
13C NMR (126 MHz, CDCl3): δC = 191.1 (C16), 161.1 (C10), 156.5 (C6), 154.6 (C9), 135.9 (C4), 134.4 
(C20), 134.0 (C17), 130.3 (C11), 129.4 (C14), 129.1 (C19), 128.6 (C13), 128.6 (C2), 128.5 (C3), 128.2 
(C18), 128.0 (C1), 126.3 (C12), 67.2 (C5), 55.1 (C15), 36.2 (C8) 









Following General Procedure 6: benzyl ((1-(2-oxo-2-phenylethyl)-3-phenyl-1H-1,2,4-triazol-5-
yl)methyl)carbamate 262 (50.0 mg, 117 μmol), ammonium formate (15.0 mg, 234 mmol) and palladium 
dihydroxide (16.0 mg, 23.4 μmol) in methanol and water (1 mL, 3:1 v:v,) were used. The crude product 
was purified by flash column chromatography eluting with 0-100% ethyl acetate in 40-60 petroleum 
ether to yield the title compound 263 as a white solid (23.0 mg, 95.9 μmol, 82%). 
Rf = 0.50 (60% EtOAc in 40-60 petroleum ether) 
IR: νmax = 2962 (m, C-H), 2938 (m, C-H), 1709 (s, C=N), 1701 (s, C=N) 
1H NMR (400 MHz, CD3OD): δH = 8.00 - 8.17 (2H, m, H3), 7.67 - 7.73 (2H, m, H11), 7.58 - 7.64 (3H, 
m, H12 & 13), 7.46 - 7.52 (3H, m, H1 & 2), 5.25 (1H, dd, J = 11.2, 4.8 Hz, H9), 4.74 - 4.89 (4H, m, 
H7 & 8) 
13C NMR (101 MHz, CD3OD): δC = 163.6 (C5), 147.5 (C6), 133.1 (C10), 131.8 (C13), 131.2 (C4), 
131.0 (C1), 130.9 (C12), 129.8 (C2), 128.9 (C11), 127.3 (C3), 58.5 (C9), 58.5 (C8), 42.5 (C7) 
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7.1. Computational Procedures 
7.1.1. Reference sets 





Collection 2: 40 high-profile synthetic drugs currently produced by the pharmaceutical industry  














Collection 3: 60 randomly selected natural products 





























Collection 3: 60 randomly selected natural products (cont.) 
 
 
Collection 3: 1,000 Maybridge Fragment Library compounds.  
See: N. Mateu, S. L. Kidd, L. Kalash, H. Sore, A. Madin, A. Bender and D. R. Spring, Chem. Eur. J. 
Accepted.310 
 
This library is based on the core 1000-member collection within the Maybridge Fragment library. 
Details of the library (including SMILES and SDF) are available from ‘http://www.maybridge.com/’ 






7.1.2. Principle Moments of Inertia 
 
Principal Moment of Inertia (PMI) was performed using Molecular Operating Environment (MOE) 
software package version 2012.10 from the Chemical Computing Group. Merck molecular force field 
94X (MMFF94x), an all-atom force field parameterised for small organic molecules with the 
Generalised Born solvation model, was used to minimise the energy potential of the library members. 
A LowModeMD search was employed for the conformation generation. Detailed settings for 
conformational search are listed below (Table 7.1).  
Only the conformer with the lowest energy was retained for principal moment of inertia (PMI) 
calculations. Normalized PMI ratios (I1/I3 and I2/I3) of these conformers were obtained from MOE 
and then plotted on a triangular graph, with the coordinates (0,1), (0.5,0.5) and (1,1) representing a 
perfect rod, disc and sphere respectively. 
Table 7.1: Conformation search settings 
Method LowModeMD 
Rejection Limit 100 
RMS Gradient 0.005 
Iteration Limit 10000 
MM Iteration Limit 500 
RMSD Limit 0.15 
Energy Window 7 






7.1.3. Prinical Component Analysis (PCA) 
 
The library was merged with two reference sets and 17 molecular descriptors were calculated (Table 
7.2) 
 
Table 7.2: 17 Descriptors selected for PCA 
Desription 
Parameter 
Total hydrophobic surface area 
ASA_H 




Log octanol/ water partition coefficient 
SlogP 




Number of H-bond acceptor atoms 
a_acc 
Number of aromatic atoms 
a_aro 
Number of H-bond donor atoms 
a_don 
Number of Nitrogen atoms 
a_nN 
Number of Oxygen atoms 
a_nO 
Number of rotatable bonds 
b_rotN 
Number of chiral centres 
chiral 




Number of rings 
rings 
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7.2.3. Efficient Synthesis of 1,3-Imidazole Heterocycles 
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7.2.4. Efficient Synthesis of 1,2-pyrazole-based Scaffolds 
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7.2.5. Efficient Synthesis of Benzimidazole-based Scaffolds 
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7.2.6. Efficient Synthesis of Imidazopyridine-based Scaffolds 
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Benzyl (1-(1-(2-oxo-2-phenylethyl)-1H-imidazo[4,5-c]pyridin-2-yl)-2-phenylethyl)carbamate (237), 





11 10 9 8 7 6 5 4 3 2 1 0



















































































































180 160 140 120 100 80 60 40 20 0

















































































































(7R,9S)-9-benzyl-7-phenyl-6,7,8,9-tetrahydropyrido[3',4':4,5]-imidazo[1,2-a]pyrazine (239) and 
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